{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\n",
    "from spacy import displacy\n",
    "import random\n",
    "import json\n",
    "import logging\n",
    "import pickle"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Loading Annotated Medical Letter document from Dataturks"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Script to convert dataturks json file to spacy required format\n",
    "**Present format**:\n",
    "\"annotation\": [{\n",
    "        \"label\": [\"Form\"],\n",
    "        \"points\": [{\n",
    "            \"start\": 8151,\n",
    "            \"end\": 8156,\n",
    "            \"text\": \"tablet\"\n",
    "        }]\n",
    "    }, {\n",
    "        \"label\": [\"Drug\"],\n",
    "        \"points\": [{\n",
    "            \"start\": 8137,\n",
    "            \"end\": 8148,\n",
    "            \"text\": \"darolutamide\"\n",
    "        }]\n",
    "    }, {\n",
    "        \"label\": [\"Adverse Event\"],\n",
    "        \"points\": [{\n",
    "            \"start\": 7958,\n",
    "            \"end\": 7965,\n",
    "            \"text\": \"asthenia\"\n",
    "        }]\n",
    "    }\n",
    "\n",
    "**Required format**:\n",
    "{'entities': [(8151, 8157, 'Form'),\n",
    "    (8137, 8149, 'Drug'),\n",
    "    (7958, 7966, 'Adverse Event'),\n",
    "    (7950, 7957, 'Adverse Event'),\n",
    "    (7771, 7778, 'Form'),\n",
    "    (7701, 7707, 'Form'),\n",
    "    (7572, 7584, 'Drug'),\n",
    "    (7511, 7520, 'Duration'),\n",
    "    (7028, 7034, 'Condition'),\n",
    "    (6936, 6942, 'Strength'),\n",
    "    (6909, 6921, 'Drug'),"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [],
   "source": [
    "# def convert_dataturks_to_spacy(data):\n",
    "#     try:\n",
    "#         training_data = []\n",
    "#         lines=[]\n",
    "#         # with open(filename, 'r') as f:\n",
    "#         #     lines = f.readlines()\n",
    "\n",
    "#         # for line in lines:\n",
    "#         # data = json.loads(dataturks_data)\n",
    "#         text = data['content']\n",
    "#         entities = []\n",
    "#         for annotation in data['annotation']:\n",
    "#             #only a single point in text annotation.\n",
    "#             point = annotation['points'][0]\n",
    "#             labels = annotation['label']\n",
    "#             # handle both list of labels or a single label.\n",
    "#             if not isinstance(labels, list):\n",
    "#                 labels = [labels]\n",
    "\n",
    "#             for label in labels:\n",
    "#                 #dataturks indices are both inclusive [start, end] but spacy is not [start, end)\n",
    "#                 entities.append((point['start'], point['end'] + 1 ,label))\n",
    "\n",
    "\n",
    "#         training_data.append((text, {\"entities\" : entities}))\n",
    "\n",
    "#         return training_data\n",
    "#     except Exception as e:\n",
    "#         logging.exception(\"Unable to process \" + \"\\n\" + \"error = \" + str(e))\n",
    "#         return None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "def convertSingleItem(dataturks_labeled_item):\n",
    "    try:\n",
    "        data = json.loads(dataturks_labeled_item)\n",
    "        text = data['content']\n",
    "        entities = []\n",
    "        for annotation in data['annotation']:\n",
    "            #only a single point in text annotation.\n",
    "            point = annotation['points'][0]\n",
    "            labels = annotation['label']\n",
    "            # handle both list of labels or a single label.\n",
    "            if not isinstance(labels, list):\n",
    "                labels = [labels]\n",
    "\n",
    "            for label in labels:\n",
    "                #dataturks indices are both inclusive [start, end] but spacy is not [start, end)\n",
    "                entities.append((point['start'], point['end'] + 1 ,label));\n",
    "\n",
    "        return (text, {\"entities\" : entities});\n",
    "\n",
    "    except Exception as e:\n",
    "        logging.exception(\"Unable to process item \" + dataturks_labeled_item + \"\\n\" + \"error = \" + str(e))\n",
    "        return None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "training_output_FilePath = './data/Train_data'\n",
    "dataturks_JSON_FilePath = './data/DrugNER.json'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def convert_dataturks_to_spacy(dataturks_JSON_FilePath, training_output_FilePath):\n",
    "    with open(training_output_FilePath, \"a+\") as f:\n",
    "        logging.info(\"File \" + training_output_FilePath + \" exists....\")\n",
    "\n",
    "    logging.info(\"Converting \" + dataturks_JSON_FilePath + \" ...\");\n",
    "\n",
    "    lines = []\n",
    "    with open(dataturks_JSON_FilePath, 'r') as f:\n",
    "        lines = f.readlines()\n",
    "\n",
    "    if (not lines or len(lines) == 0):\n",
    "        logging.exception(\n",
    "            \"Please specify a valid path to dataturks JSON output file, \" + dataturks_JSON_FilePath + \" is empty\")\n",
    "        return\n",
    "\n",
    "    count = 0;\n",
    "    success = 0\n",
    "    training_data = []\n",
    "    for line in lines:\n",
    "        result = convertSingleItem(line)\n",
    "        if (result):\n",
    "            training_data.append(result)\n",
    "            success = success + 1\n",
    "\n",
    "        count += 1;\n",
    "        if (count % 100 == 0):\n",
    "            logging.info(str(count) + \" items done ...\")\n",
    "\n",
    "\n",
    "    with open(training_output_FilePath, 'wb') as output:\n",
    "        pickle.dump(training_data, output, pickle.HIGHEST_PROTOCOL)\n",
    "\n",
    "    logging.info(\n",
    "        \"Completed: \" + str(success) + \" items done, \" + str(len(lines) - success) + \" items ignored due to errors\")\n",
    "    \n",
    "    return training_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Sanity check for format conversion"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('The dose should be prescribed using a combination of whole tablet strengths (62.5 mg, 125 mg, 250 mg, 375 mg).',\n",
       "  {'entities': [(76, 81, 'Strength'),\n",
       "    (82, 85, 'Strength'),\n",
       "    (86, 89, 'Strength'),\n",
       "    (90, 93, 'Strength'),\n",
       "    (94, 97, 'Strength'),\n",
       "    (98, 101, 'Strength'),\n",
       "    (102, 105, 'Strength'),\n",
       "    (106, 110, 'Strength')]}),\n",
       " ('Dogs   The recommended dosage of CLAVAMOX CHEWABLE Tablet is 6.25 mg/lb of body weight twice a day.',\n",
       "  {'entities': [(61, 65, 'Dosage'),\n",
       "    (66, 71, 'Dosage'),\n",
       "    (87, 92, 'Frequency'),\n",
       "    (93, 94, 'Frequency'),\n",
       "    (95, 99, 'Frequency')]}),\n",
       " ('Administer CERENIA Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days',\n",
       "  {'entities': [(63, 67, 'Dosage'),\n",
       "    (68, 74, 'Dosage'),\n",
       "    (87, 91, 'Frequency'),\n",
       "    (92, 97, 'Frequency')]}),\n",
       " ('CERENIA Injectable Solution is recommended at a dose of 1 mg/kg once daily.',\n",
       "  {'entities': [(56, 57, 'Dosage'),\n",
       "    (58, 63, 'Dosage'),\n",
       "    (64, 68, 'Frequency'),\n",
       "    (69, 75, 'Frequency')]}),\n",
       " ('The dose of GALLIPRANT (grapiprant tablets) is 0.9 mg/lb (2 mg/kg) once daily.',\n",
       "  {'entities': [(57, 59, 'Dosage'),\n",
       "    (60, 66, 'Dosage'),\n",
       "    (67, 71, 'Frequency'),\n",
       "    (72, 78, 'Frequency')]}),\n",
       " ('Dogs—Administer intravenously or intramuscularly 0.25 to 0.50 mL per 10 pounds body weight once or twice daily at 6 to 8 hour intervals.',\n",
       "  {'entities': [(49, 53, 'Dosage'),\n",
       "    (54, 56, 'Dosage'),\n",
       "    (57, 61, 'Dosage'),\n",
       "    (62, 64, 'Dosage'),\n",
       "    (65, 68, 'Dosage'),\n",
       "    (69, 71, 'Dosage'),\n",
       "    (72, 78, 'Dosage'),\n",
       "    (79, 83, 'Dosage'),\n",
       "    (84, 90, 'Dosage'),\n",
       "    (91, 95, 'Frequency'),\n",
       "    (96, 98, 'Frequency'),\n",
       "    (99, 104, 'Frequency'),\n",
       "    (105, 110, 'Frequency')]}),\n",
       " ('The established effective dose should be administered once or twice daily.',\n",
       "  {'entities': [(54, 58, 'Frequency'),\n",
       "    (59, 61, 'Frequency'),\n",
       "    (62, 67, 'Frequency'),\n",
       "    (68, 74, 'Frequency')]}),\n",
       " ('Horses—The usual parenteral dosage of furosemide in horses is approximately 0.5 mg/lb body weight (1.0 mg/kg).',\n",
       "  {'entities': [(98, 102, 'Dosage'), (103, 110, 'Dosage')]}),\n",
       " ('The usual oral dosage of furosemide tablets is 1 to 2 mg/lb body weight (approximately 2.5 to 5 mg/kg).',\n",
       "  {'entities': [(87, 90, 'Dosage'),\n",
       "    (91, 93, 'Dosage'),\n",
       "    (94, 95, 'Dosage'),\n",
       "    (96, 103, 'Dosage')]}),\n",
       " ('Administer orally once or twice daily at 6 to 8 hour intervals.',\n",
       "  {'entities': [(18, 22, 'Frequency'),\n",
       "    (23, 25, 'Frequency'),\n",
       "    (26, 31, 'Frequency'),\n",
       "    (32, 37, 'Frequency')]}),\n",
       " ('The usual dose of Furosemide Syrup 1 % is 1 to 2 mg/lb body weight (approximately 2.5 to 5 mg/kg).',\n",
       "  {'entities': [(82, 85, 'Dosage'),\n",
       "    (86, 88, 'Dosage'),\n",
       "    (89, 90, 'Dosage'),\n",
       "    (91, 98, 'Dosage')]}),\n",
       " ('Administer once or twice daily at 6- to 8-hour intervals orally.',\n",
       "  {'entities': [(11, 15, 'Frequency'),\n",
       "    (16, 18, 'Frequency'),\n",
       "    (19, 24, 'Frequency'),\n",
       "    (25, 30, 'Frequency')]}),\n",
       " ('the dose of ORBAX(orbifloxacin) Tablets is 2.5 to 7.5 mg/kg of body weight administered once daily.',\n",
       "  {'entities': [(43, 46, 'Dosage'),\n",
       "    (47, 49, 'Dosage'),\n",
       "    (50, 53, 'Dosage'),\n",
       "    (54, 59, 'Dosage'),\n",
       "    (88, 92, 'Frequency'),\n",
       "    (93, 99, 'Frequency')]}),\n",
       " ('A dose of 11 mg/kg (5 mg/lb) is recommended to produce restraint.',\n",
       "  {'entities': [(19, 21, 'Dosage'), (22, 28, 'Dosage')]}),\n",
       " ('Dosages from 22 to 33 mg/kg (10 to 15 mg/lb) produce anesthesia that is suitable for diagnostic or minor surgical procedures that do not require skeletal muscle relaxation.',\n",
       "  {'entities': [(28, 31, 'Dosage'),\n",
       "    (32, 34, 'Dosage'),\n",
       "    (35, 37, 'Dosage'),\n",
       "    (38, 44, 'Dosage')]})]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "TRAIN_DATA = convert_dataturks_to_spacy(dataturks_JSON_FilePath, training_output_FilePath)\n",
    "TRAIN_DATA"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# def train_spacy(training_pickle_file):\n",
    "    \n",
    "#     #read pickle file to load training data\n",
    "#     with open(training_pickle_file, 'rb') as input:\n",
    "#         TRAIN_DATA=pickle.load(input)\n",
    "\n",
    "#     nlp = spacy.blank('en')  # create blank Language class\n",
    "#     # create the built-in pipeline components and add them to the pipeline\n",
    "#     # nlp.create_pipe works for built-ins that are registered with spaCy\n",
    "#     if 'ner' not in nlp.pipe_names:\n",
    "#         ner = nlp.create_pipe('ner')\n",
    "#         nlp.add_pipe(ner, last=True)\n",
    "\n",
    "#     # add labels\n",
    "#     for _, annotations in TRAIN_DATA:\n",
    "#         for ent in annotations.get('entities'):\n",
    "#             ner.add_label(ent[2])\n",
    "\n",
    "#     # get names of other pipes to disable them during training\n",
    "#     other_pipes = [pipe for pipe in nlp.pipe_names if pipe != 'ner']\n",
    "#     with nlp.disable_pipes(*other_pipes):  # only train NER\n",
    "#         optimizer = nlp.begin_training()\n",
    "#         for itn in range(1):\n",
    "#             print(\"Statring iteration \" + str(itn))\n",
    "#             random.shuffle(TRAIN_DATA)\n",
    "#             losses = {}\n",
    "#             for text, annotations in TRAIN_DATA:\n",
    "#                 nlp.update(\n",
    "#                     [text],  # batch of texts\n",
    "#                     [annotations],  # batch of annotations\n",
    "#                     drop=0.2,  # dropout - make it harder to memorise data\n",
    "#                     sgd=optimizer,  # callable to update weights\n",
    "#                     losses=losses)\n",
    "#             print(losses)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "# training_pickle_file = 'Multi_Train_Drug_data'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "ename": "FileNotFoundError",
     "evalue": "[Errno 2] No such file or directory: 'Multi_Train_Drug_data'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mFileNotFoundError\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-7-2e448932016d>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[0;31m#read pickle file to load training data\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 2\u001b[0;31m \u001b[0;32mwith\u001b[0m \u001b[0mopen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtraining_pickle_file\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0;34m'rb'\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0minput\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      3\u001b[0m     \u001b[0mTRAIN_DATA\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0mpickle\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mload\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0minput\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mFileNotFoundError\u001b[0m: [Errno 2] No such file or directory: 'Multi_Train_Drug_data'"
     ]
    }
   ],
   "source": [
    "#read pickle file to load training data\n",
    "# with open(training_pickle_file, 'rb') as input:\n",
    "#     TRAIN_DATA=pickle.load(input)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('The dose should be prescribed using a combination of whole tablet strengths (62.5 mg, 125 mg, 250 mg, 375 mg).',\n",
       "  {'entities': [(76, 81, 'Strength'),\n",
       "    (82, 85, 'Strength'),\n",
       "    (86, 89, 'Strength'),\n",
       "    (90, 93, 'Strength'),\n",
       "    (94, 97, 'Strength'),\n",
       "    (98, 101, 'Strength'),\n",
       "    (102, 105, 'Strength'),\n",
       "    (106, 110, 'Strength')]}),\n",
       " ('Dogs   The recommended dosage of CLAVAMOX CHEWABLE Tablet is 6.25 mg/lb of body weight twice a day.',\n",
       "  {'entities': [(61, 65, 'Dosage'),\n",
       "    (66, 71, 'Dosage'),\n",
       "    (87, 92, 'Frequency'),\n",
       "    (93, 94, 'Frequency'),\n",
       "    (95, 99, 'Frequency')]}),\n",
       " ('Administer CERENIA Tablets orally at a minimum dose of 2 mg/kg (0.9 mg/lb) body weight once daily for up to 5 consecutive days',\n",
       "  {'entities': [(63, 67, 'Dosage'),\n",
       "    (68, 74, 'Dosage'),\n",
       "    (87, 91, 'Frequency'),\n",
       "    (92, 97, 'Frequency')]}),\n",
       " ('CERENIA Injectable Solution is recommended at a dose of 1 mg/kg once daily.',\n",
       "  {'entities': [(56, 57, 'Dosage'),\n",
       "    (58, 63, 'Dosage'),\n",
       "    (64, 68, 'Frequency'),\n",
       "    (69, 75, 'Frequency')]}),\n",
       " ('The dose of GALLIPRANT (grapiprant tablets) is 0.9 mg/lb (2 mg/kg) once daily.',\n",
       "  {'entities': [(57, 59, 'Dosage'),\n",
       "    (60, 66, 'Dosage'),\n",
       "    (67, 71, 'Frequency'),\n",
       "    (72, 78, 'Frequency')]}),\n",
       " ('Dogs—Administer intravenously or intramuscularly 0.25 to 0.50 mL per 10 pounds body weight once or twice daily at 6 to 8 hour intervals.',\n",
       "  {'entities': [(49, 53, 'Dosage'),\n",
       "    (54, 56, 'Dosage'),\n",
       "    (57, 61, 'Dosage'),\n",
       "    (62, 64, 'Dosage'),\n",
       "    (65, 68, 'Dosage'),\n",
       "    (69, 71, 'Dosage'),\n",
       "    (72, 78, 'Dosage'),\n",
       "    (79, 83, 'Dosage'),\n",
       "    (84, 90, 'Dosage'),\n",
       "    (91, 95, 'Frequency'),\n",
       "    (96, 98, 'Frequency'),\n",
       "    (99, 104, 'Frequency'),\n",
       "    (105, 110, 'Frequency')]}),\n",
       " ('The established effective dose should be administered once or twice daily.',\n",
       "  {'entities': [(54, 58, 'Frequency'),\n",
       "    (59, 61, 'Frequency'),\n",
       "    (62, 67, 'Frequency'),\n",
       "    (68, 74, 'Frequency')]}),\n",
       " ('Horses—The usual parenteral dosage of furosemide in horses is approximately 0.5 mg/lb body weight (1.0 mg/kg).',\n",
       "  {'entities': [(98, 102, 'Dosage'), (103, 110, 'Dosage')]}),\n",
       " ('The usual oral dosage of furosemide tablets is 1 to 2 mg/lb body weight (approximately 2.5 to 5 mg/kg).',\n",
       "  {'entities': [(87, 90, 'Dosage'),\n",
       "    (91, 93, 'Dosage'),\n",
       "    (94, 95, 'Dosage'),\n",
       "    (96, 103, 'Dosage')]}),\n",
       " ('Administer orally once or twice daily at 6 to 8 hour intervals.',\n",
       "  {'entities': [(18, 22, 'Frequency'),\n",
       "    (23, 25, 'Frequency'),\n",
       "    (26, 31, 'Frequency'),\n",
       "    (32, 37, 'Frequency')]}),\n",
       " ('The usual dose of Furosemide Syrup 1 % is 1 to 2 mg/lb body weight (approximately 2.5 to 5 mg/kg).',\n",
       "  {'entities': [(82, 85, 'Dosage'),\n",
       "    (86, 88, 'Dosage'),\n",
       "    (89, 90, 'Dosage'),\n",
       "    (91, 98, 'Dosage')]}),\n",
       " ('Administer once or twice daily at 6- to 8-hour intervals orally.',\n",
       "  {'entities': [(11, 15, 'Frequency'),\n",
       "    (16, 18, 'Frequency'),\n",
       "    (19, 24, 'Frequency'),\n",
       "    (25, 30, 'Frequency')]}),\n",
       " ('the dose of ORBAX(orbifloxacin) Tablets is 2.5 to 7.5 mg/kg of body weight administered once daily.',\n",
       "  {'entities': [(43, 46, 'Dosage'),\n",
       "    (47, 49, 'Dosage'),\n",
       "    (50, 53, 'Dosage'),\n",
       "    (54, 59, 'Dosage'),\n",
       "    (88, 92, 'Frequency'),\n",
       "    (93, 99, 'Frequency')]}),\n",
       " ('A dose of 11 mg/kg (5 mg/lb) is recommended to produce restraint.',\n",
       "  {'entities': [(19, 21, 'Dosage'), (22, 28, 'Dosage')]}),\n",
       " ('Dosages from 22 to 33 mg/kg (10 to 15 mg/lb) produce anesthesia that is suitable for diagnostic or minor surgical procedures that do not require skeletal muscle relaxation.',\n",
       "  {'entities': [(28, 31, 'Dosage'),\n",
       "    (32, 34, 'Dosage'),\n",
       "    (35, 37, 'Dosage'),\n",
       "    (38, 44, 'Dosage')]})]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "TRAIN_DATA"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Creating a blank Language model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "nlp = spacy.blank('en')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= []\n"
     ]
    }
   ],
   "source": [
    "doc = nlp(\"Dosages from 22 to 33 mg/kg (10 to 15 mg/lb) produce anesthesia that is suitable for diagnostic or minor surgical procedures that do not require skeletal muscle relaxation.\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Creating a NER pipeline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "if 'ner' not in nlp.pipe_names:\n",
    "    ner = nlp.create_pipe('ner')\n",
    "    nlp.add_pipe(ner, last=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Adding labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "for _, annotations in TRAIN_DATA:\n",
    "    for ent in annotations.get('entities'):\n",
    "        ner.add_label(ent[2])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "####  Get names of other pipes to disable them during training"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "other_pipes = [pipe for pipe in nlp.pipe_names if pipe != 'ner']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Train only NER"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/subashgandyer/opt/anaconda3/envs/testing/lib/python3.8/site-packages/spacy/language.py:635: UserWarning: [W033] Training a new parser or NER using a model with an empty lexeme normalization table. This may degrade the performance to some degree. If this is intentional or this language doesn't have a normalization table, please ignore this warning.\n",
      "  proc.begin_training(\n",
      "/Users/subashgandyer/opt/anaconda3/envs/testing/lib/python3.8/site-packages/spacy/language.py:635: UserWarning: [W034] Please install the package spacy-lookups-data in order to include the default lexeme normalization table for the language 'en'.\n",
      "  proc.begin_training(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Statring iteration 0\n",
      "{'ner': 212.31095018683118}\n",
      "Entities= []\n",
      "Entities= []\n",
      "Entities= []\n",
      "Statring iteration 1\n",
      "{'ner': 126.2251306126418}\n",
      "Entities= []\n",
      "Entities= []\n",
      "Entities= []\n",
      "Statring iteration 2\n",
      "{'ner': 109.64333077361681}\n",
      "Entities= ['mg/day dosage. Usual side effects are fatigue asthenia and back_Dosage', 'pain_Strength']\n",
      "Entities= []\n",
      "Entities= ['mg/kg) of body_Dosage', 'weight_Strength']\n",
      "Statring iteration 3\n",
      "{'ner': 82.49499220222052}\n",
      "Entities= ['600_Dosage', 'mg/day dosage. Usual side effects are fatigue asthenia and back pain._Dosage']\n",
      "Entities= []\n",
      "Entities= ['3_Dosage', 'mg/kg) of body weight._Dosage']\n",
      "Statring iteration 4\n",
      "{'ner': 70.05319704674285}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage', 'dosage._Frequency']\n",
      "Entities= ['3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to 3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 5\n",
      "{'ner': 42.91345645525166}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day dosage. Usual side effects_Dosage']\n",
      "Entities= []\n",
      "Entities= []\n",
      "Statring iteration 6\n",
      "{'ner': 36.86474510093745}\n",
      "Entities= ['600_Dosage', 'mg/day dosage._Dosage']\n",
      "Entities= ['to_Dosage', '3_Dosage']\n",
      "Entities= ['to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 7\n",
      "{'ner': 16.13615248610446}\n",
      "Entities= []\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL_Dosage', '/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 8\n",
      "{'ner': 6.404940423294501}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['3_Dosage', 'mL_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 9\n",
      "{'ner': 2.408965474557273}\n",
      "Entities= ['600_Dosage', 'mg/day dosage._Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 10\n",
      "{'ner': 2.427045800862397}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 11\n",
      "{'ner': 0.12181529172606441}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 12\n",
      "{'ner': 3.424720768339679}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= ['3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 13\n",
      "{'ner': 0.11967286206090878}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= ['3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 14\n",
      "{'ner': 0.2975768325356487}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 15\n",
      "{'ner': 0.005886897902704533}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 16\n",
      "{'ner': 0.07094567997246025}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 17\n",
      "{'ner': 0.00027536884165917433}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 18\n",
      "{'ner': 0.00015328160443053398}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 19\n",
      "{'ner': 2.388466142103183e-05}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 20\n",
      "{'ner': 7.178715491679143e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 21\n",
      "{'ner': 2.422057890939923e-05}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 22\n",
      "{'ner': 9.037613578921781e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 23\n",
      "{'ner': 3.6670075816053004e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 24\n",
      "{'ner': 3.030479539666591e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 25\n",
      "{'ner': 2.184468412835624e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 26\n",
      "{'ner': 1.7039340926380948e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 27\n",
      "{'ner': 6.642275574918143e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 28\n",
      "{'ner': 6.295442835564117e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 29\n",
      "{'ner': 1.9264690032237e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 30\n",
      "{'ner': 2.899625763554111e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 31\n",
      "{'ner': 8.342340752097619e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 32\n",
      "{'ner': 2.4436158534872443e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 33\n",
      "{'ner': 1.3585929091404082e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 34\n",
      "{'ner': 4.944546004363386e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 35\n",
      "{'ner': 1.8090320272582254e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 36\n",
      "{'ner': 1.9872611113966883e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 37\n",
      "{'ner': 2.106238884889597e-05}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 38\n",
      "{'ner': 4.560852898195005e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 39\n",
      "{'ner': 9.134094013881172e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 40\n",
      "{'ner': 3.269724334022594e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 41\n",
      "{'ner': 6.514710313143214e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 42\n",
      "{'ner': 1.198570383113732e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 43\n",
      "{'ner': 1.590509131450826e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 44\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 1.0945757202912574e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 45\n",
      "{'ner': 7.121874477091824e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 46\n",
      "{'ner': 1.2605051458152302e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 47\n",
      "{'ner': 2.0810911543564782e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 48\n",
      "{'ner': 2.558290046140175e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 49\n",
      "{'ner': 1.7510313219847017e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 50\n",
      "{'ner': 1.5117212271179275e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 51\n",
      "{'ner': 9.2673273823481e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 52\n",
      "{'ner': 1.1465773140728147e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 53\n",
      "{'ner': 5.700915382955962e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 54\n",
      "{'ner': 2.5142181732056396e-05}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 55\n",
      "{'ner': 6.100732927095466e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 56\n",
      "{'ner': 2.9086012836291547e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 57\n",
      "{'ner': 7.743196612914114e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 58\n",
      "{'ner': 3.8335100574370564e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 59\n",
      "{'ner': 2.8911839373354613e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 60\n",
      "{'ner': 2.8790893422417043e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 61\n",
      "{'ner': 1.0496738669458683e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 62\n",
      "{'ner': 5.142283177090612e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency', 'dosage._Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 63\n",
      "{'ner': 1.3399280173223703e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 64\n",
      "{'ner': 5.083028443810696e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 65\n",
      "{'ner': 3.6470280868646096e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 66\n",
      "{'ner': 1.0423686880110556e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 67\n",
      "{'ner': 2.6535669328485587e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 68\n",
      "{'ner': 4.3778580898326116e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 69\n",
      "{'ner': 2.3789373264584987e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 70\n",
      "{'ner': 5.630529022722816e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 71\n",
      "{'ner': 3.52667816411608e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 72\n",
      "{'ner': 8.47736268987342e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 73\n",
      "{'ner': 1.3109016094199843e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 74\n",
      "{'ner': 1.1411385308811113e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 75\n",
      "{'ner': 7.602818448037782e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 76\n",
      "{'ner': 2.8191266672127823e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 77\n",
      "{'ner': 3.889944868299012e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 78\n",
      "{'ner': 4.5071007533094477e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 79\n",
      "{'ner': 1.781058281096071e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 80\n",
      "{'ner': 8.242705715772636e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 81\n",
      "{'ner': 9.340463084061275e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 82\n",
      "{'ner': 7.156725582701197e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 83\n",
      "{'ner': 7.749949205414943e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 84\n",
      "{'ner': 3.1699091585514718e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 85\n",
      "{'ner': 6.888224485517562e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 86\n",
      "{'ner': 2.7659395948475635e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 87\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 2.9003162199313834e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 88\n",
      "{'ner': 1.4022708799203718e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 89\n",
      "{'ner': 1.0526303805594873e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 90\n",
      "{'ner': 1.4591365832636485e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 91\n",
      "{'ner': 1.7832090259178664e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 92\n",
      "{'ner': 2.8111047066062413e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 93\n",
      "{'ner': 3.0139853565276834e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 94\n",
      "{'ner': 3.744206164616611e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 95\n",
      "{'ner': 1.484835760705321e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 96\n",
      "{'ner': 1.960388073165665e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 97\n",
      "{'ner': 8.853990532404785e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 98\n",
      "{'ner': 1.8846938163951953e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 99\n",
      "{'ner': 3.686864894892094e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 100\n",
      "{'ner': 5.678407361929433e-07}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 101\n",
      "{'ner': 5.981302544326031e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 102\n",
      "{'ner': 1.9264366206382096e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 103\n",
      "{'ner': 7.857181756711803e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 104\n",
      "{'ner': 2.1624882443728657e-07}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 105\n",
      "{'ner': 6.364204433793795e-07}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 106\n",
      "{'ner': 7.373820543045417e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 107\n",
      "{'ner': 1.3536444058678023e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 108\n",
      "{'ner': 7.32839944415941e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 109\n",
      "{'ner': 6.733154674634111e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 110\n",
      "{'ner': 4.84558756029767e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 111\n",
      "{'ner': 3.4588025189812805e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 112\n",
      "{'ner': 3.785310794578838e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 113\n",
      "{'ner': 1.1804792532817291e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 114\n",
      "{'ner': 6.513355553718125e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 115\n",
      "{'ner': 2.8061700910637466e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 116\n",
      "{'ner': 4.971757015315238e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 117\n",
      "{'ner': 1.2279053854035694e-06}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 118\n",
      "{'ner': 3.626276042492826e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 119\n",
      "{'ner': 1.4408257376837745e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 120\n",
      "{'ner': 4.639661091321432e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 121\n",
      "{'ner': 2.0419310839926966e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 122\n",
      "{'ner': 2.594447249165072e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 123\n",
      "{'ner': 4.199319944671505e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 124\n",
      "{'ner': 2.8501970659489234e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 125\n",
      "{'ner': 1.0579395278640332e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 126\n",
      "{'ner': 2.152824570378667e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 127\n",
      "{'ner': 1.3268079303196933e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 128\n",
      "{'ner': 4.8341249337632216e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 129\n",
      "{'ner': 3.506712476202475e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 130\n",
      "{'ner': 1.6527217837941608e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 131\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 6.899958171540034e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 132\n",
      "{'ner': 2.440070740209781e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 133\n",
      "{'ner': 1.1358875421094409e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 134\n",
      "{'ner': 2.4775355282913364e-08}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 135\n",
      "{'ner': 2.0258100312589114e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 136\n",
      "{'ner': 5.548577201302667e-09}\n",
      "Entities= ['600_Dosage', 'mg/_Dosage', 'day_Frequency']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 137\n",
      "{'ner': 1.0754388599170533e-06}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 138\n",
      "{'ner': 2.017034585433721e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 139\n",
      "{'ner': 4.42284376596281e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 140\n",
      "{'ner': 1.2006254165928016e-07}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 141\n",
      "{'ner': 5.776937345657598e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 142\n",
      "{'ner': 9.690287944841684e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 143\n",
      "{'ner': 3.4950149304278187e-06}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 144\n",
      "{'ner': 1.5738209105998294e-07}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 145\n",
      "{'ner': 6.155056307384957e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 146\n",
      "{'ner': 7.448757818569328e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 147\n",
      "{'ner': 3.612032513649157e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 148\n",
      "{'ner': 2.8605156145522544e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 149\n",
      "{'ner': 1.702702930679037e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 150\n",
      "{'ner': 1.200514768396887e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 151\n",
      "{'ner': 6.3772748497709e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 152\n",
      "{'ner': 1.6681657312657539e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 153\n",
      "{'ner': 2.534847297628715e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 154\n",
      "{'ner': 1.4186739128862611e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 155\n",
      "{'ner': 1.2573343001748726e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 156\n",
      "{'ner': 2.311931650572905e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 157\n",
      "{'ner': 1.9863069264833703e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 158\n",
      "{'ner': 1.5038204276545835e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 159\n",
      "{'ner': 9.29740359056461e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 160\n",
      "{'ner': 4.952310670464929e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 161\n",
      "{'ner': 1.0689812498067654e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 162\n",
      "{'ner': 3.47749769853356e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 163\n",
      "{'ner': 4.891035110584499e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 164\n",
      "{'ner': 3.340258335979231e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 165\n",
      "{'ner': 2.6738085162275637e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 166\n",
      "{'ner': 6.025812814568229e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 167\n",
      "{'ner': 1.4006534785948774e-07}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 168\n",
      "{'ner': 5.602940066621223e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 169\n",
      "{'ner': 2.0347067875783864e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 170\n",
      "{'ner': 3.4474370345684954e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 171\n",
      "{'ner': 2.5932065697810376e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 172\n",
      "{'ner': 7.355118315159465e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 173\n",
      "{'ner': 4.5026806278587133e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 174\n",
      "{'ner': 2.114774236159019e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 175\n",
      "{'ner': 2.920092839116537e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 176\n",
      "{'ner': 3.705737112933353e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 177\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 3.739123655705001e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 178\n",
      "{'ner': 2.2292996288586167e-07}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 179\n",
      "{'ner': 1.3818440001562783e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 180\n",
      "{'ner': 2.7338811687716464e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 181\n",
      "{'ner': 3.0019936907308073e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 182\n",
      "{'ner': 7.421229040880826e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 183\n",
      "{'ner': 3.865555109913014e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 184\n",
      "{'ner': 1.9248096705725376e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 185\n",
      "{'ner': 2.5221401715948527e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 186\n",
      "{'ner': 1.1141996375511063e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 187\n",
      "{'ner': 1.812330773712992e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 188\n",
      "{'ner': 6.622647195030395e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 189\n",
      "{'ner': 1.2115887147310105e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 190\n",
      "{'ner': 6.290755064829486e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 191\n",
      "{'ner': 2.6458113271248442e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 192\n",
      "{'ner': 1.9610308305206222e-07}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 193\n",
      "{'ner': 5.366979770571524e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 194\n",
      "{'ner': 2.4226250729375885e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 195\n",
      "{'ner': 4.306985186000837e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 196\n",
      "{'ner': 3.2718030830533307e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 197\n",
      "{'ner': 4.150298897182809e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 198\n",
      "{'ner': 1.7552539626281352e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 199\n",
      "{'ner': 9.708078277494565e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 200\n",
      "{'ner': 8.382291113314491e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 201\n",
      "{'ner': 5.184608562592518e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 202\n",
      "{'ner': 5.3271607876100275e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 203\n",
      "{'ner': 1.0938497557257933e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 204\n",
      "{'ner': 4.117339028757568e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 205\n",
      "{'ner': 2.885272016243945e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 206\n",
      "{'ner': 3.2484772850322147e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 207\n",
      "{'ner': 3.7029747114561186e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 208\n",
      "{'ner': 3.3850632998578806e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 209\n",
      "{'ner': 3.555489708243055e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 210\n",
      "{'ner': 4.3750568289325533e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 211\n",
      "{'ner': 7.118509763664564e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 212\n",
      "{'ner': 1.8864622511067382e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 213\n",
      "{'ner': 3.820351686270726e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 214\n",
      "{'ner': 1.8609942997434567e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 215\n",
      "{'ner': 2.567483078812416e-06}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 216\n",
      "{'ner': 8.293386940638683e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 217\n",
      "{'ner': 1.1149121611867653e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 218\n",
      "{'ner': 1.4177350730362607e-07}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 219\n",
      "{'ner': 3.3302678181979345e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 220\n",
      "{'ner': 8.822256448144529e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 221\n",
      "{'ner': 5.767737819982549e-07}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 222\n",
      "{'ner': 2.0284340517724427e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 223\n",
      "{'ner': 2.8164243263003067e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= []\n",
      "Statring iteration 224\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 6.99898676460777e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= []\n",
      "Statring iteration 225\n",
      "{'ner': 8.021131499819809e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= []\n",
      "Statring iteration 226\n",
      "{'ner': 7.68147521190625e-07}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 227\n",
      "{'ner': 1.3347600359581342e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 228\n",
      "{'ner': 4.513112629019393e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 229\n",
      "{'ner': 5.098306039049074e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 230\n",
      "{'ner': 1.2754529750010232e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 231\n",
      "{'ner': 6.433757158613254e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 232\n",
      "{'ner': 1.8685868816845982e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 233\n",
      "{'ner': 2.647007194319037e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 234\n",
      "{'ner': 7.587575614813576e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 235\n",
      "{'ner': 4.783878439968993e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 236\n",
      "{'ner': 3.95432814690593e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 237\n",
      "{'ner': 2.376251566649825e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 238\n",
      "{'ner': 4.151013331009998e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 239\n",
      "{'ner': 6.764125735711663e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 240\n",
      "{'ner': 2.7593395159939337e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 241\n",
      "{'ner': 3.5167491605370465e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 242\n",
      "{'ner': 3.6344971264252753e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 243\n",
      "{'ner': 7.78973646305327e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 244\n",
      "{'ner': 6.829553350143912e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 245\n",
      "{'ner': 2.2891255736914376e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 246\n",
      "{'ner': 6.014295121876764e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 247\n",
      "{'ner': 6.644334494824831e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 248\n",
      "{'ner': 7.391476253810071e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 249\n",
      "{'ner': 7.886335266082754e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 250\n",
      "{'ner': 1.1525173898663306e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 251\n",
      "{'ner': 7.543628656111262e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 252\n",
      "{'ner': 4.5204857935403273e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 253\n",
      "{'ner': 8.877955536562539e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 254\n",
      "{'ner': 6.015255592095272e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 255\n",
      "{'ner': 7.578657976270075e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 256\n",
      "{'ner': 1.3869018984017977e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 257\n",
      "{'ner': 7.012192247873273e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 258\n",
      "{'ner': 3.294615001048544e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 259\n",
      "{'ner': 9.445174337214782e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 260\n",
      "{'ner': 9.980086228893822e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 261\n",
      "{'ner': 2.466929036497912e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 262\n",
      "{'ner': 1.0810893271660525e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 263\n",
      "{'ner': 2.066763753347822e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 264\n",
      "{'ner': 1.3584784233937125e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 265\n",
      "{'ner': 6.259928691042994e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 266\n",
      "{'ner': 1.2568123950173887e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 267\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 4.2037367599920226e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 268\n",
      "{'ner': 1.1612599250852442e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 269\n",
      "{'ner': 6.420202993909275e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 270\n",
      "{'ner': 3.72677377069402e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 271\n",
      "{'ner': 1.2250905211812036e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 272\n",
      "{'ner': 3.9245289300147513e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 273\n",
      "{'ner': 1.5678456945014412e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 274\n",
      "{'ner': 7.939022142995871e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 275\n",
      "{'ner': 9.067335983561598e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 276\n",
      "{'ner': 1.533841102504198e-08}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 277\n",
      "{'ner': 2.6447862031530114e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 278\n",
      "{'ner': 3.8631645089119786e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 279\n",
      "{'ner': 6.777193517752183e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 280\n",
      "{'ner': 6.307820208105817e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 281\n",
      "{'ner': 5.929182044370622e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 282\n",
      "{'ner': 8.608827814555418e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 283\n",
      "{'ner': 1.206257956015003e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 284\n",
      "{'ner': 2.1400709704840645e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 285\n",
      "{'ner': 1.0233528400336638e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 286\n",
      "{'ner': 1.0268163753494824e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 287\n",
      "{'ner': 6.642142771850502e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 288\n",
      "{'ner': 2.947596973765128e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 289\n",
      "{'ner': 4.4802511470499354e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 290\n",
      "{'ner': 9.354062541497811e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 291\n",
      "{'ner': 1.5283724652676744e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 292\n",
      "{'ner': 5.93047166694246e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 293\n",
      "{'ner': 3.408355237389717e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 294\n",
      "{'ner': 4.178907186531669e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 295\n",
      "{'ner': 4.240252069420547e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 296\n",
      "{'ner': 5.831644388669271e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 297\n",
      "{'ner': 8.125192700357038e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 298\n",
      "{'ner': 4.594737240217711e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 299\n",
      "{'ner': 2.0453851094555903e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 300\n",
      "{'ner': 5.891650377996116e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 301\n",
      "{'ner': 5.332549078594286e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 302\n",
      "{'ner': 1.1004261673063792e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 303\n",
      "{'ner': 5.883743579591518e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 304\n",
      "{'ner': 1.7723608805782886e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 305\n",
      "{'ner': 5.439571135662546e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 306\n",
      "{'ner': 2.7494099550180694e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 307\n",
      "{'ner': 7.667167061719972e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 308\n",
      "{'ner': 8.011868080665667e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 309\n",
      "{'ner': 1.0212381348282407e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 310\n",
      "{'ner': 1.9987948185042993e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 311\n",
      "{'ner': 9.244182048597298e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 312\n",
      "{'ner': 9.261853136223354e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 313\n",
      "{'ner': 5.81983507642777e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 314\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 7.741905656493194e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 315\n",
      "{'ner': 1.4361962859203238e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 316\n",
      "{'ner': 7.667403998842256e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 317\n",
      "{'ner': 1.438158941553499e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 318\n",
      "{'ner': 2.212690300575438e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 319\n",
      "{'ner': 2.024695343242218e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 320\n",
      "{'ner': 1.9197269236898357e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 321\n",
      "{'ner': 1.0025089407348011e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 322\n",
      "{'ner': 7.985802113939854e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 323\n",
      "{'ner': 1.1997434328438845e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 324\n",
      "{'ner': 1.0852422694834925e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 325\n",
      "{'ner': 6.761280694633592e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 326\n",
      "{'ner': 9.819197477240762e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 327\n",
      "{'ner': 5.905269333537526e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 328\n",
      "{'ner': 4.3867248629875315e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 329\n",
      "{'ner': 3.272492668709972e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 330\n",
      "{'ner': 2.396011384111615e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 331\n",
      "{'ner': 2.5077501854155823e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 332\n",
      "{'ner': 1.6163043814563127e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 333\n",
      "{'ner': 2.047894016084705e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 334\n",
      "{'ner': 1.4510205203949133e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 335\n",
      "{'ner': 5.312112331370238e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 336\n",
      "{'ner': 5.495202461786463e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 337\n",
      "{'ner': 1.9916641143479407e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 338\n",
      "{'ner': 3.176286755204886e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 339\n",
      "{'ner': 2.9239685033459773e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 340\n",
      "{'ner': 2.5075247085253683e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 341\n",
      "{'ner': 8.051267851943365e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 342\n",
      "{'ner': 6.3661050509636365e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 343\n",
      "{'ner': 1.2140613655132848e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 344\n",
      "{'ner': 3.3653070249810023e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 345\n",
      "{'ner': 9.078251625368444e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 346\n",
      "{'ner': 2.3890031843865876e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 347\n",
      "{'ner': 8.751381880754752e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 348\n",
      "{'ner': 4.73868499482524e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 349\n",
      "{'ner': 2.803526588177145e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 350\n",
      "{'ner': 9.29296580517966e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 351\n",
      "{'ner': 7.840244062249939e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 352\n",
      "{'ner': 5.4778400047629284e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 353\n",
      "{'ner': 3.629714337116467e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 354\n",
      "{'ner': 2.7784947216522596e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 355\n",
      "{'ner': 5.031850085694045e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 356\n",
      "{'ner': 1.6971929300299352e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 357\n",
      "{'ner': 2.5779482634190434e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 358\n",
      "{'ner': 1.4218668022970964e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 359\n",
      "{'ner': 1.7302117055984412e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 360\n",
      "{'ner': 6.401517731142989e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 361\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 3.7326324857704805e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 362\n",
      "{'ner': 4.0185010505295255e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 363\n",
      "{'ner': 4.7194467514397535e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 364\n",
      "{'ner': 1.9632523470354232e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 365\n",
      "{'ner': 5.454955662136623e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 366\n",
      "{'ner': 7.060325850789673e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 367\n",
      "{'ner': 9.307079110925046e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 368\n",
      "{'ner': 9.112131803541735e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 369\n",
      "{'ner': 1.130625784128097e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 370\n",
      "{'ner': 6.56281361686014e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 371\n",
      "{'ner': 1.5230567719718596e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 372\n",
      "{'ner': 2.0524157575229067e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 373\n",
      "{'ner': 1.2641574686545604e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 374\n",
      "{'ner': 4.249384863705089e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 375\n",
      "{'ner': 1.2633469063136216e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 376\n",
      "{'ner': 2.3683280766722537e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 377\n",
      "{'ner': 2.5442468532721628e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 378\n",
      "{'ner': 9.843651447774971e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 379\n",
      "{'ner': 3.292738898889766e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 380\n",
      "{'ner': 3.0564413832472595e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 381\n",
      "{'ner': 1.439725940834752e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 382\n",
      "{'ner': 1.8439112557121417e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 383\n",
      "{'ner': 1.014726834821282e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 384\n",
      "{'ner': 3.0139515923413114e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 385\n",
      "{'ner': 1.4704479554719454e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 386\n",
      "{'ner': 1.8431599496584006e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 387\n",
      "{'ner': 6.424341267823759e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 388\n",
      "{'ner': 5.055097854543172e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 389\n",
      "{'ner': 3.454259054072317e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 390\n",
      "{'ner': 1.0651879696266945e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 391\n",
      "{'ner': 8.30234204353786e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 392\n",
      "{'ner': 4.463206577440263e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 393\n",
      "{'ner': 2.7140064499833925e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 394\n",
      "{'ner': 2.6003394497248257e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 395\n",
      "{'ner': 2.3361025183649107e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 396\n",
      "{'ner': 2.9224045894932733e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 397\n",
      "{'ner': 4.148065640700784e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 398\n",
      "{'ner': 3.808220577044558e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 399\n",
      "{'ner': 7.73498231874494e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 400\n",
      "{'ner': 6.493465814460653e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 401\n",
      "{'ner': 6.094478736097933e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 402\n",
      "{'ner': 2.278902268978893e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 403\n",
      "{'ner': 2.6599637454866285e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 404\n",
      "{'ner': 1.1750179142982687e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 405\n",
      "{'ner': 5.401447224271533e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 406\n",
      "{'ner': 7.501996204531764e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 407\n",
      "{'ner': 1.7044074382135987e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 408\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 8.141724450361332e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 409\n",
      "{'ner': 2.6621745792187777e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 410\n",
      "{'ner': 3.873990259310749e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 411\n",
      "{'ner': 8.334152209262392e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 412\n",
      "{'ner': 9.962402633293423e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 413\n",
      "{'ner': 4.300140687723917e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 414\n",
      "{'ner': 5.071581355632502e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 415\n",
      "{'ner': 4.822010918986145e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 416\n",
      "{'ner': 1.056168699452282e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 417\n",
      "{'ner': 3.367330646195685e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 418\n",
      "{'ner': 2.566108171389545e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 419\n",
      "{'ner': 8.657154283236851e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 420\n",
      "{'ner': 9.145712133157389e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 421\n",
      "{'ner': 6.932608352277233e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 422\n",
      "{'ner': 2.8568706168918113e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 423\n",
      "{'ner': 2.9991866417617504e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 424\n",
      "{'ner': 2.6507489949243884e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 425\n",
      "{'ner': 3.081265413038497e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 426\n",
      "{'ner': 1.484068931238835e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 427\n",
      "{'ner': 8.647867722086127e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 428\n",
      "{'ner': 6.897864642833937e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 429\n",
      "{'ner': 3.9862048742191086e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 430\n",
      "{'ner': 1.8392811938237036e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 431\n",
      "{'ner': 1.0580056354230319e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 432\n",
      "{'ner': 2.2450633284878325e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 433\n",
      "{'ner': 6.133933663469545e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 434\n",
      "{'ner': 1.1713081149848527e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 435\n",
      "{'ner': 3.0268400608785366e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 436\n",
      "{'ner': 2.827529977894341e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 437\n",
      "{'ner': 5.164807786610267e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 438\n",
      "{'ner': 1.1055497179676599e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 439\n",
      "{'ner': 6.4850838112021225e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 440\n",
      "{'ner': 3.1854486374108487e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 441\n",
      "{'ner': 4.213628642135887e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 442\n",
      "{'ner': 2.8284760306919062e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 443\n",
      "{'ner': 2.342506934880497e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 444\n",
      "{'ner': 3.517521195154497e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 445\n",
      "{'ner': 2.6173905503108962e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 446\n",
      "{'ner': 4.1841364547612626e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 447\n",
      "{'ner': 1.291924172419031e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 448\n",
      "{'ner': 1.363178361225242e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 449\n",
      "{'ner': 4.876539135825604e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 450\n",
      "{'ner': 1.0613497249003131e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 451\n",
      "{'ner': 2.5259431628199208e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 452\n",
      "{'ner': 6.244334121975178e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 453\n",
      "{'ner': 1.2320631351792982e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 454\n",
      "{'ner': 1.5164688425721018e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 455\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 7.980021698143363e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 456\n",
      "{'ner': 1.9934017313493228e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 457\n",
      "{'ner': 2.260750789382869e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 458\n",
      "{'ner': 3.6526050089463716e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 459\n",
      "{'ner': 2.6024236785362956e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 460\n",
      "{'ner': 6.791635212897415e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 461\n",
      "{'ner': 1.1394312555273371e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 462\n",
      "{'ner': 2.8028664503696305e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 463\n",
      "{'ner': 1.3597145731333292e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 464\n",
      "{'ner': 1.0557550125679859e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 465\n",
      "{'ner': 1.5439591500073587e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 466\n",
      "{'ner': 1.467575889218861e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 467\n",
      "{'ner': 3.776516521149887e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 468\n",
      "{'ner': 2.406833587534028e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 469\n",
      "{'ner': 5.3243290132629895e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 470\n",
      "{'ner': 6.51174065946681e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 471\n",
      "{'ner': 3.1780836607509088e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 472\n",
      "{'ner': 3.3369657986628115e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 473\n",
      "{'ner': 5.915050256440598e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 474\n",
      "{'ner': 4.85351759745419e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 475\n",
      "{'ner': 5.462990235361701e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 476\n",
      "{'ner': 4.170331141984339e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 477\n",
      "{'ner': 4.69557683727162e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 478\n",
      "{'ner': 4.664799531482134e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 479\n",
      "{'ner': 9.866084122727179e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 480\n",
      "{'ner': 1.2038652713391864e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 481\n",
      "{'ner': 6.703123699526241e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 482\n",
      "{'ner': 1.4484297304270534e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 483\n",
      "{'ner': 5.029771452963476e-12}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 484\n",
      "{'ner': 4.553330513154842e-10}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 485\n",
      "{'ner': 2.549534915647483e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 486\n",
      "{'ner': 3.308013457965453e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 487\n",
      "{'ner': 2.084566079771615e-09}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 488\n",
      "{'ner': 2.053214409481128e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 489\n",
      "{'ner': 1.969629202063679e-11}\n",
      "Entities= ['600_Dosage', 'mg/day_Dosage']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 490\n",
      "{'ner': 0.29054811654229534}\n",
      "Entities= ['one_Frequency', 'form_Frequency', 'of_Frequency', 'disease_Frequency', 'that_Frequency', 'treated_Frequency', 'with_Frequency', 'this_Frequency', 'Nubeqa_Frequency', 'drug._Frequency', 'people_Frequency', 'take_Frequency', '600_Frequency', 'mg/day_Dosage', 'dosage._Frequency', 'are_Frequency', 'asthenia_Frequency', 'and_Frequency', 'back_Frequency', 'pain._Frequency']\n",
      "Entities= ['(1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL/lb)_Dosage']\n",
      "Entities= ['(1.8_Dosage', 'to_Dosage', '3_Dosage', 'mg/kg)_Dosage']\n",
      "Statring iteration 491\n",
      "{'ner': 73.86917600294872}\n",
      "Entities= ['Nubeqa_Dosage', 'is an_Dosage', 'helps_Dosage', 'in_Dosage', '-_Dosage', 'metastatic_Dosage', 'castration_Dosage', '-_Dosage', 'resistant_Dosage', 'prostate_Dosage', 'cancer_Dosage', '._Dosage', 'Prostate_Dosage', 'cancer_Dosage', 'is_Dosage', 'one_Dosage', 'form_Dosage', 'that_Dosage', 'is_Dosage', 'treated_Dosage', 'with_Dosage', 'this_Dosage', 'Nubeqa_Dosage', 'drug_Dosage', 'Usually_Dosage', 'people_Dosage', 'take_Dosage', '600_Dosage', 'day dosage_Frequency']\n",
      "Entities= ['The_Dosage', 'this_Dosage', 'injection_Dosage', 'is_Dosage', '(_Dosage', '1.2_Dosage', 'to_Dosage', '3_Dosage', 'mL_Dosage', '/lb)_Dosage', 'of body_Dosage']\n",
      "Entities= ['The_Dosage', 'tablet_Dosage', 'is_Dosage', '(_Dosage', '1.8_Dosage', 'to_Dosage', '3_Dosage', 'kg)_Strength']\n",
      "Statring iteration 492\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'ner': 131.63481439695175}\n",
      "Entities= ['600_Dosage', 'mg/day dosage. Usual side effects are fatigue asthenia and back pain._Dosage']\n",
      "Entities= []\n",
      "Entities= ['3_Dosage']\n",
      "Statring iteration 493\n",
      "{'ner': 141.32835415891478}\n",
      "Entities= []\n",
      "Entities= []\n",
      "Entities= []\n",
      "Statring iteration 494\n",
      "{'ner': 166.80757874798059}\n",
      "Entities= ['non_Dosage', 'take_Dosage', 'day_Dosage']\n",
      "Entities= ['1.2_Dosage', 'to_Dosage']\n",
      "Entities= ['(_Dosage', 'to_Dosage']\n",
      "Statring iteration 495\n",
      "{'ner': 92.15172453818792}\n",
      "Entities= ['mg/day dosage. Usual side effects are fatigue asthenia and back pain._Dosage']\n",
      "Entities= []\n",
      "Entities= []\n",
      "Statring iteration 496\n",
      "{'ner': 68.98415987260424}\n",
      "Entities= ['mg/day dosage._Dosage', 'pain._Frequency']\n",
      "Entities= ['(1.2_Dosage', 'to 3_Dosage', 'weight._Frequency']\n",
      "Entities= ['(1.8_Dosage', 'to 3_Dosage', 'mg/kg) of_Dosage', 'weight._Frequency']\n",
      "Statring iteration 497\n",
      "{'ner': 45.159398258155896}\n",
      "Entities= []\n",
      "Entities= []\n",
      "Entities= ['(1.8_Dosage']\n",
      "Statring iteration 498\n",
      "{'ner': 34.27794196772642}\n",
      "Entities= []\n",
      "Entities= []\n",
      "Entities= []\n",
      "Statring iteration 499\n",
      "{'ner': 12.547353425435062}\n",
      "Entities= []\n",
      "Entities= ['(1.2_Dosage', 'lb)_Frequency']\n",
      "Entities= ['(1.8_Dosage', 'to 3_Dosage', 'kg)_Dosage']\n"
     ]
    }
   ],
   "source": [
    "with nlp.disable_pipes(*other_pipes):\n",
    "    optimizer = nlp.begin_training()\n",
    "    for itn in range(500):\n",
    "        print(\"Statring iteration \" + str(itn))\n",
    "        random.shuffle(TRAIN_DATA)\n",
    "        losses = {}\n",
    "        for text, annotations in TRAIN_DATA:\n",
    "            nlp.update(\n",
    "                [text],  # batch of texts\n",
    "                [annotations],  # batch of annotations\n",
    "                drop=0.1,  # dropout - make it harder to memorise data\n",
    "                sgd=optimizer,  # callable to update weights\n",
    "                losses=losses)\n",
    "        print(losses)\n",
    "\n",
    "        doc = nlp(\"Nubeqa is an androgen inhibitor drug that helps in non-metastatic castration-resistant prostate cancer. Prostate cancer is also one form of disease that is treated with this Nubeqa drug. Usually people take 600 mg/day dosage. Usual side effects are fatigue asthenia and back pain.\")\n",
    "        print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))\n",
    "        doc = nlp(\"The usual dosage of this injection is (1.2 to 3 mL/lb) of body weight.\")\n",
    "        print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))\n",
    "        doc = nlp(\"The dosage of nicotin tablet is (1.8 to 3 mg/kg) of body weight.\")\n",
    "        print(\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))\n",
    "        \n",
    "#     nlp.save('model.h5')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Serializing the built model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "# One method - **Not used right now**\n",
    "bytes_data = nlp.to_bytes()\n",
    "lang = nlp.meta[\"lang\"]  # \"en\"\n",
    "pipeline = nlp.meta[\"pipeline\"]  # [\"tagger\", \"parser\", \"ner\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "# write to the disk\n",
    "nlp.to_disk('./current_spacy_drugmodel_multi-letters_v2')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load the model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "loaded_nlp = spacy.load(\"./current_spacy_drugmodel_multi-letters_v2\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Test the model with a test document"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['2.5_Dosage', 'to_Dosage', '5_Dosage', 'mg/kg)._Dosage']\n"
     ]
    }
   ],
   "source": [
    "doc = loaded_nlp(\"The usual dose of Furosemide Syrup 1 % is 1 to 2 mg/lb body weight (approximately 2.5 to 5 mg/kg).\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['0.25_Dosage', 'to_Dosage', '0.50_Dosage', 'mL_Dosage', 'per_Dosage', '10_Dosage', 'pounds_Dosage', 'body_Dosage', 'weight_Dosage', 'once_Frequency', 'or_Frequency', 'twice_Frequency', 'daily_Frequency']\n"
     ]
    }
   ],
   "source": [
    "doc2 = loaded_nlp(\"Dogs—Administer intravenously or intramuscularly 0.25 to 0.50 mL per 10 pounds body weight once or twice daily at 6 to 8 hour intervals.\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc2.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['twice_Frequency', 'a_Frequency', 'day._Frequency']\n"
     ]
    }
   ],
   "source": [
    "doc3 = loaded_nlp(\"The dosage of some drug is 10 mg/kg twice a day.\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc3.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['mg,_Strength', '125_Strength', 'mg._Strength']\n"
     ]
    }
   ],
   "source": [
    "doc4 = loaded_nlp(\"The strengths of some drug are 100 mg, 125 mg.\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc4.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "Steps Database\n",
    "- Train more with more samples [Optional]\n",
    "- Take the XML\n",
    "- Convert them into JSON\n",
    "- Pass the text of Dosage & Administration Section into this NER model\n",
    "- Extract the entities (Dosage, Frequency, Strength, and so on)\n",
    "- Repeat this for all XML files (3000+)\n",
    "\n",
    "Clean Steps\n",
    "- Clean the database\n",
    "\n",
    "API Steps\n",
    "- Wrap it around the database\n",
    "- Provide the data in a JSON format\n",
    "\n",
    "Deploy Steps\n",
    "- GCP\n",
    "- Test endpoints"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Testing other Vitrakvi documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc = loaded_nlp(\"\"\"Pharmacokinetics of VITRAKVI® (larotrectinib)\n",
    "\n",
    "FDA Approved Indication \n",
    "VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: \n",
    "have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,\n",
    "are metastatic or where surgical resection is likely to result in severe morbidity, and\n",
    "have no satisfactory alternative treatments or that have progressed following treatment.\n",
    "This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.\n",
    "\n",
    "Summary1\n",
    "The pharmacokinetics of larotrectinib were studied in healthy subjects and adult and pediatric patients with locally advanced or metastatic solid tumors.\n",
    "In adult patients who received VITRAKVI capsules 100 mg twice daily in Study LOXO-TRK-14001, peak plasma levels (Cmax) of larotrectinib were achieved at approximately 1 hour after dosing and steady state was reached within 3 days. \n",
    "The mean absolute bioavailability of VITRAKVI capsules was 34% (range: 32% to 37%). In healthy subjects, the AUC of VITRAKVI oral solution was similar to that of the capsules and the Cmax was 36% higher with the oral solution.\n",
    "Larotrectinib is metabolized predominantly by CYP3A4.\n",
    "Following oral administration of a single [14C] radiolabeled 100 mg dose of larotrectinib to healthy subjects, 58% (5% unchanged) of the administered radioactivity was recovered in feces and 39% (20% unchanged) was recovered in urine. \n",
    "In healthy subjects who received a single dose of VITRAKVI capsules, systemic exposure (Cmax and AUC) of larotrectinib was dose proportional over the dose range of 100 mg to 400 mg (1 to 4 times the recommended adult dose) and slightly greater than proportional at doses of 600 mg to 900 mg (6 to 9 times the recommended adult dose).\n",
    "\n",
    "Prescribing Information1\n",
    "The pharmacokinetics of larotrectinib were studied in healthy subjects and adult and pediatric patients with locally advanced or metastatic solid tumors.\n",
    "In healthy subjects who received a single dose of VITRAKVI capsules, systemic exposure (Cmax and AUC) of larotrectinib was dose proportional over the dose range of 100 mg to 400 mg (1 to 4 times the recommended adult dose) and slightly greater than proportional at doses of 600 mg to 900 mg (6 to 9 times the recommended adult dose). In adult patients who received VITRAKVI capsules 100 mg twice daily in Study LOXO-TRK-14001, peak plasma levels (Cmax) of larotrectinib were achieved at approximately 1 hour after dosing and steady-state was reached within 3 days. Mean steady-state larotrectinib [coefficient of variation (CV%)] for Cmax was 788 (81%) ng/mL and AUC0-24hr was 4351 (97%) ng*h/mL.\n",
    "\n",
    "Absorption\n",
    "The mean absolute bioavailability of VITRAKVI capsules was 34% (range: 32% to 37%). In healthy subjects, the AUC of VITRAKVI oral solution was similar to that of the capsules and the Cmax was 36% higher with the oral solution.\n",
    "Effect of Food\n",
    "The AUC of larotrectinib was similar and the Cmax was reduced by 35% after oral administration of a single 100 mg capsule of VITRAKVI to healthy subjects taken with a high-fat meal (approximately 900 calories, 58 grams carbohydrate, 56 grams fat and 43 grams protein) compared to the Cmax and AUC in the fasted state.\n",
    "Distribution1\n",
    "The mean (CV%) volume of distribution (Vss) of larotrectinib is 48 (38%) L following intravenous administration of larotrectinib in healthy subjects. Larotrectinib is 70% bound to human plasma proteins in vitro and binding is independent of drug concentrations. The blood-to-plasma concentration ratio is 0.9.\n",
    "Elimination1\n",
    "The mean (CV%) clearance (CL/F) of larotrectinib is 98 (44%) L/h and the half-life is 2.9 hours following oral administration of VITRAKVI in healthy subjects. \n",
    "Metabolism\n",
    "Larotrectinib is metabolized predominantly by CYP3A4. Following oral administration of a single [14C] radiolabeled 100 mg dose of larotrectinib to healthy subjects, unchanged larotrectinib constituted 19% and an O-linked glucuronide constituted 26% of the major circulating radioactive drug components in plasma. \n",
    "Excretion\n",
    "Following oral administration of a single [14C] radiolabeled 100 mg dose of larotrectinib to healthy subjects, 58% (5% unchanged) of the administered radioactivity was recovered in feces and 39% (20% unchanged) was recovered in urine. \n",
    "Specific Populations1\n",
    "Age (range: 28 days to 82 years), sex, and body weight (range: 3.8 to 179 kg) had no clinically meaningful effect on the pharmacokinetics of larotrectinib. \n",
    "Pediatric Patients\n",
    "In pediatric patients, the larotrectinib geometric mean (%CV) AUC0-24hr by age subgroup was: 3348 (66%) ng*h/mL in patients 1 month to < 2 years (n = 9), 4135 (36%) ng*h/mL in patients 2 to < 12 years (n = 15), and 3108 (69%) ng*h/mL and in patients 12 to < 18 years (n = 9). \n",
    "Patients with Renal Impairment \n",
    "Following oral administration of a single 100 mg dose of VITRAKVI capsules in subjects with end-stage renal disease (e.g., subjects who required dialysis), the AUC0-inf of larotrectinib increased 1.5-fold and Cmax increased 1.3-fold as compared to that in subjects with normal renal function (creatinine clearance ≥ 90 mL/min as estimated by Cockcroft-Gault). The pharmacokinetics of VITRAKVI in patients with moderate to severe renal impairment (creatinine clearance ≤ 60 mL/min) have not been studied. \n",
    "\n",
    "Patients with Hepatic Impairment \n",
    "Following oral administration of a single 100 mg dose of VITRAKVI capsules, the AUC0-INF of larotrectinib increased 1.3-fold in subjects with mild hepatic impairment (Child-Pugh A), 2-fold in subjects with moderate hepatic impairment (Child-Pugh B) and 3.2-fold in subjects with severe hepatic impairment (Child-Pugh C) as compared to that in subjects with normal hepatic function. The Cmax was similar in subjects with mild and moderate hepatic impairment and the Cmax of larotrectinib increased 1.5-fold in subjects with severe hepatic impairment as compared to that in subjects with normal hepatic function.\n",
    "Drug Interaction Studies1\n",
    "Clinical Studies \n",
    "Effect of Strong CYP3A Inhibitors: Coadministration of a single 100 mg dose of VITRAKVI capsules with a strong CYP3A inhibitor (itraconazole) increased the AUC0-INF of larotrectinib by 4.3-fold and the Cmax by 2.8-fold as compared to VITRAKVI administered alone. The effects of CYP3A moderate and weak inhibitors on the pharmacokinetics of larotrectinib have not been studied. \n",
    "Effect of Strong CYP3A Inducers: Coadministration of a single 100 mg dose of VITRAKVI capsules with a strong CYP3A inducer (rifampin) decreased the AUC0-INF of larotrectinib by 81% and of Cmax by 71% as compared to VITRAKVI administered alone. The effects of CYP3A weak and moderate inducers on the pharmacokinetics of larotrectinib have not been studied. \n",
    "Effect of Strong P-glycoprotein (P-gp) Inhibitors: Coadministration of a single 100 mg dose of VITRAKVI capsules with a P-gp inhibitor (rifampin) increased the AUC0-INF of larotrectinib by 1.7-fold and the Cmax by 1.8-fold as compared to VITRAKVI administered alone. \n",
    "Effect of Larotrectinib on CYP3A4 Substrates: Coadministration of VITRAKVI capsules 100 mg twice daily with a sensitive CYP3A4 substrate (midazolam) increased both the AUC0-INF and Cmax of midazolam by 1.7-fold as compared to midazolam administered alone. The AUC0-INF and Cmax of 1-hydroxymidazolam, the main metabolite of midazolam, were both increased 1.4-fold as compared to when midazolam was administered alone.\n",
    "In Vitro Studies\n",
    "Effect of Transporter on Larotrectinib: Larotrectinib is a substrate for P-gp and BCRP. Larotrectinib is not a substrate of OAT1, OAT3, OCT1, OCT2, OATP1B1, or OATP1B3.\n",
    "Effect of Larotrectinib on Transporters: Larotrectinib is not an inhibitor of BCRP, P-gp, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, BSEP, MATE1 and MATE2-K at clinically relevant concentrations.\n",
    "Effect of Larotrectinib on CYP Substrates: Larotrectinib is not an inhibitor or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 at clinically relevant concentrations.\n",
    "\n",
    "\n",
    "Published Literature2-4\n",
    "\n",
    "Pharmacokinetics in Adults2,3 \n",
    "\n",
    "A Phase 1, multicenter, open-label, 3+3 dose-escalation and safety 1 study was conducted to evaluate the safety, maximum-tolerated dose, and pharmacokinetic parameters of larotrectinib in adults with advanced solid tumors. Larotrectinib was administered for a single day between 3 to 7 days before the start of Cycle 1, in which subjects received QD or BID doses for continuous 28-day cycles.2-3 Plasma concentrations were quantified by a validated LC-MS/MS assay after the single-day dose, and on days 1 and 8 of Cycle 1.3 Table 1 contains the pharmacokinetic parameters of larotrectinib at different dose levels. The concentration-time curve for days 1 and 8 of cycle 1 is shown in Figure 1.\n",
    "\n",
    "Figure 1a: The horizontal line representing TRKA IC50 refers to the total plasma concentration of larotrectinib that is associated with an unbound concentration of larotrectinib that is equal to its IC50 for inhibition of NGF-stimulated activity in a cellular assay. The TRKA IC90 is modeled from IC50 data. The IC50 and IC90 values for TRKB and TRKC are not shown, but are similar to those of TRKA.\n",
    "\n",
    "Figure 1b: AUC data with additional dose schedules. Dotted lines in the right panel are inferred pharmacokinetics from the evening BID dose\n",
    "\n",
    "Figure 1c: Cmax of larotrectinib. The horizontal line representing TRKA IC90 refers to the total plasma concentration of larotrectinib that is associated with an unbound concentration of larotrectinib that is equal to its IC90 for inhibition of NGF-stimulated activity in a cellular assay. The IC90 values for TRKB and TRKC are not shown, but are similar to those of TRKA. \n",
    "\n",
    "Pharmacokinetics in Pediatric Patients4 \n",
    "\n",
    "A multicenter, open-label Phase 1/2 study was conducted to evaluate the safety including dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics and efficacy of oral larotrectinib in pediatric patients.4  \n",
    "\n",
    "The larotrectinib AUC and Cmax increased proportionally with dose per body surface area (BSA). There was no apparent difference in Cmax or AUC in patients treated with capsule versus liquid formulation or among different pediatric age groups. The concentration-time curve for adults with 100mg BID and pediatric with capsule and liquid formulation (100mg/m2 BID, maximum 100mg per dose) is shown in Figure 3.  Figure 4 shows AUC data by age groups.4 \n",
    "\n",
    "Figure 2: Concentration-Time Curve (Adults vs. Pediatric)\n",
    "\n",
    "Figure 3: AUC data by Age Groups\n",
    "\n",
    "\"\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/subashgandyer/anaconda3/lib/python3.7/runpy.py:193: UserWarning: [W011] It looks like you're calling displacy.serve from within a Jupyter notebook or a similar environment. This likely means you're already running a local web server, so there's no need to make displaCy start another one. Instead, you should be able to replace displacy.serve with displacy.render to show the visualization.\n",
      "  \"__main__\", mod_spec)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "<html lang=\"en\">\n",
       "    <head>\n",
       "        <title>displaCy</title>\n",
       "    </head>\n",
       "\n",
       "    <body style=\"font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr\">\n",
       "<figure style=\"margin-bottom: 6rem\">\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "® (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ")</br></br>FDA Approved Indication </br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of adult and pediatric patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    solid tumors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " that: </br>have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,</br>are metastatic or where surgical resection is likely to result in severe morbidity, and</br>have no satisfactory alternative treatments or that have progressed following treatment.</br>This \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indication\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indication\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " may be contingent upon verification and description of clinical benefit in confirmatory trials.</br></br>Summary1</br>The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " were studied in healthy subjects and adult and pediatric patients with locally advanced or metastatic \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    solid tumors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ".</br>In adult patients who received \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " twice daily in Study LOXO-TRK-14001, \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    peak plasma levels\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       ") of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " were achieved at approximately 1 hour after \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dosing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and steady state was reached within 3 days. </br>The mean absolute \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " was 34% (range: 32% to 37%). In healthy subjects, the \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    oral solution\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " was similar to that of the \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " and the \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " was 36% higher with the \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    oral solution\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       ".</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is metabolized predominantly by CYP3A4.</br>Following oral \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of a single [14C] radiolabeled \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " to healthy subjects, 58% (5% unchanged) of the \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administered\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " radioactivity was recovered in feces and 39% (20% unchanged) was recovered in urine. </br>In healthy subjects who received a single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       ", systemic exposure (\n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " was \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " proportional over the dose range of \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (1 to 4 times the recommended adult \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") and slightly greater than proportional at doses of \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    600 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " to 900 mg (6 to 9 times the recommended adult \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ").</br></br>Prescribing Information1</br>The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " were studied in healthy subjects and adult and pediatric patients with locally advanced or metastatic \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    solid tumors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ".</br>In healthy subjects who received a single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       ", systemic exposure (\n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " was \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " proportional over the dose range of \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (1 to 4 times the recommended adult \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") and slightly greater than proportional at doses of \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    600 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    900 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (6 to 9 times the recommended adult \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "). In adult patients who received \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " twice daily in Study LOXO-TRK-14001, \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    peak plasma levels\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       ") of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " were achieved at approximately 1 hour after \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dosing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and steady-state was reached within 3 days. Mean steady-state \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " [coefficient of variation (CV%)] for \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " was 788 (81%) ng/mL and AUC0-24hr was 4351 (97%) ng*h/mL.</br></br>Absorption</br>The mean absolute bioavailability of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " was 34% (range: 32% to 37%). In healthy subjects, the \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    oral solution\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " was similar to that of the \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " and the \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " was 36% higher with the \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    oral solution\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       ".</br>Effect of Food</br>The \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " was similar and the \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " was reduced by 35% after oral \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of a single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsule\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " to healthy subjects taken with a high-fat meal (approximately 900 calories, 58 grams carbohydrate, 56 grams fat and 43 grams protein) compared to the \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " in the fasted state.</br>Distribution1</br>The mean (CV%) volume of distribution (Vss) of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is 48 (38%) L following intravenous \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in healthy subjects. \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is 70% bound to human plasma proteins in vitro and binding is independent of drug concentrations. The blood-to-plasma concentration ratio is 0.9.</br>Elimination1</br>The mean (CV%) clearance (CL/F) of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is 98 (44%) L/h and the half-life is 2.9 hours following oral \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in healthy subjects. </br>Metabolism</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is metabolized predominantly by CYP3A4. Following oral \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of a single [14C] radiolabeled \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " to healthy subjects, unchanged \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " constituted 19% and an O-linked glucuronide constituted 26% of the major circulating radioactive drug components in plasma. </br>Excretion</br>Following oral \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of a single [14C] radiolabeled \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " to healthy subjects, 58% (5% unchanged) of the \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administered\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " radioactivity was recovered in feces and 39% (20% unchanged) was recovered in urine. </br>Specific Populations1</br>Age (range: 28 days to 82 years), sex, and body weight (range: 3.8 to 179 kg) had no clinically meaningful effect on the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ". </br>Pediatric Patients</br>In pediatric patients, the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " geometric mean (%CV) AUC0-24hr by age subgroup was: 3348 (66%) ng*h/mL in patients 1 month to &lt; 2 years (n = 9), 4135 (36%) ng*h/mL in patients 2 to &lt; 12 years (n = 15), and 3108 (69%) ng*h/mL and in patients 12 to &lt; 18 years (n = 9). </br>Patients with Renal Impairment </br>Following oral \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of a single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " in subjects with end-stage renal disease (e.g., subjects who required dialysis), the AUC0-inf of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " increased 1.5-fold and \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " increased 1.3-fold as compared to that in subjects with normal renal function (creatinine clearance ≥ 90 mL/min as estimated by Cockcroft-Gault). The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in patients with moderate to severe renal impairment (creatinine clearance ≤ 60 mL/min) have not been studied. </br></br>Patients with Hepatic Impairment </br>Following oral \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of a single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       ", the AUC0-INF of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " increased 1.3-fold in subjects with mild hepatic impairment (Child-Pugh A), 2-fold in subjects with moderate hepatic impairment (Child-Pugh B) and 3.2-fold in subjects with severe hepatic impairment (Child-Pugh C) as compared to that in subjects with normal hepatic function. The \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " was similar in subjects with mild and moderate hepatic impairment and the \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " increased 1.5-fold in subjects with severe hepatic impairment as compared to that in subjects with normal hepatic function.</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Drug Interaction\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Studies1</br>Clinical Studies </br>Effect of Strong CYP3A Inhibitors: Coadministration of a single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " with a strong CYP3A inhibitor (itraconazole) increased the AUC0-INF of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " by 4.3-fold and the \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " by 2.8-fold as compared to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administered\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " alone. The effects of CYP3A moderate and weak inhibitors on the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " have not been studied. </br>Effect of Strong CYP3A Inducers: Coadministration of a single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " with a strong CYP3A inducer (rifampin) decreased the AUC0-INF of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " by 81% and of \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " by 71% as compared to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administered\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " alone. The effects of CYP3A weak and moderate inducers on the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " have not been studied. </br>Effect of Strong P-glycoprotein (P-gp) Inhibitors: Coadministration of a single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " with a P-gp inhibitor (rifampin) increased the AUC0-INF of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " by 1.7-fold and the \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " by 1.8-fold as compared to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administered\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " alone. </br>Effect of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " on CYP3A4 Substrates: Coadministration of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    VITRAKVI\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsules\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " twice daily with a sensitive CYP3A4 substrate (midazolam) increased both the AUC0-INF and \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    midazolam\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " by 1.7-fold as compared to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    midazolam\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administered\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " alone. The AUC0-INF and \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " of 1-hydroxymidazolam, the main metabolite of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    midazolam\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", were both increased 1.4-fold as compared to when \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    midazolam\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " was \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administered\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " alone.</br>In Vitro Studies</br>Effect of Transporter on \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ": \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is a substrate for P-gp and BCRP. \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is not a substrate of OAT1, OAT3, OCT1, OCT2, OATP1B1, or OATP1B3.</br>Effect of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " on Transporters: \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is not an inhibitor of BCRP, P-gp, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, BSEP, MATE1 and MATE2-K at clinically relevant concentrations.</br>Effect of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " on CYP Substrates: \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is not an inhibitor or inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 at clinically relevant concentrations.</br></br></br>Published Literature2-4</br></br>\n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " in Adults2,3 </br></br>A Phase 1, multicenter, open-label, 3+3 \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "-escalation and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " 1 study was conducted to evaluate the safety, maximum-tolerated \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", and pharmacokinetic parameters of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in adults with advanced \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    solid tumors\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ". \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " was administered for a single day between 3 to 7 days before the start of Cycle 1, in which subjects received QD or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    BID\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " doses for continuous 28-day cycles.2-3 Plasma concentrations were quantified by a validated LC-MS/MS assay after the single-day \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", and on days 1 and 8 of Cycle 1.3 Table 1 contains the pharmacokinetic parameters of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " at different \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " levels. The concentration-time curve for days 1 and 8 of cycle 1 is shown in Figure 1.</br></br>Figure 1a: The horizontal line representing TRKA IC50 refers to the total \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " that is associated with an unbound concentration of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " that is equal to its IC50 for inhibition of NGF-stimulated activity in a cellular assay. The TRKA IC90 is modeled from IC50 data. The IC50 and IC90 values for TRKB and TRKC are not shown, but are similar to those of TRKA.</br></br>Figure 1b: \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " data with additional \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " schedules. Dotted lines in the right panel are inferred \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " from the evening \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    BID\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br></br>Figure 1c: \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ". The horizontal line representing TRKA IC90 refers to the total plasma concentration of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " that is associated with an unbound concentration of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " that is equal to its IC90 for inhibition of NGF-stimulated activity in a cellular assay. The IC90 values for TRKB and TRKC are not shown, but are similar to those of TRKA. </br></br>\n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " in Pediatric Patients4 </br></br>A multicenter, open-label Phase 1/2 study was conducted to evaluate the \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " including dose-limiting toxicities (DLT), maximum tolerated \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (MTD), \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #d9ffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    efficacy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Efficacy</span>\n",
       "</mark>\n",
       " of oral \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in pediatric patients.4  </br></br>The \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    larotrectinib\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " increased proportionally with \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " per body surface area (BSA). There was no apparent difference in \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Cmax\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " in patients treated with \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsule\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " versus \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    liquid formulation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " or among different pediatric age groups. The concentration-time curve for adults with \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    BID\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and pediatric with \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsule\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    liquid formulation\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "/m2 \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    BID\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", maximum \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " per \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") is shown in Figure 3.  Figure 4 shows \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " data by age groups.4 </br></br>Figure 2: Concentration-Time Curve (Adults vs. Pediatric)</br></br>Figure 3: \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " data by Age Groups\n",
       "\n",
       "</div>\n",
       "</figure>\n",
       "</body>\n",
       "</html>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Using the 'ent' visualizer\n",
      "Serving on http://0.0.0.0:5000 ...\n",
      "\n",
      "Shutting down server on port 5000.\n"
     ]
    }
   ],
   "source": [
    "colors = {\"DRUG\":\"#ff9ff0\",\n",
    "         \"DISEASE\": \"turquoise\",\n",
    "         \"ADVERSE EVENT\": \"tomato\",\n",
    "         \"CONDITION\": \"lavender\",\n",
    "         \"DOSAGE\": \"#ffa500\",\n",
    "         \"INDICATION\": \"#ffe6ff\",\n",
    "         \"PHARMACOKINETICS\": \"#b3b3cc\",\n",
    "         \"DOSING\": \"#ffd9b3\",\n",
    "         \"EFFICACY\": \"#d9ffb3\",\n",
    "         \"CONTRAINDICATIONS\": \"#ffa366\",\n",
    "         \"SAFETY\": \"#80ff80\",\n",
    "         \"DRUG INTERACTION\": \"#b3d9ff\",\n",
    "         \"FOOD INTERACTION\": \"#3399ff\",\n",
    "         \"BIOAVAILABILITY\": \"#ff9900\",\n",
    "         \"ABSORPTION\": \"#ccccb3\",\n",
    "         \"AUC\": \"#00ff55\",\n",
    "         \"CMAX\": \"#ff531a\",\n",
    "         \"MFS\": \"#d966ff\",\n",
    "         \"OS\": \"#5c5cd6\",\n",
    "         \"TTPP\": \"#0088cc\",\n",
    "         \"PFS\": \"#ffcccc\",\n",
    "         \"QOL\": \"#cc00cc\",\n",
    "         \"OBJECTIVE\": \"#ffffb3\",\n",
    "         \"PLASMA CONCENTRATION\": \"#ffff1a\",\n",
    "         \"DOSAGE FORM\": \"#f2f2f2\",\n",
    "         \"TMAX\": \"#b3ffff\",\n",
    "         \"ENDPOINT\": \"#ccddff\",\n",
    "         \"DISCONTINUATION\": \"#ccffcc\",\n",
    "         \"DEATH\": \"#ccffe6\",\n",
    "         \"ADMINISTRATION\": \"#ff4da6\"}\n",
    "options = {\"ents\": [\"DRUG\", \"DISEASE\", \"ADVERSE EVENT\", \"CONDITION\", \"DOSAGE\", \"INDICATION\", \"PHARMACOKINETICS\", \"DOSING\", \"EFFICACY\", \"CONTRAINDICATIONS\", \"SAFETY\", \"DRUG INTERACTION\", \"FOOD INTERACTION\", \"BIOAVAILABILITY\", \"ABSORPTION\", \"AUC\", \"CMAX\", \"MFS\", \"OS\", \"TTPP\", \"PFS\", \"QOL\", \"OBJECTIVE\", \"PLASMA CONCENTRATION\", \"DOSAGE FORM\", \"TMAX\", \"ENDPOINT\", \"DISCONTINUATION\", \"DEATH\", \"ADMINISTRATION\"], \"colors\": colors}\n",
    "displacy.serve(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Testing the built NER model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['Nubeqa_Drug', 'non-metastatic castration-resistant prostate cancer_Disease', 'Nubeqa_Drug', '600 mg/day_Dosage', 'asthenia_Drug', 'back_Condition']\n"
     ]
    }
   ],
   "source": [
    "doc = nlp(\"Nubeqa is an androgen inhibitor drug that helps in non-metastatic castration-resistant prostate cancer. Prostate cancer is also one form of disease that is treated with this Nubeqa drug. Usually people take 600 mg/day dosage. Usual side effects are fatigue asthenia and back pain.\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is an androgen inhibitor drug that helps in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". Prostate cancer is also one form of disease that is treated with this \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " drug. Usually people take \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    600 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " dosage. Usual side effects are fatigue \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " pain.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, jupyter=True, style='ent')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['Nubeqa_Drug', 'non-metastatic castration-resistant prostate cancer_Disease', '600 mg/day_Dosage', 'fatigue_Adverse Event', 'back_Condition']\n"
     ]
    }
   ],
   "source": [
    "doc = nlp(\"Nubeqa is an androgen inhibitor drug that helps in non-metastatic castration-resistant prostate cancer. Usually people take 600 mg/day dosage. Usual side effects are fatigue and back pain.\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is an androgen inhibitor drug that helps in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". Usually people take \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    600 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " dosage. Usual side effects are \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " pain.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, jupyter=True, style='ent')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['Nubeqa_Drug', '600 mg/day_Dosage', 'back_Adverse Event']\n"
     ]
    }
   ],
   "source": [
    "doc = nlp(\"Nubeqa helps in castration-resistant prostate cancer. It is to be administered as a 600 mg/day dosage. Usually fatigue and back pain are the side effects for this drug.\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " helps in castration-resistant prostate cancer. It is to be administered as a \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    600 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " dosage. Usually fatigue and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " pain are the side effects for this drug.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, jupyter=True, style='ent')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['Nubeqa_Drug']\n"
     ]
    }
   ],
   "source": [
    "doc = nlp(\"Nubeqa\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, jupyter=True, style='ent')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['non-metastatic castration-resistant prostate cancer_Disease']\n"
     ]
    }
   ],
   "source": [
    "doc = nlp(\"non-metastatic castration-resistant prostate cancer\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       "</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, jupyter=True, style='ent')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['600 mg_Strength', 'day_Condition']\n"
     ]
    }
   ],
   "source": [
    "doc = nlp(\"600 mg/day dosage.\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    600 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Strength</span>\n",
       "</mark>\n",
       "/\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " dosage.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, jupyter=True, style='ent')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['fatigue_Adverse Event', 'back_Adverse Event']\n"
     ]
    }
   ],
   "source": [
    "doc = nlp(\"fatigue and back pain are the side effects for this drug.\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " pain are the side effects for this drug.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, jupyter=True, style='ent')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "#### Wrapping all above steps into a python script"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def train_spacy(TRAIN_DATA):\n",
    "    # TRAIN_DATA = convert_dataturks_to_spacy(filename);\n",
    "    # TRAIN_DATA = convert_dataturks_to_spacy(data)\n",
    "    nlp = spacy.blank('en')  # create blank Language class\n",
    "    # create the built-in pipeline components and add them to the pipeline\n",
    "    # nlp.create_pipe works for built-ins that are registered with spaCy\n",
    "    if 'ner' not in nlp.pipe_names:\n",
    "        ner = nlp.create_pipe('ner')\n",
    "        nlp.add_pipe(ner, last=True)\n",
    "\n",
    "    # add labels\n",
    "    for _, annotations in TRAIN_DATA:\n",
    "        for ent in annotations.get('entities'):\n",
    "            ner.add_label(ent[2])\n",
    "\n",
    "    # get names of other pipes to disable them during training\n",
    "    other_pipes = [pipe for pipe in nlp.pipe_names if pipe != 'ner']\n",
    "    with nlp.disable_pipes(*other_pipes):  # only train NER\n",
    "        optimizer = nlp.begin_training()\n",
    "        for itn in range(1000):\n",
    "            print(\"Statring iteration \" + str(itn))\n",
    "            random.shuffle(TRAIN_DATA)\n",
    "            losses = {}\n",
    "            for text, annotations in TRAIN_DATA:\n",
    "                nlp.update(\n",
    "                    [text],  # batch of texts\n",
    "                    [annotations],  # batch of annotations\n",
    "                    drop=0.1,  # dropout - make it harder to memorise data\n",
    "                    sgd=optimizer,  # callable to update weights\n",
    "                    losses=losses)\n",
    "            print(losses)\n",
    "\n",
    "            doc = nlp(\"Nubeqa is an androgen inhibitor drug that helps in non-metastatic castration-resistant prostate cancer. Prostate cancer is also one form of disease that is treated with this Nubeqa drug. Usually people take 600 mg/day dosage. Usual side effects are fatigue asthenia and back pain.\")\n",
    "            print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))\n",
    "            doc = nlp(\"Nubeqa is an androgen inhibitor drug that helps in non-metastatic castration-resistant prostate cancer. Usually people take 600 mg/day dosage. Usual side effects are fatigue and back pain.\")\n",
    "            print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))\n",
    "\n",
    "    \n",
    "    #do prediction\n",
    "    doc = nlp(\"Nubeqa is an androgen inhibitor drug that helps in non-metastatic castration-resistant prostate cancer. Prostate cancer is also one form of disease that is treated with this Nubeqa drug. Usually people take 600 mg/day dosage. Usual side effects are fatigue asthenia and back pain.\")\n",
    "    print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))\n",
    "\n",
    "    doc = nlp(\"Nubeqa is an androgen inhibitor drug that helps in non-metastatic castration-resistant prostate cancer. Usually people take 600 mg/day dosage. Usual side effects are fatigue and back pain.\")\n",
    "    print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "training_data = convert_dataturks_to_spacy(data)\n",
    "training_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "train_spacy(training_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Entity Extraction Demo from Saved Trained Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [],
   "source": [
    "import spacy\n",
    "from spacy import displacy\n",
    "import random\n",
    "import json\n",
    "import logging"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [],
   "source": [
    "# loaded_nlp = spacy.load(\"./current_spacy_model\")\n",
    "loaded_nlp = spacy.load(\"./current_spacy_model_multi-letters\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Entities= ['Nubeqa_Drug', 'androgen inhibitor_Drug', 'non-metastatic castration-resistant prostate cancer_Condition', 'Nubeqa_Drug', '600 mg_Strength', 'fatigue_Adverse Event', 'asthenia_Adverse Event', 'back pain_Adverse Event']\n"
     ]
    }
   ],
   "source": [
    "doc = loaded_nlp(\"Nubeqa is an androgen inhibitor drug that helps in non-metastatic castration-resistant prostate cancer. Prostate cancer is also one form of disease that is treated with this Nubeqa drug. Usually people take 600 mg/day dosage. Usual side effects are fatigue asthenia and back pain.\")\n",
    "print (\"Entities= \" + str([\"\" + str(ent.text) + \"_\" + str(ent.label_) for ent in doc.ents]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/subashgandyer/anaconda3/lib/python3.7/runpy.py:193: UserWarning: [W011] It looks like you're calling displacy.serve from within a Jupyter notebook or a similar environment. This likely means you're already running a local web server, so there's no need to make displaCy start another one. Instead, you should be able to replace displacy.serve with displacy.render to show the visualization.\n",
      "  \"__main__\", mod_spec)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "<html lang=\"en\">\n",
       "    <head>\n",
       "        <title>displaCy</title>\n",
       "    </head>\n",
       "\n",
       "    <body style=\"font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr\">\n",
       "<figure style=\"margin-bottom: 6rem\">\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " drug that helps in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ". Prostate cancer is also one form of disease that is treated with this \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " drug. Usually people take 600 mg/day dosage. Usual side effects are \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ".</div>\n",
       "</figure>\n",
       "</body>\n",
       "</html>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Using the 'ent' visualizer\n",
      "Serving on http://0.0.0.0:5000 ...\n",
      "\n",
      "Shutting down server on port 5000.\n"
     ]
    }
   ],
   "source": [
    "colors = {\"DRUG1\": \"linear-gradient(90deg, #aa9cfc, #fc9ce7)\",\n",
    "          \"DRUG\":\"#ff9ff0\",\n",
    "         \"DISEASE\": \"turquoise\",\n",
    "         \"ADVERSE EVENT\": \"tomato\",\n",
    "         \"CONDITION\": \"lavender\",\n",
    "         \"DOSAGE\": \"#ffa500\"}\n",
    "options = {\"ents\": [\"DRUG\", \"DISEASE\", \"ADVERSE EVENT\", \"CONDITION\", \"DOSAGE\"], \"colors\": colors}\n",
    "displacy.serve(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Testing other out of sample documents"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Document 1 - Nubeqa (US-NUBEQA-76043-S.docx-3.pdf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc = loaded_nlp(\"\"\"Clinical Data on NUBEQA®   (darolutamide) in Patients with Progressive Metastatic Castrate Resistant Prostate Cancer\n",
    "Summary:\n",
    "● Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.1 \n",
    "● Nubeqa is not approved for use in patients with progressive metastatic castrate resistant prostate cancer.\n",
    "● Phase 1–2 clinical trial was conducted to assess safety and tolerability of darolutamide in men with progressive metastatic castration-resistant prostate cancer.2    Secondary objectives were to determine the  pharmacokinetics , and  antitumor activity  as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts.2 \n",
    "o An open-label, nonrandomized phase 1 dose escalation portion and a phase 2 portion included randomized dose expansion and long-term follow-up.\n",
    "o Twenty-four patients were enrolled in the   dose escalation phase. No intra-patient dose escalation was permitted. Patients received 200 mg/day (n=4); 400 mg/day (n=7); 600 mg/day (n=3); 1000 mg/day (n=4); 1400 mg/day (n=3); 1800 mg/day (n=3).\n",
    "o In the phase 2 part of the study (n=112):\n",
    "▪ Thirty-eight patients were assigned to receive 200 mg/day (11\n",
    "chemotherapy naïve and CYP17inhibitor (CYP17i); naïve 9 post\n",
    "chemotherapy and CYP17i naïve; 18 post CYPi).\n",
    "▪ Thirty-seven patients were   assigned to receive 400 mg/day (9\n",
    "[chemotherapy naïve and CYP17i) naïve]; 9 [post chemotherapy and\n",
    "CYP17i naïve]; 19 [post CYPi]).\n",
    "▪ Thirty-five patients were   assigned to receive 1400 mg/day (8\n",
    "[chemotherapy naïve and CYP17i) naïve]; 10 [post chemotherapy and\n",
    "CYP17i naïve]; 17 [post CYPi]).\n",
    "▪ Pharmacokinetic analysis darolutamide showed rapid absorption and the\n",
    "median t max  ranged 3·0–5·1 hours for darolutamide and 1.5–5.0 h for the diastereo isomer keto-darolutamide on day 1. The mean metabolite to parent ratio (area under the curve, AUC) at steady state was 1.6–2.3:1. The exposure of darolutamide (AUC t a  nd C max)  at steady state increased in a linear, dose-related manner up to 1400 mg daily dose.\n",
    "o Most common Grade 3 adverse events were fatigue or asthenia 2 (2%), back pain 2 (2%) and arthralgia 2 (2%).\n",
    "o PK response (≥ 50% decrease in PSA) by week 12 was observed with all doses and all treatment groups, but significantly fewer were seen in patients previously treated with CYP17 inhibitors than in those who were naïve to both chemotherapy and CYP17 inhibitors.\n",
    "o RECIST responses or stable disease in soft tissue, and stabilized disease in bone was observed at all dose levels. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients\n",
    "NUBEQA®  (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    " o Circulating tumor cell measured at baseline and at week 12 (available in 87 of 124 patients) 41 (82%) patients maintained favorable circulating tumor cell counts (<5 cells per 7·5 mL of blood) at week 12. In the patients with ≥5 cells counts at baseline, 14 (38%) converted to < 5 cells counts, and nine (18%) patients converted from < 5 cells counts to ≥5 cells counts.\n",
    "o Patients (58%) who were both chemotherapy and CYP17 inhibitor-naïve converted from ≥5 cells counts to < 5 cells counts.\n",
    "o The median time to PSA progression in phase 1–2 (including all dose levels) was 72.3 weeks (95% CI 24.3–not reached [NR]) for patients who were naive for both chemotherapy and CYP17 inhibitor.\n",
    "o Median  time to radiological progression  was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36.4–NR).\n",
    "● An open randomized phase 1 trial ( ARAFOR ) evaluated  bioavailability  and  effect of food on pharmacokinetics of darolutamide.3    The study compared relative bioavailability of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with chemotherapy naïve metastatic castrate resistant prostate cancer.  The study also assessed  the effect of food on the bioavailability of darolutamide tablet products tablet A (TabA) and tablet B (TabB). The study also evaluated short term safety and tolerability and in an extension component long-term safety and tolerability, which was ongoing at the time of presentation.3 \n",
    "o Patients were randomized to one of 3 treatment sequences in each group .  There were three treatment periods for each patient during the PK Component which included administration of two darolutamide 300 mg test tablets (TabA or TabB) in both fasted and fed conditions, or administration of darolutamide 100 mg capsule at 600 mg dose in fed state. There was at least a 7 day wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day\n",
    "o Thirty men with metastatic chemotherapy naïve CRPC were enrolled. Area under the curve (AUC) and maximum concentration (C max)  values were approximately two times lower after administration at fast. With high fat meal the C max  occurred about 2-3 hours later. The  food effect  was similar in all groups.\n",
    "o The pharmacokinetics observed with the two new  tablet  formulations were comparable with the pharmacokinetics of the  capsule  formulation.\n",
    "o The PSA response rate (≥50% PSA decline) was 87% (26/30), with a median PSA decrease of 71% (-96, 5) at week 4\n",
    "o Most commonly reported adverse events (>10%) were fatigue/asthenia (13%), nausea (10%), erythema (10%) and urinary tract disorder (10%); all being mild events except one nausea event (grade 3).\n",
    "Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.1 \n",
    "Nubeqa is not approved for use in patients with progressive metastatic castrate resistant prostate cancer.\n",
    "A Phase 1–2 clinical trial was conducted to assess darolutamide in men with progressive metastatic castration-resistant prostate cancer.2    The primary objectives of the trial were to\n",
    "NUBEQA®  (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "       \n",
    " assess safety and tolerability and to define a maximum tolerated dose. Secondary objectives were to determine the pharmacokinetics, and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by  imaging of soft tissue and bone lesions , and by changes in circulating tumor cell counts.\n",
    "In an open-label, multicenter trial with a nonrandomized phase 1 dose escalation portion, a phase 2 portion included randomized dose expansion and long-term follow-up.2    Patients with adenocarcinoma of the prostate with progressive metastatic disease despite ongoing androgen-deprivation therapy were enrolled.\n",
    "The phase 1 dose-escalation part of the study was not randomized.1    The patients sequentially entered the phase 1 part of the study. In the phase 2 portion, patients were randomly assigned (ratio 1:1) by blocks of four and two to 200 mg or 400 mg daily doses of darolutamide with previous treatment (chemotherapy-naive and CYP17 inhibitor-naive; post-chemotherapy and CYP17 inhibitor-naive; and post- CYP17 inhibitor) as stratification factors. The third expanded dose level, patients were randomly assigned into 200 mg, 400 mg, or 1400 mg daily doses.\n",
    "Three to six patients sequentially received 200 mg (100 mg twice daily) to 400 mg, 600 mg, 1000 mg, 1400 mg, or 1800 mg.2    In the absence of grade 3 or higher treatment-related adverse events within the first 28 days patients were permitted to continue darolutamide treatment in the absence of disease progression.2    No intra-patient dose escalation was permitted.\n",
    "The phase 2 part of the study included three expanded cohorts (200 mg, 400 mg, and 1400 mg daily dose) each containing about 35 patients.2    A total of 136 patients were enrolled (24 were enrolled in the dose-escalation phase and 112 randomly assigned to receive either 200 mg, 400 mg, or 1400 mg of darolutamide). Of the 24 patients enrolled in dose escalation phase; 200 mg/day (n=4, 1 discontinued protocol violation); 400 mg/day (n=7, 1 discontinued due to AE); 600 mg/day (n=3, 0 discontinued); 1000 mg/day (n=4, 1 discontinued due to AE); 1400 mg/day (n=3, 0 discontinued); 1800 mg/day (n=3, 0 discontinued). Allocation of the 112 patients randomized in the phase 2 part of the study is presented in Figure 1. Two patients randomized did not receive darolutamide.\n",
    " NUBEQA®  (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Figure 1: Trial profile of the phase 2 part of the study1 \n",
    " Select baseline characteristic of patients are presented in Table 1.2  Table 1: Select Baseline Characteristics2 \n",
    "        Phase1 (n=24)\n",
    " Phase 2 Group 1\n",
    "     Group 2\n",
    "  Group 3\n",
    "          200mg (n=38)\n",
    "      400mg (n=37)\n",
    "   1400 (n=35)\n",
    "   Age (years)\n",
    "      69 (64–74)\n",
    " 67 (65–73)\n",
    "      68 (64–75)\n",
    "   73 (64–78)\n",
    "   PSA (ng/ml)\n",
    "      27 (13–96)\n",
    " 109 (43–352)\n",
    "      95 (45–255)\n",
    "   155 (31–382)\n",
    " LDH (U/L)\n",
    "  249 (192–412)\n",
    "   220 (195–292)\n",
    "    232 (202–322)\n",
    "    226 (201–322)\n",
    "   Chemotherapy-naive and CYP17 inhibitor-naive\n",
    "    14 (58\n",
    "11 (29%)\n",
    "    9 (24%)\n",
    " 8 (23%)\n",
    "   Post-chemotherapy and CYP17 inhibitor-naïve\n",
    "      7 (29%)\n",
    " 9 (24%)\n",
    "      9 (24%)\n",
    "   10 (29%)\n",
    " Post-CYP17 inhibitor\n",
    "  3 (13%)\n",
    "   18 (47%)\n",
    "    19 (51%)\n",
    "    17 (49%)\n",
    "   Total Gleason Score <8\n",
    "> 8\n",
    " 15 (68%) 7 (32%)\n",
    "15 (42%) 21 (58%)\n",
    "  20 (59%) 14 (41%)\n",
    " 15 (46%) 18 (55%)\n",
    "  NUBEQA®  (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    "   Missing\n",
    " 2\n",
    "  2\n",
    "   3\n",
    "   2\n",
    "   ECOG PS 0\n",
    "1\n",
    "    17 (71%) 7 (29%)\n",
    "19 (50%) 19 (50%)\n",
    "    20 (54%) 17 (46%)\n",
    " 16 (46%) 19 (54%)\n",
    " Circulating tumor cell counts <5 cells/7.5mL of blood\n",
    "> 5 cells/7.5mL of blood\n",
    "   13 (54%) 9 (38%)\n",
    "   18 (47%) 17 (45%)\n",
    "    18 (49%) 17 (46%)\n",
    "    16 (46%) 14 (40%)\n",
    "   Disease localization Bone disease\n",
    "Bone only\n",
    "Bone and soft tissue Soft-tissue disease Lymph node Visceral\n",
    "No radiologic evidence of mets\n",
    "    15 (63%) 6 (25%) 9 (38%) 17 (71%) 17 (71%) 1 (4%) 1 (4%)\n",
    "34 (89%) 12 (32%) 22 (58%) 26 (68%) 18 (47%) 10 (26%) 0\n",
    "    32 (86%) 11 (30%) 21 (57%) 26 (70%) 24 (65%) 8 (22%) 0\n",
    " 32 (91%) 20 (57%) 12 (34%) 15 (43%) 7 (20%) 8 (23%) 0\n",
    " Bone metastases 0\n",
    "1-4 5-20 >20\n",
    "  9 (38%) 3 (13%) 7 (29%) 5 (21%)\n",
    "  6 (16%) 10 (26%) 11 (29%) 11 (29%)\n",
    "   5 (14%) 13 (35%) 9 (24%) 10 (27%)\n",
    "   3 (9%) 6 (17%) 8 (23%) 18 (51%)\n",
    "  PSA=prostate-specific antigen. LDH=lactate dehydrogenase. ECOG=Eastern Cooperative Oncology Group. NA=not assessable, Mets=metastases\n",
    "The median time on darolutamide therapy was 24-8 (IQR 24.8-25.2) months for the phase 1 part of the study and 11 months (IQR 8.3-14.0) months for phase 2 part of the trial.1    Most common reason for discontinuation was disease progression and 5 (4%) of 124 patients discontinued for adverse events.\n",
    "Common adverse events occurring in greater than equal to 10% of patients are presented in Table 2 below.2 \n",
    "Table 2: Most Common Adverse Events Occurring in  >  10% of Patients2 \n",
    "        Grade 1\n",
    "   Grade 2\n",
    "  Grade 3\n",
    "   Fatigue or asthenia\n",
    "      27 (22%)\n",
    "    13 (10%)\n",
    "   2 (2%)\n",
    "   Back pain\n",
    "      16 (13%)\n",
    "    13 (10%)\n",
    "   2 (2%)\n",
    "   Arthralgia\n",
    "      15 (12%)\n",
    "    9 (7%)\n",
    "   2 (2%)\n",
    "   Constipation\n",
    "      14 (11%)\n",
    "    5 (4%)\n",
    "   0\n",
    "   Decreased appetite\n",
    "      15 (12%)\n",
    "    1 (<1%)\n",
    "   0\n",
    "   Nausea\n",
    "      12 (10%)\n",
    "    4 (3%)\n",
    "   0\n",
    " Peripheral edema\n",
    "  13 (10%)\n",
    "    2 (2%)\n",
    "    0\n",
    " Pharmacokinetic analysis darolutamide showed rapid absorbed and the median t max  were 3·0–5·1 h for darolutamide and 1·5–5·0 hours for keto-darolutamide on day 1.2    The mean metabolite to parent ratio (area under the curve, AUC) at steady state was 1·6–2·3:1. The exposure of darolutamide (AUC t  and C max)  at steady state increased in a linear, dose-related manner up to 1400 mg daily dose.\n",
    "NUBEQA®  (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Antitumor activity as measured by in PSA from baseline are presented in Figure 2.\n",
    "Figure 2: Percentage in PSA Decline at Week 12 From Baseline2 \n",
    " RECIST responses or stable disease in soft tissue, and stabilized disease in bone are shown in table 4.2    No differences in response by dose were noted in soft tissue and bone. This variable was not formally evaluated due to the small number of patients within each dose group and subgroup. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients (table 3).\n",
    "Table 3: Imaging Results at Week 12 Using RECIST2 \n",
    "NUBEQA ® (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    "  Measured baseline and 12-week circulating tumor cell results were available in 87 of 124 patients.2    Circulating conversion rates of circulating tumor cells are presented in table 4 below.\n",
    "Table 4: Circulating Tumor Cells at Week 12: Expanded dose Levels2 \n",
    "        Chemotherapy naïve/CYP17i naïve (n=37*)\n",
    " Post Chemotherapy/CYP17i naïve\n",
    "(n=32*)\n",
    "    Post CYP 17i (n=55*)\n",
    "     < at Baseline\n",
    "    (n=18)\n",
    " (n=16)\n",
    "     (n=25)\n",
    "     <5 at week 12\n",
    "    15 (88%)\n",
    " 10 (91%)\n",
    "     16 (73%)\n",
    "     ≥5 at week 12\n",
    "    2 (12%)\n",
    " 1 (9%)\n",
    "     6 (27%)\n",
    "     NA at week 12\n",
    "    1\n",
    " 5\n",
    "     3\n",
    "     ≥5 at baseline\n",
    "    (n=16)\n",
    " (n=13)\n",
    "     (n=24)\n",
    "     <5 at week 12\n",
    "    7 (58%)\n",
    " 7 (58%)\n",
    "     0\n",
    " ≥5 at week 12\n",
    "    5 (42%)\n",
    "   ,5 (42%)\n",
    "   1213 (100%)\n",
    "  NUBEQA ® (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    "  NA at week 12\n",
    "   4\n",
    "  1\n",
    "  11\n",
    "NA=not assessable. CTC count is expressed as cells per 7·5 mL of blood. These data include patients with missing baseline CTC. *Total number includes three patients with missing baseline. †Total number includes six patients with missing baseline.\n",
    "The median serum testosterone level at baseline was 0·4 nmol/L (IQR 0·4–0·6; n=124) and castrate concentrations were maintained at week 12 (0·4 nmol/L [0·4–0·6]; n=111).2 \n",
    "The median time to PSA progression in phase 1–2 (including all dose levels) was 72·3 weeks (95% CI 24·3–not reached [NR]) for patients who were naive to both chemotherapy and CYP17 inhibitor; 20·3 weeks (95% CI 16·9–26·1) for those who had received chemotherapy but not a CYP17 inhibitor, and 19·3 weeks (95% CI 14·1–27·1) for those who had received a CYP17 inhibitor (figure 3).2 \n",
    "Figure 3: Time to PSA Progression2 \n",
    "Median time to radiological progression was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36·4–NR); 50·4 weeks (95% CI 12·1–NR) for those who had received chemotherapy but not a CYP17 inhibitor; and 12·7 weeks (95% CI 12·0–36·3) for those who had received a CYP17 inhibitor (figure 4).2 \n",
    "Figure 4: Time to Radiologic Progression2 \n",
    "NUBEQA ® (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    " \n",
    "  Highest pre-specified daily dose of 1800 mg and a maximum tolerated dose was not reached; no dose-limiting toxic effects were noted and dose escalation was discontinued because of a plasma concentration plateau of darolutamide.\n",
    "An open randomized phase 1 trial (ARAFOR) evaluated bioavailability and effect of food on bioavailability of  darolutamide .3    The study compared relative bioavailability of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with chemotherapy naïve metastatic castrate resistant prostate cancer. The study also assessed the effect of food on the bioavailability of  darolutamide  tablet products tablet A (TabA) and tablet B (TabB). The study also evaluated short term safety and tolerability and in an extension component long-term safety and tolerability (was ongoing at the time of presentation)\n",
    "The PK Component consisted of two concurrent groups, which evaluated TabA and (TabB), and capsule.3    Patients were randomized to one of 3 treatment sequences in each group.3     There were three treatment periods for each patient during the PK Component which included administration of two  darolutamide  300 mg test tablet (TabA or TabB) in both fasted and fed conditions, or administration of  darolutamide  100 mg capsule at 600 mg dose in fed state. There was at least 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day.\n",
    "Thirty  men with metastatic chemotherapy-naïve CRPC were enrolled; the median age of the patients was 68 years (Table 5).3 \n",
    "NUBEQA ® (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Table 5: Select Baseline Characteristics3 \n",
    "   Characteristic\n",
    "       Age Median (range\n",
    "     68 (54-86)\n",
    " Baseline PSA (ng/mL)\n",
    "  18.2 (4-555)\n",
    " Disease localization\n",
    "Bone only\n",
    "Soft tissue only\n",
    "Both bone and soft tissue\n",
    "   14 (46.7%) 3 (10%) 13 (43.3%)\n",
    "   LHRH\n",
    "     30 (100%\n",
    "   Previous antiandrogen therapy\n",
    "     22 (73.3%)\n",
    " Median Gleason score\n",
    "  7.0\n",
    "PSA = prostate specific antigen LHRH=Leutinizing hormone releasing hormone\n",
    "All thirty patients completed the 4-week visit.3    Up to cut-off point 29/30 patients are continuing and 20 patients have completed 12 weeks in the trial so far. The PSA response rate (≥ 50% PSA decline) was 87% (26/30), with a median PSA decrease of -71% (-96, 5) at week 4 (Figure 5).\n",
    "NUBEQA ® (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Figure 5: Maximum Change (%) in PSA during Trial3 \n",
    "Data on PSA at 12 weeks were available in 20 patients and are presented in Figure 6.3  Figure 6: Change in PSA (%) at 12 Weeks2 \n",
    "Darolutamide  was well tolerated. Most commonly reported adverse events (>10%) were fatigue/asthenia (13%), nausea (10%), erythema (10%) and urinary tract disorder (10%); all being mild events except one nausea event (grade 3).3 \n",
    "Food interaction was seen when  darolutamide  formulations (600 mg) were administered after a high fat content breakfast compared to administration in a fasted state.3    AUC and C max  values were approximately two times lower after administration at fast. With high fat meal the C max occurred about 2-3 hours later, indicating a delay in gastric emptying of DAROLUTAMIDE after\n",
    "NUBEQA ® (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "  \n",
    " the high fat meal. The food effect was similar in all groups. The pharmacokinetics observed with the two new tablet formulations were comparable with the pharmacokinetics of the capsule formulation (figure 5).3 \n",
    "Figure 7: Concentration Time Curves of the Three Formulation with and Without Food3 \n",
    "Most commonly reported adverse events (>10%) were fatigue/asthenia (13%), nausea (10%), erythema (10%) and urinary tract disorder (10%); all being mild events except one nausea event (grade 3).3 \n",
    "A Phase 3 trial (ARAMIS) evaluated the safety and efficacy of darolutamide in patients with high risk non-metastatic castrate resistant prostate cancer and can be accessed on the clinicaltrials.gov  https://www.clinicaltrials.gov/ct2/show/NCT02200614?term=ODM+201&rank=4\n",
    "A Randomized, Double-blind, Placebo Controlled Phase III Study of darolutamide Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer has been initiated and listed on the clinicaltrials.gov.  https://www.clinicaltrials.gov/ct2/show/NCT02799602?term=ODM+201&rank=9\n",
    "   NUBEQA ® (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    "REV: 0719\n",
    "References:\n",
    "1. NUBEQA®    (darolutamide) tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer\n",
    "HealthCare Pharmaceuticals, July 2019.\n",
    "2. Fizazi K, Massard C, Bono P, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.  Lancet Oncol 2  014; 15: 975–85. http://www.ncbi.nlm.nih.gov/pubmed/24974051\n",
    "3. Massard C, Tammela T, Vjaters, et al. A study of ODM-201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy naïve castrate-resistant prostate cancer (CRPC). Presented at 2014 Genitourinary Cancers Symposium, January 2014 in San Francisco CA.\n",
    " NUBEQA ® (  darolutamide) Clinical Data (ARADES & ARAFOR)\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\"\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/subashgandyer/anaconda3/lib/python3.7/runpy.py:193: UserWarning: [W011] It looks like you're calling displacy.serve from within a Jupyter notebook or a similar environment. This likely means you're already running a local web server, so there's no need to make displaCy start another one. Instead, you should be able to replace displacy.serve with displacy.render to show the visualization.\n",
      "  \"__main__\", mod_spec)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "<html lang=\"en\">\n",
       "    <head>\n",
       "        <title>displaCy</title>\n",
       "    </head>\n",
       "\n",
       "    <body style=\"font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr\">\n",
       "<figure style=\"margin-bottom: 6rem\">\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Clinical Data on NUBEQA®   (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") in Patients with Progressive Metastatic Castrate Resistant Prostate Cancer</br>Summary:</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is not approved for use in patients with progressive metastatic castrate resistant prostate cancer.</br>● Phase 1–2 clinical trial was conducted to assess \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men with progressive metastatic castration-resistant prostate cancer.2    Secondary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " were to determine the  \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " , and  antitumor activity  as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts.2 </br>o An open-label, nonrandomized phase 1 dose escalation portion and a phase 2 portion included randomized dose expansion and long-term follow-up.</br>o Twenty-four patients were enrolled in the   dose escalation phase. No intra-patient dose escalation was permitted. Patients received \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=7); 600 mg/day (n=3); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3).</br>o In the phase 2 part of the study (n=112):</br>▪ Thirty-eight patients were assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (11</br>chemotherapy naïve and CYP17inhibitor (CYP17i); naïve 9 post</br>chemotherapy and CYP17i naïve; 18 post CYPi).</br>▪ Thirty-seven patients were   assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (9</br>[chemotherapy naïve and CYP17i) naïve]; 9 [post chemotherapy and</br>CYP17i naïve]; 19 [post CYPi]).</br>▪ Thirty-five patients were   assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (8</br>[chemotherapy naïve and CYP17i) naïve]; 10 [post chemotherapy and</br>CYP17i naïve]; 17 [post CYPi]).</br>▪ \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " showed rapid \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    absorption\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " and the</br>median \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    t max\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "  ranged 3·0–5·1 hours for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1.5–5.0 h\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " for the diastereo isomer keto-darolutamide on day 1. The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1.6–2.3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t a  nd C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose.</br>o Most common Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%) and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%).</br>o PK response (≥ 50% decrease in PSA) by week 12 was observed with all doses and all treatment groups, but significantly fewer were seen in patients previously treated with CYP17 inhibitors than in those who were naïve to both chemotherapy and CYP17 inhibitors.</br>o RECIST responses or stable disease in soft tissue, and stabilized disease in bone was observed at all dose levels. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA®  \n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "(  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> o Circulating tumor cell measured at baseline and at week 12 (available in 87 of 124 patients) 41 (82%) patients maintained favorable circulating tumor cell counts (&lt;5 cells per 7·5 mL of blood) at week 12. In the patients with ≥5 cells counts at baseline, 14 (38%) converted to &lt; 5 cells \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    counts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", and nine (18%) patients converted from &lt; 5 cells counts to ≥5 cells \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    counts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ".</br>o Patients (58%) who were both \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    CYP17\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " inhibitor-naïve converted from ≥5 cells counts to &lt; 5 cells counts.</br>o The median time to PSA progression in phase 1–2 (including all dose levels) was 72.3 weeks (95% CI 24.3–not reached [NR]) for patients who were naive for both chemotherapy and CYP17 inhibitor.</br>o Median  time to radiological progression  was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36.4–NR).</br>● An open randomized phase 1 trial ( ARAFOR ) evaluated  bioavailability  and  effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide.3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "    The study compared relative \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with \n",
       "<mark class=\"entity\" style=\"background: turquoise; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy naïve metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ".  The study also assessed  the effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " tablet products tablet A (TabA) and tablet B (TabB). The study also evaluated short term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and in an extension component long-term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", which was ongoing at the time of presentation.3 </br>o Patients were randomized to one of 3 treatment sequences in each group .  There were three treatment periods for each patient during the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " Component which included \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of two \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 300 mg test tablets (TabA or TabB) in both \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " conditions, or \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 100 mg capsule at 600 mg dose in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state. There was at least a 7 day wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day</br>o Thirty men with metastatic chemotherapy naïve CRPC were enrolled. Area under the curve (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") and maximum concentration (C max)  values were approximately two times lower after \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " at fast. With high fat meal the C max  occurred about 2-3 hours later. The  \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " effect  was similar in all groups.</br>o The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " observed with the two new  tablet  formulations were comparable with the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of the  capsule  formulation.</br>o The PSA response rate (≥50% PSA decline) was 87% (26/30), with a median PSA decrease of 71% (-96, 5) at week 4</br>o Most commonly reported \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (&gt;10%) were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "/\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%), nausea (10%), erythema (10%) and urinary tract disorder (10%); all being mild events except one nausea event (grade 3).</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1 \n",
       "Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " is not approved for use in patients with progressive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>A Phase 1–2 clinical trial was conducted to assess \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men with progressive metastatic castration-resistant prostate cancer.2    The primary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " of the trial were to</br>NUBEQA®  (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>       </br> assess \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and to define a maximum tolerated dose. Secondary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " were to determine the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by  imaging of soft tissue and bone lesions , and by changes in circulating tumor cell counts.</br>In an open-label, multicenter trial with a nonrandomized phase 1 dose escalation portion, a phase 2 portion included randomized dose expansion and long-term follow-up.2    Patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adenocarcinoma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " of the prostate with progressive metastatic disease despite ongoing \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       "-deprivation therapy were enrolled.</br>The phase 1 dose-escalation part of the study was not randomized.1    The patients sequentially entered the phase 1 part of the study. In the phase 2 portion, patients were randomly assigned (ratio 1:1) by blocks of four and two to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " doses of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " with previous treatment (chemotherapy-naive and CYP17 inhibitor-naive; post-chemotherapy and CYP17 inhibitor-naive; and post- CYP17 inhibitor) as stratification factors. The third expanded dose level, patients were randomly assigned into \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " doses.</br>Three to six patients sequentially received \n",
       "<mark class=\"entity\" style=\"background: #ffa500; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    twice daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", 600 mg, \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " or 1800 mg.2    In the absence of grade 3 or higher treatment-related adverse events within the first 28 days patients were permitted to continue \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " treatment in the absence of disease progression.2    No intra-patient dose escalation was permitted.</br>The phase 2 part of the study included three expanded cohorts (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", and \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose) each containing about 35 patients.2    A total of 136 patients were enrolled (24 were enrolled in the \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "-escalation phase and 112 randomly assigned to receive either 200 mg, \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg of darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "). Of the 24 patients enrolled in dose escalation phase; \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4, 1 discontinued protocol violation); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=7, 1 discontinued due to AE); 600 mg/day (n=3, 0 discontinued); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4, 1 discontinued due to AE); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3, 0 discontinued); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3, 0 discontinued). Allocation of the 112 patients randomized in the phase 2 part of the study is presented in Figure 1. Two patients randomized did not receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br> \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       "®  (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Figure 1: Trial profile of the phase 2 part of the study1 </br> Select baseline characteristic of patients are presented in Table 1.2  Table 1: Select Baseline Characteristics2 </br>        Phase1 (n=24)</br> Phase 2 Group 1</br>     Group 2</br>  Group 3</br>          \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=38)</br>      \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=37)</br>   1400 (n=35)</br>   Age (years)</br>      69 (64–74)</br> 67 (65–73)</br>      68 (64–75)</br>   73 (64–78)</br>   PSA (ng/ml)</br>      27 (13–96)</br> 109 (43–352)</br>      95 (45–255)</br>   155 (31–382)</br> LDH (U/L)</br>  249 (192–412)</br>   220 (195–292)</br>    232 (202–322)</br>    226 (201–322)</br>   Chemotherapy-naive and CYP17 inhibitor-naive</br>    14 (58</br>11 (29%)</br>    9 (24%)</br> 8 (23%)</br>   Post-chemotherapy and CYP17 inhibitor-naïve</br>      7 (29%)</br> 9 (24%)</br>      9 (24%)</br>   10 (29%)</br> Post-\n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    CYP17\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " inhibitor</br>  3 (13%)</br>   18 (47%)</br>    19 (51%)</br>    17 (49%)</br>   Total Gleason Score &lt;8</br>&gt; 8</br> 15 (68%) 7 (32%)</br>15 (42%) 21 (58%)</br>  20 (59%) 14 (41%)</br> 15 (46%) 18 (55%)</br>  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "®  (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>   Missing</br> 2</br>  2</br>   3</br>   2</br>   ECOG PS 0</br>1</br>    17 (71%) 7 (29%)</br>19 (50%) 19 (50%)</br>    20 (54%) 17 (46%)</br> 16 (46%) 19 (54%)</br> Circulating tumor cell counts &lt;5 cells/7.5mL of blood</br>&gt; 5 cells/7.5mL of blood</br>   13 (54%) 9 (38%)</br>   18 (47%) 17 (45%)</br>    18 (49%) 17 (46%)</br>    16 (46%) 14 (40%)</br>   Disease localization Bone disease</br>Bone only</br>Bone and soft tissue Soft-tissue disease Lymph node Visceral</br>No radiologic evidence of mets</br>    15 (63%) 6 (25%) 9 (38%) 17 (71%) 17 (71%) 1 (4%) 1 (4%)</br>34 (89%) 12 (32%) 22 (58%) 26 (68%) 18 (47%) 10 (26%) 0</br>    32 (86%) 11 (30%) 21 (57%) 26 (70%) 24 (65%) 8 (22%) 0</br> 32 (91%) 20 (57%) 12 (34%) 15 (43%) 7 (20%) 8 (23%) 0</br> \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Bone metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " 0</br>1-4 5-20 &gt;20</br>  9 (38%) 3 (13%) 7 (29%) 5 (21%)</br>  6 (16%) 10 (26%) 11 (29%) 11 (29%)</br>   5 (14%) 13 (35%) 9 (24%) 10 (27%)</br>   3 (9%) 6 (17%) 8 (23%) 18 (51%)</br>  PSA=prostate-specific antigen. LDH=lactate dehydrogenase. ECOG=Eastern Cooperative Oncology Group. NA=not assessable, \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Mets=metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       "</br>The median \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    time\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " therapy was 24-8 (IQR 24.8-25.2) months for the phase 1 part of the study and 11 months (IQR 8.3-14.0) months for phase 2 part of the trial.1    Most common reason for discontinuation was disease progression and 5 (4%) of 124 patients discontinued for \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ".</br>Common \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " occurring in greater than equal to 10% of patients are presented in Table 2 below.2 </br>Table 2: Most Common Adverse Events Occurring in  &gt;  10% of \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Patients2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " </br>        Grade 1</br>   Grade 2</br>  Grade 3</br>   Fatigue or \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>      27 (22%)</br>    13 (10%)</br>   2 (2%)</br>   \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>      16 (13%)</br>    13 (10%)</br>   2 (2%)</br>   \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>      15 (12%)</br>    9 (7%)</br>   2 (2%)</br>   Constipation</br>      14 (11%)</br>    5 (4%)</br>   0</br>   Decreased appetite</br>      15 (12%)</br>    1 (&lt;1%)</br>   0</br>   \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>      12 (10%)</br>    4 (3%)</br>   0</br> \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Peripheral edema\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>  13 (10%)</br>    2 (2%)</br>    0</br> \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " analysis \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorbed and the median t max  were 3·0–5·1 h for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and 1·5–5·0 hours for keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " on day 1.2    The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1·6–2·3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t  and C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose.</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Antitumor \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    activity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " as measured by in PSA from baseline are presented in Figure 2.</br>Figure 2: Percentage in PSA Decline at Week 12 From Baseline2 </br> RECIST responses or stable disease in soft tissue, and stabilized disease in bone are shown in table 4.2    No differences in response by dose were noted in soft tissue and bone. This variable was not formally evaluated due to the small number of patients within each dose group and subgroup. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients (table 3).</br>Table 3: Imaging Results at Week 12 Using RECIST2 </br>NUBEQA ® (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>  Measured baseline and 12-week circulating tumor cell results were available in 87 of 124 patients.2    Circulating conversion \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    rates\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of circulating tumor cells are presented in table 4 below.</br>Table 4: Circulating Tumor Cells at Week 12: Expanded dose Levels2 </br>        Chemotherapy naïve/CYP17i naïve (n=37*)</br> Post Chemotherapy/CYP17i naïve</br>(n=32*)</br>    Post CYP 17i (n=55*)</br>     &lt; at Baseline</br>    (n=18)</br> (n=16)</br>     (n=25)</br>     &lt;5 at week 12</br>    15 (88%)</br> 10 (91%)</br>     16 (73%)</br>     ≥5 at week 12</br>    2 (12%)</br> 1 (9%)</br>     6 (27%)</br>     NA at week 12</br>    1</br> 5</br>     3</br>     ≥5 at baseline</br>    (n=16)</br> (n=13)</br>     (n=24)</br>     &lt;5 at week 12</br>    7 (58%)</br> 7 (58%)</br>     0</br> ≥5 at week 12</br>    5 (42%)</br>   ,5 (42%)</br>   1213 (100%)</br>  \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>  NA at week 12</br>   4</br>  1</br>  11</br>NA=not assessable. CTC count is expressed as cells per 7·5 mL of blood. These data include patients with missing baseline CTC. *Total number includes three patients with missing baseline. †Total number includes six patients with missing baseline.</br>The median serum testosterone level at baseline was 0·4 nmol/L (IQR 0·4–0·6; n=124) and castrate concentrations were maintained at week 12 (0·4 nmol/L [0·4–0·6]; n=111).2 </br>The median time to PSA progression in phase 1–2 (including all dose levels) was 72·3 weeks (95% CI 24·3–not reached [NR]) for patients who were naive to both chemotherapy and CYP17 inhibitor; 20·3 weeks (95% CI 16·9–26·1) for those who had received chemotherapy but not a CYP17 inhibitor, and 19·3 weeks (95% CI 14·1–27·1) for those who had received a CYP17 inhibitor (figure 3).2 </br>Figure 3: Time to PSA Progression2 </br>Median time to radiological progression was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36·4–NR); 50·4 weeks (95% CI 12·1–NR) for those who had received chemotherapy but not a CYP17 inhibitor; and 12·7 weeks (95% CI 12·0–36·3) for those who had received a CYP17 inhibitor (figure 4).2 </br>Figure 4: Time to Radiologic Progression2 </br>NUBEQA ® (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br>  Highest pre-specified daily dose of \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and a maximum tolerated dose was not reached; no \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "-limiting toxic effects were noted and dose escalation was discontinued because of a \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " plateau of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>An open randomized phase 1 trial (ARAFOR) evaluated \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " .3    The study compared relative \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with \n",
       "<mark class=\"entity\" style=\"background: turquoise; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy naïve metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". The study also assessed the effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "  tablet products tablet A (TabA) and tablet B (TabB). The study also evaluated short term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and in an extension component long-term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (was ongoing at the time of presentation)</br>The \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " Component consisted of two concurrent groups, which evaluated TabA and (TabB), and capsule.3    Patients were randomized to one of 3 treatment sequences in each group.3     There were three treatment periods for each patient during the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " Component which included \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of two  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "  300 mg test \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tablet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " (TabA or TabB) in both \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " conditions, or \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "  100 mg capsule at 600 mg dose in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state. There was at least 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day.</br>Thirty  men with metastatic chemotherapy-naïve CRPC were enrolled; the median age of the patients was 68 years (Table 5).3 </br>NUBEQA ® (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Table 5: Select Baseline Characteristics3 </br>   Characteristic</br>       Age Median (range</br>     68 (54-86)</br> Baseline PSA (ng/mL)</br>  18.2 (4-555)</br> Disease localization</br>Bone only</br>Soft tissue only</br>Both bone and soft tissue</br>   14 (46.7%) 3 (10%) 13 (43.3%)</br>   LHRH</br>     30 (100%</br>   Previous antiandrogen therapy</br>     22 (73.3%)</br> Median Gleason score</br>  7.0</br>PSA = prostate specific antigen LHRH=Leutinizing hormone releasing hormone</br>All thirty patients completed the 4-week visit.3    Up to cut-off point 29/30 patients are continuing and 20 patients have completed 12 weeks in the trial so far. The PSA response rate (≥ 50% PSA decline) was 87% (26/30), with a median PSA decrease of -71% (-96, 5) at week 4 (Figure 5).</br>NUBEQA ® (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Figure 5: Maximum Change (%) in PSA during Trial3 </br>Data on PSA at 12 weeks were available in 20 patients and are presented in Figure 6.3  Figure 6: Change in PSA (%) at 12 Weeks2 </br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       "  was well tolerated. Most commonly reported \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (&gt;10%) were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "/\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%), nausea (10%), erythema (10%) and urinary tract disorder (10%); all being mild events except one nausea event (grade 3).3 </br>Food interaction was seen when  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "  formulations (600 mg) were administered after a high fat content breakfast compared to \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " in a \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state.3    \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " and C max  values were approximately two times lower after \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " at fast. With high fat meal the C max occurred about 2-3 hours later, indicating a delay in gastric emptying of \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    DAROLUTAMIDE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    after\n",
       "\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " ® (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>  </br> the high fat meal. The \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " effect was similar in all groups. The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " observed with the two new \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tablet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " formulations were comparable with the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of the capsule formulation (figure 5).3 </br>Figure 7: Concentration Time Curves of the Three Formulation with and Without Food3 </br>Most commonly reported \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (&gt;10%) were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "/\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%), nausea (10%), erythema (10%) and urinary tract disorder (10%); all being mild events except one nausea event (grade 3).3 </br>A Phase 3 trial (ARAMIS) evaluated the \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and efficacy of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in patients with high risk \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and can be accessed on the clinicaltrials.gov  https://www.clinicaltrials.gov/ct2/show/NCT02200614?term=ODM+201&amp;rank=4</br>A Randomized, Double-blind, Placebo Controlled Phase III Study of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer has been initiated and listed on the clinicaltrials.gov.  https://www.clinicaltrials.gov/ct2/show/NCT02799602?term=ODM+201&amp;rank=9</br>   NUBEQA ® (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>REV: 0719</br>References:</br>1. NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer</br>HealthCare Pharmaceuticals, July 2019.</br>2. Fizazi K, Massard C, Bono P, et al. Activity and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.  Lancet Oncol 2  014; 15: 975–85. http://www.ncbi.nlm.nih.gov/pubmed/24974051</br>3. Massard C, Tammela T, Vjaters, et al. A study of ODM-201 formulations with a \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " extension phase in patients with metastatic chemotherapy naïve castrate-resistant prostate cancer (CRPC). Presented at 2014 Genitourinary Cancers Symposium, January 2014 in San Francisco CA.</br> NUBEQA ® (  \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Clinical Data (ARADES &amp; ARAFOR)\n",
       "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>\n",
       "</figure>\n",
       "</body>\n",
       "</html>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Using the 'ent' visualizer\n",
      "Serving on http://0.0.0.0:5000 ...\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "127.0.0.1 - - [05/Mar/2020 10:55:43] \"GET / HTTP/1.1\" 200 104456\n",
      "127.0.0.1 - - [05/Mar/2020 10:55:44] \"GET /favicon.ico HTTP/1.1\" 200 104456\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Shutting down server on port 5000.\n"
     ]
    }
   ],
   "source": [
    "colors = {\"DRUG\":\"#ff9ff0\",\n",
    "         \"DISEASE\": \"turquoise\",\n",
    "         \"ADVERSE EVENT\": \"tomato\",\n",
    "         \"CONDITION\": \"lavender\",\n",
    "         \"DOSAGE\": \"#ffa500\",\n",
    "         \"INDICATION\": \"#ffe6ff\",\n",
    "         \"PHARMACOKINETICS\": \"#b3b3cc\",\n",
    "         \"DOSING\": \"#ffd9b3\",\n",
    "         \"EFFICACY\": \"#d9ffb3\",\n",
    "         \"CONTRAINDICATIONS\": \"#ffa366\",\n",
    "         \"SAFETY\": \"#80ff80\",\n",
    "         \"DRUG INTERACTION\": \"#b3d9ff\",\n",
    "         \"FOOD INTERACTION\": \"#3399ff\",\n",
    "         \"BIOAVAILABILITY\": \"#ff9900\",\n",
    "         \"ABSORPTION\": \"#ccccb3\",\n",
    "         \"AUC\": \"#00ff55\",\n",
    "         \"CMAX\": \"#ff531a\",\n",
    "         \"MFS\": \"#d966ff\",\n",
    "         \"OS\": \"#5c5cd6\",\n",
    "         \"TTPP\": \"#0088cc\",\n",
    "         \"PFS\": \"#ffcccc\",\n",
    "         \"QOL\": \"#cc00cc\",\n",
    "         \"OBJECTIVE\": \"#ffffb3\",\n",
    "         \"PLASMA CONCENTRATION\": \"#ffff1a\",\n",
    "         \"DOSAGE FORM\": \"#f2f2f2\",\n",
    "         \"TMAX\": \"#b3ffff\",\n",
    "         \"ENDPOINT\": \"#ccddff\",\n",
    "         \"DISCONTINUATION\": \"#ccffcc\",\n",
    "         \"DEATH\": \"#ccffe6\",\n",
    "         \"ADMINISTRATION\": \"#ff4da6\"}\n",
    "options = {\"ents\": [\"DRUG\", \"DISEASE\", \"ADVERSE EVENT\", \"CONDITION\", \"DOSAGE\", \"INDICATION\", \"PHARMACOKINETICS\", \"DOSING\", \"EFFICACY\", \"CONTRAINDICATIONS\", \"SAFETY\", \"DRUG INTERACTION\", \"FOOD INTERACTION\", \"BIOAVAILABILITY\", \"ABSORPTION\", \"AUC\", \"CMAX\", \"MFS\", \"OS\", \"TTPP\", \"PFS\", \"QOL\", \"OBJECTIVE\", \"PLASMA CONCENTRATION\", \"DOSAGE FORM\", \"TMAX\", \"ENDPOINT\", \"DISCONTINUATION\", \"DEATH\", \"ADMINISTRATION\"], \"colors\": colors}\n",
    "displacy.serve(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Phase 1/2 Study of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") in Patients with Progressive Metastatic Castrate Resistant Prostate Cancer (ARADES)</br>Summary:</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is not approved for use in patients with progressive metastatic castrate resistant prostate cancer.</br>● Phase 1–2 clinical trial was conducted to assess \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men with progressive metastatic castration-resistant prostate cancer.2    Secondary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " were to determine the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts.</br>o An open-label, nonrandomized phase 1 dose escalation portion and a phase 2 included randomized dose expansion and long-term follow-up.</br>o Twenty-four patients were enrolled in the   dose escalation phase. No intra-patient dose escalation was permitted. Patients received \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=7); 600 mg/day (n=3); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3).</br>● In the phase 2 part of the study (n=112):</br>o Thirty-eight patients were assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (11 chemotherapy</br>naïve and CYP17inhibitor (CYP17i) naïve; 9 post chemotherapy and CYP17i</br>naïve; 18 post CYPi).</br>o Thirty-seven patients were assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (9 [chemotherapy</br>naïve and CYP17i) naïve]; 9 [post chemotherapy and CYP17i naïve]; 19 [post</br>CYPi]).</br>o Thirty-five patients were assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (8 [chemotherapy</br>naïve and CYP17i) naïve]; 10 [post chemotherapy and CYP17i naïve]; 17 [post</br>CYPi]).</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorption and the median</br>\n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    t\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " max  ranged \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    3.0–5.1 hours\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1.5–5.0 h\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " for the diastereo isomer keto-darolutamide on day 1. The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1.6–2.3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t and C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose.</br>● Most\n",
       "(2%) and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%).</br>common Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2</br>● PSA response (≥ 50% decrease in PSA) by week 12 was observed with all doses and all treatment groups, but significantly fewer were seen in patients previously treated with CYP17 inhibitors than in those who were naïve to both chemotherapy and CYP17 inhibitors.</br>● RECIST responses or stable disease in soft tissue, and stabilized disease in bone was observed at all dose levels. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients</br>NUBEQA ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br> ● Circulating tumor cell measured at baseline and at week 12 (available in 87 of 124 patients) 41 (82%) patients maintained favorable circulating tumor cell counts (&lt; 5 cells per 7·5 mL of blood) at week 12. In the patients with ≥5 cells counts at baseline, 14 (38%) converted to &lt; 5 cells \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    counts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", and nine (18%) patients converted from &lt; 5 cells counts to ≥5 cells counts.</br>● Patients (58%) who were both chemotherapy and CYP17 inhibitor-naïve converted from ≥5 cells \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    counts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " to &lt; 5 cells counts.</br>● The median time to PSA progression in phase 1–2 (including all dose levels) was 72.3 weeks (95% CI 24.3–not reached [NR]) for patients who were naive for both chemotherapy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    CYP17\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " inhibitor.</br>● Median time to radiological progression was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36.4–NR).</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1 \n",
       "Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " is not approved for use in patients with progressive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>A Phase 1–2 clinical trial was conducted to assess \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men with progressive metastatic castration-resistant prostate cancer.2    The primary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " of the trial were to assess \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and to define a maximum tolerated dose. Secondary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " were to determine the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts.</br>A proportion of patients in an open-label, multicenter, nonrandomized phase 1 dose escalation study were permitted to continue into a phase 2 part of the study and were randomized in dose expansion and long-term follow-up.2    Patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adenocarcinoma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " of the prostate with progressive metastatic disease despite ongoing \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       "-deprivation therapy were enrolled.</br>The phase 1 dose-escalation part of the study was not randomized.2    The patients sequentially entered the phase 1 part of the study. In the phase 2, patients were randomly assigned (ratio 1:1) by blocks of four and two to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " doses of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " with previous treatment (chemotherapy-naive and CYP17 inhibitor-naive; post-chemotherapy and CYP17 inhibitor-naive; and post- CYP17 inhibitor) as stratification factors. The third expanded dose level, patients were randomly assigned to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " doses.</br>Three to six patients sequentially received \n",
       "<mark class=\"entity\" style=\"background: #ffa500; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    twice daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") which was increased to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", 600 mg, \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and 1800 mg.2    In the absence of grade 3 or higher treatment-related adverse events within the first 28 days, patients   were permitted to continue \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " treatment in the absence of disease progression.2    No   intra-patient dose escalation was permitted.</br>The phase 2 part of the study included three expanded cohorts (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", and \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose) each containing about 35 patients.2    A total of 136 patients were enrolled (24 were</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> enrolled in the dose-escalation phase and 112 randomly assigned to receive either 200 mg, \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg of darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "). Of the 24 patients enrolled in dose escalation phase; \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4, 1 discontinued protocol violation); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=7, 1 discontinued due to AE); 600 mg/day (n=3, 0 discontinued); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4, 1 discontinued due to AE); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3, 0 discontinued); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3, 0 discontinued). Allocation of the 112 patients randomized in the phase 2 part of the study is presented in Figure 1. Two patients randomized did not receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>Figure 1: Trial profile of the phase 2 part of the study2 </br> Select baseline characteristic of patients are presented in Table 1.2  Table 1: Select Baseline Characteristics2 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®  \n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "(\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br>        Phase1 (n=24)</br> Phase 2 Group 1</br>     Group 2</br>  Group 3</br>          \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=38)</br>      \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=37)</br>   1400 (n=35)</br>   Age (years)</br>      69 (64–74)</br> 67 (65–73)</br>      68 (64–75)</br>   73 (64–78)</br>   PSA (ng/ml)</br>      27 (13–96)</br> 109 (43–352)</br>      95 (45–255)</br>   155 (31–382)</br> LDH (U/L)</br>  249 (192–412)</br>  220 (195–292)</br>   232 (202–322)</br>   226 (201–322)</br>  </br>                                                                                                                                          Chemotherapy-naive and CYP17 inhibitor-naive</br>     14 (58</br> 11 (29%)</br>     9 (24%)</br>  8 (23%)</br>   Post-chemotherapy and CYP17 inhibitor-naïve</br>      7 (29%)</br> 9 (24%)</br>      9 (24%)</br>   10 (29%)</br> Post-\n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    CYP17\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " inhibitor</br>  3 (13%)</br>   18 (47%)</br>    19 (51%)</br>    17 (49%)</br>   Total Gleason Score &lt;8</br>&gt; 8</br>Missing</br>    15 (68%) 7 (32%) 2</br>15 (42%) 21 (58%) 2</br>    20 (59%) 14 (41%) 3</br> 15 (46%) 18 (55%) 2</br>   ECOG PS 0</br>1</br>      17 (71%) 7 (29%)</br> 19 (50%) 19 (50%)</br>      20 (54%) 17 (46%)</br>   16 (46%) 19 (54%)</br> Circulating tumor cell counts &lt;5 cells/7.5mL of blood</br>&gt; 5 cells/7.5mL of blood</br>  13 (54%) 9 (38%)</br>   18 (47%) 17 (45%)</br>    18 (49%) 17 (46%)</br>    16 (46%) 14 (40%)</br>   Disease localization Bone disease</br>Bone only</br>Bone and soft tissue Soft-tissue disease Lymph node Visceral</br>No radiologic evidence of mets</br>    15 (63%) 6 (25%) 9 (38%) 17 (71%) 17 (71%) 1 (4%) 1 (4%)</br>34 (89%) 12 (32%) 22 (58%) 26 (68%) 18 (47%) 10 (26%) 0</br>    32 (86%) 11 (30%) 21 (57%) 26 (70%) 24 (65%) 8 (22%) 0</br> 32 (91%) 20 (57%) 12 (34%) 15 (43%) 7 (20%) 8 (23%) 0</br> \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Bone metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " 0</br>1-4 5-20 &gt;20</br>  9 (38%) 3 (13%) 7 (29%) 5 (21%)</br>  6 (16%) 10 (26%) 11 (29%) 11 (29%)</br>   5 (14%) 13 (35%) 9 (24%) 10 (27%)</br>   3 (9%) 6 (17%) 8 (23%) 18 (51%)</br>  PSA=prostate-specific antigen. LDH=lactate dehydrogenase. ECOG=Eastern Cooperative Oncology Group. NA=not assessable, \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Mets=metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       "</br>The median \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    time\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " therapy was 24-8 (IQR 24.8-25.2) months for the phase 1 part of the study and 11 months (IQR 8.3-14.0) months for phase 2 part of the trial.2    Most common reason for discontinuation was disease progression and 5 (4%) of 124 patients discontinued for \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ".</br>Common \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " occurring in greater than equal to 10% of patients are presented in Table 2 below.2 </br>Table 2: Most Common Adverse Events Occurring in  &gt;  10% of \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Patients2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " </br>Fatigue or \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " pain \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " Constipation Decreased appetite \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Peripheral edema\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>Grade 1</br>27 (22%) 16 (13%) 15 (12%) 14 (11%) 15 (12%) 12 (10%) 13 (10%)</br>Grade 2</br>13 (10%) 13 (10%) 9 (7%) 5 (4%) 1 (&lt;1%) 4 (3%) 2 (2%)</br>Grade 3</br>2 (2%) 2 (2%) 2 (2%) 0</br>0 0 0</br>NUBEQA ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorbed and the median t max  were 3·0–5·1 h for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and 1·5–5·0 hours for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " on day 1.2    The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1·6–2·3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t  and C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose.</br>Antitumor activity as measured by in PSA from baseline are presented in Figure 2</br>Figure 2: Percentage in PSA Decline at Week 12 From Baseline2 </br> RECIST responses or stable disease in soft tissue, and stabilized disease in bone are shown in table 4.2    No differences in response by dose were noted in soft tissue and bone. This variable was not formally evaluated due to the small number of patients within each dose group and subgroup. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients (table 3).</br>Table 3: Imaging Results at Week 12 Using RECIST2 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br>  Measured baseline and 12-week circulating tumor cell results were available in 87 of 124 patients.2    Circulating conversion \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    rates\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of circulating tumor cells are presented in table 4 below.</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> Table 4: Circulating Tumor Cells at Week 12: Expanded dose Levels2 </br>        Chemotherapy naïve/CYP17i naïve (n=37*)</br> Post Chemotherapy/CYP17i naïve</br>(n=32*)</br>    Post CYP 17i (n=55*)</br>     &lt; at Baseline</br>    (n=18)</br> (n=16)</br>     (n=25)</br>     &lt;5 at week 12</br>    15 (88%)</br> 10 (91%)</br>     16 (73%)</br>     ≥5 at week 12</br>    2 (12%)</br> 1 (9%)</br>     6 (27%)</br>     NA at week 12</br>    1</br> 5</br>     3</br>     ≥5 at baseline</br>    (n=16)</br> (n=13)</br>     (n=24)</br>     &lt;5 at week 12</br>    7 (58%)</br> 7 (58%)</br>     0</br>     ≥5 at week 12</br>    5 (42%)</br> ,5 (42%)</br>     1213 (100%)</br> NA at week 12</br>    4</br>   1</br>   11</br>  NA=not assessable. CTC count is expressed as cells per 7·5 mL of blood. These data include patients with missing baseline CTC. *Total number includes three patients with missing baseline. †   Total number includes six patients with missing baseline.</br>The median serum testosterone level at baseline was 0·4 nmol/L (IQR 0·4–0·6; n=124) and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    castrate concentrations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " were maintained at week 12 (0·4 nmol/L [0·4–0·6]; n=111).2 </br>The median time to PSA progression in phase 1–2 (including all dose levels) was 72·3 weeks (95% CI 24·3–not reached [NR]) for patients who were naive to both chemotherapy and CYP17 inhibitor; 20·3 weeks (95% CI 16·9–26·1) for those who had received chemotherapy but not a CYP17 inhibitor, and 19·3 weeks (95% CI 14·1–27·1) for those who had received a CYP17 inhibitor (figure 3).2 </br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> Figure 3: Time to PSA Progression2 </br>Median time to radiological progression was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36·4–NR); 50·4 weeks (95% CI 12·1–NR) for those who had received chemotherapy but not a CYP17 inhibitor; and 12·7 weeks (95% CI 12·0–36·3) for those who had received a CYP17 inhibitor (figure 4).2 </br>Figure 4: Time to Radiologic Progression2 </br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br>  Highest pre-specified daily dose of \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and a maximum tolerated dose was not reached; no \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "-limiting toxic effects were noted and dose escalation was discontinued because of a \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " plateau of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>A Phase 3 trial (ARAMIS) evaluated the \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and efficacy of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in patients with high risk \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and can be accessed on the clinicaltrials.gov  https://www.clinicaltrials.gov/ct2/show/NCT02200614?term=ODM+201&amp;rank=4</br>A Randomized, Double-blind, Placebo Controlled Phase III Study of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer has been initiated and listed on the clinicaltrials.gov.  https://www.clinicaltrials.gov/ct2/show/NCT02799602?term=ODM+201&amp;rank=9</br>REV: 0719</br>References:</br>1. NUBEQA® (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer</br>HealthCare Pharmaceuticals, July 2019.</br>2. Fizazi K, Massard C, Bono P, et al. Activity and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br>  </br>phase 2 dose expansion trial.  Lancet Oncol 2  014; 15: 975–85. http://www.ncbi.nlm.nih.gov/pubmed/24974051</br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES\n",
       "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "colors = {\"DRUG\":\"#ff9ff0\",\n",
    "         \"DISEASE\": \"turquoise\",\n",
    "         \"ADVERSE EVENT\": \"tomato\",\n",
    "         \"CONDITION\": \"lavender\",\n",
    "         \"DOSAGE\": \"#ffa500\",\n",
    "         \"INDICATION\": \"#ffe6ff\",\n",
    "         \"PHARMACOKINETICS\": \"#b3b3cc\",\n",
    "         \"DOSING\": \"#ffd9b3\",\n",
    "         \"EFFICACY\": \"#d9ffb3\",\n",
    "         \"CONTRAINDICATIONS\": \"#ffa366\",\n",
    "         \"SAFETY\": \"#80ff80\",\n",
    "         \"DRUG INTERACTION\": \"#b3d9ff\",\n",
    "         \"FOOD INTERACTION\": \"#3399ff\",\n",
    "         \"BIOAVAILABILITY\": \"#ff9900\",\n",
    "         \"ABSORPTION\": \"#ccccb3\",\n",
    "         \"AUC\": \"#00ff55\",\n",
    "         \"CMAX\": \"#ff531a\",\n",
    "         \"MFS\": \"#d966ff\",\n",
    "         \"OS\": \"#5c5cd6\",\n",
    "         \"TTPP\": \"#0088cc\",\n",
    "         \"PFS\": \"#ffcccc\",\n",
    "         \"QOL\": \"#cc00cc\",\n",
    "         \"OBJECTIVE\": \"#ffffb3\",\n",
    "         \"PLASMA CONCENTRATION\": \"#ffff1a\",\n",
    "         \"DOSAGE FORM\": \"#f2f2f2\",\n",
    "         \"TMAX\": \"#b3ffff\",\n",
    "         \"ENDPOINT\": \"#ccddff\",\n",
    "         \"DISCONTINUATION\": \"#ccffcc\",\n",
    "         \"DEATH\": \"#ccffe6\",\n",
    "         \"ADMINISTRATION\": \"#ff4da6\"}\n",
    "options = {\"ents\": [\"DRUG\", \"DISEASE\", \"ADVERSE EVENT\", \"CONDITION\", \"DOSAGE\", \"INDICATION\", \"PHARMACOKINETICS\", \"DOSING\", \"EFFICACY\", \"CONTRAINDICATIONS\", \"SAFETY\", \"DRUG INTERACTION\", \"FOOD INTERACTION\", \"BIOAVAILABILITY\", \"ABSORPTION\", \"AUC\", \"CMAX\", \"MFS\", \"OS\", \"TTPP\", \"PFS\", \"QOL\", \"OBJECTIVE\", \"PLASMA CONCENTRATION\", \"DOSAGE FORM\", \"TMAX\", \"ENDPOINT\", \"DISCONTINUATION\", \"DEATH\", \"ADMINISTRATION\"], \"colors\": colors}\n",
    "displacy.render(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Document 2 - Nubeqa (US-NUBEQA-76044-S.docx-2.pdf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc = loaded_nlp(\"\"\"Phase 1/2 Study of NUBEQA®    (darolutamide) in Patients with Progressive Metastatic Castrate Resistant Prostate Cancer (ARADES)\n",
    "Summary:\n",
    "● Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.1 \n",
    "● Nubeqa is not approved for use in patients with progressive metastatic castrate resistant prostate cancer.\n",
    "● Phase 1–2 clinical trial was conducted to assess safety and tolerability of darolutamide in men with progressive metastatic castration-resistant prostate cancer.2    Secondary objectives were to determine the pharmacokinetics, and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts.\n",
    "o An open-label, nonrandomized phase 1 dose escalation portion and a phase 2 included randomized dose expansion and long-term follow-up.\n",
    "o Twenty-four patients were enrolled in the   dose escalation phase. No intra-patient dose escalation was permitted. Patients received 200 mg/day (n=4); 400 mg/day (n=7); 600 mg/day (n=3); 1000 mg/day (n=4); 1400 mg/day (n=3); 1800 mg/day (n=3).\n",
    "● In the phase 2 part of the study (n=112):\n",
    "o Thirty-eight patients were assigned to receive 200 mg/day (11 chemotherapy\n",
    "naïve and CYP17inhibitor (CYP17i) naïve; 9 post chemotherapy and CYP17i\n",
    "naïve; 18 post CYPi).\n",
    "o Thirty-seven patients were assigned to receive 400 mg/day (9 [chemotherapy\n",
    "naïve and CYP17i) naïve]; 9 [post chemotherapy and CYP17i naïve]; 19 [post\n",
    "CYPi]).\n",
    "o Thirty-five patients were assigned to receive 1400 mg/day (8 [chemotherapy\n",
    "naïve and CYP17i) naïve]; 10 [post chemotherapy and CYP17i naïve]; 17 [post\n",
    "CYPi]).\n",
    "o Pharmacokinetic analysis darolutamide showed rapid absorption and the median\n",
    "t max  ranged 3.0–5.1 hours for darolutamide and 1.5–5.0 h for the diastereo isomer keto-darolutamide on day 1. The mean metabolite to parent ratio (area under the curve, AUC) at steady state was 1.6–2.3:1. The exposure of darolutamide (AUC t and C max)  at steady state increased in a linear, dose-related manner up to 1400 mg daily dose.\n",
    "● Most\n",
    "(2%) and arthralgia 2 (2%).\n",
    "common Grade 3 adverse events were fatigue or asthenia 2 (2%), back pain 2\n",
    "● PSA response (≥ 50% decrease in PSA) by week 12 was observed with all doses and all treatment groups, but significantly fewer were seen in patients previously treated with CYP17 inhibitors than in those who were naïve to both chemotherapy and CYP17 inhibitors.\n",
    "● RECIST responses or stable disease in soft tissue, and stabilized disease in bone was observed at all dose levels. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients\n",
    "NUBEQA ®  (darolutamide): ARADES\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    ".\n",
    " ● Circulating tumor cell measured at baseline and at week 12 (available in 87 of 124 patients) 41 (82%) patients maintained favorable circulating tumor cell counts (< 5 cells per 7·5 mL of blood) at week 12. In the patients with ≥5 cells counts at baseline, 14 (38%) converted to < 5 cells counts, and nine (18%) patients converted from < 5 cells counts to ≥5 cells counts.\n",
    "● Patients (58%) who were both chemotherapy and CYP17 inhibitor-naïve converted from ≥5 cells counts to < 5 cells counts.\n",
    "● The median time to PSA progression in phase 1–2 (including all dose levels) was 72.3 weeks (95% CI 24.3–not reached [NR]) for patients who were naive for both chemotherapy and CYP17 inhibitor.\n",
    "● Median time to radiological progression was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36.4–NR).\n",
    "Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.1 \n",
    "Nubeqa is not approved for use in patients with progressive metastatic castrate resistant prostate cancer.\n",
    "A Phase 1–2 clinical trial was conducted to assess darolutamide in men with progressive metastatic castration-resistant prostate cancer.2    The primary objectives of the trial were to assess safety and tolerability and to define a maximum tolerated dose. Secondary objectives were to determine the pharmacokinetics, and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts.\n",
    "A proportion of patients in an open-label, multicenter, nonrandomized phase 1 dose escalation study were permitted to continue into a phase 2 part of the study and were randomized in dose expansion and long-term follow-up.2    Patients with adenocarcinoma of the prostate with progressive metastatic disease despite ongoing androgen-deprivation therapy were enrolled.\n",
    "The phase 1 dose-escalation part of the study was not randomized.2    The patients sequentially entered the phase 1 part of the study. In the phase 2, patients were randomly assigned (ratio 1:1) by blocks of four and two to 200 mg or 400 mg daily doses of darolutamide with previous treatment (chemotherapy-naive and CYP17 inhibitor-naive; post-chemotherapy and CYP17 inhibitor-naive; and post- CYP17 inhibitor) as stratification factors. The third expanded dose level, patients were randomly assigned to 200 mg, 400 mg, or 1400 mg daily doses.\n",
    "Three to six patients sequentially received 200 mg (100 mg twice daily) which was increased to 400 mg, 600 mg, 1000 mg, 1400 mg, and 1800 mg.2    In the absence of grade 3 or higher treatment-related adverse events within the first 28 days, patients   were permitted to continue darolutamide treatment in the absence of disease progression.2    No   intra-patient dose escalation was permitted.\n",
    "The phase 2 part of the study included three expanded cohorts (200 mg, 400 mg, and 1400 mg daily dose) each containing about 35 patients.2    A total of 136 patients were enrolled (24 were\n",
    "NUBEQA ®  (darolutamide): ARADES\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    ".\n",
    "\n",
    " enrolled in the dose-escalation phase and 112 randomly assigned to receive either 200 mg, 400 mg, or 1400 mg of darolutamide). Of the 24 patients enrolled in dose escalation phase; 200 mg/day (n=4, 1 discontinued protocol violation); 400 mg/day (n=7, 1 discontinued due to AE); 600 mg/day (n=3, 0 discontinued); 1000 mg/day (n=4, 1 discontinued due to AE); 1400 mg/day (n=3, 0 discontinued); 1800 mg/day (n=3, 0 discontinued). Allocation of the 112 patients randomized in the phase 2 part of the study is presented in Figure 1. Two patients randomized did not receive darolutamide.\n",
    "Figure 1: Trial profile of the phase 2 part of the study2 \n",
    " Select baseline characteristic of patients are presented in Table 1.2  Table 1: Select Baseline Characteristics2 \n",
    "NUBEQA ®  (darolutamide): ARADES\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    ".\n",
    "        Phase1 (n=24)\n",
    " Phase 2 Group 1\n",
    "     Group 2\n",
    "  Group 3\n",
    "          200mg (n=38)\n",
    "      400mg (n=37)\n",
    "   1400 (n=35)\n",
    "   Age (years)\n",
    "      69 (64–74)\n",
    " 67 (65–73)\n",
    "      68 (64–75)\n",
    "   73 (64–78)\n",
    "   PSA (ng/ml)\n",
    "      27 (13–96)\n",
    " 109 (43–352)\n",
    "      95 (45–255)\n",
    "   155 (31–382)\n",
    " LDH (U/L)\n",
    "  249 (192–412)\n",
    "  220 (195–292)\n",
    "   232 (202–322)\n",
    "   226 (201–322)\n",
    "  \n",
    "                                                                                                                                          Chemotherapy-naive and CYP17 inhibitor-naive\n",
    "     14 (58\n",
    " 11 (29%)\n",
    "     9 (24%)\n",
    "  8 (23%)\n",
    "   Post-chemotherapy and CYP17 inhibitor-naïve\n",
    "      7 (29%)\n",
    " 9 (24%)\n",
    "      9 (24%)\n",
    "   10 (29%)\n",
    " Post-CYP17 inhibitor\n",
    "  3 (13%)\n",
    "   18 (47%)\n",
    "    19 (51%)\n",
    "    17 (49%)\n",
    "   Total Gleason Score <8\n",
    "> 8\n",
    "Missing\n",
    "    15 (68%) 7 (32%) 2\n",
    "15 (42%) 21 (58%) 2\n",
    "    20 (59%) 14 (41%) 3\n",
    " 15 (46%) 18 (55%) 2\n",
    "   ECOG PS 0\n",
    "1\n",
    "      17 (71%) 7 (29%)\n",
    " 19 (50%) 19 (50%)\n",
    "      20 (54%) 17 (46%)\n",
    "   16 (46%) 19 (54%)\n",
    " Circulating tumor cell counts <5 cells/7.5mL of blood\n",
    "> 5 cells/7.5mL of blood\n",
    "  13 (54%) 9 (38%)\n",
    "   18 (47%) 17 (45%)\n",
    "    18 (49%) 17 (46%)\n",
    "    16 (46%) 14 (40%)\n",
    "   Disease localization Bone disease\n",
    "Bone only\n",
    "Bone and soft tissue Soft-tissue disease Lymph node Visceral\n",
    "No radiologic evidence of mets\n",
    "    15 (63%) 6 (25%) 9 (38%) 17 (71%) 17 (71%) 1 (4%) 1 (4%)\n",
    "34 (89%) 12 (32%) 22 (58%) 26 (68%) 18 (47%) 10 (26%) 0\n",
    "    32 (86%) 11 (30%) 21 (57%) 26 (70%) 24 (65%) 8 (22%) 0\n",
    " 32 (91%) 20 (57%) 12 (34%) 15 (43%) 7 (20%) 8 (23%) 0\n",
    " Bone metastases 0\n",
    "1-4 5-20 >20\n",
    "  9 (38%) 3 (13%) 7 (29%) 5 (21%)\n",
    "  6 (16%) 10 (26%) 11 (29%) 11 (29%)\n",
    "   5 (14%) 13 (35%) 9 (24%) 10 (27%)\n",
    "   3 (9%) 6 (17%) 8 (23%) 18 (51%)\n",
    "  PSA=prostate-specific antigen. LDH=lactate dehydrogenase. ECOG=Eastern Cooperative Oncology Group. NA=not assessable, Mets=metastases\n",
    "The median time on darolutamide therapy was 24-8 (IQR 24.8-25.2) months for the phase 1 part of the study and 11 months (IQR 8.3-14.0) months for phase 2 part of the trial.2    Most common reason for discontinuation was disease progression and 5 (4%) of 124 patients discontinued for adverse events.\n",
    "Common adverse events occurring in greater than equal to 10% of patients are presented in Table 2 below.2 \n",
    "Table 2: Most Common Adverse Events Occurring in  >  10% of Patients2 \n",
    "Fatigue or asthenia Back pain Arthralgia Constipation Decreased appetite Nausea\n",
    "Peripheral edema\n",
    "Grade 1\n",
    "27 (22%) 16 (13%) 15 (12%) 14 (11%) 15 (12%) 12 (10%) 13 (10%)\n",
    "Grade 2\n",
    "13 (10%) 13 (10%) 9 (7%) 5 (4%) 1 (<1%) 4 (3%) 2 (2%)\n",
    "Grade 3\n",
    "2 (2%) 2 (2%) 2 (2%) 0\n",
    "0 0 0\n",
    "NUBEQA ®  (darolutamide): ARADES\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    ".\n",
    "\n",
    " Pharmacokinetic analysis darolutamide showed rapid absorbed and the median t max  were 3·0–5·1 h for darolutamide and 1·5–5·0 hours for darolutamide on day 1.2    The mean metabolite to parent ratio (area under the curve, AUC) at steady state was 1·6–2·3:1. The exposure of darolutamide (AUC t  and C max)  at steady state increased in a linear, dose-related manner up to 1400 mg daily dose.\n",
    "Antitumor activity as measured by in PSA from baseline are presented in Figure 2\n",
    "Figure 2: Percentage in PSA Decline at Week 12 From Baseline2 \n",
    " RECIST responses or stable disease in soft tissue, and stabilized disease in bone are shown in table 4.2    No differences in response by dose were noted in soft tissue and bone. This variable was not formally evaluated due to the small number of patients within each dose group and subgroup. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients (table 3).\n",
    "Table 3: Imaging Results at Week 12 Using RECIST2 \n",
    "NUBEQA ®  (darolutamide): ARADES\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    ".\n",
    "\n",
    "  Measured baseline and 12-week circulating tumor cell results were available in 87 of 124 patients.2    Circulating conversion rates of circulating tumor cells are presented in table 4 below.\n",
    "NUBEQA®    (darolutamide): ARADES\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    ".\n",
    "\n",
    " Table 4: Circulating Tumor Cells at Week 12: Expanded dose Levels2 \n",
    "        Chemotherapy naïve/CYP17i naïve (n=37*)\n",
    " Post Chemotherapy/CYP17i naïve\n",
    "(n=32*)\n",
    "    Post CYP 17i (n=55*)\n",
    "     < at Baseline\n",
    "    (n=18)\n",
    " (n=16)\n",
    "     (n=25)\n",
    "     <5 at week 12\n",
    "    15 (88%)\n",
    " 10 (91%)\n",
    "     16 (73%)\n",
    "     ≥5 at week 12\n",
    "    2 (12%)\n",
    " 1 (9%)\n",
    "     6 (27%)\n",
    "     NA at week 12\n",
    "    1\n",
    " 5\n",
    "     3\n",
    "     ≥5 at baseline\n",
    "    (n=16)\n",
    " (n=13)\n",
    "     (n=24)\n",
    "     <5 at week 12\n",
    "    7 (58%)\n",
    " 7 (58%)\n",
    "     0\n",
    "     ≥5 at week 12\n",
    "    5 (42%)\n",
    " ,5 (42%)\n",
    "     1213 (100%)\n",
    " NA at week 12\n",
    "    4\n",
    "   1\n",
    "   11\n",
    "  NA=not assessable. CTC count is expressed as cells per 7·5 mL of blood. These data include patients with missing baseline CTC. *Total number includes three patients with missing baseline. †   Total number includes six patients with missing baseline.\n",
    "The median serum testosterone level at baseline was 0·4 nmol/L (IQR 0·4–0·6; n=124) and castrate concentrations were maintained at week 12 (0·4 nmol/L [0·4–0·6]; n=111).2 \n",
    "The median time to PSA progression in phase 1–2 (including all dose levels) was 72·3 weeks (95% CI 24·3–not reached [NR]) for patients who were naive to both chemotherapy and CYP17 inhibitor; 20·3 weeks (95% CI 16·9–26·1) for those who had received chemotherapy but not a CYP17 inhibitor, and 19·3 weeks (95% CI 14·1–27·1) for those who had received a CYP17 inhibitor (figure 3).2 \n",
    "NUBEQA®    (darolutamide): ARADES\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    ".\n",
    "\n",
    " Figure 3: Time to PSA Progression2 \n",
    "Median time to radiological progression was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36·4–NR); 50·4 weeks (95% CI 12·1–NR) for those who had received chemotherapy but not a CYP17 inhibitor; and 12·7 weeks (95% CI 12·0–36·3) for those who had received a CYP17 inhibitor (figure 4).2 \n",
    "Figure 4: Time to Radiologic Progression2 \n",
    " NUBEQA®    (darolutamide): ARADES\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    ".\n",
    "\n",
    "  Highest pre-specified daily dose of 1800 mg and a maximum tolerated dose was not reached; no dose-limiting toxic effects were noted and dose escalation was discontinued because of a plasma concentration plateau of darolutamide.\n",
    "A Phase 3 trial (ARAMIS) evaluated the safety and efficacy of darolutamide in patients with high risk non-metastatic castrate resistant prostate cancer and can be accessed on the clinicaltrials.gov  https://www.clinicaltrials.gov/ct2/show/NCT02200614?term=ODM+201&rank=4\n",
    "A Randomized, Double-blind, Placebo Controlled Phase III Study of darolutamide Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer has been initiated and listed on the clinicaltrials.gov.  https://www.clinicaltrials.gov/ct2/show/NCT02799602?term=ODM+201&rank=9\n",
    "REV: 0719\n",
    "References:\n",
    "1. NUBEQA® (darolutamide) tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer\n",
    "HealthCare Pharmaceuticals, July 2019.\n",
    "2. Fizazi K, Massard C, Bono P, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised\n",
    "NUBEQA®    (darolutamide): ARADES\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    ".\n",
    "  \n",
    "phase 2 dose expansion trial.  Lancet Oncol 2  014; 15: 975–85. http://www.ncbi.nlm.nih.gov/pubmed/24974051\n",
    " NUBEQA®    (darolutamide): ARADES\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\"\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/subashgandyer/anaconda3/lib/python3.7/runpy.py:193: UserWarning: [W011] It looks like you're calling displacy.serve from within a Jupyter notebook or a similar environment. This likely means you're already running a local web server, so there's no need to make displaCy start another one. Instead, you should be able to replace displacy.serve with displacy.render to show the visualization.\n",
      "  \"__main__\", mod_spec)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "<html lang=\"en\">\n",
       "    <head>\n",
       "        <title>displaCy</title>\n",
       "    </head>\n",
       "\n",
       "    <body style=\"font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr\">\n",
       "<figure style=\"margin-bottom: 6rem\">\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Phase 1/2 Study of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") in Patients with Progressive Metastatic Castrate Resistant Prostate Cancer (ARADES)</br>Summary:</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is not approved for use in patients with progressive metastatic castrate resistant prostate cancer.</br>● Phase 1–2 clinical trial was conducted to assess \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men with progressive metastatic castration-resistant prostate cancer.2    Secondary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " were to determine the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts.</br>o An open-label, nonrandomized phase 1 dose escalation portion and a phase 2 included randomized dose expansion and long-term follow-up.</br>o Twenty-four patients were enrolled in the   dose escalation phase. No intra-patient dose escalation was permitted. Patients received \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=7); 600 mg/day (n=3); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3).</br>● In the phase 2 part of the study (n=112):</br>o Thirty-eight patients were assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (11 chemotherapy</br>naïve and CYP17inhibitor (CYP17i) naïve; 9 post chemotherapy and CYP17i</br>naïve; 18 post CYPi).</br>o Thirty-seven patients were assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (9 [chemotherapy</br>naïve and CYP17i) naïve]; 9 [post chemotherapy and CYP17i naïve]; 19 [post</br>CYPi]).</br>o Thirty-five patients were assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (8 [chemotherapy</br>naïve and CYP17i) naïve]; 10 [post chemotherapy and CYP17i naïve]; 17 [post</br>CYPi]).</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorption and the median</br>\n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    t\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " max  ranged \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    3.0–5.1 hours\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1.5–5.0 h\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " for the diastereo isomer keto-darolutamide on day 1. The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1.6–2.3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t and C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose.</br>● Most\n",
       "(2%) and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%).</br>common Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2</br>● PSA response (≥ 50% decrease in PSA) by week 12 was observed with all doses and all treatment groups, but significantly fewer were seen in patients previously treated with CYP17 inhibitors than in those who were naïve to both chemotherapy and CYP17 inhibitors.</br>● RECIST responses or stable disease in soft tissue, and stabilized disease in bone was observed at all dose levels. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients</br>NUBEQA ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br> ● Circulating tumor cell measured at baseline and at week 12 (available in 87 of 124 patients) 41 (82%) patients maintained favorable circulating tumor cell counts (&lt; 5 cells per 7·5 mL of blood) at week 12. In the patients with ≥5 cells counts at baseline, 14 (38%) converted to &lt; 5 cells \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    counts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", and nine (18%) patients converted from &lt; 5 cells counts to ≥5 cells counts.</br>● Patients (58%) who were both chemotherapy and CYP17 inhibitor-naïve converted from ≥5 cells \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    counts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " to &lt; 5 cells counts.</br>● The median time to PSA progression in phase 1–2 (including all dose levels) was 72.3 weeks (95% CI 24.3–not reached [NR]) for patients who were naive for both chemotherapy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    CYP17\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " inhibitor.</br>● Median time to radiological progression was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36.4–NR).</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1 \n",
       "Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " is not approved for use in patients with progressive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>A Phase 1–2 clinical trial was conducted to assess \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men with progressive metastatic castration-resistant prostate cancer.2    The primary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " of the trial were to assess \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and to define a maximum tolerated dose. Secondary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " were to determine the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts.</br>A proportion of patients in an open-label, multicenter, nonrandomized phase 1 dose escalation study were permitted to continue into a phase 2 part of the study and were randomized in dose expansion and long-term follow-up.2    Patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adenocarcinoma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " of the prostate with progressive metastatic disease despite ongoing \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       "-deprivation therapy were enrolled.</br>The phase 1 dose-escalation part of the study was not randomized.2    The patients sequentially entered the phase 1 part of the study. In the phase 2, patients were randomly assigned (ratio 1:1) by blocks of four and two to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " doses of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " with previous treatment (chemotherapy-naive and CYP17 inhibitor-naive; post-chemotherapy and CYP17 inhibitor-naive; and post- CYP17 inhibitor) as stratification factors. The third expanded dose level, patients were randomly assigned to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " doses.</br>Three to six patients sequentially received \n",
       "<mark class=\"entity\" style=\"background: #ffa500; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    twice daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") which was increased to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", 600 mg, \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and 1800 mg.2    In the absence of grade 3 or higher treatment-related adverse events within the first 28 days, patients   were permitted to continue \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " treatment in the absence of disease progression.2    No   intra-patient dose escalation was permitted.</br>The phase 2 part of the study included three expanded cohorts (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", and \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose) each containing about 35 patients.2    A total of 136 patients were enrolled (24 were</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> enrolled in the dose-escalation phase and 112 randomly assigned to receive either 200 mg, \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg of darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "). Of the 24 patients enrolled in dose escalation phase; \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4, 1 discontinued protocol violation); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=7, 1 discontinued due to AE); 600 mg/day (n=3, 0 discontinued); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4, 1 discontinued due to AE); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3, 0 discontinued); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3, 0 discontinued). Allocation of the 112 patients randomized in the phase 2 part of the study is presented in Figure 1. Two patients randomized did not receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>Figure 1: Trial profile of the phase 2 part of the study2 </br> Select baseline characteristic of patients are presented in Table 1.2  Table 1: Select Baseline Characteristics2 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®  \n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "(\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br>        Phase1 (n=24)</br> Phase 2 Group 1</br>     Group 2</br>  Group 3</br>          \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=38)</br>      \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=37)</br>   1400 (n=35)</br>   Age (years)</br>      69 (64–74)</br> 67 (65–73)</br>      68 (64–75)</br>   73 (64–78)</br>   PSA (ng/ml)</br>      27 (13–96)</br> 109 (43–352)</br>      95 (45–255)</br>   155 (31–382)</br> LDH (U/L)</br>  249 (192–412)</br>  220 (195–292)</br>   232 (202–322)</br>   226 (201–322)</br>  </br>                                                                                                                                          Chemotherapy-naive and CYP17 inhibitor-naive</br>     14 (58</br> 11 (29%)</br>     9 (24%)</br>  8 (23%)</br>   Post-chemotherapy and CYP17 inhibitor-naïve</br>      7 (29%)</br> 9 (24%)</br>      9 (24%)</br>   10 (29%)</br> Post-\n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    CYP17\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " inhibitor</br>  3 (13%)</br>   18 (47%)</br>    19 (51%)</br>    17 (49%)</br>   Total Gleason Score &lt;8</br>&gt; 8</br>Missing</br>    15 (68%) 7 (32%) 2</br>15 (42%) 21 (58%) 2</br>    20 (59%) 14 (41%) 3</br> 15 (46%) 18 (55%) 2</br>   ECOG PS 0</br>1</br>      17 (71%) 7 (29%)</br> 19 (50%) 19 (50%)</br>      20 (54%) 17 (46%)</br>   16 (46%) 19 (54%)</br> Circulating tumor cell counts &lt;5 cells/7.5mL of blood</br>&gt; 5 cells/7.5mL of blood</br>  13 (54%) 9 (38%)</br>   18 (47%) 17 (45%)</br>    18 (49%) 17 (46%)</br>    16 (46%) 14 (40%)</br>   Disease localization Bone disease</br>Bone only</br>Bone and soft tissue Soft-tissue disease Lymph node Visceral</br>No radiologic evidence of mets</br>    15 (63%) 6 (25%) 9 (38%) 17 (71%) 17 (71%) 1 (4%) 1 (4%)</br>34 (89%) 12 (32%) 22 (58%) 26 (68%) 18 (47%) 10 (26%) 0</br>    32 (86%) 11 (30%) 21 (57%) 26 (70%) 24 (65%) 8 (22%) 0</br> 32 (91%) 20 (57%) 12 (34%) 15 (43%) 7 (20%) 8 (23%) 0</br> \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Bone metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " 0</br>1-4 5-20 &gt;20</br>  9 (38%) 3 (13%) 7 (29%) 5 (21%)</br>  6 (16%) 10 (26%) 11 (29%) 11 (29%)</br>   5 (14%) 13 (35%) 9 (24%) 10 (27%)</br>   3 (9%) 6 (17%) 8 (23%) 18 (51%)</br>  PSA=prostate-specific antigen. LDH=lactate dehydrogenase. ECOG=Eastern Cooperative Oncology Group. NA=not assessable, \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Mets=metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       "</br>The median \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    time\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " therapy was 24-8 (IQR 24.8-25.2) months for the phase 1 part of the study and 11 months (IQR 8.3-14.0) months for phase 2 part of the trial.2    Most common reason for discontinuation was disease progression and 5 (4%) of 124 patients discontinued for \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ".</br>Common \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " occurring in greater than equal to 10% of patients are presented in Table 2 below.2 </br>Table 2: Most Common Adverse Events Occurring in  &gt;  10% of \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Patients2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " </br>Fatigue or \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " pain \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " Constipation Decreased appetite \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Peripheral edema\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>Grade 1</br>27 (22%) 16 (13%) 15 (12%) 14 (11%) 15 (12%) 12 (10%) 13 (10%)</br>Grade 2</br>13 (10%) 13 (10%) 9 (7%) 5 (4%) 1 (&lt;1%) 4 (3%) 2 (2%)</br>Grade 3</br>2 (2%) 2 (2%) 2 (2%) 0</br>0 0 0</br>NUBEQA ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorbed and the median t max  were 3·0–5·1 h for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and 1·5–5·0 hours for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " on day 1.2    The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1·6–2·3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t  and C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose.</br>Antitumor activity as measured by in PSA from baseline are presented in Figure 2</br>Figure 2: Percentage in PSA Decline at Week 12 From Baseline2 </br> RECIST responses or stable disease in soft tissue, and stabilized disease in bone are shown in table 4.2    No differences in response by dose were noted in soft tissue and bone. This variable was not formally evaluated due to the small number of patients within each dose group and subgroup. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients (table 3).</br>Table 3: Imaging Results at Week 12 Using RECIST2 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br>  Measured baseline and 12-week circulating tumor cell results were available in 87 of 124 patients.2    Circulating conversion \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    rates\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of circulating tumor cells are presented in table 4 below.</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> Table 4: Circulating Tumor Cells at Week 12: Expanded dose Levels2 </br>        Chemotherapy naïve/CYP17i naïve (n=37*)</br> Post Chemotherapy/CYP17i naïve</br>(n=32*)</br>    Post CYP 17i (n=55*)</br>     &lt; at Baseline</br>    (n=18)</br> (n=16)</br>     (n=25)</br>     &lt;5 at week 12</br>    15 (88%)</br> 10 (91%)</br>     16 (73%)</br>     ≥5 at week 12</br>    2 (12%)</br> 1 (9%)</br>     6 (27%)</br>     NA at week 12</br>    1</br> 5</br>     3</br>     ≥5 at baseline</br>    (n=16)</br> (n=13)</br>     (n=24)</br>     &lt;5 at week 12</br>    7 (58%)</br> 7 (58%)</br>     0</br>     ≥5 at week 12</br>    5 (42%)</br> ,5 (42%)</br>     1213 (100%)</br> NA at week 12</br>    4</br>   1</br>   11</br>  NA=not assessable. CTC count is expressed as cells per 7·5 mL of blood. These data include patients with missing baseline CTC. *Total number includes three patients with missing baseline. †   Total number includes six patients with missing baseline.</br>The median serum testosterone level at baseline was 0·4 nmol/L (IQR 0·4–0·6; n=124) and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    castrate concentrations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " were maintained at week 12 (0·4 nmol/L [0·4–0·6]; n=111).2 </br>The median time to PSA progression in phase 1–2 (including all dose levels) was 72·3 weeks (95% CI 24·3–not reached [NR]) for patients who were naive to both chemotherapy and CYP17 inhibitor; 20·3 weeks (95% CI 16·9–26·1) for those who had received chemotherapy but not a CYP17 inhibitor, and 19·3 weeks (95% CI 14·1–27·1) for those who had received a CYP17 inhibitor (figure 3).2 </br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> Figure 3: Time to PSA Progression2 </br>Median time to radiological progression was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36·4–NR); 50·4 weeks (95% CI 12·1–NR) for those who had received chemotherapy but not a CYP17 inhibitor; and 12·7 weeks (95% CI 12·0–36·3) for those who had received a CYP17 inhibitor (figure 4).2 </br>Figure 4: Time to Radiologic Progression2 </br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br>  Highest pre-specified daily dose of \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and a maximum tolerated dose was not reached; no \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "-limiting toxic effects were noted and dose escalation was discontinued because of a \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " plateau of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>A Phase 3 trial (ARAMIS) evaluated the \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and efficacy of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in patients with high risk \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and can be accessed on the clinicaltrials.gov  https://www.clinicaltrials.gov/ct2/show/NCT02200614?term=ODM+201&amp;rank=4</br>A Randomized, Double-blind, Placebo Controlled Phase III Study of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer has been initiated and listed on the clinicaltrials.gov.  https://www.clinicaltrials.gov/ct2/show/NCT02799602?term=ODM+201&amp;rank=9</br>REV: 0719</br>References:</br>1. NUBEQA® (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer</br>HealthCare Pharmaceuticals, July 2019.</br>2. Fizazi K, Massard C, Bono P, et al. Activity and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br>  </br>phase 2 dose expansion trial.  Lancet Oncol 2  014; 15: 975–85. http://www.ncbi.nlm.nih.gov/pubmed/24974051</br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES\n",
       "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>\n",
       "</figure>\n",
       "</body>\n",
       "</html>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Using the 'ent' visualizer\n",
      "Serving on http://0.0.0.0:5000 ...\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "127.0.0.1 - - [05/Mar/2020 10:57:15] \"GET / HTTP/1.1\" 200 67049\n",
      "127.0.0.1 - - [05/Mar/2020 10:57:15] \"GET /favicon.ico HTTP/1.1\" 200 67049\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Shutting down server on port 5000.\n"
     ]
    }
   ],
   "source": [
    "colors = {\"DRUG\":\"#ff9ff0\",\n",
    "         \"DISEASE\": \"turquoise\",\n",
    "         \"ADVERSE EVENT\": \"tomato\",\n",
    "         \"CONDITION\": \"lavender\",\n",
    "         \"DOSAGE\": \"#ffa500\",\n",
    "         \"INDICATION\": \"#ffe6ff\",\n",
    "         \"PHARMACOKINETICS\": \"#b3b3cc\",\n",
    "         \"DOSING\": \"#ffd9b3\",\n",
    "         \"EFFICACY\": \"#d9ffb3\",\n",
    "         \"CONTRAINDICATIONS\": \"#ffa366\",\n",
    "         \"SAFETY\": \"#80ff80\",\n",
    "         \"DRUG INTERACTION\": \"#b3d9ff\",\n",
    "         \"FOOD INTERACTION\": \"#3399ff\",\n",
    "         \"BIOAVAILABILITY\": \"#ff9900\",\n",
    "         \"ABSORPTION\": \"#ccccb3\",\n",
    "         \"AUC\": \"#00ff55\",\n",
    "         \"CMAX\": \"#ff531a\",\n",
    "         \"MFS\": \"#d966ff\",\n",
    "         \"OS\": \"#5c5cd6\",\n",
    "         \"TTPP\": \"#0088cc\",\n",
    "         \"PFS\": \"#ffcccc\",\n",
    "         \"QOL\": \"#cc00cc\",\n",
    "         \"OBJECTIVE\": \"#ffffb3\",\n",
    "         \"PLASMA CONCENTRATION\": \"#ffff1a\",\n",
    "         \"DOSAGE FORM\": \"#f2f2f2\",\n",
    "         \"TMAX\": \"#b3ffff\",\n",
    "         \"ENDPOINT\": \"#ccddff\",\n",
    "         \"DISCONTINUATION\": \"#ccffcc\",\n",
    "         \"DEATH\": \"#ccffe6\",\n",
    "         \"ADMINISTRATION\": \"#ff4da6\"}\n",
    "options = {\"ents\": [\"DRUG\", \"DISEASE\", \"ADVERSE EVENT\", \"CONDITION\", \"DOSAGE\", \"INDICATION\", \"PHARMACOKINETICS\", \"DOSING\", \"EFFICACY\", \"CONTRAINDICATIONS\", \"SAFETY\", \"DRUG INTERACTION\", \"FOOD INTERACTION\", \"BIOAVAILABILITY\", \"ABSORPTION\", \"AUC\", \"CMAX\", \"MFS\", \"OS\", \"TTPP\", \"PFS\", \"QOL\", \"OBJECTIVE\", \"PLASMA CONCENTRATION\", \"DOSAGE FORM\", \"TMAX\", \"ENDPOINT\", \"DISCONTINUATION\", \"DEATH\", \"ADMINISTRATION\"], \"colors\": colors}\n",
    "displacy.serve(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Phase 1/2 Study of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") in Patients with Progressive Metastatic Castrate Resistant Prostate Cancer (ARADES)</br>Summary:</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is not approved for use in patients with progressive metastatic castrate resistant prostate cancer.</br>● Phase 1–2 clinical trial was conducted to assess \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men with progressive metastatic castration-resistant prostate cancer.2    Secondary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " were to determine the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts.</br>o An open-label, nonrandomized phase 1 dose escalation portion and a phase 2 included randomized dose expansion and long-term follow-up.</br>o Twenty-four patients were enrolled in the   dose escalation phase. No intra-patient dose escalation was permitted. Patients received \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=7); 600 mg/day (n=3); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3).</br>● In the phase 2 part of the study (n=112):</br>o Thirty-eight patients were assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (11 chemotherapy</br>naïve and CYP17inhibitor (CYP17i) naïve; 9 post chemotherapy and CYP17i</br>naïve; 18 post CYPi).</br>o Thirty-seven patients were assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (9 [chemotherapy</br>naïve and CYP17i) naïve]; 9 [post chemotherapy and CYP17i naïve]; 19 [post</br>CYPi]).</br>o Thirty-five patients were assigned to receive \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (8 [chemotherapy</br>naïve and CYP17i) naïve]; 10 [post chemotherapy and CYP17i naïve]; 17 [post</br>CYPi]).</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorption and the median</br>\n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    t\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " max  ranged \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    3.0–5.1 hours\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1.5–5.0 h\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " for the diastereo isomer keto-darolutamide on day 1. The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1.6–2.3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t and C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose.</br>● Most\n",
       "(2%) and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%).</br>common Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2</br>● PSA response (≥ 50% decrease in PSA) by week 12 was observed with all doses and all treatment groups, but significantly fewer were seen in patients previously treated with CYP17 inhibitors than in those who were naïve to both chemotherapy and CYP17 inhibitors.</br>● RECIST responses or stable disease in soft tissue, and stabilized disease in bone was observed at all dose levels. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients</br>NUBEQA ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br> ● Circulating tumor cell measured at baseline and at week 12 (available in 87 of 124 patients) 41 (82%) patients maintained favorable circulating tumor cell counts (&lt; 5 cells per 7·5 mL of blood) at week 12. In the patients with ≥5 cells counts at baseline, 14 (38%) converted to &lt; 5 cells \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    counts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", and nine (18%) patients converted from &lt; 5 cells counts to ≥5 cells counts.</br>● Patients (58%) who were both chemotherapy and CYP17 inhibitor-naïve converted from ≥5 cells \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    counts\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " to &lt; 5 cells counts.</br>● The median time to PSA progression in phase 1–2 (including all dose levels) was 72.3 weeks (95% CI 24.3–not reached [NR]) for patients who were naive for both chemotherapy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    CYP17\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " inhibitor.</br>● Median time to radiological progression was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36.4–NR).</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1 \n",
       "Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " is not approved for use in patients with progressive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>A Phase 1–2 clinical trial was conducted to assess \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men with progressive metastatic castration-resistant prostate cancer.2    The primary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " of the trial were to assess \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and to define a maximum tolerated dose. Secondary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " were to determine the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts.</br>A proportion of patients in an open-label, multicenter, nonrandomized phase 1 dose escalation study were permitted to continue into a phase 2 part of the study and were randomized in dose expansion and long-term follow-up.2    Patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adenocarcinoma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " of the prostate with progressive metastatic disease despite ongoing \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       "-deprivation therapy were enrolled.</br>The phase 1 dose-escalation part of the study was not randomized.2    The patients sequentially entered the phase 1 part of the study. In the phase 2, patients were randomly assigned (ratio 1:1) by blocks of four and two to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " doses of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " with previous treatment (chemotherapy-naive and CYP17 inhibitor-naive; post-chemotherapy and CYP17 inhibitor-naive; and post- CYP17 inhibitor) as stratification factors. The third expanded dose level, patients were randomly assigned to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " doses.</br>Three to six patients sequentially received \n",
       "<mark class=\"entity\" style=\"background: #ffa500; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    twice daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") which was increased to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", 600 mg, \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and 1800 mg.2    In the absence of grade 3 or higher treatment-related adverse events within the first 28 days, patients   were permitted to continue \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " treatment in the absence of disease progression.2    No   intra-patient dose escalation was permitted.</br>The phase 2 part of the study included three expanded cohorts (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", and \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose) each containing about 35 patients.2    A total of 136 patients were enrolled (24 were</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> enrolled in the dose-escalation phase and 112 randomly assigned to receive either 200 mg, \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ", or \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg of darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "). Of the 24 patients enrolled in dose escalation phase; \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4, 1 discontinued protocol violation); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=7, 1 discontinued due to AE); 600 mg/day (n=3, 0 discontinued); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=4, 1 discontinued due to AE); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3, 0 discontinued); \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3, 0 discontinued). Allocation of the 112 patients randomized in the phase 2 part of the study is presented in Figure 1. Two patients randomized did not receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>Figure 1: Trial profile of the phase 2 part of the study2 </br> Select baseline characteristic of patients are presented in Table 1.2  Table 1: Select Baseline Characteristics2 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®  \n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "(\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br>        Phase1 (n=24)</br> Phase 2 Group 1</br>     Group 2</br>  Group 3</br>          \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=38)</br>      \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=37)</br>   1400 (n=35)</br>   Age (years)</br>      69 (64–74)</br> 67 (65–73)</br>      68 (64–75)</br>   73 (64–78)</br>   PSA (ng/ml)</br>      27 (13–96)</br> 109 (43–352)</br>      95 (45–255)</br>   155 (31–382)</br> LDH (U/L)</br>  249 (192–412)</br>  220 (195–292)</br>   232 (202–322)</br>   226 (201–322)</br>  </br>                                                                                                                                          Chemotherapy-naive and CYP17 inhibitor-naive</br>     14 (58</br> 11 (29%)</br>     9 (24%)</br>  8 (23%)</br>   Post-chemotherapy and CYP17 inhibitor-naïve</br>      7 (29%)</br> 9 (24%)</br>      9 (24%)</br>   10 (29%)</br> Post-\n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    CYP17\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " inhibitor</br>  3 (13%)</br>   18 (47%)</br>    19 (51%)</br>    17 (49%)</br>   Total Gleason Score &lt;8</br>&gt; 8</br>Missing</br>    15 (68%) 7 (32%) 2</br>15 (42%) 21 (58%) 2</br>    20 (59%) 14 (41%) 3</br> 15 (46%) 18 (55%) 2</br>   ECOG PS 0</br>1</br>      17 (71%) 7 (29%)</br> 19 (50%) 19 (50%)</br>      20 (54%) 17 (46%)</br>   16 (46%) 19 (54%)</br> Circulating tumor cell counts &lt;5 cells/7.5mL of blood</br>&gt; 5 cells/7.5mL of blood</br>  13 (54%) 9 (38%)</br>   18 (47%) 17 (45%)</br>    18 (49%) 17 (46%)</br>    16 (46%) 14 (40%)</br>   Disease localization Bone disease</br>Bone only</br>Bone and soft tissue Soft-tissue disease Lymph node Visceral</br>No radiologic evidence of mets</br>    15 (63%) 6 (25%) 9 (38%) 17 (71%) 17 (71%) 1 (4%) 1 (4%)</br>34 (89%) 12 (32%) 22 (58%) 26 (68%) 18 (47%) 10 (26%) 0</br>    32 (86%) 11 (30%) 21 (57%) 26 (70%) 24 (65%) 8 (22%) 0</br> 32 (91%) 20 (57%) 12 (34%) 15 (43%) 7 (20%) 8 (23%) 0</br> \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Bone metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " 0</br>1-4 5-20 &gt;20</br>  9 (38%) 3 (13%) 7 (29%) 5 (21%)</br>  6 (16%) 10 (26%) 11 (29%) 11 (29%)</br>   5 (14%) 13 (35%) 9 (24%) 10 (27%)</br>   3 (9%) 6 (17%) 8 (23%) 18 (51%)</br>  PSA=prostate-specific antigen. LDH=lactate dehydrogenase. ECOG=Eastern Cooperative Oncology Group. NA=not assessable, \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Mets=metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       "</br>The median \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    time\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " therapy was 24-8 (IQR 24.8-25.2) months for the phase 1 part of the study and 11 months (IQR 8.3-14.0) months for phase 2 part of the trial.2    Most common reason for discontinuation was disease progression and 5 (4%) of 124 patients discontinued for \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ".</br>Common \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " occurring in greater than equal to 10% of patients are presented in Table 2 below.2 </br>Table 2: Most Common Adverse Events Occurring in  &gt;  10% of \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Patients2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " </br>Fatigue or \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff531a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Cmax</span>\n",
       "</mark>\n",
       " pain \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " Constipation Decreased appetite \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Peripheral edema\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>Grade 1</br>27 (22%) 16 (13%) 15 (12%) 14 (11%) 15 (12%) 12 (10%) 13 (10%)</br>Grade 2</br>13 (10%) 13 (10%) 9 (7%) 5 (4%) 1 (&lt;1%) 4 (3%) 2 (2%)</br>Grade 3</br>2 (2%) 2 (2%) 2 (2%) 0</br>0 0 0</br>NUBEQA ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorbed and the median t max  were 3·0–5·1 h for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and 1·5–5·0 hours for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " on day 1.2    The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1·6–2·3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t  and C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose.</br>Antitumor activity as measured by in PSA from baseline are presented in Figure 2</br>Figure 2: Percentage in PSA Decline at Week 12 From Baseline2 </br> RECIST responses or stable disease in soft tissue, and stabilized disease in bone are shown in table 4.2    No differences in response by dose were noted in soft tissue and bone. This variable was not formally evaluated due to the small number of patients within each dose group and subgroup. The highest activity was noted in patients who were chemotherapy-naive and CYP17 inhibitor-naive patients (table 3).</br>Table 3: Imaging Results at Week 12 Using RECIST2 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br>  Measured baseline and 12-week circulating tumor cell results were available in 87 of 124 patients.2    Circulating conversion \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    rates\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of circulating tumor cells are presented in table 4 below.</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> Table 4: Circulating Tumor Cells at Week 12: Expanded dose Levels2 </br>        Chemotherapy naïve/CYP17i naïve (n=37*)</br> Post Chemotherapy/CYP17i naïve</br>(n=32*)</br>    Post CYP 17i (n=55*)</br>     &lt; at Baseline</br>    (n=18)</br> (n=16)</br>     (n=25)</br>     &lt;5 at week 12</br>    15 (88%)</br> 10 (91%)</br>     16 (73%)</br>     ≥5 at week 12</br>    2 (12%)</br> 1 (9%)</br>     6 (27%)</br>     NA at week 12</br>    1</br> 5</br>     3</br>     ≥5 at baseline</br>    (n=16)</br> (n=13)</br>     (n=24)</br>     &lt;5 at week 12</br>    7 (58%)</br> 7 (58%)</br>     0</br>     ≥5 at week 12</br>    5 (42%)</br> ,5 (42%)</br>     1213 (100%)</br> NA at week 12</br>    4</br>   1</br>   11</br>  NA=not assessable. CTC count is expressed as cells per 7·5 mL of blood. These data include patients with missing baseline CTC. *Total number includes three patients with missing baseline. †   Total number includes six patients with missing baseline.</br>The median serum testosterone level at baseline was 0·4 nmol/L (IQR 0·4–0·6; n=124) and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    castrate concentrations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " were maintained at week 12 (0·4 nmol/L [0·4–0·6]; n=111).2 </br>The median time to PSA progression in phase 1–2 (including all dose levels) was 72·3 weeks (95% CI 24·3–not reached [NR]) for patients who were naive to both chemotherapy and CYP17 inhibitor; 20·3 weeks (95% CI 16·9–26·1) for those who had received chemotherapy but not a CYP17 inhibitor, and 19·3 weeks (95% CI 14·1–27·1) for those who had received a CYP17 inhibitor (figure 3).2 </br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br> Figure 3: Time to PSA Progression2 </br>Median time to radiological progression was not reached for patients who were naive to both chemotherapy and CYP17 inhibitor (95% CI 36·4–NR); 50·4 weeks (95% CI 12·1–NR) for those who had received chemotherapy but not a CYP17 inhibitor; and 12·7 weeks (95% CI 12·0–36·3) for those who had received a CYP17 inhibitor (figure 4).2 </br>Figure 4: Time to Radiologic Progression2 </br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br></br>  Highest pre-specified daily dose of \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and a maximum tolerated dose was not reached; no \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "-limiting toxic effects were noted and dose escalation was discontinued because of a \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " plateau of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ".</br>A Phase 3 trial (ARAMIS) evaluated the \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and efficacy of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in patients with high risk \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and can be accessed on the clinicaltrials.gov  https://www.clinicaltrials.gov/ct2/show/NCT02200614?term=ODM+201&amp;rank=4</br>A Randomized, Double-blind, Placebo Controlled Phase III Study of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer has been initiated and listed on the clinicaltrials.gov.  https://www.clinicaltrials.gov/ct2/show/NCT02799602?term=ODM+201&amp;rank=9</br>REV: 0719</br>References:</br>1. NUBEQA® (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer</br>HealthCare Pharmaceuticals, July 2019.</br>2. Fizazi K, Massard C, Bono P, et al. Activity and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>.</br>  </br>phase 2 dose expansion trial.  Lancet Oncol 2  014; 15: 975–85. http://www.ncbi.nlm.nih.gov/pubmed/24974051</br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARADES\n",
       "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "colors = {\"DRUG\":\"#ff9ff0\",\n",
    "         \"DISEASE\": \"turquoise\",\n",
    "         \"ADVERSE EVENT\": \"tomato\",\n",
    "         \"CONDITION\": \"lavender\",\n",
    "         \"DOSAGE\": \"#ffa500\",\n",
    "         \"INDICATION\": \"#ffe6ff\",\n",
    "         \"PHARMACOKINETICS\": \"#b3b3cc\",\n",
    "         \"DOSING\": \"#ffd9b3\",\n",
    "         \"EFFICACY\": \"#d9ffb3\",\n",
    "         \"CONTRAINDICATIONS\": \"#ffa366\",\n",
    "         \"SAFETY\": \"#80ff80\",\n",
    "         \"DRUG INTERACTION\": \"#b3d9ff\",\n",
    "         \"FOOD INTERACTION\": \"#3399ff\",\n",
    "         \"BIOAVAILABILITY\": \"#ff9900\",\n",
    "         \"ABSORPTION\": \"#ccccb3\",\n",
    "         \"AUC\": \"#00ff55\",\n",
    "         \"CMAX\": \"#ff531a\",\n",
    "         \"MFS\": \"#d966ff\",\n",
    "         \"OS\": \"#5c5cd6\",\n",
    "         \"TTPP\": \"#0088cc\",\n",
    "         \"PFS\": \"#ffcccc\",\n",
    "         \"QOL\": \"#cc00cc\",\n",
    "         \"OBJECTIVE\": \"#ffffb3\",\n",
    "         \"PLASMA CONCENTRATION\": \"#ffff1a\",\n",
    "         \"DOSAGE FORM\": \"#f2f2f2\",\n",
    "         \"TMAX\": \"#b3ffff\",\n",
    "         \"ENDPOINT\": \"#ccddff\",\n",
    "         \"DISCONTINUATION\": \"#ccffcc\",\n",
    "         \"DEATH\": \"#ccffe6\",\n",
    "         \"ADMINISTRATION\": \"#ff4da6\"}\n",
    "options = {\"ents\": [\"DRUG\", \"DISEASE\", \"ADVERSE EVENT\", \"CONDITION\", \"DOSAGE\", \"INDICATION\", \"PHARMACOKINETICS\", \"DOSING\", \"EFFICACY\", \"CONTRAINDICATIONS\", \"SAFETY\", \"DRUG INTERACTION\", \"FOOD INTERACTION\", \"BIOAVAILABILITY\", \"ABSORPTION\", \"AUC\", \"CMAX\", \"MFS\", \"OS\", \"TTPP\", \"PFS\", \"QOL\", \"OBJECTIVE\", \"PLASMA CONCENTRATION\", \"DOSAGE FORM\", \"TMAX\", \"ENDPOINT\", \"DISCONTINUATION\", \"DEATH\", \"ADMINISTRATION\"], \"colors\": colors}\n",
    "displacy.render(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Document 3 - Nubeqa(US-NUBEQA-76047-S.docx.pdf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc = loaded_nlp(\"\"\"NUBEQA®   (darolutamide) and Central Nervous System-related Adverse Events\n",
    "Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.1 \n",
    "Background\n",
    "Darolutamide is a second-generation Androgen Receptor (AR) inhibitor.2    Second-generation AR inhibitors share antagonist activity on GABA-A, a ligand-gated chloride ion channel. Inhibition of this channel has been suggested to induce seizures.3    This mechanism is, however, dependent on local concentrations in the central nervous system (CNS). Prior to darolutamide, second-generation AR inhibitors evaluated in placebo-controlled randomized trials in patients with high-risk non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) reported significant CNS-related events, despite exclusion of patients with a history of CNS-related events.\n",
    "According to the Center for Disease Control in prevention, approximately 1.2 % of the general United States population were reported as having epilepsy. Although the prevalence of epilepsy appears low, the Institute for Clinical and Economic Review (ICER) has identified CNS-related events such as falls, fractures, and seizures to be treatment emergent adverse events (TEAEs) of interest for anti-androgen therapies.4 \n",
    "This letter will discuss CNS-related events reported in trials with darolutamide including the most recent Phase III, randomized, double-blind, placebo-controlled multinational study, evaluating the efficacy and safety of darolutamide in men being treated with androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC) and have a high risk of developing metastases -- ARAMIS.  2,3,5-9\n",
    "Summary\n",
    "● Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.1 \n",
    "● ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and safety of darolutamide in men being treated with androgen deprivation\n",
    "therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC) and have a high risk of developing metastases. The primary endpoint of the study was metastasis-free survival (MFS). MFS was defined as the time from randomization to evidence of metastasis (new or progressive regional pathological lymph nodes were not defined as metastasis) or death from any cause, whichever occurred first.\n",
    "o Darolutamide demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% versus placebo [HR .41 (95% CI 0.34 – 0.50);  P  <0.001]. The most common adverse reactions (≥2%) reported were fatigue, pain in extremity, and rash.  5 \n",
    "NUBEQA ®  (darolutamide): CNS-related AEs\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    " ● In addition to evaluation of metastasis-free survival (MFS), safety was evaluated, including CNS-related events.    Patients with a history or risk of a seizure were included.6 \n",
    "o The most frequent CNS-related TEAEs (all grades) occurring in ≥5% of patients included fatigue (including asthenia) (12.1% [115/954] vs 8.7% [48/554] in the darolutamide vs placebo arms, respectively).7 \n",
    "o Most of the adverse events reported were Grade 1 or 2 (54.6% with darolutamide and 54.2% with placebo).\n",
    "o Grade 3 fatigue including asthenia was reported in 0.6% of patients in the darolutamide arm vs 1.1% in the placebo arm.7  7\n",
    "o No Grade 4 or Grade 5 CNS-related adverse event occurred in either arm.  ● Phase I and II (ARADES study) enrolled 134 patients with progressive metastatic\n",
    "castration-resistant prostate cancer (mCRPC). Patients with a history, or risk, of a seizure were included.2 \n",
    "o Data from the ARADES safety database were reviewed for potential seizure or seizure-related adverse events2 \n",
    "▪ The following adverse event (AE) terms were used identify patients with AEs potentially related to seizures: seizure, syncope, presyncope, loss of consciousness, depressed level of consciousness, encephalopathy, and transient ischemic attack, hallucinations, vasovagal syndrome, nonpathologic fractures, urinary or fecal incontinence, tonic-clonic activity, abnormal electroencephalograms (EEGs).2 \n",
    "▪ Medical histories and use of concomitant anti-seizure medications were reviewed, as well as concomitant medications that are indicated for treatment of any seizure-related disorders. Medications that could lower the seizure threshold were also identified, along with any seizure or seizure-like condition.2 \n",
    "o Twenty one percent of the patients had concomitant medications indicated for epilepsy or other seizure-related disorders.2    Twelve patients had  > 1 of the above listed AE. None of the patients experienced seizures or related disorders while receiving darolutamide; one seizure event was reported to occur 27 days after stopping treatment. There were 5 fall events, 1 syncope, 1 presyncope, and 4 urinary incontinence cases – all interpreted by the investigators as not related to darolutamide treatment and not leading to treatment discontinuation. Careful evaluation of these cases suggested that these events were unlikely to be related to seizure.2 \n",
    "● ARAFOR, an open-label randomized phase I trial, evaluated the bioavailability and effect of food on the bioavailability of darolutamide. The study compared relative bioavailability of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with chemotherapy-naïve mCRPC. In addition, the study evaluated short term safety and tolerability and in an extension component long-term safety and tolerability.8 \n",
    "o Thirty men with metastatic chemotherapy-naïve CRPC were enrolled; the median age of the patients was 68 years.\n",
    "NUBEQA ®  (darolutamide): CNS-related AEs\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    " \n",
    " o A total of 22 of 30 patients (73%) reported AEs; most were grade 1–2 (114 of 125 [91%]).\n",
    "▪ The most common reported CNS-related AE was fatigue (all grade 1; n = 4/30 [13%]).\n",
    "▪ No dose reductions were necessary.\n",
    "▪ No seizures were reported.\n",
    "● In preclinical mouse and rat models, darolutamide showed negligible brain penetration at\n",
    "pharmacological doses.2    Brain/plasma ratio of darolutamide’s main active metabolite, keto-darolutamide, was also negligible after darolutamide administration (Table 5). Quantitative whole body autoradiography (QWBA) in rats confirmed the minimal penetration of Darolutamide into the brain.3    In rodent studies, brain exposures to darolutamide in terms of AUC (0-24) were very low with 4.5% of plasma exposure after single dose and 2.1 - 3.9% after repeated doses. Darolutamide has negligible brain penetration in nonclinical models.2 \n",
    "Clinical Data\n",
    "Darolutamide has been shown to have negligible brain penetration at pharmacological doses in preclinicalmodels.2   Consistentwiththispre-clinicalobservation,minimalreportsofCNSevents were observed in clinical trials, including ARAMIS,6    ARADES2    and ARAFOR.8    See brief summaries of these studies below.\n",
    "Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)\n",
    "ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and safety of darolutamide in men being treated with androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC) and have a high risk of developing metastases.7    Patients (N = 1509) were randomized 2:1 to receive darolutamide 600 mg orally twice daily plus ADT versus matching placebo. In addition to evaluation of metastasis-free survival as the primary efficacy variable, safety was evaluated including CNS-related events.    Patients with a history or risk of a seizure were included.8 \n",
    "Overall, 12 patients in the darolutamide arm had a medical history of seizure, including 2 patients (0.2%) with reported episodes prior to entering the study and 10 patients (1.0%) with ongoing epilepsy. In the placebo arm, 1 patient (0.2%) reported having post-traumatic epilepsy, which was ongoing at study entry.6    None of the patients with a medical history of seizure had a seizure during the trial. The most frequent CNS-related TEAEs (all grades) occurring in ≥ 5% of patents included fatigue (including asthenia) (12.1% [115/954] vs 8.7% [48/554] in the darolutamide vs placebo arms, respectively). See Table 1 below.7 \n",
    "Most adverse events reported were Grade 1 or 2 (54.6% with darolutamide and 54.2% with placebo). Grade 3 fatigue including asthenia (0.6% vs 1.1%) were reported in the darolutamide vs placebo arm, respectively. No Grade 4 or Grade 5 CNS-related adverse event occurred in either arm. See Table 1.7 \n",
    "NUBEQA ®  (darolutamide): CNS-related AEs\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " For the incidence of darolutamide CNS-related TEAEs of particular interest in the nonmetastatic castration resist prostate cancer space (nmCRPC) see Table 2 .7 \n",
    "Table 1\n",
    "Table 2\n",
    "    ARAMIS: Total of CNS- related TEAEs with an Incidence of  ≥ 5%7 \n",
    "     Preferred term, n (%)\n",
    "   Darolutamide N = 954\n",
    "  Placebo N = 554\n",
    "     Fatigue\n",
    "    115 (12.1)\n",
    "   48 (8.7)\n",
    " Hot flush\n",
    "    50 (5.2)\n",
    "    23 (4.2)\n",
    "        ARAMIS: CNS-related TEAEs of Interest7 \n",
    "    Darolutamide N=954\n",
    "Placebo N=554\n",
    "                        AE\n",
    "Any Grade, n (%)\n",
    "Grade 3, %\n",
    "Grade 4 %\n",
    "Grade 5, %\n",
    "Any Grade, n (%)\n",
    "Grade 3, %\n",
    "Grade 4 %\n",
    "Grade 5, %\n",
    "                                Fatigue, including asthenia\n",
    "151 (15.8)\n",
    "0.6\n",
    "0\n",
    "0\n",
    "63 (11.4)\n",
    "1.1\n",
    "0\n",
    "0\n",
    "                    Seizure\n",
    "2 (0.2)\n",
    "0\n",
    "1 (0.2)\n",
    "0\n",
    "                      Cognitive disorder\n",
    "4 (0.4)\n",
    "0\n",
    "0\n",
    "0\n",
    "1 (0.2)\n",
    "0\n",
    "0\n",
    "0\n",
    "                                Memory impairment\n",
    "Disturbance in attention\n",
    "5 (0.5)\n",
    "0\n",
    "0\n",
    "0\n",
    "7 (1.3)\n",
    "0\n",
    "0\n",
    "0\n",
    "                                0\n",
    "0\n",
    "0\n",
    "0\n",
    "1 (0.2)\n",
    "0\n",
    "0\n",
    "0\n",
    "                                Amnesia\n",
    "1 (0.1)\n",
    "0\n",
    "0\n",
    "0\n",
    "3 (0.5)\n",
    "0\n",
    "0\n",
    "0\n",
    "                    Hot flush\n",
    "50 (5.2)\n",
    "0\n",
    "-\n",
    "-\n",
    "23 (4.6)\n",
    "0\n",
    "-\n",
    "-\n",
    "            Metastatic Castration-Resistant Prostate Cancer (mCRPC)\n",
    "The ARADES trial, an open-label, multicenter trial with a non-randomized Phase I dose escalation portion and a Phase II randomized dose expansion phase, enrolled patients with progressive, metastatic castration-resistant prostate cancer (mCRPC).2    Patients with a history of seizures or were at risk of seizures were not excluded. Concomitant medications that may have lowered the seizure threshold were not an exclusion criteria for the patients in the trials. To assess whether treatment with Darolutamide is possibly associated with seizures, the ARADES safety database was reviewed for potential seizure or seizure-related AEs.\n",
    "The safety data were reviewed using the following AE terminology in order to identify patients with AE potentially related to seizures were: seizure, syncope, presyncope, loss of consciousness, depressed level of consciousness, encephalopathy, transient ischemic attack, hallucinations, vasovagal syndrome, urinary or fecal incontinence, tonic-clonic activity and abnormal EEGs.2 \n",
    "NUBEQA ®  (darolutamide): CNS-related AEs\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Patients’ medical histories and use of concomitant anti-seizure medications, as well as concomitant medications that were indicated for the treatment of any seizure-related disorders were reviewed. Medications that lower the seizure threshold or induce seizure-like conditions were also reviewed.2 \n",
    "Patients (N = 134) in the ARADES trial had progressive, mCRPC with serum testosterone levels <30 ng/mL. They were either chemotherapy-naïve or had ≤2 prior chemotherapy regimens. Baseline characteristics are presented in Table 3.2 \n",
    "Table 3: Baseline Characteristics.2 \n",
    "        Total N=134\n",
    "   CYP17i-naïve, chemo-naïve, N\n",
    "     42 (31.3)\n",
    "   CYP17i-naïve, post-chemo\n",
    "     35 (26.1)\n",
    "   Post-CYP17i\n",
    "     57 (42.5)\n",
    "   Age, median years (range)\n",
    "     60 (53-89)\n",
    "   PSA ng/mL, median (range)\n",
    "     99 (3-5000)\n",
    "   Time from diagnosis to study treatment, median months (range)\n",
    "    69 (10-231)\n",
    " Disease localization, N (%): Bone disease only\n",
    "Soft Tissue only\n",
    "Soft and Bone Disease\n",
    "   49 (36.6) 20 (14.9) 64 (47.8)\n",
    "   Seizure (and like) event history %\n",
    "    11 (8.2)\n",
    " Time on Study Drug (days) Mean (SD)\n",
    "Median (min, max)\n",
    "  184 (131.0) 168 (1,684)\n",
    "In the ARADES trial, there were 38 medications with indications to treat epilepsy or other seizure-related disorders (11 insomnia, 8 anxiety, 10 pain, 3 epilepsy, 2 depression, 1 polyneuropathy, 1 alcohol abuse, 1 bowel incontinence, and 1 restless leg syndrome).2 \n",
    "Sixteen patients reported at least one of the prespecified seizure-related AEs mentioned above (Table 4).2    There were 1 syncope, 1 presyncope, and 5 urinary incontinence, 2 collapses, 2 fecal incontinence cases that were all considered as not drug-related by the investigator.2    Only one report of urinary incontinence that occurred 256 days after the start of treatment with 700 mg twice daily was considered drug-related. Other than that, none of these AEs was considered a seizure-like event and none led to study drug discontinuation.2 \n",
    "None of the patients experienced seizures or related disorders while receiving darolutamide.2    A seizure event was reported after the patient had his end of trial visit, 27 days after stopping the darolutamide. This patient had collapses in his medical history and one during the trial (Table 4), along with anemia, which was noted by the investigators to be a confounder of this event.\n",
    "NUBEQA ®  (darolutamide): CNS-related AEs\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Table 4. Central Nervous System-Related Adverse Events During Study.2 \n",
    "  Phase\n",
    "    Dose\n",
    "   Event\n",
    "   Days in Study\n",
    "   Relevant Medical History\n",
    "     I\n",
    " 500 mg\n",
    "Urinary incontinence\n",
    "    0\n",
    " Stress urinary incontinence due to prostatectomy\n",
    "     I\n",
    "    300 mg\n",
    " Presyncope\n",
    "      7\n",
    "   Presyncope 15 yrs ago\n",
    "     II\n",
    "    200 mg\n",
    " Fecal incontinence\n",
    "      47\n",
    "   Fecal incontinence\n",
    "     II\n",
    "    700 mg\n",
    " Urinary incontinence\n",
    "      256\n",
    "        II\n",
    "    200 mg\n",
    " Urinary incontinence\n",
    "      255\n",
    "   Oxazepam\n",
    " II\n",
    "     700 mg\n",
    "    Urinary incontinence\n",
    "    229\n",
    "         II\n",
    " 200 mg\n",
    "Collapse\n",
    "    86\n",
    " Collapses in medical history (one during trial) Anemia\n",
    "     II\n",
    "    100 mg\n",
    " Collapse\n",
    "      220\n",
    "    II\n",
    "     100 mg\n",
    "    Fecal and urinary incontinence\n",
    "    65\n",
    "       II\n",
    "  100 mg\n",
    " Syncope\n",
    "  218\n",
    " Temazepam for insomnia Lorazepam, alcohol abuse\n",
    " The ARAFOR trial, an open-label, randomized, multicenter phase I trial, evaluated the bioavailability and effect of food on the bioavailability of darolutamide. The study compared relative bioavailability of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with chemotherapy-naïve mCRPC. The study also assessed the effect of food on the bioavailability of darolutamide tablet products tablet A (TabA) and tablet B (TabB). In addition, the study evaluated short term safety and tolerability and in an extension component long-term safety and tolerability. Thirty men with metastatic chemotherapy-naïve CRPC were enrolled; the median age of the patients was 68 years.8 \n",
    "The pharmacokinetic (PK) component consisted of two concurrent groups, which evaluated TabA and (TabB), and capsule. Patients were randomized to one of 3 treatment sequences in each group. There were three treatment periods for each patient during the PK Component which included administration of two darolutamide 300 mg test tablet (TabA or TabB) in both fasted and fed conditions, or administration of darolutamide 100 mg capsule at 600 mg dose in fed state. There was at least 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day.8 \n",
    "All patients completed the PK component and entered the extension component at the 4-week visit. During the extension, patients were treated with a darolutamide 600 mg capsule taken with food twice daily. Treatment continued until disease progression or an intolerable AE.8 \n",
    "NUBEQA®    (darolutamide): CNS-related AEs\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    "All 30 patients completed the first 12 weeks in the extension. A total of 22 of 30 patients (73%) reported AEs; most were grade 1–2 (114 of 125 [91%]). The most common CNS-related AE was fatigue (all grade 1) in 4 patients (13%). Headache was reported as an AE in 2 patients (7%). No dose reductions were made and no seizures were reported.8 \n",
    "Pre-Clinical Data\n",
    "In preclinical, rat and mouse, models, darolutamide showed negligible brain penetration at pharmacological doses.2    Brain/plasma ratio of the main active metabolite, keto-darolutamide, was also negligible after darolutamide administration (Table 5). Quantitative whole body autoradiography (QWBA) in rats confirmed the minimal penetration of darolutamide into the brain. In rodent studies, brain exposures to darolutamide in terms of AUC (0-24) were very low with 4.5% of plasma exposure after single dose and 2.1 - 3.9% after repeated doses. Darolutamide has negligible brain penetration in nonclinical models.  2\n",
    "Table 5: Brain Penetration of Darolutamide.2 \n",
    "REV: 07/2019 References:\n",
    "1. NUBEQA®    (darolutamide) tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.\n",
    "2. Shore ND, Bono P, Massard C, et al. J Clin Oncol 32, 2014 (suppl 4; abstr 275) Presented at the 2014 Genitourinary Cancers Symposia. San Francisco, CA\n",
    "3. Foster, WR, Car, BD, Shi, H, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate, 2011; 71: 480–488.  https://www.ncbi.nlm.nih.gov/pubmed/20878947\n",
    "4. Institute for Clinical and Economic Review (ICER), 2018\n",
    "5. Clegg NJ, Wongvipat J, Joseph J, et al. ARN-509: a novel anti-androgen for prostate cancer treatment.  Cancer\n",
    "Res . 2012;72(6):1494-1503.  https://www.ncbi.nlm.nih.gov/pubmed/22266222\n",
    "6. Data on file, Bayer Pharmaceutical, Whippany, NJ\n",
    "7. Fizazi K et al. Darolutamide in nonmetastatic prostate cancer Oral presentation at: [ASCO GU]; February 14 – 16, 2019; San Francisco CA.\n",
    "8. Institute for Clinical and Economic Review (ICER), 2018\n",
    "9. Massard C, Penttinen HM, Vjaters E, et al. Pharmacokinetics, antitumor activity, and safety of ODM-201 in\n",
    "patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016 May;69(5):834-40.  https://www.ncbi.nlm.nih.gov/pubmed/26463318\n",
    "NUBEQA®    (darolutamide): CNS-related AEs\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\"\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">NUBEQA®   (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") and Central Nervous System-related Adverse Events</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>Background</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is a second-generation Androgen Receptor (AR) inhibitor.2    Second-generation AR inhibitors share antagonist activity on GABA-A, a ligand-gated chloride ion \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    channel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ". Inhibition of this \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    channel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " has been suggested to induce seizures.3    This mechanism is, however, dependent on local \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    concentrations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " in the central nervous system (CNS). Prior to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", second-generation AR inhibitors evaluated in placebo-controlled randomized trials in patients with high-risk \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic Castration-Resistant Prostate Cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") reported \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    significant CNS-related events, despite exclusion of patients with a history\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " of CNS-related events.</br>According to the Center for Disease Control in prevention, approximately 1.2 % of the general United States population were reported as having epilepsy. Although the prevalence of epilepsy appears low, the Institute for Clinical and Economic Review (ICER) has identified CNS-related events such as falls, fractures, and seizures to be treatment emergent \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (TEAEs) of interest for anti-\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " therapies.4 </br>This letter will discuss CNS-related events reported in trials with \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " including the most recent Phase III, randomized, double-blind, placebo-controlled multinational study, evaluating the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men being treated with androgen deprivation therapy (ADT) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") and have a high risk of developing metastases -- ARAMIS.  2,3,5-9</br>Summary</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men being treated with androgen deprivation</br>therapy (ADT) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") and have a high risk of developing metastases. The primary \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of the study was metastasis-free survival (MFS). MFS was defined as the time from randomization to evidence of metastasis (new or progressive regional pathological lymph nodes were not defined as metastasis) or death from any cause, whichever occurred first.</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% versus placebo [HR .41 (95% CI 0.34 – 0.50);  P  &lt;0.001]. The most common adverse reactions (≥2%) reported were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", pain in extremity, and rash.  5 </br>NUBEQA ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> ● In addition to evaluation of metastasis-free survival (MFS), \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " was evaluated, including CNS-related events.    Patients with a history or risk of a seizure were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    included.6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " </br>o The most frequent CNS-related TEAEs (all grades) occurring in ≥5% of patients included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") (12.1% [115/954] vs 8.7% [48/554] in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arms, respectively).7 </br>o Most of the adverse events reported were Grade 1 or 2 (54.6% with \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and 54.2% with placebo).</br>o Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " was reported in 0.6% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs 1.1% in the placebo arm.7  7</br>o No Grade 4 or Grade 5 CNS-related adverse event occurred in either arm.  ● Phase I and II (ARADES study) enrolled 134 patients with progressive metastatic</br>castration-resistant prostate cancer (mCRPC). Patients with a history, or risk, of a seizure were included.2 </br>o Data from the ARADES \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " database were reviewed for potential seizure or seizure-related adverse events2 </br>▪ The following adverse event (AE) terms were used identify patients with AEs potentially related to seizures: seizure, syncope, presyncope, loss of consciousness, depressed level of consciousness, encephalopathy, and transient ischemic attack, hallucinations, vasovagal syndrome, nonpathologic fractures, urinary or fecal incontinence, tonic-clonic activity, abnormal electroencephalograms (EEGs).2 </br>▪ Medical histories and use of concomitant anti-seizure medications were reviewed, as well as concomitant medications that are \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " for treatment of any seizure-related disorders. Medications that could lower the seizure threshold were also identified, along with any seizure or seizure-like condition.2 </br>o Twenty one percent of the patients had \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    concomitant medications\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for epilepsy or other seizure-related disorders.2    Twelve patients had  &gt; 1 of the above listed AE. None of the patients experienced seizures or related disorders while receiving \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "; one seizure event was reported to occur 27 days after stopping treatment. There were 5 fall events, 1 syncope, 1 presyncope, and 4 urinary incontinence cases – all interpreted by the investigators as not related to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " treatment and not leading to treatment discontinuation. Careful evaluation of these cases suggested that these events were unlikely to be related to seizure.2 </br>● ARAFOR, an open-label randomized phase I trial, evaluated the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ". The study compared relative \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with \n",
       "<mark class=\"entity\" style=\"background: turquoise; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy-naïve mCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". In addition, the study evaluated short term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and in an extension component long-term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and tolerability.8 </br>o Thirty men with metastatic chemotherapy-naïve CRPC were enrolled; the median age of the patients was 68 years.</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br> o A total of 22 of 30 patients (73%) reported AEs; most were grade 1–2 (114 of 125 [91%]).</br>▪ The most common reported CNS-related AE was fatigue (all grade 1; n = 4/30 [13%]).</br>▪ No dose reductions were necessary.</br>▪ No seizures were reported.</br>● In preclinical mouse and rat models, \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed negligible brain penetration at</br>pharmacological doses.2    Brain/\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma ratio\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "’s main active metabolite, keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", was also negligible after \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " administration (Table 5). Quantitative whole body autoradiography (QWBA) in rats confirmed the minimal penetration of \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " into the brain.3    In rodent studies, brain exposures to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in terms of \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " (0-24) were very low with 4.5% of plasma exposure after single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and 2.1 - 3.9% after repeated doses. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " has negligible brain penetration in nonclinical models.2 </br>Clinical Data</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " has been shown to have negligible brain penetration at pharmacological doses in preclinicalmodels.2   Consistentwiththispre-clinicalobservation,minimalreportsofCNSevents were observed in clinical trials, including ARAMIS,6    ARADES2    and ARAFOR.8    See brief summaries of these studies below.</br>Non-metastatic Castration-resistant Prostate Cancer (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ")</br>ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men being treated with androgen deprivation therapy (ADT) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") and have a high risk of developing metastases.7    Patients (N = 1509) were randomized 2:1 to receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 600 mg orally twice daily plus ADT versus matching placebo. In addition to evaluation of metastasis-free survival as the primary efficacy variable, \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " was evaluated including CNS-related events.    Patients with a history or risk of a seizure were included.8 </br>Overall, 12 patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm had a medical history of seizure, including 2 patients (0.2%) with reported episodes prior to entering the study and 10 patients (1.0%) with ongoing epilepsy. In the placebo arm, 1 patient (0.2%) reported having post-traumatic epilepsy, which was ongoing at study entry.6    None of the patients with a medical history of seizure had a seizure during the trial. The most frequent CNS-related TEAEs (all grades) occurring in ≥ 5% of patents included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") (12.1% [115/954] vs 8.7% [48/554] in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arms, respectively). See Table 1 below.7 </br>Most adverse events reported were Grade 1 or 2 (54.6% with \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and 54.2% with placebo). Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (0.6% vs 1.1%) were reported in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arm, respectively. No Grade 4 or Grade 5 CNS-related adverse event occurred in either arm. See Table 1.7 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> For the incidence of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " CNS-related TEAEs of particular interest in the nonmetastatic castration resist prostate cancer space (nmCRPC) see Table 2 .7 </br>Table 1</br>Table 2</br>    ARAMIS: Total of CNS- related TEAEs with an Incidence of  ≥ 5%7 </br>     Preferred term, n (%)</br>   \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 954</br>  Placebo N = 554</br>     Fatigue</br>    115 (12.1)</br>   48 (8.7)</br> Hot flush</br>    50 (5.2)</br>    23 (4.2)</br>        ARAMIS: CNS-related TEAEs of Interest7 </br>    \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N=954</br>Placebo N=554</br>                        AE</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>                                Fatigue, including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>151 (15.8)</br>0.6</br>0</br>0</br>63 (11.4)</br>1.1</br>0</br>0</br>                    Seizure</br>2 (0.2)</br>0</br>1 (0.2)</br>0</br>                      Cognitive disorder</br>4 (0.4)</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Memory impairment</br>Disturbance in attention</br>5 (0.5)</br>0</br>0</br>0</br>7 (1.3)</br>0</br>0</br>0</br>                                0</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Amnesia</br>1 (0.1)</br>0</br>0</br>0</br>3 (0.5)</br>0</br>0</br>0</br>                    Hot flush</br>50 (5.2)</br>0</br>-</br>-</br>23 (4.6)</br>0</br>-</br>-</br>            Metastatic Castration-Resistant Prostate Cancer (mCRPC)</br>The ARADES trial, an open-label, multicenter trial with a non-randomized Phase I dose escalation portion and a Phase II randomized dose expansion phase, enrolled patients with progressive, metastatic castration-resistant prostate cancer (mCRPC).2    Patients with a history of seizures or were at risk of seizures were not excluded. Concomitant medications that may have lowered the seizure threshold were not an exclusion criteria for the patients in the trials. To assess whether treatment with \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " is possibly associated with seizures, the ARADES \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " database was reviewed for potential seizure or seizure-related AEs.</br>The \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " data were reviewed using the following AE terminology in order to identify patients with AE potentially related to seizures were: seizure, syncope, presyncope, loss of consciousness, depressed level of consciousness, encephalopathy, transient ischemic attack, hallucinations, vasovagal syndrome, urinary or fecal incontinence, tonic-clonic activity and abnormal EEGs.2 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Patients’ medical histories and use of concomitant anti-seizure medications, as well as concomitant medications that were \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " for the treatment of any seizure-related disorders were reviewed. Medications that lower the seizure threshold or induce seizure-like conditions were also reviewed.2 </br>Patients (N = 134) in the ARADES trial had progressive, mCRPC with serum testosterone levels &lt;30 ng/mL. They were either chemotherapy-naïve or had ≤2 prior chemotherapy regimens. Baseline characteristics are presented in Table 3.2 </br>Table 3: Baseline Characteristics.2 </br>        Total N=134</br>   CYP17i-naïve, chemo-naïve, N</br>     42 (31.3)</br>   CYP17i-naïve, post-chemo</br>     35 (26.1)</br>   Post-CYP17i</br>     57 (42.5)</br>   Age, median years (range)</br>     60 (53-89)</br>   PSA ng/mL, median (range)</br>     99 (3-5000)</br>   Time from diagnosis to study treatment, median months (range)</br>    69 (10-231)</br> Disease localization, N (%): Bone disease only</br>Soft Tissue only</br>Soft and Bone Disease</br>   49 (36.6) 20 (14.9) 64 (47.8)</br>   Seizure (and like) event history %</br>    11 (8.2)</br> Time on Study Drug (days) Mean (SD)</br>Median (min, max)</br>  184 (131.0) 168 (1,684)</br>In the ARADES trial, there were 38 medications with indications to treat epilepsy or other seizure-related disorders (11 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    insomnia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", 8 anxiety, 10 pain, 3 epilepsy, 2 depression, 1 polyneuropathy, 1 alcohol abuse, 1 bowel incontinence, and 1 restless leg syndrome).2 </br>Sixteen patients reported at least one of the prespecified seizure-related AEs mentioned above (Table 4).2    There were 1 syncope, 1 presyncope, and 5 urinary incontinence, 2 collapses, 2 fecal incontinence cases that were all considered as not drug-related by the investigator.2    Only one report of urinary incontinence that occurred 256 days after the start of treatment with 700 mg \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    twice daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " was considered drug-related. Other than that, none of these AEs was considered a seizure-like event and none led to study drug \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    discontinuation.2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " </br>None of the patients experienced seizures or related disorders while receiving darolutamide.2    A seizure event was reported after the patient had his end of trial visit, 27 days after stopping the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ". This patient had collapses in his medical history and one during the trial (Table 4), along with \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", which was noted by the investigators to be a confounder of this event.</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Table 4. Central Nervous System-Related Adverse Events During Study.2 </br>  Phase</br>    Dose</br>   Event</br>   Days in Study</br>   Relevant Medical History</br>     I</br> 500 mg</br>Urinary incontinence</br>    0</br> Stress urinary incontinence due to prostatectomy</br>     I</br>    300 mg</br> Presyncope</br>      7</br>   Presyncope 15 yrs ago</br>     II</br>    \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br> Fecal incontinence</br>      47</br>   Fecal incontinence</br>     II</br>    \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    700 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br> Urinary incontinence</br>      256</br>        II</br>    \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br> Urinary incontinence</br>      255</br>   Oxazepam</br> II</br>     \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    700 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br>    Urinary incontinence</br>    229</br>         II</br> \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br>Collapse</br>    86</br> Collapses in medical history (one during trial) \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>     II</br>    \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br> Collapse</br>      220</br>    II</br>     \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br>    Fecal and urinary incontinence</br>    65</br>       II</br>  \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br> Syncope</br>  218</br> Temazepam for \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    insomnia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " Lorazepam, alcohol abuse</br> The ARAFOR trial, an open-label, randomized, multicenter phase I trial, evaluated the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ". The study compared relative \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with \n",
       "<mark class=\"entity\" style=\"background: turquoise; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy-naïve mCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". The study also assessed the effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " tablet products tablet A (TabA) and tablet B (TabB). In addition, the study evaluated short term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and in an extension component long-term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ". Thirty men with metastatic chemotherapy-naïve CRPC were enrolled; the median age of the patients was 68 years.8 </br>The pharmacokinetic (PK) component consisted of two concurrent groups, which evaluated TabA and (TabB), and capsule. Patients were randomized to one of 3 treatment sequences in each group. There were three treatment periods for each patient during the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " Component which included \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of two \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 300 mg test \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tablet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " (TabA or TabB) in both \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " conditions, or \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 100 mg capsule at 600 mg dose in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state. There was at least 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day.8 </br>All patients completed the PK component and entered the extension component at the 4-week visit. During the extension, patients were treated with a \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 600 mg \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsule\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " taken with food twice daily. Treatment continued until disease progression or an intolerable AE.8 </br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>All 30 patients completed the first 12 weeks in the extension. A total of 22 of 30 patients (73%) reported AEs; most were grade 1–2 (114 of 125 [91%]). The most common CNS-related AE was fatigue (all grade 1) in 4 patients (13%). Headache was reported as an AE in 2 patients (7%). No dose reductions were made and no seizures were reported.8 </br>Pre-Clinical Data</br>In preclinical, rat and mouse, models, \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed negligible brain penetration at pharmacological doses.2    Brain/plasma ratio of the main active metabolite, keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", was also negligible after \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " administration (Table 5). Quantitative whole body autoradiography (QWBA) in rats confirmed the minimal penetration of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " into the brain. In rodent studies, brain exposures to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in terms of \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " (0-24) were very low with 4.5% of plasma exposure after single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and 2.1 - 3.9% after repeated doses. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " has negligible brain penetration in nonclinical models.  2</br>Table 5: Brain Penetration of Darolutamide.2 </br>REV: 07/2019 References:</br>1. NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.</br>2. Shore ND, Bono P, Massard C, et al. J Clin Oncol 32, 2014 (suppl 4; abstr 275) Presented at the 2014 Genitourinary Cancers Symposia. San Francisco, CA</br>3. Foster, WR, Car, BD, Shi, H, et al. Drug safety is a barrier to the discovery and development of new \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor antagonists\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ". Prostate, 2011; 71: 480–488.  https://www.ncbi.nlm.nih.gov/pubmed/20878947</br>4. Institute for Clinical and Economic Review (ICER), 2018</br>5. Clegg NJ, Wongvipat J, Joseph J, et al. ARN-509: a novel anti-\n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for prostate cancer treatment.  Cancer</br>Res . 2012;72(6):1494-1503.  https://www.ncbi.nlm.nih.gov/pubmed/22266222</br>6. Data on file, Bayer Pharmaceutical, Whippany, NJ</br>7. Fizazi K et al. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " in nonmetastatic prostate cancer Oral presentation at: [ASCO GU]; February 14 – 16, 2019; San Francisco CA.</br>8. Institute for Clinical and Economic Review (ICER), 2018</br>9. Massard C, Penttinen HM, Vjaters E, et al. \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", antitumor activity, and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of ODM-201 in</br>patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016 May;69(5):834-40.  https://www.ncbi.nlm.nih.gov/pubmed/26463318</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs\n",
       "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/subashgandyer/anaconda3/lib/python3.7/runpy.py:193: UserWarning: [W011] It looks like you're calling displacy.serve from within a Jupyter notebook or a similar environment. This likely means you're already running a local web server, so there's no need to make displaCy start another one. Instead, you should be able to replace displacy.serve with displacy.render to show the visualization.\n",
      "  \"__main__\", mod_spec)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "<html lang=\"en\">\n",
       "    <head>\n",
       "        <title>displaCy</title>\n",
       "    </head>\n",
       "\n",
       "    <body style=\"font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr\">\n",
       "<figure style=\"margin-bottom: 6rem\">\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">NUBEQA®   (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") and Central Nervous System-related Adverse Events</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>Background</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is a second-generation Androgen Receptor (AR) inhibitor.2    Second-generation AR inhibitors share antagonist activity on GABA-A, a ligand-gated chloride ion \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    channel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ". Inhibition of this \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    channel\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " has been suggested to induce seizures.3    This mechanism is, however, dependent on local \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    concentrations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " in the central nervous system (CNS). Prior to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", second-generation AR inhibitors evaluated in placebo-controlled randomized trials in patients with high-risk \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic Castration-Resistant Prostate Cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") reported \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    significant CNS-related events, despite exclusion of patients with a history\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " of CNS-related events.</br>According to the Center for Disease Control in prevention, approximately 1.2 % of the general United States population were reported as having epilepsy. Although the prevalence of epilepsy appears low, the Institute for Clinical and Economic Review (ICER) has identified CNS-related events such as falls, fractures, and seizures to be treatment emergent \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (TEAEs) of interest for anti-\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " therapies.4 </br>This letter will discuss CNS-related events reported in trials with \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " including the most recent Phase III, randomized, double-blind, placebo-controlled multinational study, evaluating the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men being treated with androgen deprivation therapy (ADT) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") and have a high risk of developing metastases -- ARAMIS.  2,3,5-9</br>Summary</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men being treated with androgen deprivation</br>therapy (ADT) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") and have a high risk of developing metastases. The primary \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of the study was metastasis-free survival (MFS). MFS was defined as the time from randomization to evidence of metastasis (new or progressive regional pathological lymph nodes were not defined as metastasis) or death from any cause, whichever occurred first.</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% versus placebo [HR .41 (95% CI 0.34 – 0.50);  P  &lt;0.001]. The most common adverse reactions (≥2%) reported were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", pain in extremity, and rash.  5 </br>NUBEQA ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> ● In addition to evaluation of metastasis-free survival (MFS), \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " was evaluated, including CNS-related events.    Patients with a history or risk of a seizure were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    included.6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " </br>o The most frequent CNS-related TEAEs (all grades) occurring in ≥5% of patients included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") (12.1% [115/954] vs 8.7% [48/554] in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arms, respectively).7 </br>o Most of the adverse events reported were Grade 1 or 2 (54.6% with \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and 54.2% with placebo).</br>o Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " was reported in 0.6% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs 1.1% in the placebo arm.7  7</br>o No Grade 4 or Grade 5 CNS-related adverse event occurred in either arm.  ● Phase I and II (ARADES study) enrolled 134 patients with progressive metastatic</br>castration-resistant prostate cancer (mCRPC). Patients with a history, or risk, of a seizure were included.2 </br>o Data from the ARADES \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " database were reviewed for potential seizure or seizure-related adverse events2 </br>▪ The following adverse event (AE) terms were used identify patients with AEs potentially related to seizures: seizure, syncope, presyncope, loss of consciousness, depressed level of consciousness, encephalopathy, and transient ischemic attack, hallucinations, vasovagal syndrome, nonpathologic fractures, urinary or fecal incontinence, tonic-clonic activity, abnormal electroencephalograms (EEGs).2 </br>▪ Medical histories and use of concomitant anti-seizure medications were reviewed, as well as concomitant medications that are \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " for treatment of any seizure-related disorders. Medications that could lower the seizure threshold were also identified, along with any seizure or seizure-like condition.2 </br>o Twenty one percent of the patients had \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    concomitant medications\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for epilepsy or other seizure-related disorders.2    Twelve patients had  &gt; 1 of the above listed AE. None of the patients experienced seizures or related disorders while receiving \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "; one seizure event was reported to occur 27 days after stopping treatment. There were 5 fall events, 1 syncope, 1 presyncope, and 4 urinary incontinence cases – all interpreted by the investigators as not related to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " treatment and not leading to treatment discontinuation. Careful evaluation of these cases suggested that these events were unlikely to be related to seizure.2 </br>● ARAFOR, an open-label randomized phase I trial, evaluated the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ". The study compared relative \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with \n",
       "<mark class=\"entity\" style=\"background: turquoise; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy-naïve mCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". In addition, the study evaluated short term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and in an extension component long-term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and tolerability.8 </br>o Thirty men with metastatic chemotherapy-naïve CRPC were enrolled; the median age of the patients was 68 years.</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br> o A total of 22 of 30 patients (73%) reported AEs; most were grade 1–2 (114 of 125 [91%]).</br>▪ The most common reported CNS-related AE was fatigue (all grade 1; n = 4/30 [13%]).</br>▪ No dose reductions were necessary.</br>▪ No seizures were reported.</br>● In preclinical mouse and rat models, \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed negligible brain penetration at</br>pharmacological doses.2    Brain/\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma ratio\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "’s main active metabolite, keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", was also negligible after \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " administration (Table 5). Quantitative whole body autoradiography (QWBA) in rats confirmed the minimal penetration of \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " into the brain.3    In rodent studies, brain exposures to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in terms of \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " (0-24) were very low with 4.5% of plasma exposure after single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and 2.1 - 3.9% after repeated doses. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " has negligible brain penetration in nonclinical models.2 </br>Clinical Data</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " has been shown to have negligible brain penetration at pharmacological doses in preclinicalmodels.2   Consistentwiththispre-clinicalobservation,minimalreportsofCNSevents were observed in clinical trials, including ARAMIS,6    ARADES2    and ARAFOR.8    See brief summaries of these studies below.</br>Non-metastatic Castration-resistant Prostate Cancer (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ")</br>ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men being treated with androgen deprivation therapy (ADT) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") and have a high risk of developing metastases.7    Patients (N = 1509) were randomized 2:1 to receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 600 mg orally twice daily plus ADT versus matching placebo. In addition to evaluation of metastasis-free survival as the primary efficacy variable, \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " was evaluated including CNS-related events.    Patients with a history or risk of a seizure were included.8 </br>Overall, 12 patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm had a medical history of seizure, including 2 patients (0.2%) with reported episodes prior to entering the study and 10 patients (1.0%) with ongoing epilepsy. In the placebo arm, 1 patient (0.2%) reported having post-traumatic epilepsy, which was ongoing at study entry.6    None of the patients with a medical history of seizure had a seizure during the trial. The most frequent CNS-related TEAEs (all grades) occurring in ≥ 5% of patents included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") (12.1% [115/954] vs 8.7% [48/554] in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arms, respectively). See Table 1 below.7 </br>Most adverse events reported were Grade 1 or 2 (54.6% with \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and 54.2% with placebo). Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (0.6% vs 1.1%) were reported in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arm, respectively. No Grade 4 or Grade 5 CNS-related adverse event occurred in either arm. See Table 1.7 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> For the incidence of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " CNS-related TEAEs of particular interest in the nonmetastatic castration resist prostate cancer space (nmCRPC) see Table 2 .7 </br>Table 1</br>Table 2</br>    ARAMIS: Total of CNS- related TEAEs with an Incidence of  ≥ 5%7 </br>     Preferred term, n (%)</br>   \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 954</br>  Placebo N = 554</br>     Fatigue</br>    115 (12.1)</br>   48 (8.7)</br> Hot flush</br>    50 (5.2)</br>    23 (4.2)</br>        ARAMIS: CNS-related TEAEs of Interest7 </br>    \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N=954</br>Placebo N=554</br>                        AE</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>                                Fatigue, including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>151 (15.8)</br>0.6</br>0</br>0</br>63 (11.4)</br>1.1</br>0</br>0</br>                    Seizure</br>2 (0.2)</br>0</br>1 (0.2)</br>0</br>                      Cognitive disorder</br>4 (0.4)</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Memory impairment</br>Disturbance in attention</br>5 (0.5)</br>0</br>0</br>0</br>7 (1.3)</br>0</br>0</br>0</br>                                0</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Amnesia</br>1 (0.1)</br>0</br>0</br>0</br>3 (0.5)</br>0</br>0</br>0</br>                    Hot flush</br>50 (5.2)</br>0</br>-</br>-</br>23 (4.6)</br>0</br>-</br>-</br>            Metastatic Castration-Resistant Prostate Cancer (mCRPC)</br>The ARADES trial, an open-label, multicenter trial with a non-randomized Phase I dose escalation portion and a Phase II randomized dose expansion phase, enrolled patients with progressive, metastatic castration-resistant prostate cancer (mCRPC).2    Patients with a history of seizures or were at risk of seizures were not excluded. Concomitant medications that may have lowered the seizure threshold were not an exclusion criteria for the patients in the trials. To assess whether treatment with \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " is possibly associated with seizures, the ARADES \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " database was reviewed for potential seizure or seizure-related AEs.</br>The \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " data were reviewed using the following AE terminology in order to identify patients with AE potentially related to seizures were: seizure, syncope, presyncope, loss of consciousness, depressed level of consciousness, encephalopathy, transient ischemic attack, hallucinations, vasovagal syndrome, urinary or fecal incontinence, tonic-clonic activity and abnormal EEGs.2 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Patients’ medical histories and use of concomitant anti-seizure medications, as well as concomitant medications that were \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " for the treatment of any seizure-related disorders were reviewed. Medications that lower the seizure threshold or induce seizure-like conditions were also reviewed.2 </br>Patients (N = 134) in the ARADES trial had progressive, mCRPC with serum testosterone levels &lt;30 ng/mL. They were either chemotherapy-naïve or had ≤2 prior chemotherapy regimens. Baseline characteristics are presented in Table 3.2 </br>Table 3: Baseline Characteristics.2 </br>        Total N=134</br>   CYP17i-naïve, chemo-naïve, N</br>     42 (31.3)</br>   CYP17i-naïve, post-chemo</br>     35 (26.1)</br>   Post-CYP17i</br>     57 (42.5)</br>   Age, median years (range)</br>     60 (53-89)</br>   PSA ng/mL, median (range)</br>     99 (3-5000)</br>   Time from diagnosis to study treatment, median months (range)</br>    69 (10-231)</br> Disease localization, N (%): Bone disease only</br>Soft Tissue only</br>Soft and Bone Disease</br>   49 (36.6) 20 (14.9) 64 (47.8)</br>   Seizure (and like) event history %</br>    11 (8.2)</br> Time on Study Drug (days) Mean (SD)</br>Median (min, max)</br>  184 (131.0) 168 (1,684)</br>In the ARADES trial, there were 38 medications with indications to treat epilepsy or other seizure-related disorders (11 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    insomnia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", 8 anxiety, 10 pain, 3 epilepsy, 2 depression, 1 polyneuropathy, 1 alcohol abuse, 1 bowel incontinence, and 1 restless leg syndrome).2 </br>Sixteen patients reported at least one of the prespecified seizure-related AEs mentioned above (Table 4).2    There were 1 syncope, 1 presyncope, and 5 urinary incontinence, 2 collapses, 2 fecal incontinence cases that were all considered as not drug-related by the investigator.2    Only one report of urinary incontinence that occurred 256 days after the start of treatment with 700 mg \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    twice daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " was considered drug-related. Other than that, none of these AEs was considered a seizure-like event and none led to study drug \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    discontinuation.2\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " </br>None of the patients experienced seizures or related disorders while receiving darolutamide.2    A seizure event was reported after the patient had his end of trial visit, 27 days after stopping the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ". This patient had collapses in his medical history and one during the trial (Table 4), along with \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", which was noted by the investigators to be a confounder of this event.</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Table 4. Central Nervous System-Related Adverse Events During Study.2 </br>  Phase</br>    Dose</br>   Event</br>   Days in Study</br>   Relevant Medical History</br>     I</br> 500 mg</br>Urinary incontinence</br>    0</br> Stress urinary incontinence due to prostatectomy</br>     I</br>    300 mg</br> Presyncope</br>      7</br>   Presyncope 15 yrs ago</br>     II</br>    \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br> Fecal incontinence</br>      47</br>   Fecal incontinence</br>     II</br>    \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    700 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br> Urinary incontinence</br>      256</br>        II</br>    \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br> Urinary incontinence</br>      255</br>   Oxazepam</br> II</br>     \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    700 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br>    Urinary incontinence</br>    229</br>         II</br> \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br>Collapse</br>    86</br> Collapses in medical history (one during trial) \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>     II</br>    \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br> Collapse</br>      220</br>    II</br>     \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br>    Fecal and urinary incontinence</br>    65</br>       II</br>  \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    100 mg\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       "</br> Syncope</br>  218</br> Temazepam for \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    insomnia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " Lorazepam, alcohol abuse</br> The ARAFOR trial, an open-label, randomized, multicenter phase I trial, evaluated the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ". The study compared relative \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with \n",
       "<mark class=\"entity\" style=\"background: turquoise; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy-naïve mCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". The study also assessed the effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " tablet products tablet A (TabA) and tablet B (TabB). In addition, the study evaluated short term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and in an extension component long-term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ". Thirty men with metastatic chemotherapy-naïve CRPC were enrolled; the median age of the patients was 68 years.8 </br>The pharmacokinetic (PK) component consisted of two concurrent groups, which evaluated TabA and (TabB), and capsule. Patients were randomized to one of 3 treatment sequences in each group. There were three treatment periods for each patient during the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " Component which included \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of two \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 300 mg test \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tablet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " (TabA or TabB) in both \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " conditions, or \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 100 mg capsule at 600 mg dose in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state. There was at least 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day.8 </br>All patients completed the PK component and entered the extension component at the 4-week visit. During the extension, patients were treated with a \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 600 mg \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    capsule\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " taken with food twice daily. Treatment continued until disease progression or an intolerable AE.8 </br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>All 30 patients completed the first 12 weeks in the extension. A total of 22 of 30 patients (73%) reported AEs; most were grade 1–2 (114 of 125 [91%]). The most common CNS-related AE was fatigue (all grade 1) in 4 patients (13%). Headache was reported as an AE in 2 patients (7%). No dose reductions were made and no seizures were reported.8 </br>Pre-Clinical Data</br>In preclinical, rat and mouse, models, \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed negligible brain penetration at pharmacological doses.2    Brain/plasma ratio of the main active metabolite, keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", was also negligible after \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " administration (Table 5). Quantitative whole body autoradiography (QWBA) in rats confirmed the minimal penetration of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " into the brain. In rodent studies, brain exposures to \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in terms of \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " (0-24) were very low with 4.5% of plasma exposure after single \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    dose\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " and 2.1 - 3.9% after repeated doses. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " has negligible brain penetration in nonclinical models.  2</br>Table 5: Brain Penetration of Darolutamide.2 </br>REV: 07/2019 References:</br>1. NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.</br>2. Shore ND, Bono P, Massard C, et al. J Clin Oncol 32, 2014 (suppl 4; abstr 275) Presented at the 2014 Genitourinary Cancers Symposia. San Francisco, CA</br>3. Foster, WR, Car, BD, Shi, H, et al. Drug safety is a barrier to the discovery and development of new \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor antagonists\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ". Prostate, 2011; 71: 480–488.  https://www.ncbi.nlm.nih.gov/pubmed/20878947</br>4. Institute for Clinical and Economic Review (ICER), 2018</br>5. Clegg NJ, Wongvipat J, Joseph J, et al. ARN-509: a novel anti-\n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for prostate cancer treatment.  Cancer</br>Res . 2012;72(6):1494-1503.  https://www.ncbi.nlm.nih.gov/pubmed/22266222</br>6. Data on file, Bayer Pharmaceutical, Whippany, NJ</br>7. Fizazi K et al. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " in nonmetastatic prostate cancer Oral presentation at: [ASCO GU]; February 14 – 16, 2019; San Francisco CA.</br>8. Institute for Clinical and Economic Review (ICER), 2018</br>9. Massard C, Penttinen HM, Vjaters E, et al. \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", antitumor activity, and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of ODM-201 in</br>patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016 May;69(5):834-40.  https://www.ncbi.nlm.nih.gov/pubmed/26463318</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): CNS-related AEs\n",
       "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>\n",
       "</figure>\n",
       "</body>\n",
       "</html>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Using the 'ent' visualizer\n",
      "Serving on http://0.0.0.0:5000 ...\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "127.0.0.1 - - [05/Mar/2020 10:58:53] \"GET / HTTP/1.1\" 200 82406\n",
      "127.0.0.1 - - [05/Mar/2020 10:58:54] \"GET /favicon.ico HTTP/1.1\" 200 82406\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Shutting down server on port 5000.\n"
     ]
    }
   ],
   "source": [
    "displacy.serve(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Document 4 - Nubeqa (US-NUBEQA-76049-S.docx-2.pdf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc = loaded_nlp(\"\"\"NUBEQA®    (darolutamide) Safety Data\n",
    "Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of\n",
    "patients with non-metastatic castration-resistant prostate cancer.1 \n",
    "Background\n",
    "Darolutamide is a second-generation Androgen Receptor (AR) inhibitor given concurrently with androgen deprivation therapy (ADT) for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).1 \n",
    "There is a need for agents that not only provide significant clinical benefit but also have a tolerable safety profile with minimal detriment to patient quality of life.2    Darolutamide is structurally distinct from other second-generation AR inhibitors. It is a more polar molecule with a flexible structure. Increased flexibility, higher polarity, and increased hydrogen bond-forming potential are associated with low blood brain barrier penetration in preclinical models.7  .\n",
    "This letter will discuss adverse events reported in the ARAMIS, ARADES and ARAFOR trials.3  -6\n",
    "Summary\n",
    "● Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.1 \n",
    "● ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and safety of darolutamide in men being treated with androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC) and have a high risk of developing metastases. The primary endpoint of the study was metastasis-free survival (MFS). MFS was defined as the time from randomization to evidence of metastasis (new or progressive regional pathological lymph nodes were not defined as metastasis) or death from any cause, whichever occurred first.3  -4\n",
    "o Darolutamide demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% versus placebo [HR .41 (95% CI 0.34 – 0.50);  P  <0.001].  3\n",
    "● In addition to evaluation of Metastasis-free Survival as the primary efficacy variable, safety was evaluated.\n",
    "o After a median exposure of 14.8 months in the darolutamide arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial (N = 1220/1508; [darolutamide arm, n = 794; placebo arm, n = 426]). The majority of adverse events reported in both arms were Grade 1 or 2 [54.4% (821/1508)].3    The incidence of common adverse events were reported in ≤10% of patients in both the darolutamide and placebo arms, with only fatigue (including asthenia) reported at an incidence of >10% in both arms.3 \n",
    "Exposure-adjusted Adverse Events\n",
    "Darolutamide Safety Data\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    " ▪ After adjustment for duration of treatment or observation period (median exposure of 14.8 months in the darolutamide arm versus 11.04 months in the placebo arm), differences in the incidence of adverse events of interest between both arms decreased or were no longer evident.3 \n",
    "o The most common Grade 3 or 4 events were hypertension (3.1% of patients in the darolutamide plus ADT arm versus 2.2% of patients in the placebo plus ADT arm.) and urinary retention (1.6% of patients in the darolutamide plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 \n",
    "o Treatment discontinuations occurred in 35.5% (339/954) of patients in the darolutamide arm vs. 63.9% (354/554) of patients in the placebo arm.3 \n",
    "● ARADES, an open-label, multicenter trial with a non-randomized Phase I dose escalation portion and a Phase II randomized dose expansion phase, enrolled patients (N = 134) with progressive, metastatic castration-resistant prostate cancer (mCRPC).5    Patients with a history of seizures or were at risk of seizures were included.5 \n",
    "o In the placebo arm, treatment discontinuations due to adverse events occurred in 8.5% (47/554) of patients; treatment discontinuations due to metastasis occurred in 23.3% (129/554) of patients.5 \n",
    "o The most common adverse events (all grades) were fatigue including asthenia (31%, arthralgia (16%) and pain (15%). Most adverse events reported were Grade 1 or 2.5 \n",
    "o Grade 3 and 4 adverse events reported in 22% (n = 27) and <2% (n = 2) patients, respectively. Darolutamide was tolerated up to the highest dose studied (1800 mg/day) and the maximum tolerated dose was not reached. None of the reported events were deemed by the investigator to be drug-related. No seizures were reported.5 \n",
    "o Adverse events considered drug-related were reported in 35% (n = 44) patients and included fatigue including asthenia in 12% (n = 15) of patients, hot flushes in 5% (n = 6) of patients, decreased appetite in 4% (n = 5) of patients and diarrhea in 2% (n = 3) of patients.5 \n",
    "▪ One grade 3 event (fatigue including asthenia) was deemed by the investigator to be possibly drug-related. No grade 4 events were deemed to be drug-related.5 \n",
    "● ARAFOR, a two-part, multicenter, international, open-label, Phase I study, evaluated the pharmacokinetic (PK), safety and tolerability of darolutamide (ODM-201) in patients (N = 30) with progressive metastatic castration resistant prostate cancer (mCRPC). Patients with a history of seizures or were at risk of seizures were included.6 \n",
    "o After a median reporting period of 15.3 months (95% CI 9.7 months – NR), 73% (22/30) of patients reported adverse events.6 \n",
    "o The majority of the AE’s reported were Grade 1 or 2. The most common AEs were reported included fatigue (13%, n = 4) [All grade 1] and nausea (13%, n = 4) [All grade 1 – 3].6 \n",
    "o Twenty percent (20%) of AEs reported were considered treatment-related.\n",
    "Darolutamide Safety Data\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " ▪ Treatment-related AEs were fatigue, decreased appetite, headache, abdominal pain, solar dermatitis, tinnitus, and dysgeusia. All treatment-related AEs were Grade 1.6 \n",
    "o No seizures were reported.6  6 o No dose reductions were necessary. \n",
    "Clinical Data\n",
    "Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) ARAMIS Trial3  -4\n",
    "Study Design\n",
    "ARAMIS, a Phase III, multinational, randomized, double blind, placebo-controlled study, evaluated the efficacy and safety of darolutamide in men undergoing treatment with androgen deprivation therapy (ADT*   ) for non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of developing metastases. High risk was defined as PSADT of ≤ 10 months and PSA ≥ 2ng/ml. Patients included in the study had an ECOG performance status of 0-1 and adequate hematologic, renal, and liver function. Additionally, patients with a history of seizures or at risk for seizures were included.3 \n",
    "Patients (N=1509) were randomized 2:1 to receive darolutamide 600 mg tablets orally twice daily with food plus ADT versus matching placebo plus ADT. Key baseline characteristics of the majority of the patient population in the ARAMIS study were: a median age of 74; Gleason score of ≥7; absence of regional pathological lymph nodes; ≥2 prior hormonal therapy agents with a PSADT ≤6 months, and no baseline osteoclast targeted therapy. Patients on the ARAMIS study were stratified according to PSADT (PSADT;  <  6 months vs. > 6 months) and use of osteoclast-targeted therapy (yes vs. no). All assessments were obtained at baseline and every 16 weeks.3 \n",
    "The primary endpoint of the study was metastasis free-survival (MFS) [defined as time between randomization and evidence of metastasis or death from any cause, whichever occurs first. Secondary endpoints included OS, Time to Pain Progression, Time to Initiation of First Cytotoxic Chemotherapy and Time to First Symptomatic Skeletal Event (SSE). Exploratory endpoints included PFS and Time to PSA Progression.3 \n",
    "Safety Results3 \n",
    "After a median exposure of 14.8 months in the darolutamide arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial\n",
    "(N = 1220/1508; [darolutamide arm, n = 794; placebo arm, n = 426]). The incidence of adverse events were generally similar between treatment arms and the majority were Grade 1 or 2 [54.4% (821/5108)].3    The incidence of common events was low with only fatigue reported at an incidence of >10%. Grades 3 or 4 adverse events occurred in 22.8% (344/1508) of the total safety population (24.7% of patients in the darolutamide arm versus 19.5% of patients in the placebo arm). The most frequent Grade 3 or 4 adverse events included hypertension (3.1% of patients in the darolutamide plus ADT arm versus 2.2% of patients in the placebo plus ADT\n",
    "Darolutamide Safety Data\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    " \n",
    " arm.) and urinary retention (1.6% of patients in the darolutamide plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 \n",
    "Table 1 shows the Treatment Emergent Adverse Events (TEAEs) for the total safety population (N = 1508). TEAEs (all grades) occurring in ≥5% of patients reported in Table 6 below, in the darolutamide versus placebo arms, respectively, included fatigue (including asthenia) (12.1% [115/954, vs 8.7% [48/554]). Other TEAEs occurring in ≥5% in the darolutamide arm included back pain (8.8%), arthralgia (8.1%), diarrhea (6.9%), hypertension (7.3%), constipation (TEAEs occurring in 6.3%), pain in extremity (5.8%), anemia (5.6%) and hot flush (5.2%).3  Approximately 14% of TEAEs led to a dose modification in the darolutamide arm versus 9.4% of TEAEs in the placebo arm.\n",
    "After a median follow-up of 17.9 months, treatment discontinuations were similar between both arms.4    Discontinuations due to adverse events occurred in 8.9% of patients in the darolutamide arm vs 8.7% of patients in the placebo arm. Discontinuations due to metastasis occurred in 11.7% vs 23.3% of patients; and discontinuations due to investigator judgment occurred in 5.7% vs 16.4% of patients, in the darolutamide vs placebo arms, respectively. Discontinuations due to protocol deviation and to other reasons unspecified occurred in 1.4% vs 1.3% and 0.6% vs 0.4% in the darolutamide vs placebo arm, respectively. Additionally, 7.1% vs 14.1% of patients in the darolutamide vs placebo arm respectively decided not to continue trial participation. It should be noted that one person in the darolutamide arm was randomized but did not receive treatment.4 \n",
    "A total of 55 deaths occurred during the trial with 3.9% of deaths occurring in the darolutamide arm versus 3.2% occurring in the placebo arm.3    See Table 1 below.\n",
    "The Institute for Clinical and Economic Review (ICER) has identified events such as falls, fractures, cardiovascular events and deaths due to AE’s, etc. to be TEAE’s of interest for anti-androgen therapies.2    For the incidence of TEAE’s of interest reported for darolutamide, see Tables 2 - 4.3 \n",
    "    Table 1. ARAMIS: Summary of TEAEs3 \n",
    "      Darolutamide N = 954\n",
    "     Placebo N = 554\n",
    "  Total N = 1508\n",
    "     Exposure, median (months)\n",
    " 14.8\n",
    "      11.04\n",
    "        Any AE, n (%)\n",
    " 794 (83.2)\n",
    "      426 (76.9)\n",
    "   1220 (80.9)\n",
    "     Worst grade\n",
    "               Grade 1 or 2\n",
    " 521 (54.6)\n",
    "      300 (54.2)\n",
    "   821 (54.4)\n",
    " Grade 3 or 4\n",
    "   236 (24.7)\n",
    "    108 (19.5)\n",
    "    344 (22.8)\n",
    "     Grade 5\n",
    "37 (3.9)\n",
    "    18 (3.2)\n",
    " 55 (3.6)\n",
    "     Serious\n",
    " 237 (24.8)\n",
    "      111 (20.0)\n",
    "   348 (23.1)\n",
    " Leading to dose modification\n",
    "   135 (14.2)\n",
    "    52 (9.4)\n",
    "    187 (12.4)\n",
    "   Leading to permanent discontinuation\n",
    "85 (8.9)\n",
    "  48 (8.7)\n",
    " 133 (8.8)\n",
    "           AE, adverse event, TEAE, treatment emergent adverse event\n",
    "Table 2. ARAMIS: Total of TEAEs with an Incidence of  ≥ 5%3 \n",
    "Darolutamide Safety Data\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "     \n",
    "                                                                                                                    Preferred term, n (%)\n",
    "   Darolutamide N = 954\n",
    "  Placebo N = 554\n",
    "     Fatigue\n",
    "    115 (12.1)\n",
    "   48 (8.7)\n",
    "     Back pain\n",
    "    84 (8.8)\n",
    "   50 (9.0)\n",
    "     Arthralgia\n",
    "    77 (8.1)\n",
    "   51 (9.2)\n",
    "     Diarrhea\n",
    "    66 (6.9)\n",
    "   31 (5.6)\n",
    "     Hypertension\n",
    "    70 (7.3)\n",
    "   33 (6.0)\n",
    "     Constipation\n",
    "    60 (6.3)\n",
    "   34 (6.1)\n",
    "     Pain in extremity\n",
    "    55 (5.8)\n",
    "   18 (3.2)\n",
    "     Anemia\n",
    "    53 (5.6)\n",
    "   25 (4.2)\n",
    "     Hot flush\n",
    "    50 (5.2)\n",
    "   23 (4.2)\n",
    "     Nausea\n",
    "    48 (5.0)\n",
    "   32 (5.8)\n",
    "     Bone Fracture\n",
    "    40 (4.2)\n",
    "   21 (3.8)\n",
    "     Fall\n",
    "    40 (4.2)\n",
    "   26 (4.7)\n",
    "     Rash\n",
    "    24 (2.6)\n",
    "   4 (0.7)\n",
    " Weight decreased\n",
    "    34 (3.6)\n",
    "    12 (2.2)\n",
    "                   Table 3. ARAMIS: TEAEs of Interest3 \n",
    "    Darolutamide N=954\n",
    "Placebo N=554\n",
    "                        AE\n",
    "Any Grade, n (%)\n",
    "Grade 3, %\n",
    "Grade 4 %\n",
    "Grade 5, %\n",
    "Any Grade, n (%)\n",
    "Grade 3, %\n",
    "Grade 4 %\n",
    "Grade 5, %\n",
    "                                Bone Fracture\n",
    "40 (4.2)\n",
    "0.9\n",
    "0\n",
    "0\n",
    "21 (3.8)\n",
    "0.9\n",
    "0\n",
    "0\n",
    "                    Fall\n",
    "40 (4.2)\n",
    "0.8\n",
    "0\n",
    "0\n",
    "26 (4.7)\n",
    "0.7\n",
    "0\n",
    "0\n",
    "                      Fatigue, including asthenia\n",
    "151 (15.8)\n",
    "0.6\n",
    "0\n",
    "0\n",
    "63 (11.4)\n",
    "1.1\n",
    "0\n",
    "0\n",
    "                    Seizure\n",
    "2 (0.2)\n",
    "0\n",
    "1 (0.2)\n",
    "0\n",
    "                      Cognitive disorder\n",
    "4 (0.4)\n",
    "0\n",
    "0\n",
    "0\n",
    "1 (0.2)\n",
    "0\n",
    "0\n",
    "0\n",
    "                                Memory impairment\n",
    "5 (0.5)\n",
    "0\n",
    "0\n",
    "0\n",
    "7 (1.3)\n",
    "0\n",
    "0\n",
    "0\n",
    "                                Disturbance in attention\n",
    "0\n",
    "0\n",
    "0\n",
    "0\n",
    "1 (0.2)\n",
    "0\n",
    "0\n",
    "0\n",
    "                                Amnesia\n",
    "1 (0.1)\n",
    "0\n",
    "0\n",
    "0\n",
    "3 (0.5)\n",
    "0\n",
    "0\n",
    "0\n",
    "                    Rash\n",
    "24 (2.6)\n",
    "0.1\n",
    "0\n",
    "0\n",
    "4 (0.7)\n",
    "0\n",
    "0\n",
    "0\n",
    "                      Weight decreased\n",
    "34 (3.6)\n",
    "0\n",
    "0\n",
    "0\n",
    "12 (2.2)\n",
    "0\n",
    "0\n",
    "0\n",
    "                    Hot flush\n",
    "50 (5.2)\n",
    "0\n",
    "-\n",
    "-\n",
    "23 (4.6)\n",
    "0\n",
    "-\n",
    "-\n",
    "                 Increased bilirubin\n",
    "18 (1.9)\n",
    "0.1\n",
    "0\n",
    "0\n",
    "0\n",
    "0\n",
    "0\n",
    "0\n",
    "                 Table 4. AE\n",
    "Hypertension\n",
    "ARAMIS: TEAEs of Interest3    continued Darolutamide\n",
    "N=954 Any Grade 3, Grade 4 Grade 5,\n",
    "Placebo N=554\n",
    "n (%) n (%)\n",
    "70 (7.3) 3.4 0 0 33 (6.0) 2.3 0 0\n",
    "Any\n",
    "Grade, % % % Grade, % % %\n",
    "Darolutamide Safety Data\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "Grade 3,\n",
    "Grade 4 Grade 5,\n",
    "\n",
    "    Cerebral and intracranial hemorrhage\n",
    "  2 (0.2)\n",
    "  0\n",
    "     0\n",
    "   0\n",
    " 2 (0.4)\n",
    "  0.2\n",
    "     0\n",
    "  0.2\n",
    " Cerebral infarction and stroke\n",
    "  4 (0.4)\n",
    "  0.3\n",
    "  0\n",
    "     0\n",
    "    4 (0.7)\n",
    "    0.4\n",
    "  0\n",
    "    0.2\n",
    "   Cerebral ischemic infarction and stroke\n",
    " 5 (0.5)\n",
    " 0.1\n",
    "    0.2\n",
    " 0.1\n",
    "2 (0.4)\n",
    " 0.2\n",
    "    0\n",
    " 0.2\n",
    "   Acute myocardial infarction\n",
    "   5 (0.5)\n",
    "   0.2\n",
    "      0.2\n",
    "    0.1\n",
    " 1 (0.2)\n",
    "   0\n",
    "      0\n",
    "   0\n",
    " Cardiac failure\n",
    "  18 (1.9)\n",
    "  0.1\n",
    "  0.1\n",
    "     0.3\n",
    "    5 (0.9)\n",
    "    0\n",
    "  0\n",
    "    0.5\n",
    "   Coronary artery disorders\n",
    " 31 (3.2)\n",
    " 1.3\n",
    " 0.4\n",
    "   0.3\n",
    "  14 (2.5)\n",
    "  0.4\n",
    " 0\n",
    "  0.2\n",
    "  Ischemic coronary artery disorders\n",
    " 24 (2.5\n",
    " 0.7\n",
    " 0.4\n",
    "  0.2\n",
    " 11 (2.0)\n",
    "  0.4\n",
    " 0\n",
    " 0.2\n",
    "       Exposure-adjusted Adverse Events\n",
    "After adjustment for duration of treatment or observation period (After a median exposure of 14.8 months in the darolutamide arm versus 11.04 months in the placebo arm), differences in the incidence of adverse events of interest between both arms decreased or no longer evident.3  See table 5 below.\n",
    "    Table 5 Exposure-adjusted Adverse events3  ( patients per 100 years of exposure )\n",
    "     Adverse events of interests\n",
    "   Darolutamide Exposure-adjusted incidence (N = 954)\n",
    "  Placebo Exposure-adjusted incidence (N = 554)\n",
    "     Fatigue or asthenic conditions\n",
    "    11.3\n",
    "   11.1\n",
    "     Back pain\n",
    "    6.3\n",
    "   8.8\n",
    "     Arthralgia\n",
    "    5.8\n",
    "   9.0\n",
    "     Diarrhea\n",
    "    4.9\n",
    "   5.5\n",
    "     Hypertension\n",
    "    4.7\n",
    "   5.1\n",
    "     Constipation\n",
    "    4.5\n",
    "   6.0\n",
    "     Pain in extremity\n",
    "    4.1\n",
    "   3.2\n",
    "     Anemia\n",
    "    4.0\n",
    "   4.4\n",
    "     Hot flush\n",
    "    3.7\n",
    "   4.1\n",
    "     Nausea\n",
    "    3.6\n",
    "   5.6\n",
    "     Weight loss\n",
    "    2.5\n",
    "   2.1\n",
    "     Falls\n",
    "    2.7\n",
    "   4.1\n",
    "     Bone fracture\n",
    "    3.0\n",
    "   3.5\n",
    "     Memory impairment\n",
    "    0.4\n",
    "   1.2\n",
    "     Cognitive disorder\n",
    "    0.3\n",
    "   0.2\n",
    " Seizure\n",
    "    0.2\n",
    "    0.2\n",
    "                  Metastatic Castration-Resistant Prostate Cancer (mCRPC)\n",
    "Darolutamide Safety Data\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " ARADES Trial 5 Study Design\n",
    "The ARADES trial, an open-label, multicenter trial with a non-randomized Phase I dose escalation portion and a Phase II randomized dose expansion phase, enrolled patients with progressive, metastatic castration-resistant prostate cancer (mCRPC). Patients with a history of seizures or were at risk of seizures were included.5 \n",
    "Patients (N = 134) in the ARADES trial had progressive, mCRPC with serum testosterone levels <30 ng/m and were either chemotherapy-naïve or had ≤2 prior chemotherapy regimens.5 \n",
    "Baseline characteristics are presented in Table 6.5  Table 6: Baseline Characteristics.5 \n",
    "        Total N=134\n",
    "   CYP17i-naïve, chemo-naïve, N\n",
    "     42 (31.3)\n",
    "   CYP17i-naïve, post-chemo\n",
    "     35 (26.1)\n",
    "   Post-CYP17i\n",
    "     57 (42.5)\n",
    "   Age, median years (range)\n",
    "     60 (53-89)\n",
    "   PSA ng/mL, median (range)\n",
    "     99 (3-5000)\n",
    "   Time from diagnosis to study treatment, median months (range)\n",
    "    69 (10-231)\n",
    " Disease localization, N(%): Bone disease only\n",
    "Soft Tissue only\n",
    "Soft and Bone Disease\n",
    "   49 (36.6) 20 (14.9) 64 (47.8)\n",
    "   Seizure (and like) event history %\n",
    "    11 (8.2)\n",
    " Time on Study Drug (days) Mean (SD)\n",
    "Median (min, max)\n",
    "  184 (131.0) 168 (1,684)\n",
    "    Safety Results 5\n",
    "The most common adverse events (all grades) were fatigue including asthenia (31%, arthralgia (16%) and pain (15%). Most adverse events reported were Grade 1 or 2. Grade 3 and 4 adverse events reported in 22% (n = 27) and <2% (n = 2) patients, respectively. Darolutamide was tolerated up to the highest dose studied (1800 mg/day) with the maximum tolerated dose was not reached. No seizures were reported.3    See table 7 below.\n",
    "Adverse events considered drug-related were reported in 35% (n = 44) patients and included fatigue including asthenia in 12% (n = 15) of patients, hot flushes in 5% (n = 6) of patients, decreased appetite in 4% (n = 5) of patients and diarrhea in 2% (n = 3) of patients. One grade 3 event (fatigue including asthenia) was deemed by the investigator to be possibly drug-related. No grade 4 events were deemed to be drug-related.5 \n",
    "Darolutamide Safety Data\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Table 7\n",
    "    ARADES: TEAEs with an Incidence of  ≥ 10% (n = 134) – darolutamide 200 – 1800 mg/day5 \n",
    "  Adverse Event\n",
    "    Grade 1\n",
    "     Grade 2\n",
    "     Grade 3\n",
    "    Total*\n",
    "     Fatigue including Asthenia\n",
    " 30 (22%)\n",
    " 13 (10%)\n",
    " 2 (1%)\n",
    " 41 (31%)\n",
    "     Back pain\n",
    "    17 (13%)\n",
    "    13 (10%)\n",
    "    2 (1%)\n",
    "   28 (21%)\n",
    "     Arthralgia\n",
    "    18 (13%)\n",
    "    9 (7%)\n",
    "    2 (1%)\n",
    "   22 (16%)\n",
    "     Pain\n",
    "    9 (7%)\n",
    "    8 (6%)\n",
    "    3 (2%)\n",
    "   20 (15%)\n",
    "     Constipation\n",
    "    15 (11%)\n",
    "    5 (4%)\n",
    "    0\n",
    "   18(13%)\n",
    "     Nausea\n",
    "    14 (10%)\n",
    "    4 (3%)\n",
    "    0\n",
    "   17 (13%)\n",
    "     Decreased appetite\n",
    "    15 (11%)\n",
    "    1 (<1%)\n",
    "    0\n",
    "   16 (12%)\n",
    " Peripheral edema\n",
    "    14 (10%)\n",
    "     2 (1%)\n",
    "     0\n",
    "    16 (12%)\n",
    "      *Total may be less than the sum of the grade because patients may have had adverse events of several grades.\n",
    "Darolutamide Safety Data\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " ARAFOR Trial 6 Study Design\n",
    "ARAFOR, a two-part, multicenter, international, open-label, Phase I study, evaluated the pharmacokinetic (Pk), safety and tolerability of darolutamide (ODM-201) in patients (N = 30) with progressive metastatic castration resistant prostate cancer (mCRPC). Patients eligible for the study had to meet the following inclusion criteria: ≥18 years of age with progressive mCRPC, testosterone level <1.7 nmol/L, ECOG performance status of 0-1, chemotherapy naïve, and asymptomatic or mildly symptomatic. Patients without bilateral orchiectomy were to continue on gonadotropin-releasing hormone therapy. Patients with brain metastases or previous treatment with a second-generation Androgen Receptor antagonist or CYP17 inhibitor was excluded.6 \n",
    "The first part of the study (Pk analysis) was a randomized open-label, two arm, three-period crossover study. The second part of the study (safety analysis) was an open-label extension to evaluate long-term safety and tolerability. The primary endpoint of the first part of the study was PK of tablet products compared to the capsule formulation and effect of food. The endpoints in the second part of the study were safety and effects on PSA and lesions.6 \n",
    "Safety Results 6\n",
    "After a median reporting period of 15.3 months (95% CI 9.7 months – NR), 73% (22/30) of patients reported adverse events. The majority of the AE’s reported were Grade 1 or 2. The most common AEs were reported included fatigue (13%, n = 4) [All grade 1] and nausea (13%, n = 4) [All grade 1 – 3]. Twenty percent (20%) of AEs reported were considered treatment-related. Treatment-related AEs were fatigue (13%), decreased appetite, headache, abdominal pain, solar dermatitis, tinnitus, and dysgeusia. All treatment-related AEs were Grade 1. No seizures were reported6 \n",
    "No dose reductions were necessary. One patient (3.3%) died due to cancer progression. Two patients (6.7%) discontinued due to an AE (neuroendocrine carcinoma and respiratory failure). These AEs were not consider treatment-related by the investigator.6    For AEs reported in >5% of patients, see table 8 below.\n",
    "Darolutamide Safety Data\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    "Table 8. Adverse Events occurring in >5% of patients by Grade6  (Safety Population, N = 30)\n",
    "Adverse event\n",
    "Grade 1 n (%)\n",
    "Grade 2 n (%)\n",
    "Grade 3 n (%)\n",
    "Total n (%)\n",
    "Nausea\n",
    "3 (10)\n",
    "1 (3)\n",
    "1 (3)\n",
    "4 (13)\n",
    "Fatigue\n",
    "4 (13)\n",
    "0\n",
    "0\n",
    "4 (13)\n",
    "Bone pain\n",
    "1 (3)\n",
    "2 (7)\n",
    "1 (3)\n",
    "3 (10)\n",
    "Abdominal pain\n",
    "3 (10)\n",
    "0\n",
    "0\n",
    "3 (10)\n",
    "Back pain\n",
    "0\n",
    "2 (7)\n",
    "1 (3)\n",
    "3 (10)\n",
    "Diarrhea\n",
    "2 (7)\n",
    "1 (3)\n",
    "0\n",
    "3 (10)\n",
    "Hematuria\n",
    "2 (7)\n",
    "1 (3)\n",
    "0\n",
    "3 (10)\n",
    "Erysipelas\n",
    "2 (7)\n",
    "1 (3)\n",
    "0\n",
    "2 (7)\n",
    "Pain in extremity\n",
    "2 (7)\n",
    "1 (3)\n",
    "0\n",
    "2 (7)\n",
    "Cough\n",
    "2 (7)\n",
    "0\n",
    "0\n",
    "2 (7)\n",
    "Dysuria\n",
    "2 (7)\n",
    "0\n",
    "0\n",
    "2 (7)\n",
    "Headache\n",
    "2 (7)\n",
    "0\n",
    "0\n",
    "2 (7)\n",
    "Hypertension\n",
    "0\n",
    "2 (7)\n",
    "0\n",
    "2 (7)\n",
    "Influenza\n",
    "2 (7)\n",
    "0\n",
    "0\n",
    "2 (7)\n",
    "Rhinorrhea\n",
    "2 (7)\n",
    "0\n",
    "0\n",
    "2 (7)\n",
    "Rib fracture\n",
    "2 (7)\n",
    "0\n",
    "0\n",
    "2 (7)\n",
    "Skin ulcer\n",
    "2 (7)\n",
    "0\n",
    "0\n",
    "2 (7)\n",
    "Solar dermatitis\n",
    "2 (7)\n",
    "0\n",
    "0\n",
    "2 (7)\n",
    "REV 0719 References/ Enclosure(s): (Bolded)\n",
    "1. NUBEQA®    (darolutamide) tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.\n",
    "2. Institute for Clinical and Economic Review (ICER), 2018\n",
    "3. Fizazi K, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer). Oral presentation at: [ASCO\n",
    "GU]; February 14 – 16, 2019; San Francisco CA. Presentation number #GU19.\n",
    "4. Fizazi K, Shore N, Tammela TL, et. Darolutamide in nonmetastatic castration-resistant prostate cancer;  N Eng J\n",
    "M, 20  19, PP 1 – 12,DOI: 10.1056/NEJMMoa1815671\n",
    "5. Fizazi K, et al. Activity and safety of odm-201 in patients with progressive metastatic castration-resistant\n",
    "prostate cancer (ARADES): an open-label phase I dose-escalation and randomized phase II dose expansion\n",
    "trial.  Lancet Oncol , 2014;15:975-985\n",
    "6. Massard C, et al. Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with\n",
    "chemotherapy-naïve metastatic castration-resistant prostate cancer: an open-label phase I study.  Eur Urol\n",
    "2016;69:834-840.\n",
    "7. Pajouhesh H, Lenz GR.  NeuroRx . 2005;2:541–553\n",
    "Darolutamide Safety Data\n",
    "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\"\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Safety Data</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of</br>patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>Background</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is a second-generation Androgen Receptor (AR) inhibitor given concurrently with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " deprivation therapy (ADT) for the treatment of \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (nmCRPC).1 </br>There is a need for agents that not only provide significant clinical benefit but also have a tolerable \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " profile with minimal detriment to patient quality of life.2    \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " is structurally distinct from other second-generation AR inhibitors. It is a more polar molecule with a \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    flexible\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " structure. Increased flexibility, higher polarity, and increased hydrogen bond-forming potential are associated with low blood brain barrier penetration in preclinical models.7  .</br>This letter will discuss adverse events reported in the ARAMIS, ARADES and ARAFOR trials.3  -6</br>Summary</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men being treated with androgen deprivation therapy (ADT) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") and have a high risk of developing metastases. The primary \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of the study was metastasis-free survival (MFS). MFS was defined as the time from randomization to evidence of metastasis (new or progressive regional pathological lymph nodes were not defined as metastasis) or death from any cause, whichever occurred first.3  -4</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% versus placebo [HR .41 (95% CI 0.34 – 0.50);  P  &lt;0.001].  3</br>● In addition to evaluation of Metastasis-free Survival as the primary efficacy variable, \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " was evaluated.</br>o After a median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial (N = 1220/1508; [\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm, n = 794; placebo arm, n = 426]). The majority of adverse events reported in both arms were Grade 1 or 2 [54.4% (821/1508)].3    The incidence of common adverse events were reported in ≤10% of patients in both the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and placebo arms, with only \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") reported at an incidence of &gt;10% in both arms.3 </br>Exposure-adjusted Adverse Events</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> ▪ After adjustment for duration of treatment or observation period (median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm), differences in the incidence of adverse events of interest between both arms decreased or were no longer evident.3 </br>o The most common Grade 3 or 4 events were hypertension (3.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.2% of patients in the placebo plus ADT arm.) and urinary retention (1.6% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 </br>o Treatment discontinuations occurred in 35.5% (339/954) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs. 63.9% (354/554) of patients in the placebo arm.3 </br>● ARADES, an open-label, multicenter trial with a non-randomized Phase I dose escalation portion and a Phase II randomized dose expansion phase, enrolled patients (N = 134) with progressive, metastatic castration-resistant prostate cancer (mCRPC).5    Patients with a history of seizures or were at risk of seizures were included.5 </br>o In the placebo arm, treatment discontinuations due to adverse events occurred in 8.5% (47/554) of patients; treatment discontinuations due to metastasis occurred in 23.3% (129/554) of patients.5 </br>o The most common adverse events (all grades) were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (31%, \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (16%) and pain (15%). Most adverse events reported were Grade 1 or 2.5 </br>o Grade 3 and 4 adverse events reported in 22% (n = 27) and &lt;2% (n = 2) patients, respectively. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " was tolerated up to the highest dose studied (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") and the maximum tolerated dose was not reached. None of the reported events were deemed by the investigator to be drug-related. No seizures were reported.5 </br>o Adverse events considered drug-related were reported in 35% (n = 44) patients and included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " in 12% (n = 15) of patients, hot flushes in 5% (n = 6) of patients, decreased appetite in 4% (n = 5) of patients and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " in 2% (n = 3) of patients.5 </br>▪ One grade 3 event (\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") was deemed by the investigator to be possibly drug-related. No grade 4 events were deemed to be drug-related.5 </br>● ARAFOR, a two-part, multicenter, international, open-label, Phase I study, evaluated the pharmacokinetic (PK), \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (ODM-201) in patients (N = 30) with progressive metastatic castration resistant prostate cancer (mCRPC). Patients with a history of seizures or were at risk of seizures were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    included.6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " </br>o After a median reporting period of 15.3 months (95% CI 9.7 months – NR), 73% (22/30) of patients reported adverse events.6 </br>o The majority of the AE’s reported were Grade 1 or 2. The most common AEs were reported included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%, n = 4) [All grade 1] and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%, n = 4) [All grade 1 – 3].6 </br>o Twenty percent (20%) of AEs reported were considered treatment-related.</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> ▪ Treatment-related AEs were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", decreased appetite, headache, abdominal pain, solar dermatitis, tinnitus, and dysgeusia. All treatment-related AEs were Grade 1.6 </br>o No seizures were reported.6  6 o No dose reductions were necessary. </br>Clinical Data</br>Non-metastatic Castration-Resistant Prostate Cancer (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") ARAMIS Trial3  -4</br>Study Design</br>ARAMIS, a Phase III, multinational, randomized, double blind, placebo-controlled study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men undergoing treatment with androgen deprivation therapy (ADT*   ) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (nmCRPC) with a high risk of developing \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ". High risk was defined as PSADT of ≤ 10 months and PSA ≥ 2ng/ml. Patients included in the study had an ECOG performance status of 0-1 and adequate hematologic, renal, and liver function. Additionally, patients with a history of seizures or at risk for seizures were included.3 </br>Patients (N=1509) were randomized 2:1 to receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 600 mg tablets orally twice daily with food plus ADT versus matching placebo plus ADT. Key baseline characteristics of the majority of the patient population in the ARAMIS study were: a median age of 74; Gleason score of ≥7; absence of regional pathological lymph nodes; ≥2 prior hormonal therapy agents with a PSADT ≤6 months, and no baseline osteoclast targeted therapy. Patients on the ARAMIS study were stratified according to PSADT (PSADT;  &lt;  6 months vs. &gt; 6 months) and use of osteoclast-targeted therapy (yes vs. no). All assessments were obtained at baseline and every 16 weeks.3 </br>The primary \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of the study was metastasis free-survival (MFS) [defined as time between randomization and evidence of metastasis or death from any cause, whichever occurs first. Secondary endpoints included OS, Time to Pain Progression, Time to Initiation of First Cytotoxic Chemotherapy and Time to First Symptomatic Skeletal Event (SSE). Exploratory endpoints included PFS and Time to PSA Progression.3 </br>Safety Results3 </br>After a median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial</br>(N = 1220/1508; [\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm, n = 794; placebo arm, n = 426]). The incidence of adverse events were generally similar between treatment arms and the majority were Grade 1 or 2 [54.4% (821/5108)].3    The incidence of common events was low with only \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " reported at an incidence of &gt;10%. Grades 3 or 4 adverse events occurred in 22.8% (344/1508) of the total \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " population (24.7% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 19.5% of patients in the placebo arm). The most frequent Grade 3 or 4 adverse events included hypertension (3.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.2% of patients in the placebo plus ADT</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br> arm.) and urinary retention (1.6% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 </br>Table 1 shows the Treatment Emergent Adverse Events (TEAEs) for the total \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " population (N = 1508). TEAEs (all grades) occurring in ≥5% of patients reported in Table 6 below, in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " versus placebo arms, respectively, included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") (12.1% [115/954, vs 8.7% [48/554]). Other TEAEs occurring in ≥5% in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (8.8%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (8.1%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (6.9%), hypertension (7.3%), constipation (TEAEs occurring in 6.3%), pain in extremity (5.8%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (5.6%) and hot flush (5.2%).3  Approximately 14% of TEAEs led to a dose modification in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 9.4% of TEAEs in the placebo arm.</br>After a median follow-up of 17.9 months, treatment discontinuations were similar between both arms.4    Discontinuations due to adverse events occurred in 8.9% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs 8.7% of patients in the placebo arm. Discontinuations due to metastasis occurred in 11.7% vs 23.3% of patients; and discontinuations due to investigator judgment occurred in 5.7% vs 16.4% of patients, in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arms, respectively. Discontinuations due to protocol deviation and to other reasons unspecified occurred in 1.4% vs 1.3% and 0.6% vs 0.4% in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arm, respectively. Additionally, 7.1% vs 14.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arm respectively decided not to continue trial participation. It should be noted that one person in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm was randomized but did not receive treatment.4 </br>A total of 55 deaths occurred during the trial with 3.9% of deaths occurring in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 3.2% occurring in the placebo arm.3    See Table 1 below.</br>The Institute for Clinical and Economic Review (ICER) has identified events such as falls, fractures, cardiovascular events and deaths due to AE’s, etc. to be TEAE’s of interest for anti-\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " therapies.2    For the incidence of TEAE’s of interest reported for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", see Tables 2 - 4.3 </br>    Table 1. ARAMIS: Summary of TEAEs3 </br>      \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 954</br>     Placebo N = 554</br>  Total N = 1508</br>     Exposure, median (months)</br> 14.8</br>      11.04</br>        Any AE, n (%)</br> 794 (83.2)</br>      426 (76.9)</br>   1220 (80.9)</br>     Worst grade</br>               Grade 1 or 2</br> 521 (54.6)</br>      300 (54.2)</br>   821 (54.4)</br> Grade 3 or 4</br>   236 (24.7)</br>    108 (19.5)</br>    344 (22.8)</br>     Grade 5</br>37 (3.9)</br>    18 (3.2)</br> 55 (3.6)</br>     Serious</br> 237 (24.8)</br>      111 (20.0)</br>   348 (23.1)</br> Leading to dose modification</br>   135 (14.2)</br>    52 (9.4)</br>    187 (12.4)</br>   Leading to permanent discontinuation</br>85 (8.9)</br>  48 (8.7)</br> 133 (8.8)</br>           AE, adverse event, TEAE, treatment emergent adverse event</br>Table 2. ARAMIS: Total of TEAEs with an Incidence of  ≥ 5%3 </br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>     </br>                                                                                                                    Preferred term, n (%)</br>   \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 954</br>  Placebo N = 554</br>     Fatigue</br>    115 (12.1)</br>   48 (8.7)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    84 (8.8)</br>   50 (9.0)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    77 (8.1)</br>   51 (9.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    66 (6.9)</br>   31 (5.6)</br>     Hypertension</br>    70 (7.3)</br>   33 (6.0)</br>     Constipation</br>    60 (6.3)</br>   34 (6.1)</br>     Pain in extremity</br>    55 (5.8)</br>   18 (3.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    53 (5.6)</br>   25 (4.2)</br>     Hot flush</br>    50 (5.2)</br>   23 (4.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    48 (5.0)</br>   32 (5.8)</br>     Bone Fracture</br>    40 (4.2)</br>   21 (3.8)</br>     Fall</br>    40 (4.2)</br>   26 (4.7)</br>     Rash</br>    24 (2.6)</br>   4 (0.7)</br> Weight decreased</br>    34 (3.6)</br>    12 (2.2)</br>                   Table 3. ARAMIS: TEAEs of Interest3 </br>    \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N=954</br>Placebo N=554</br>                        AE</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>                                Bone Fracture</br>40 (4.2)</br>0.9</br>0</br>0</br>21 (3.8)</br>0.9</br>0</br>0</br>                    Fall</br>40 (4.2)</br>0.8</br>0</br>0</br>26 (4.7)</br>0.7</br>0</br>0</br>                      Fatigue, including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>151 (15.8)</br>0.6</br>0</br>0</br>63 (11.4)</br>1.1</br>0</br>0</br>                    Seizure</br>2 (0.2)</br>0</br>1 (0.2)</br>0</br>                      Cognitive disorder</br>4 (0.4)</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Memory impairment</br>5 (0.5)</br>0</br>0</br>0</br>7 (1.3)</br>0</br>0</br>0</br>                                Disturbance in attention</br>0</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Amnesia</br>1 (0.1)</br>0</br>0</br>0</br>3 (0.5)</br>0</br>0</br>0</br>                    Rash</br>24 (2.6)</br>0.1</br>0</br>0</br>4 (0.7)</br>0</br>0</br>0</br>                      Weight decreased</br>34 (3.6)</br>0</br>0</br>0</br>12 (2.2)</br>0</br>0</br>0</br>                    Hot flush</br>50 (5.2)</br>0</br>-</br>-</br>23 (4.6)</br>0</br>-</br>-</br>                 Increased bilirubin</br>18 (1.9)</br>0.1</br>0</br>0</br>0</br>0</br>0</br>0</br>                 Table 4. AE</br>Hypertension</br>ARAMIS: TEAEs of Interest3    continued \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       "</br>N=954 Any Grade 3, Grade 4 Grade 5,</br>Placebo N=554</br>n (%) n (%)</br>70 (7.3) 3.4 0 0 33 (6.0) 2.3 0 0</br>Any</br>Grade, % % % Grade, % % %</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>Grade 3,</br>Grade 4 Grade 5,</br></br>    Cerebral and intracranial hemorrhage</br>  2 (0.2)</br>  0</br>     0</br>   0</br> 2 (0.4)</br>  0.2</br>     0</br>  0.2</br> Cerebral infarction and stroke</br>  4 (0.4)</br>  0.3</br>  0</br>     0</br>    4 (0.7)</br>    0.4</br>  0</br>    0.2</br>   Cerebral ischemic infarction and stroke</br> 5 (0.5)</br> 0.1</br>    0.2</br> 0.1</br>2 (0.4)</br> 0.2</br>    0</br> 0.2</br>   Acute myocardial infarction</br>   5 (0.5)</br>   0.2</br>      0.2</br>    0.1</br> 1 (0.2)</br>   0</br>      0</br>   0</br> Cardiac failure</br>  18 (1.9)</br>  0.1</br>  0.1</br>     0.3</br>    5 (0.9)</br>    0</br>  0</br>    0.5</br>   Coronary artery disorders</br> 31 (3.2)</br> 1.3</br> 0.4</br>   0.3</br>  14 (2.5)</br>  0.4</br> 0</br>  0.2</br>  Ischemic coronary artery disorders</br> 24 (2.5</br> 0.7</br> 0.4</br>  0.2</br> 11 (2.0)</br>  0.4</br> 0</br> 0.2</br>       Exposure-adjusted Adverse Events</br>After adjustment for duration of treatment or observation period (After a median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm), differences in the incidence of adverse events of interest between both arms decreased or no longer evident.3  See table 5 below.</br>    Table 5 Exposure-adjusted Adverse events3  ( patients per 100 years of exposure )</br>     Adverse events of interests</br>   \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Exposure-adjusted incidence (N = 954)</br>  Placebo Exposure-adjusted incidence (N = 554)</br>     Fatigue or asthenic conditions</br>    11.3</br>   11.1</br>     Back pain</br>    6.3</br>   8.8</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    5.8</br>   9.0</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    4.9</br>   5.5</br>     Hypertension</br>    4.7</br>   5.1</br>     Constipation</br>    4.5</br>   6.0</br>     Pain in extremity</br>    4.1</br>   3.2</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    4.0</br>   4.4</br>     Hot flush</br>    3.7</br>   4.1</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    3.6</br>   5.6</br>     Weight loss</br>    2.5</br>   2.1</br>     Falls</br>    2.7</br>   4.1</br>     Bone fracture</br>    3.0</br>   3.5</br>     Memory impairment</br>    0.4</br>   1.2</br>     Cognitive disorder</br>    0.3</br>   0.2</br> Seizure</br>    0.2</br>    0.2</br>                  Metastatic Castration-Resistant Prostate Cancer (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    mCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ")</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> ARADES Trial 5 Study Design</br>The ARADES trial, an open-label, multicenter trial with a non-randomized Phase I dose escalation portion and a Phase II randomized dose expansion phase, enrolled patients with progressive, metastatic castration-resistant prostate cancer (mCRPC). Patients with a history of seizures or were at risk of seizures were included.5 </br>Patients (N = 134) in the ARADES trial had progressive, mCRPC with serum testosterone levels &lt;30 ng/m and were either chemotherapy-naïve or had ≤2 prior chemotherapy regimens.5 </br>Baseline characteristics are presented in Table 6.5  Table 6: Baseline Characteristics.5 </br>        Total N=134</br>   CYP17i-naïve, chemo-naïve, N</br>     42 (31.3)</br>   CYP17i-naïve, post-chemo</br>     35 (26.1)</br>   Post-CYP17i</br>     57 (42.5)</br>   Age, median years (range)</br>     60 (53-89)</br>   PSA ng/mL, median (range)</br>     99 (3-5000)</br>   Time from diagnosis to study treatment, median months (range)</br>    69 (10-231)</br> Disease localization, N(%): Bone disease only</br>Soft Tissue only</br>Soft and Bone Disease</br>   49 (36.6) 20 (14.9) 64 (47.8)</br>   Seizure (and like) event history %</br>    11 (8.2)</br> Time on Study Drug (days) Mean (SD)</br>Median (min, max)</br>  184 (131.0) 168 (1,684)</br>    Safety Results 5</br>The most common adverse events (all grades) were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (31%, \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (16%) and pain (15%). Most adverse events reported were Grade 1 or 2. Grade 3 and 4 adverse events reported in 22% (n = 27) and &lt;2% (n = 2) patients, respectively. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " was tolerated up to the highest dose studied (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") with the maximum tolerated dose was not reached. No seizures were reported.3    See table 7 below.</br>Adverse events considered drug-related were reported in 35% (n = 44) patients and included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " in 12% (n = 15) of patients, hot flushes in 5% (n = 6) of patients, decreased appetite in 4% (n = 5) of patients and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " in 2% (n = 3) of patients. One grade 3 event (\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") was deemed by the investigator to be possibly drug-related. No grade 4 events were deemed to be drug-related.5 </br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Table 7</br>    ARADES: TEAEs with an Incidence of  ≥ 10% (n = 134) – \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 200 – \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " </br>  Adverse Event</br>    Grade 1</br>     Grade 2</br>     Grade 3</br>    Total*</br>     Fatigue including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br> 30 (22%)</br> 13 (10%)</br> 2 (1%)</br> 41 (31%)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    17 (13%)</br>    13 (10%)</br>    2 (1%)</br>   28 (21%)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    18 (13%)</br>    9 (7%)</br>    2 (1%)</br>   22 (16%)</br>     Pain</br>    9 (7%)</br>    8 (6%)</br>    3 (2%)</br>   20 (15%)</br>     Constipation</br>    15 (11%)</br>    5 (4%)</br>    0</br>   18(13%)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    14 (10%)</br>    4 (3%)</br>    0</br>   17 (13%)</br>     Decreased appetite</br>    15 (11%)</br>    1 (&lt;1%)</br>    0</br>   16 (12%)</br> \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Peripheral edema\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    14 (10%)</br>     2 (1%)</br>     0</br>    16 (12%)</br>      *Total may be less than the sum of the grade because patients may have had \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " of several grades.</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> ARAFOR Trial 6 Study Design</br>ARAFOR, a two-part, multicenter, international, open-label, Phase I study, evaluated the pharmacokinetic (Pk), \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (ODM-201) in patients (N = 30) with progressive metastatic castration resistant prostate cancer (mCRPC). Patients eligible for the study had to meet the following inclusion criteria: ≥18 years of age with progressive mCRPC, testosterone level &lt;1.7 nmol/L, ECOG performance status of 0-1, chemotherapy naïve, and asymptomatic or mildly symptomatic. Patients without bilateral orchiectomy were to continue on gonadotropin-releasing hormone therapy. Patients with brain metastases or previous treatment with a second-generation Androgen Receptor antagonist or CYP17 inhibitor was excluded.6 </br>The first part of the study (Pk analysis) was a randomized open-label, two arm, three-period crossover study. The second part of the study (\n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " analysis) was an open-label extension to evaluate long-term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ". The primary \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of the first part of the study was PK of tablet products compared to the capsule formulation and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       ". The endpoints in the second part of the study were \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and effects on PSA and lesions.6 </br>Safety Results 6</br>After a median reporting period of 15.3 months (95% CI 9.7 months – NR), 73% (22/30) of patients reported \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ". The majority of the AE’s reported were Grade 1 or 2. The most common AEs were reported included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%, n = 4) [All grade 1] and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%, n = 4) [All grade 1 – 3]. Twenty percent (20%) of AEs reported were considered treatment-related. Treatment-related AEs were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%), decreased appetite, headache, abdominal pain, solar dermatitis, tinnitus, and dysgeusia. All treatment-related AEs were Grade 1. No seizures were reported6 </br>No dose reductions were necessary. One patient (3.3%) died due to cancer progression. Two patients (6.7%) discontinued due to an AE (neuroendocrine carcinoma and respiratory failure). These AEs were not consider treatment-related by the investigator.6    For AEs reported in &gt;5% of patients, see table 8 below.</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>Table 8. Adverse Events occurring in &gt;5% of patients by Grade6  (Safety Population, N = 30)</br>Adverse event</br>Grade 1 n (%)</br>Grade 2 n (%)</br>Grade 3 n (%)</br>Total n (%)</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>3 (10)</br>1 (3)</br>1 (3)</br>4 (13)</br>Fatigue</br>4 (13)</br>0</br>0</br>4 (13)</br>Bone pain</br>1 (3)</br>2 (7)</br>1 (3)</br>3 (10)</br>Abdominal pain</br>3 (10)</br>0</br>0</br>3 (10)</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>0</br>2 (7)</br>1 (3)</br>3 (10)</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>2 (7)</br>1 (3)</br>0</br>3 (10)</br>Hematuria</br>2 (7)</br>1 (3)</br>0</br>3 (10)</br>Erysipelas</br>2 (7)</br>1 (3)</br>0</br>2 (7)</br>Pain in extremity</br>2 (7)</br>1 (3)</br>0</br>2 (7)</br>Cough</br>2 (7)</br>0</br>0</br>2 (7)</br>Dysuria</br>2 (7)</br>0</br>0</br>2 (7)</br>Headache</br>2 (7)</br>0</br>0</br>2 (7)</br>Hypertension</br>0</br>2 (7)</br>0</br>2 (7)</br>Influenza</br>2 (7)</br>0</br>0</br>2 (7)</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Rhinorrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>2 (7)</br>0</br>0</br>2 (7)</br>Rib fracture</br>2 (7)</br>0</br>0</br>2 (7)</br>Skin ulcer</br>2 (7)</br>0</br>0</br>2 (7)</br>Solar dermatitis</br>2 (7)</br>0</br>0</br>2 (7)</br>REV 0719 References/ Enclosure(s): (Bolded)</br>1. NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.</br>2. Institute for Clinical and Economic Review (ICER), 2018</br>3. Fizazi K, et al. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " in nonmetastatic, castration-resistant prostate cancer). Oral presentation at: [ASCO</br>GU]; February 14 – 16, 2019; San Francisco CA. Presentation number #GU19.</br>4. Fizazi K, Shore N, Tammela TL, et. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " in nonmetastatic castration-resistant prostate cancer;  N Eng J</br>M, 20  19, PP 1 – 12,DOI: 10.1056/NEJMMoa1815671</br>5. Fizazi K, et al. Activity and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of odm-201 in patients with progressive metastatic castration-resistant</br>prostate cancer (ARADES): an open-label phase I dose-escalation and randomized phase II dose expansion</br>trial.  Lancet Oncol , 2014;15:975-985</br>6. Massard C, et al. \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", antitumor activity, and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of ODM-201 in patients with</br>chemotherapy-naïve metastatic castration-resistant prostate cancer: an open-label phase I study.  Eur Urol</br>2016;69:834-840.</br>7. Pajouhesh H, Lenz GR.  NeuroRx . \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    2005;2:541–553\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data\n",
       "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/subashgandyer/anaconda3/lib/python3.7/runpy.py:193: UserWarning: [W011] It looks like you're calling displacy.serve from within a Jupyter notebook or a similar environment. This likely means you're already running a local web server, so there's no need to make displaCy start another one. Instead, you should be able to replace displacy.serve with displacy.render to show the visualization.\n",
      "  \"__main__\", mod_spec)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "<html lang=\"en\">\n",
       "    <head>\n",
       "        <title>displaCy</title>\n",
       "    </head>\n",
       "\n",
       "    <body style=\"font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr\">\n",
       "<figure style=\"margin-bottom: 6rem\">\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") Safety Data</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of</br>patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>Background</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is a second-generation Androgen Receptor (AR) inhibitor given concurrently with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " deprivation therapy (ADT) for the treatment of \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (nmCRPC).1 </br>There is a need for agents that not only provide significant clinical benefit but also have a tolerable \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " profile with minimal detriment to patient quality of life.2    \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " is structurally distinct from other second-generation AR inhibitors. It is a more polar molecule with a \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    flexible\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " structure. Increased flexibility, higher polarity, and increased hydrogen bond-forming potential are associated with low blood brain barrier penetration in preclinical models.7  .</br>This letter will discuss adverse events reported in the ARAMIS, ARADES and ARAFOR trials.3  -6</br>Summary</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men being treated with androgen deprivation therapy (ADT) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") and have a high risk of developing metastases. The primary \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of the study was metastasis-free survival (MFS). MFS was defined as the time from randomization to evidence of metastasis (new or progressive regional pathological lymph nodes were not defined as metastasis) or death from any cause, whichever occurred first.3  -4</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% versus placebo [HR .41 (95% CI 0.34 – 0.50);  P  &lt;0.001].  3</br>● In addition to evaluation of Metastasis-free Survival as the primary efficacy variable, \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " was evaluated.</br>o After a median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial (N = 1220/1508; [\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm, n = 794; placebo arm, n = 426]). The majority of adverse events reported in both arms were Grade 1 or 2 [54.4% (821/1508)].3    The incidence of common adverse events were reported in ≤10% of patients in both the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and placebo arms, with only \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") reported at an incidence of &gt;10% in both arms.3 </br>Exposure-adjusted Adverse Events</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> ▪ After adjustment for duration of treatment or observation period (median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm), differences in the incidence of adverse events of interest between both arms decreased or were no longer evident.3 </br>o The most common Grade 3 or 4 events were hypertension (3.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.2% of patients in the placebo plus ADT arm.) and urinary retention (1.6% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 </br>o Treatment discontinuations occurred in 35.5% (339/954) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs. 63.9% (354/554) of patients in the placebo arm.3 </br>● ARADES, an open-label, multicenter trial with a non-randomized Phase I dose escalation portion and a Phase II randomized dose expansion phase, enrolled patients (N = 134) with progressive, metastatic castration-resistant prostate cancer (mCRPC).5    Patients with a history of seizures or were at risk of seizures were included.5 </br>o In the placebo arm, treatment discontinuations due to adverse events occurred in 8.5% (47/554) of patients; treatment discontinuations due to metastasis occurred in 23.3% (129/554) of patients.5 </br>o The most common adverse events (all grades) were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (31%, \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (16%) and pain (15%). Most adverse events reported were Grade 1 or 2.5 </br>o Grade 3 and 4 adverse events reported in 22% (n = 27) and &lt;2% (n = 2) patients, respectively. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " was tolerated up to the highest dose studied (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") and the maximum tolerated dose was not reached. None of the reported events were deemed by the investigator to be drug-related. No seizures were reported.5 </br>o Adverse events considered drug-related were reported in 35% (n = 44) patients and included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " in 12% (n = 15) of patients, hot flushes in 5% (n = 6) of patients, decreased appetite in 4% (n = 5) of patients and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " in 2% (n = 3) of patients.5 </br>▪ One grade 3 event (\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") was deemed by the investigator to be possibly drug-related. No grade 4 events were deemed to be drug-related.5 </br>● ARAFOR, a two-part, multicenter, international, open-label, Phase I study, evaluated the pharmacokinetic (PK), \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (ODM-201) in patients (N = 30) with progressive metastatic castration resistant prostate cancer (mCRPC). Patients with a history of seizures or were at risk of seizures were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    included.6\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " </br>o After a median reporting period of 15.3 months (95% CI 9.7 months – NR), 73% (22/30) of patients reported adverse events.6 </br>o The majority of the AE’s reported were Grade 1 or 2. The most common AEs were reported included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%, n = 4) [All grade 1] and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%, n = 4) [All grade 1 – 3].6 </br>o Twenty percent (20%) of AEs reported were considered treatment-related.</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> ▪ Treatment-related AEs were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", decreased appetite, headache, abdominal pain, solar dermatitis, tinnitus, and dysgeusia. All treatment-related AEs were Grade 1.6 </br>o No seizures were reported.6  6 o No dose reductions were necessary. </br>Clinical Data</br>Non-metastatic Castration-Resistant Prostate Cancer (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nmCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ") ARAMIS Trial3  -4</br>Study Design</br>ARAMIS, a Phase III, multinational, randomized, double blind, placebo-controlled study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men undergoing treatment with androgen deprivation therapy (ADT*   ) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (nmCRPC) with a high risk of developing \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ". High risk was defined as PSADT of ≤ 10 months and PSA ≥ 2ng/ml. Patients included in the study had an ECOG performance status of 0-1 and adequate hematologic, renal, and liver function. Additionally, patients with a history of seizures or at risk for seizures were included.3 </br>Patients (N=1509) were randomized 2:1 to receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 600 mg tablets orally twice daily with food plus ADT versus matching placebo plus ADT. Key baseline characteristics of the majority of the patient population in the ARAMIS study were: a median age of 74; Gleason score of ≥7; absence of regional pathological lymph nodes; ≥2 prior hormonal therapy agents with a PSADT ≤6 months, and no baseline osteoclast targeted therapy. Patients on the ARAMIS study were stratified according to PSADT (PSADT;  &lt;  6 months vs. &gt; 6 months) and use of osteoclast-targeted therapy (yes vs. no). All assessments were obtained at baseline and every 16 weeks.3 </br>The primary \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of the study was metastasis free-survival (MFS) [defined as time between randomization and evidence of metastasis or death from any cause, whichever occurs first. Secondary endpoints included OS, Time to Pain Progression, Time to Initiation of First Cytotoxic Chemotherapy and Time to First Symptomatic Skeletal Event (SSE). Exploratory endpoints included PFS and Time to PSA Progression.3 </br>Safety Results3 </br>After a median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial</br>(N = 1220/1508; [\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm, n = 794; placebo arm, n = 426]). The incidence of adverse events were generally similar between treatment arms and the majority were Grade 1 or 2 [54.4% (821/5108)].3    The incidence of common events was low with only \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " reported at an incidence of &gt;10%. Grades 3 or 4 adverse events occurred in 22.8% (344/1508) of the total \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " population (24.7% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 19.5% of patients in the placebo arm). The most frequent Grade 3 or 4 adverse events included hypertension (3.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.2% of patients in the placebo plus ADT</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br> arm.) and urinary retention (1.6% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 </br>Table 1 shows the Treatment Emergent Adverse Events (TEAEs) for the total \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " population (N = 1508). TEAEs (all grades) occurring in ≥5% of patients reported in Table 6 below, in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " versus placebo arms, respectively, included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") (12.1% [115/954, vs 8.7% [48/554]). Other TEAEs occurring in ≥5% in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (8.8%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (8.1%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (6.9%), hypertension (7.3%), constipation (TEAEs occurring in 6.3%), pain in extremity (5.8%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (5.6%) and hot flush (5.2%).3  Approximately 14% of TEAEs led to a dose modification in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 9.4% of TEAEs in the placebo arm.</br>After a median follow-up of 17.9 months, treatment discontinuations were similar between both arms.4    Discontinuations due to adverse events occurred in 8.9% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs 8.7% of patients in the placebo arm. Discontinuations due to metastasis occurred in 11.7% vs 23.3% of patients; and discontinuations due to investigator judgment occurred in 5.7% vs 16.4% of patients, in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arms, respectively. Discontinuations due to protocol deviation and to other reasons unspecified occurred in 1.4% vs 1.3% and 0.6% vs 0.4% in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arm, respectively. Additionally, 7.1% vs 14.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arm respectively decided not to continue trial participation. It should be noted that one person in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm was randomized but did not receive treatment.4 </br>A total of 55 deaths occurred during the trial with 3.9% of deaths occurring in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 3.2% occurring in the placebo arm.3    See Table 1 below.</br>The Institute for Clinical and Economic Review (ICER) has identified events such as falls, fractures, cardiovascular events and deaths due to AE’s, etc. to be TEAE’s of interest for anti-\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " therapies.2    For the incidence of TEAE’s of interest reported for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", see Tables 2 - 4.3 </br>    Table 1. ARAMIS: Summary of TEAEs3 </br>      \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 954</br>     Placebo N = 554</br>  Total N = 1508</br>     Exposure, median (months)</br> 14.8</br>      11.04</br>        Any AE, n (%)</br> 794 (83.2)</br>      426 (76.9)</br>   1220 (80.9)</br>     Worst grade</br>               Grade 1 or 2</br> 521 (54.6)</br>      300 (54.2)</br>   821 (54.4)</br> Grade 3 or 4</br>   236 (24.7)</br>    108 (19.5)</br>    344 (22.8)</br>     Grade 5</br>37 (3.9)</br>    18 (3.2)</br> 55 (3.6)</br>     Serious</br> 237 (24.8)</br>      111 (20.0)</br>   348 (23.1)</br> Leading to dose modification</br>   135 (14.2)</br>    52 (9.4)</br>    187 (12.4)</br>   Leading to permanent discontinuation</br>85 (8.9)</br>  48 (8.7)</br> 133 (8.8)</br>           AE, adverse event, TEAE, treatment emergent adverse event</br>Table 2. ARAMIS: Total of TEAEs with an Incidence of  ≥ 5%3 </br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>     </br>                                                                                                                    Preferred term, n (%)</br>   \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 954</br>  Placebo N = 554</br>     Fatigue</br>    115 (12.1)</br>   48 (8.7)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    84 (8.8)</br>   50 (9.0)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    77 (8.1)</br>   51 (9.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    66 (6.9)</br>   31 (5.6)</br>     Hypertension</br>    70 (7.3)</br>   33 (6.0)</br>     Constipation</br>    60 (6.3)</br>   34 (6.1)</br>     Pain in extremity</br>    55 (5.8)</br>   18 (3.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    53 (5.6)</br>   25 (4.2)</br>     Hot flush</br>    50 (5.2)</br>   23 (4.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    48 (5.0)</br>   32 (5.8)</br>     Bone Fracture</br>    40 (4.2)</br>   21 (3.8)</br>     Fall</br>    40 (4.2)</br>   26 (4.7)</br>     Rash</br>    24 (2.6)</br>   4 (0.7)</br> Weight decreased</br>    34 (3.6)</br>    12 (2.2)</br>                   Table 3. ARAMIS: TEAEs of Interest3 </br>    \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N=954</br>Placebo N=554</br>                        AE</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>                                Bone Fracture</br>40 (4.2)</br>0.9</br>0</br>0</br>21 (3.8)</br>0.9</br>0</br>0</br>                    Fall</br>40 (4.2)</br>0.8</br>0</br>0</br>26 (4.7)</br>0.7</br>0</br>0</br>                      Fatigue, including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>151 (15.8)</br>0.6</br>0</br>0</br>63 (11.4)</br>1.1</br>0</br>0</br>                    Seizure</br>2 (0.2)</br>0</br>1 (0.2)</br>0</br>                      Cognitive disorder</br>4 (0.4)</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Memory impairment</br>5 (0.5)</br>0</br>0</br>0</br>7 (1.3)</br>0</br>0</br>0</br>                                Disturbance in attention</br>0</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Amnesia</br>1 (0.1)</br>0</br>0</br>0</br>3 (0.5)</br>0</br>0</br>0</br>                    Rash</br>24 (2.6)</br>0.1</br>0</br>0</br>4 (0.7)</br>0</br>0</br>0</br>                      Weight decreased</br>34 (3.6)</br>0</br>0</br>0</br>12 (2.2)</br>0</br>0</br>0</br>                    Hot flush</br>50 (5.2)</br>0</br>-</br>-</br>23 (4.6)</br>0</br>-</br>-</br>                 Increased bilirubin</br>18 (1.9)</br>0.1</br>0</br>0</br>0</br>0</br>0</br>0</br>                 Table 4. AE</br>Hypertension</br>ARAMIS: TEAEs of Interest3    continued \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       "</br>N=954 Any Grade 3, Grade 4 Grade 5,</br>Placebo N=554</br>n (%) n (%)</br>70 (7.3) 3.4 0 0 33 (6.0) 2.3 0 0</br>Any</br>Grade, % % % Grade, % % %</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>Grade 3,</br>Grade 4 Grade 5,</br></br>    Cerebral and intracranial hemorrhage</br>  2 (0.2)</br>  0</br>     0</br>   0</br> 2 (0.4)</br>  0.2</br>     0</br>  0.2</br> Cerebral infarction and stroke</br>  4 (0.4)</br>  0.3</br>  0</br>     0</br>    4 (0.7)</br>    0.4</br>  0</br>    0.2</br>   Cerebral ischemic infarction and stroke</br> 5 (0.5)</br> 0.1</br>    0.2</br> 0.1</br>2 (0.4)</br> 0.2</br>    0</br> 0.2</br>   Acute myocardial infarction</br>   5 (0.5)</br>   0.2</br>      0.2</br>    0.1</br> 1 (0.2)</br>   0</br>      0</br>   0</br> Cardiac failure</br>  18 (1.9)</br>  0.1</br>  0.1</br>     0.3</br>    5 (0.9)</br>    0</br>  0</br>    0.5</br>   Coronary artery disorders</br> 31 (3.2)</br> 1.3</br> 0.4</br>   0.3</br>  14 (2.5)</br>  0.4</br> 0</br>  0.2</br>  Ischemic coronary artery disorders</br> 24 (2.5</br> 0.7</br> 0.4</br>  0.2</br> 11 (2.0)</br>  0.4</br> 0</br> 0.2</br>       Exposure-adjusted Adverse Events</br>After adjustment for duration of treatment or observation period (After a median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm), differences in the incidence of adverse events of interest between both arms decreased or no longer evident.3  See table 5 below.</br>    Table 5 Exposure-adjusted Adverse events3  ( patients per 100 years of exposure )</br>     Adverse events of interests</br>   \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Exposure-adjusted incidence (N = 954)</br>  Placebo Exposure-adjusted incidence (N = 554)</br>     Fatigue or asthenic conditions</br>    11.3</br>   11.1</br>     Back pain</br>    6.3</br>   8.8</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    5.8</br>   9.0</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    4.9</br>   5.5</br>     Hypertension</br>    4.7</br>   5.1</br>     Constipation</br>    4.5</br>   6.0</br>     Pain in extremity</br>    4.1</br>   3.2</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    4.0</br>   4.4</br>     Hot flush</br>    3.7</br>   4.1</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    3.6</br>   5.6</br>     Weight loss</br>    2.5</br>   2.1</br>     Falls</br>    2.7</br>   4.1</br>     Bone fracture</br>    3.0</br>   3.5</br>     Memory impairment</br>    0.4</br>   1.2</br>     Cognitive disorder</br>    0.3</br>   0.2</br> Seizure</br>    0.2</br>    0.2</br>                  Metastatic Castration-Resistant Prostate Cancer (\n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    mCRPC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ")</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> ARADES Trial 5 Study Design</br>The ARADES trial, an open-label, multicenter trial with a non-randomized Phase I dose escalation portion and a Phase II randomized dose expansion phase, enrolled patients with progressive, metastatic castration-resistant prostate cancer (mCRPC). Patients with a history of seizures or were at risk of seizures were included.5 </br>Patients (N = 134) in the ARADES trial had progressive, mCRPC with serum testosterone levels &lt;30 ng/m and were either chemotherapy-naïve or had ≤2 prior chemotherapy regimens.5 </br>Baseline characteristics are presented in Table 6.5  Table 6: Baseline Characteristics.5 </br>        Total N=134</br>   CYP17i-naïve, chemo-naïve, N</br>     42 (31.3)</br>   CYP17i-naïve, post-chemo</br>     35 (26.1)</br>   Post-CYP17i</br>     57 (42.5)</br>   Age, median years (range)</br>     60 (53-89)</br>   PSA ng/mL, median (range)</br>     99 (3-5000)</br>   Time from diagnosis to study treatment, median months (range)</br>    69 (10-231)</br> Disease localization, N(%): Bone disease only</br>Soft Tissue only</br>Soft and Bone Disease</br>   49 (36.6) 20 (14.9) 64 (47.8)</br>   Seizure (and like) event history %</br>    11 (8.2)</br> Time on Study Drug (days) Mean (SD)</br>Median (min, max)</br>  184 (131.0) 168 (1,684)</br>    Safety Results 5</br>The most common adverse events (all grades) were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (31%, \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (16%) and pain (15%). Most adverse events reported were Grade 1 or 2. Grade 3 and 4 adverse events reported in 22% (n = 27) and &lt;2% (n = 2) patients, respectively. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " was tolerated up to the highest dose studied (\n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       ") with the maximum tolerated dose was not reached. No seizures were reported.3    See table 7 below.</br>Adverse events considered drug-related were reported in 35% (n = 44) patients and included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " in 12% (n = 15) of patients, hot flushes in 5% (n = 6) of patients, decreased appetite in 4% (n = 5) of patients and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " in 2% (n = 3) of patients. One grade 3 event (\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") was deemed by the investigator to be possibly drug-related. No grade 4 events were deemed to be drug-related.5 </br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Table 7</br>    ARADES: TEAEs with an Incidence of  ≥ 10% (n = 134) – \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 200 – \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " </br>  Adverse Event</br>    Grade 1</br>     Grade 2</br>     Grade 3</br>    Total*</br>     Fatigue including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br> 30 (22%)</br> 13 (10%)</br> 2 (1%)</br> 41 (31%)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    17 (13%)</br>    13 (10%)</br>    2 (1%)</br>   28 (21%)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    18 (13%)</br>    9 (7%)</br>    2 (1%)</br>   22 (16%)</br>     Pain</br>    9 (7%)</br>    8 (6%)</br>    3 (2%)</br>   20 (15%)</br>     Constipation</br>    15 (11%)</br>    5 (4%)</br>    0</br>   18(13%)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    14 (10%)</br>    4 (3%)</br>    0</br>   17 (13%)</br>     Decreased appetite</br>    15 (11%)</br>    1 (&lt;1%)</br>    0</br>   16 (12%)</br> \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Peripheral edema\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    14 (10%)</br>     2 (1%)</br>     0</br>    16 (12%)</br>      *Total may be less than the sum of the grade because patients may have had \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " of several grades.</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> ARAFOR Trial 6 Study Design</br>ARAFOR, a two-part, multicenter, international, open-label, Phase I study, evaluated the pharmacokinetic (Pk), \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (ODM-201) in patients (N = 30) with progressive metastatic castration resistant prostate cancer (mCRPC). Patients eligible for the study had to meet the following inclusion criteria: ≥18 years of age with progressive mCRPC, testosterone level &lt;1.7 nmol/L, ECOG performance status of 0-1, chemotherapy naïve, and asymptomatic or mildly symptomatic. Patients without bilateral orchiectomy were to continue on gonadotropin-releasing hormone therapy. Patients with brain metastases or previous treatment with a second-generation Androgen Receptor antagonist or CYP17 inhibitor was excluded.6 </br>The first part of the study (Pk analysis) was a randomized open-label, two arm, three-period crossover study. The second part of the study (\n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " analysis) was an open-label extension to evaluate long-term \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ". The primary \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of the first part of the study was PK of tablet products compared to the capsule formulation and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       ". The endpoints in the second part of the study were \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and effects on PSA and lesions.6 </br>Safety Results 6</br>After a median reporting period of 15.3 months (95% CI 9.7 months – NR), 73% (22/30) of patients reported \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ". The majority of the AE’s reported were Grade 1 or 2. The most common AEs were reported included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%, n = 4) [All grade 1] and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%, n = 4) [All grade 1 – 3]. Twenty percent (20%) of AEs reported were considered treatment-related. Treatment-related AEs were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%), decreased appetite, headache, abdominal pain, solar dermatitis, tinnitus, and dysgeusia. All treatment-related AEs were Grade 1. No seizures were reported6 </br>No dose reductions were necessary. One patient (3.3%) died due to cancer progression. Two patients (6.7%) discontinued due to an AE (neuroendocrine carcinoma and respiratory failure). These AEs were not consider treatment-related by the investigator.6    For AEs reported in &gt;5% of patients, see table 8 below.</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data</br>Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>Table 8. Adverse Events occurring in &gt;5% of patients by Grade6  (Safety Population, N = 30)</br>Adverse event</br>Grade 1 n (%)</br>Grade 2 n (%)</br>Grade 3 n (%)</br>Total n (%)</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>3 (10)</br>1 (3)</br>1 (3)</br>4 (13)</br>Fatigue</br>4 (13)</br>0</br>0</br>4 (13)</br>Bone pain</br>1 (3)</br>2 (7)</br>1 (3)</br>3 (10)</br>Abdominal pain</br>3 (10)</br>0</br>0</br>3 (10)</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>0</br>2 (7)</br>1 (3)</br>3 (10)</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>2 (7)</br>1 (3)</br>0</br>3 (10)</br>Hematuria</br>2 (7)</br>1 (3)</br>0</br>3 (10)</br>Erysipelas</br>2 (7)</br>1 (3)</br>0</br>2 (7)</br>Pain in extremity</br>2 (7)</br>1 (3)</br>0</br>2 (7)</br>Cough</br>2 (7)</br>0</br>0</br>2 (7)</br>Dysuria</br>2 (7)</br>0</br>0</br>2 (7)</br>Headache</br>2 (7)</br>0</br>0</br>2 (7)</br>Hypertension</br>0</br>2 (7)</br>0</br>2 (7)</br>Influenza</br>2 (7)</br>0</br>0</br>2 (7)</br>\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Rhinorrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>2 (7)</br>0</br>0</br>2 (7)</br>Rib fracture</br>2 (7)</br>0</br>0</br>2 (7)</br>Skin ulcer</br>2 (7)</br>0</br>0</br>2 (7)</br>Solar dermatitis</br>2 (7)</br>0</br>0</br>2 (7)</br>REV 0719 References/ Enclosure(s): (Bolded)</br>1. NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.</br>2. Institute for Clinical and Economic Review (ICER), 2018</br>3. Fizazi K, et al. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " in nonmetastatic, castration-resistant prostate cancer). Oral presentation at: [ASCO</br>GU]; February 14 – 16, 2019; San Francisco CA. Presentation number #GU19.</br>4. Fizazi K, Shore N, Tammela TL, et. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " in nonmetastatic castration-resistant prostate cancer;  N Eng J</br>M, 20  19, PP 1 – 12,DOI: 10.1056/NEJMMoa1815671</br>5. Fizazi K, et al. Activity and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of odm-201 in patients with progressive metastatic castration-resistant</br>prostate cancer (ARADES): an open-label phase I dose-escalation and randomized phase II dose expansion</br>trial.  Lancet Oncol , 2014;15:975-985</br>6. Massard C, et al. \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", antitumor activity, and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of ODM-201 in patients with</br>chemotherapy-naïve metastatic castration-resistant prostate cancer: an open-label phase I study.  Eur Urol</br>2016;69:834-840.</br>7. Pajouhesh H, Lenz GR.  NeuroRx . \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    2005;2:541–553\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " Safety Data\n",
       "Disclaimer -  This information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>\n",
       "</figure>\n",
       "</body>\n",
       "</html>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Using the 'ent' visualizer\n",
      "Serving on http://0.0.0.0:5000 ...\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "127.0.0.1 - - [05/Mar/2020 10:59:26] \"GET / HTTP/1.1\" 200 87340\n",
      "127.0.0.1 - - [05/Mar/2020 10:59:27] \"GET /favicon.ico HTTP/1.1\" 200 87340\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Shutting down server on port 5000.\n"
     ]
    }
   ],
   "source": [
    "displacy.serve(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Document 5 - Nubeqa (US-NUBEQA-76050-S.docx-2.pdf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc = loaded_nlp(\"\"\"NUBEQA®   (darolutamide) Pharmacokinetics\n",
    "● Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.1 \n",
    "● Pharmacokinetics of darolutamide were determine as a part of the phase1-2 study, which determined dose escalation, dose expansion, and long term follow-up.1 \n",
    "o Pharmacokinetics were determined in patients receiving 200 mg/day (n=3), 400 mg/day (n=7), 600 mg/day (n=3) 1000 mg/day (n=3), 1400 mg/day (n=3), 1800 mg/day (n=3) with food. No intra-patient escalation was permitted.\n",
    "o Pharmacokinetic analysis of darolutamide showed rapid absorbed and the median t max  ranged 3.0–5.1 hours for darolutamide and 1.5–5.0 h for diastereo isomer keto-darolutamide on day 1. The mean metabolite to parent ratio (area under the curve, AUC) at steady state was 1.6–2.3:1. The exposure of darolutamide (AUC t a  nd C max)  at steady state increased in a linear, dose-related manner up to 1400 mg daily dose.\n",
    "o Most common Grade 3 adverse events occurring in  >  10% of patients were fatigue or asthenia 2 (2%), back pain 2 (2%) and arthralgia 2 (2%).\n",
    "● An open randomized phase 1 study evaluated safety and tolerability, bioavailability and effect of food on bioavailability of darolutamide in patients with metastatic chemotherapy naïve CRPC.2    The study compared relative bioavailability of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with chemotherapy naïve metastatic castrate resistant prostate cancer.\n",
    "o Patients were randomized to one of 3 treatment sequences in each group.   There were three treatment periods for each patient during the PK Component which included administration of two darolutamide 300 mg test tablet (Tab A or Tab B) in both fasted and fed conditions, or administration of darolutamide 100 mg capsule at 600 mg dose in fed state. There was at least 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day\n",
    "o Thirty men with were enrolled. Area under the concentration curve (AUC) and maximum concentration (C max)  values were approximately two times lower after administration at fast. With high fat meal the C max  occurred about 2-3 hours later. The food effect was similar in all groups.\n",
    "o The pharmacokinetics observed with the two new tablet formulations were comparable with the pharmacokinetics of the capsule formulation\n",
    "Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.Phase 1-2 study\n",
    "Phase 1–2 clinical trial was conducted to assess darolutamide in men with progressive metastatic castration-resistant prostate cancer.1    The primary objectives of the trial were to\n",
    "Darolutamide Pharmacokinetics\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    " \n",
    " assess safety and tolerability and to define a maximum tolerated dose. Secondary objectives were to determine the pharmacokinetics, and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts. Tolerability and outcome measures are discussed elsewhere.\n",
    "Blood samples were collected for the pharmacokinetics analyses. We identified plasma concentrations of diastereoisomers [S,R]-darolutamide and [S,S]-darolutamide, and the major metabolite keto-darolutamide by liquid chromatography-tandem mass spectrometry (LC-MS/MS); Darolutamide concentration was the sum of [S,R]-darolutamide and [S,S]-darolutamide concentrations.1 \n",
    "Pharmacokinetic analysis of darolutamide showed rapid absorbed and the median t max  were 3·0–5·1 h for darolutamide and 1.5–5.0 h for keto-darolutamide on day 1.1    The mean metabolite to parent ratio (area under the curve, AUC) at steady state was 1.6–2.3:1. The exposure of darolutamide (AUC t  and C max)  at steady state increased in a linear, dose-related manner up to 1400 mg daily dose. Dose escalation was discontinued because of darolutamide plasma concentration plateau. Steady-state plasma concentrations were reached after 1 week of continuous treatment. The mean half-life of darolutamide independent of dose was 15.8 hours (SD 13.8) at steady state after 200–1800 mg daily doses. The mean half-life of keto-darolutamide was 10.0 hours (3.8) at steady state after 200–1800 mg daily doses.\n",
    "Mean  +  standard deviations steady state concentrations at various doses are presented in Figure 1.1 \n",
    "Figure 1: Mean  +  SD Concentrations of DAROLUTAMIDE 1\n",
    "Darolutamide mean C max  by dose are presented in Figure 2a, and mean  +  SD areas under concentration curve (AUC) of darolutamide is presented in Figure 2b.1 \n",
    "Darolutamide Pharmacokinetics\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "    \n",
    "  Figure 2a: Mean  +  SD C max  Based on Dose1 \n",
    "   Figure 2b: AUC of Darolutamide by Dose\n",
    "          Most common Grade 3 adverse events occurring in  >  10% of patients were fatigue or asthenia 2 (2%), back pain 2 (2%) and arthralgia 2 (2%).\n",
    "Phase I bioavailability study\n",
    "An open randomized phase 1 trial (ARAFOR) evaluated bioavailability and effect of food on bioavailability of darolutamide.2    The study compared relative bioavailability of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with  chemotherapy naïve metastatic castrate resistant prostate cancer. The study also assessed  the effect of food on the bioavailability of darolutamide tablet products tablet A (Tab A) and tablet B (Tab B).\n",
    "The PK Component consisted of two concurrent groups, which evaluated Tab A and (Tab B), and capsule. Patients were randomized to one of 3 treatment sequences in each group.2     There were three treatment periods for each patient during the PK Component which included administration of two darolutamide 300 mg test tablets (Tab A or Tab B) in both fasted and fed conditions, or administration of darolutamide (6 x100 mg) capsules at 600 mg dose in fed state. There was at least a 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day\n",
    "Thirty  men with metastatic chemotherapy-naïve CRPC were enrolled.2    Food interaction was seen when darolutamide formulations (600 mg) were administered after a high fat content breakfast compared to administration in fasted state. AUC and C max  values were approximately\n",
    "Darolutamide Pharmacokinetics\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    " \n",
    "two times lower after administration at fast. With high fat meal the C max  occurred about 2-3 hours later, indicating the delayed gastric emptying of darolutamide after the high fat meal. The food effect was similar in all groups. The pharmacokinetics observed with the two new tablet formulations were comparable with the pharmacokinetics of the capsule formulation (figure 4\n",
    "Figure 4: Concentration Time Curves of the Three Formulation with and Without Food2 \n",
    "Most commonly reported adverse events (>10%) were fatigue/asthenia (13%), nausea (10%), erythema (10%) and urinary tract disorder (10%); all being mild events except one nausea event (grade 3).\n",
    "REV: 0719 Reference:\n",
    "1. NUBEQA®    (darolutamide) tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.\n",
    "2. Fizazi K, Massard C, Bono P, et al. Activity and safety of ODM 201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.  Lancet Oncol  2014; 15: 975–85. http://www.ncbi.nlm.nih.gov/pubmed/24974051\n",
    "3. Massard C, Tammela T, Vjaters, et al. A study of ODM 201 formulations with a safety and tolerability extension phase in patients with metastatic chemotherapy naïve castrate-resistant prostate cancer (CRPC). Presented at 2014 Genitourinary Cancers Symposium, January 2014 in San Francisco CA.\n",
    "Darolutamide Pharmacokinetics\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\"\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">NUBEQA®   (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " were determine as a part of the phase1-2 study, which determined dose escalation, dose expansion, and long term follow-up.1 </br>o \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " were determined in patients receiving \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3), \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=7), 600 mg/day (n=3) \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3), \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3), \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3) with \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       ". No intra-patient escalation was permitted.</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorbed and the median t max  ranged \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    3.0–5.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " hours for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1.5–5.0 h\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " for diastereo isomer keto-darolutamide on day 1. The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1.6–2.3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t a  nd C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose.</br>o Most common Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " occurring in  &gt;  10% of patients were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%) and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%).</br>● An open randomized phase 1 study evaluated \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in patients with metastatic chemotherapy naïve CRPC.2    The study compared relative \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with \n",
       "<mark class=\"entity\" style=\"background: turquoise; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy naïve metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ".</br>o Patients were randomized to one of 3 treatment sequences in each group.   There were three treatment periods for each patient during the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " Component which included \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of two \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 300 mg test \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tablet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " (Tab A or Tab B) in both \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " conditions, or \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 100 mg capsule at 600 mg dose in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state. There was at least 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day</br>o Thirty men with were enrolled. Area under the concentration curve (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") and maximum concentration (C max)  values were approximately two times lower after \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " at fast. With high fat meal the C max  occurred about 2-3 hours later. The \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " effect was similar in all groups.</br>o The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " observed with the two new \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tablet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " formulations were comparable with the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of the capsule formulation</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ".Phase 1-2 study</br>Phase 1–2 clinical trial was conducted to assess \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men with progressive metastatic castration-resistant prostate cancer.1    The primary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " of the trial were to</br>Darolutamide \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br> assess \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and to define a maximum tolerated dose. Secondary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " were to determine the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts. \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and outcome measures are discussed elsewhere.</br>Blood samples were collected for the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " analyses. We identified \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentrations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " of diastereoisomers [S,R]-darolutamide and [S,S]-darolutamide, and the major metabolite keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " by liquid chromatography-tandem mass spectrometry (LC-MS/MS); \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " concentration was the sum of [S,R]-darolutamide and [S,S]-darolutamide concentrations.1 </br>\n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorbed and the median t max  were 3·0–5·1 h for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and 1.5–5.0 h for keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " on day 1.1    The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1.6–2.3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t  and C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose. Dose escalation was discontinued because of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " plateau. Steady-state \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentrations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " were reached after 1 week of continuous treatment. The mean half-life of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " independent of dose was 15.8 hours (SD 13.8) at steady state after \n",
       "<mark class=\"entity\" style=\"background: #ffa500; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200–1800 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " doses. The mean half-life of keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " was 10.0 hours (3.8) at steady state after \n",
       "<mark class=\"entity\" style=\"background: #ffa500; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200–1800 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " doses.</br>Mean  +  standard deviations steady state concentrations at various doses are presented in Figure 1.1 </br>Figure 1: Mean  +  SD Concentrations of \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    DAROLUTAMIDE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " 1</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " mean C max  by dose are presented in Figure 2a, and mean  +  SD areas under concentration curve (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is presented in Figure 2b.1 </br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>    </br>  Figure 2a: Mean  +  SD C max  Based on Dose1 </br>   Figure 2b: \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " by Dose</br>          Most common Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " occurring in  &gt;  10% of patients were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%) and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%).</br>Phase I \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " study</br>An open randomized phase 1 trial (ARAFOR) evaluated \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of darolutamide.2    The study compared relative \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with  \n",
       "<mark class=\"entity\" style=\"background: turquoise; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy naïve metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". The study also assessed  the effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " tablet products tablet A (Tab A) and tablet B (Tab B).</br>The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " Component consisted of two concurrent groups, which evaluated Tab A and (Tab B), and capsule. Patients were randomized to one of 3 treatment sequences in each group.2     There were three treatment periods for each patient during the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " Component which included \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of two \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 300 mg test tablets (Tab A or Tab B) in both \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " conditions, or \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (6 x100 mg) capsules at 600 mg dose in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state. There was at least a 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day</br>Thirty  men with metastatic chemotherapy-naïve CRPC were enrolled.2    Food interaction was seen when \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " formulations (600 mg) were administered after a high fat content breakfast compared to \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state. \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " and C max  values were approximately</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br>two times lower after \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " at fast. With high fat meal the C max  occurred about 2-3 hours later, indicating the delayed gastric emptying of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " after the high fat meal. The \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " effect was similar in all groups. The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " observed with the two new \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tablet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " formulations were comparable with the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of the capsule formulation (figure 4</br>Figure 4: Concentration Time Curves of the Three Formulation with and Without Food2 </br>Most commonly reported \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (&gt;10%) were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "/\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%), nausea (10%), erythema (10%) and urinary tract disorder (10%); all being mild events except one nausea event (grade 3).</br>REV: 0719 Reference:</br>1. NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.</br>2. Fizazi K, Massard C, Bono P, et al. Activity and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of ODM 201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.  Lancet Oncol  2014; 15: 975–85. http://www.ncbi.nlm.nih.gov/pubmed/24974051</br>3. Massard C, Tammela T, Vjaters, et al. A study of ODM 201 formulations with a \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " extension phase in patients with metastatic chemotherapy naïve castrate-resistant prostate cancer (CRPC). Presented at 2014 Genitourinary Cancers Symposium, January 2014 in San Francisco CA.</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "\n",
       "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/subashgandyer/anaconda3/lib/python3.7/runpy.py:193: UserWarning: [W011] It looks like you're calling displacy.serve from within a Jupyter notebook or a similar environment. This likely means you're already running a local web server, so there's no need to make displaCy start another one. Instead, you should be able to replace displacy.serve with displacy.render to show the visualization.\n",
      "  \"__main__\", mod_spec)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "<html lang=\"en\">\n",
       "    <head>\n",
       "        <title>displaCy</title>\n",
       "    </head>\n",
       "\n",
       "    <body style=\"font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr\">\n",
       "<figure style=\"margin-bottom: 6rem\">\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">NUBEQA®   (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " were determine as a part of the phase1-2 study, which determined dose escalation, dose expansion, and long term follow-up.1 </br>o \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " were determined in patients receiving \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3), \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=7), 600 mg/day (n=3) \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1000 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3), \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3), \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1800 mg/day\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " (n=3) with \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       ". No intra-patient escalation was permitted.</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorbed and the median t max  ranged \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    3.0–5.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " hours for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #b3ffff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1.5–5.0 h\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Tmax</span>\n",
       "</mark>\n",
       " for diastereo isomer keto-darolutamide on day 1. The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1.6–2.3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t a  nd C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose.</br>o Most common Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " occurring in  &gt;  10% of patients were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%) and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%).</br>● An open randomized phase 1 study evaluated \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in patients with metastatic chemotherapy naïve CRPC.2    The study compared relative \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with \n",
       "<mark class=\"entity\" style=\"background: turquoise; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy naïve metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ".</br>o Patients were randomized to one of 3 treatment sequences in each group.   There were three treatment periods for each patient during the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " Component which included \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of two \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 300 mg test \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tablet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " (Tab A or Tab B) in both \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " conditions, or \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 100 mg capsule at 600 mg dose in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state. There was at least 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day</br>o Thirty men with were enrolled. Area under the concentration curve (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") and maximum concentration (C max)  values were approximately two times lower after \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " at fast. With high fat meal the C max  occurred about 2-3 hours later. The \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " effect was similar in all groups.</br>o The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " observed with the two new \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tablet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " formulations were comparable with the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of the capsule formulation</br>\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ".Phase 1-2 study</br>Phase 1–2 clinical trial was conducted to assess \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men with progressive metastatic castration-resistant prostate cancer.1    The primary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " of the trial were to</br>Darolutamide \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br> assess \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and to define a maximum tolerated dose. Secondary \n",
       "<mark class=\"entity\" style=\"background: #ffffb3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    objectives\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Objective</span>\n",
       "</mark>\n",
       " were to determine the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       ", and antitumor activity as defined by changes in serum prostate-specific antigen (PSA), by imaging of soft tissue and bone lesions, and by changes in circulating tumor cell counts. \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " and outcome measures are discussed elsewhere.</br>Blood samples were collected for the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " analyses. We identified \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentrations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " of diastereoisomers [S,R]-darolutamide and [S,S]-darolutamide, and the major metabolite keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " by liquid chromatography-tandem mass spectrometry (LC-MS/MS); \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " concentration was the sum of [S,R]-darolutamide and [S,S]-darolutamide concentrations.1 </br>\n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetic analysis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " showed rapid absorbed and the median t max  were 3·0–5·1 h for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and 1.5–5.0 h for keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " on day 1.1    The mean metabolite to parent ratio (area under the curve, \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") at steady state was 1.6–2.3:1. The exposure of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " t  and C max)  at steady state increased in a linear, dose-related manner up to \n",
       "<mark class=\"entity\" style=\"background: #ffd9b3; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    1400 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosing</span>\n",
       "</mark>\n",
       " dose. Dose escalation was discontinued because of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " plateau. Steady-state \n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    plasma concentrations\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       " were reached after 1 week of continuous treatment. The mean half-life of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " independent of dose was 15.8 hours (SD 13.8) at steady state after \n",
       "<mark class=\"entity\" style=\"background: #ffa500; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200–1800 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " doses. The mean half-life of keto-\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " was 10.0 hours (3.8) at steady state after \n",
       "<mark class=\"entity\" style=\"background: #ffa500; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    200–1800 mg daily\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage</span>\n",
       "</mark>\n",
       " doses.</br>Mean  +  standard deviations steady state concentrations at various doses are presented in Figure 1.1 </br>Figure 1: Mean  +  SD Concentrations of \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    DAROLUTAMIDE\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " 1</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " mean C max  by dose are presented in Figure 2a, and mean  +  SD areas under concentration curve (\n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       ") of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " is presented in Figure 2b.1 </br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>    </br>  Figure 2a: Mean  +  SD C max  Based on Dose1 </br>   Figure 2b: \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " by Dose</br>          Most common Grade 3 \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " occurring in  &gt;  10% of patients were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " or \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%) and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " 2 (2%).</br>Phase I \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " study</br>An open randomized phase 1 trial (ARAFOR) evaluated \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " and effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of darolutamide.2    The study compared relative \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of 600 mg tablets (tablet A and tablet B) and capsule (reference) formulations in patients with  \n",
       "<mark class=\"entity\" style=\"background: turquoise; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    chemotherapy naïve metastatic castrate resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Disease</span>\n",
       "</mark>\n",
       ". The study also assessed  the effect of \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " on the \n",
       "<mark class=\"entity\" style=\"background: #ff9900; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    bioavailability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Bioavailability</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " tablet products tablet A (Tab A) and tablet B (Tab B).</br>The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " Component consisted of two concurrent groups, which evaluated Tab A and (Tab B), and capsule. Patients were randomized to one of 3 treatment sequences in each group.2     There were three treatment periods for each patient during the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    PK\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " Component which included \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of two \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 300 mg test tablets (Tab A or Tab B) in both \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " conditions, or \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (6 x100 mg) capsules at 600 mg dose in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fed\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state. There was at least a 7 days wash-out period between the three study treatment administrations. The total daily dose was 600 mg/day</br>Thirty  men with metastatic chemotherapy-naïve CRPC were enrolled.2    Food interaction was seen when \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " formulations (600 mg) were administered after a high fat content breakfast compared to \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fasted\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " state. \n",
       "<mark class=\"entity\" style=\"background: #00ff55; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    AUC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">AUC</span>\n",
       "</mark>\n",
       " and C max  values were approximately</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br>two times lower after \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    administration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " at fast. With high fat meal the C max  occurred about 2-3 hours later, indicating the delayed gastric emptying of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " after the high fat meal. The \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    food\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " effect was similar in all groups. The \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " observed with the two new \n",
       "<mark class=\"entity\" style=\"background: #f2f2f2; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tablet\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Dosage Form</span>\n",
       "</mark>\n",
       " formulations were comparable with the \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       " of the capsule formulation (figure 4</br>Figure 4: Concentration Time Curves of the Three Formulation with and Without Food2 </br>Most commonly reported \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    adverse events\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (&gt;10%) were \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "/\n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (13%), nausea (10%), erythema (10%) and urinary tract disorder (10%); all being mild events except one nausea event (grade 3).</br>REV: 0719 Reference:</br>1. NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.</br>2. Fizazi K, Massard C, Bono P, et al. Activity and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of ODM 201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.  Lancet Oncol  2014; 15: 975–85. http://www.ncbi.nlm.nih.gov/pubmed/24974051</br>3. Massard C, Tammela T, Vjaters, et al. A study of ODM 201 formulations with a \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " extension phase in patients with metastatic chemotherapy naïve castrate-resistant prostate cancer (CRPC). Presented at 2014 Genitourinary Cancers Symposium, January 2014 in San Francisco CA.</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #b3b3cc; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Pharmacokinetics\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Pharmacokinetics</span>\n",
       "</mark>\n",
       "\n",
       "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>\n",
       "</figure>\n",
       "</body>\n",
       "</html>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Using the 'ent' visualizer\n",
      "Serving on http://0.0.0.0:5000 ...\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "127.0.0.1 - - [05/Mar/2020 11:00:01] \"GET / HTTP/1.1\" 200 63514\n",
      "127.0.0.1 - - [05/Mar/2020 11:00:01] \"GET /favicon.ico HTTP/1.1\" 200 63514\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Shutting down server on port 5000.\n"
     ]
    }
   ],
   "source": [
    "displacy.serve(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Document 6 - Nubeqa (US-NUBEQA-76051-S.docx-2.pdf)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 119,
   "metadata": {},
   "outputs": [],
   "source": [
    "doc = loaded_nlp(\"\"\"ARAMIS: A Phase III Study of darolutamide in Men with High-risk Non-metastatic Castration-resistant Prostate Cancer\n",
    "Summary\n",
    "● Nubeqa®    (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.1 \n",
    "● ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and safety of darolutamide in men being treated with androgen deprivation therapy (ADT*) for non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of developing metastases.1    Patients (N = 1509) were randomized 2:1 to receive darolutamide 600 mg tablets orally twice daily plus ADT* versus matching placebo plus ADT*. The primary endpoint of the study was metastasis-free survival (MFS). MFS was defined as the time from randomization to evidence of metastasis (new or progressive regional pathological lymph nodes were not defined as metastasis) or death from any cause, whichever occurred first. Secondary endpoints included overall survival (OS), Time to Pain Progression (TTPP), Time to Initiation of Cytotoxic Chemotherapy and Time to First Symptomatic Skeletal Event (SSE) and Safety and tolerability. Exploratory endpoints included Progression-free Survival (PFS), and Time to PSA Progression.2 \n",
    "Primary Endpoint\n",
    "o Darolutamide demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% versus placebo [HR .41 (95% CI 0.34 – 0.50);  P  <0.001].4 \n",
    "Secondary Endpoints\n",
    "o At interim analysis, the secondary endpoint of median overall survival (OS) was not reached [NR;  P-  value = 0.045; HR 0.71 (95% CI 0.50 – 0.99)]. The  P -value did not reach the pre-defined threshold of 0.0005 for statistical significance.\n",
    "▪ The significance of all other secondary endpoints was dependent on OS meeting statistical significance as per hierarchal methodology.\n",
    "o Time to Pain Progression (TTPP) was 40.31 months [95% CI 33.2 – 41.2] in the darolutamide arm vs. 25.36 months [95% CI 19.09 – 29.36] in the placebo arm. The HR of 0.65 [(95% CI 0.53 – 0.79);  P  <0.001] demonstrated a 35% risk reduction in the time to pain progression compared to placebo.4 \n",
    "o The median Time to Initiation of First Cytotoxic Chemotherapy was NR in the darolutamide arm vs 38.2 months (95% CI 35.55 – 41.89) in the placebo arm. The HR of 0.43 [(95% CI 0.31 – 0.60);  P  <0.001] demonstrated a 57% risk reduction in the time to initiation of First Cytotoxic Chemotherapy compared to placebo.4 \n",
    "The median Time to First Symptomatic Skeletal Event was not reached in either arm. At the time of analysis, 1.7% (16/955) of patients in the darolutamide arm experienced a SSE versus 3.2% (18/554) of patients in the placebo arm. The HR 0.43 [(95% CI 0.22 – 0.84),  P=  0.011] demonstrated a 57% risk reduction in the Time to First Symptomatic Skeletal Event compared to placebo.4 \n",
    "NUBEQA ®  (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "o\n",
    " * Common previous hormonal therapies for prostate cancer (received by ≥10% of all patients) included leuprolide (52%), goserelin (32%), triptorelin (29%), bicalutamide (66%), flutamide (13%), and cyproterone (11%).\n",
    "Exploratory Endpoints\n",
    "o The median PFS was 36.8 months (95% CI 32.92 – NR) in the darolutamide arm versus 14.8 months (95% CI 11.83 – 14.33) in the placebo arm;  P <0.001.4 \n",
    "o The median Time to PSA Progression was 33.2 months (95% CI 25.89 – NR) in the darolutamide arm versus 7.3 months (95% CI 13.94 – 7.39) in the placebo arm;\n",
    "P<  0.001; HR 0.13 (95% CI 0.11 – 0.16) demonstrating an 87% decrease in the risk of PSA Progression compared to placebo.4 \n",
    "Safety\n",
    "o After a median exposure of 14.8 months in the darolutamide arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial (N = 1220/1508; [darolutamide arm, n = 794; placebo arm, n = 426]). The majority of adverse events reported in both arms were Grade 1 or 2 [54.4% (821/1508)].2    The incidence of common adverse events were reported in ≤10% of patients in both the darolutamide and placebo arms, with only fatigue (including asthenia) reported at an incidence of >10% in both arms.3 \n",
    "o The most common Grade 3 or 4 events were hypertension (3.1% of patients in the darolutamide plus ADT arm versus 2.2% of patients in the placebo plus ADT arm.) and urinary retention (1.6% of patients in the darolutamide plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 \n",
    "o Treatment discontinuations occurred in 35.5% (339/954) of patients in the darolutamide arm vs. 63.9% (354/554) of patients in the placebo arm.2 \n",
    "Clinical Data\n",
    "Study Design 2\n",
    "ARAMIS, a Phase III, multinational, randomized, double blind, placebo-controlled study, evaluated the efficacy and safety of darolutamide in men undergoing treatment with androgen deprivation therapy (ADT*   ) for non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of developing metastases. High risk was defined as PSADT of ≤ 10 months and PSA ≥ 2ng/ml. Patients included in the study had an ECOG performance status of 0-1 and adequate hematologic, renal, and liver function. Additionally, patients with a history of seizures or at risk for seizures were included.2 \n",
    "Patients (N=1509) were randomized 2:1 to receive darolutamide 600 mg tablets orally twice daily with food plus ADT versus matching placebo plus ADT. Key baseline characteristics of the majority of the patient population in the ARAMIS study were: a median age of 74; Gleason score of ≥7; absence of regional pathological lymph nodes; ≥2 prior hormonal therapy agents with a PSADT ≤6 months, and no baseline osteoclast targeted therapy. Patients on the ARAMIS study were stratified according to PSADT (PSADT;  <  6 months vs. > 6 months) and use of\n",
    "NUBEQA ®  (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    " \n",
    " osteoclast-targeted therapy (yes vs. no). All assessments were obtained at baseline and every 16 weeks. For a complete detail of patient demographics and characteristics, see table 1 and 2 below.2 \n",
    "    Table 1. ARAMIS: Patient Demographics3 \n",
    "        Darolutamide N = 955\n",
    "   Placebo N = 554\n",
    "  Total N = 1509\n",
    " Age , median, years\n",
    "    74.0\n",
    "     74.0\n",
    "    74.0\n",
    "     Age group, n (%)\n",
    "     <65\n",
    "   113 (11.8)\n",
    "   84 (15.2)\n",
    "  197 (13.1)\n",
    "     65 - 74\n",
    "    373 (39.1)\n",
    "    216 (39.0)\n",
    "   589 (39.0)\n",
    "     75 – 84\n",
    "    384 (40.2)\n",
    "    209 (37.7)\n",
    "   593 (39.3)\n",
    " ≥85\n",
    "    85 (8.9)\n",
    "     45 (8.1)\n",
    "    130 (8.6)\n",
    "     Race, n (%)*\n",
    "  Asian\n",
    "    122 (12.8)\n",
    "     71 (12.8)\n",
    "    193 (12.8)\n",
    "     Black or African-American\n",
    " 28 (2.9)\n",
    " 24 (4.3)\n",
    " 52 (3.4)\n",
    "     Other\n",
    "    9 (0.9)\n",
    "    6 (1.1)\n",
    "   15 (1.0)\n",
    " White\n",
    "    760 (79.6)\n",
    "     434 (78.3)\n",
    "    1194 (79.1)\n",
    "     Weight\n",
    "     N\n",
    "   953\n",
    "   552\n",
    "  1505\n",
    "     Missing, n\n",
    "    2\n",
    "    2\n",
    "   4\n",
    " Median, kg\n",
    "    82.40\n",
    "     82.00\n",
    "    82.00\n",
    "     Geographical region, n (%)\n",
    "     North America\n",
    "   108 (11.3)\n",
    "   76 (13.7)\n",
    "  184 (12.2)\n",
    "     Asia Pacific\n",
    "    119 (12.5)\n",
    "    67 (12.1)\n",
    "   186 (12.3)\n",
    " Rest of the world\n",
    "    728 (76.2)\n",
    "     411 (74.2)\n",
    "    1139 (75.5)\n",
    "                 *Race data was missing for 36 (3.8%) and 19 (3.4%) of patients in the darolutamide and placebo arms, respectively\n",
    "    Table 2. ARAMIS: Patient Characteristics3 \n",
    "        Darolutamide N = 955\n",
    "   Placebo N = 554\n",
    "  Total N = 1509\n",
    "     Base line PSADT ≤6 months, n (%)\n",
    "    667 (69.8)\n",
    "    371 (67.0)\n",
    "   1038 (68.8)\n",
    "     PSADT, months, mean (median)\n",
    "    4.84 (4.39)\n",
    "    4.89 (4.65)\n",
    "   4.86 (4.45)\n",
    " PSA, ng/mL, mean (median)\n",
    "     18.7 (9.0)\n",
    "      19.8 (9.7)\n",
    "     19.1 (9.3)\n",
    "   No baseline osteoclast-target therapy, n (%)\n",
    "  924 (96.8)\n",
    "   522 (94.2)\n",
    "  1446 (95.8)\n",
    "     ECOG PS, n (%)\n",
    "     0\n",
    "   650 (68.1)\n",
    "   391 (70.6)\n",
    "  1041 (69.0)\n",
    " 1\n",
    "    305 (31.9)\n",
    "     163 (29.4)\n",
    "    468 (31.0)\n",
    "     Gleason total score (Factor1 + Factor2), n (%)\n",
    "     Missing\n",
    "   27 (2.8)\n",
    "   17 (3.1)\n",
    "  44 (2.9)\n",
    " <7\n",
    "     217 (22.7)\n",
    "      142 (25.6)\n",
    "     359 (23.8)\n",
    "   ≥7\n",
    "  711 (74.5)\n",
    "   395 (71.3)\n",
    "  1106 (73.3)\n",
    "     Prior hormonal therapy, n (%)103 (18.6)\n",
    "           NUBEQA ®  (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    "      1\n",
    "   177 (18.5)\n",
    "   103 (18.6)\n",
    "  280 (18.6)\n",
    "     ≥2\n",
    "    727 (76.1)\n",
    "    420 (75.8)\n",
    "   1147 (76.0)\n",
    " Not applicable*\n",
    "    51 (5.3)\n",
    "     31 (5.6)\n",
    "    82 (5.4)\n",
    "     Baseline presence of regional pathological lymph nodes by central imaging review, n (%)\n",
    "     No\n",
    "   792 (82.9)\n",
    "   396 (71.5)\n",
    "  1188 (78.7)\n",
    " Yes\n",
    "    163 (17.1)\n",
    "     158 (28.5)\n",
    "    321 (21.3)\n",
    "     *Patients who underwent surgical castration were not required to have been/ be treated with hormonal drug therapy\n",
    "Efficacy Results3  Primary Endpoint: Metastasis Free Survival\n",
    "After a median follow-up of 17.9 months, darolutamide demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% compared to placebo [HR .41 (95% CI 0.34 – 0.50);  P  <0.001]. This improvement in MFS was consistent among patients irrespective of baseline characteristics, therapy and demographic See table 3 and figures 1 & 2 below.3 \n",
    "     Table 3. ARAMIS: Metastasis-Free Survival (MFS)3 \n",
    "        Darolutamide\n",
    "  Placebo\n",
    "     N\n",
    "    955\n",
    "   554\n",
    " Events, n (%)\n",
    "     221 (23.1)\n",
    "     216 (39.0)\n",
    "     Median, months (95% CI)\n",
    " 40.37 (34.33 – NR)\n",
    " 18.43 (15.51 – 22.34)\n",
    "     Baseline metastases, n (%)\n",
    "    50 (5.2)\n",
    "    39 (7.0)\n",
    "      2-sided  P -value\n",
    "  <0.001\n",
    " HR (95% CI)\n",
    "   0.41 (0.34 – 0.50)\n",
    "        NUBEQA ®  (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Figure 1 Kaplan-Meier Analysis of Metastasis-free Survival3 \n",
    " NUBEQA ®  (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Figure 2    Subgroup Analysis of Metastasis-free Survival3 \n",
    " Secondary Endpoints4  Overall Survival\n",
    "Due to the data being immature at the time of analysis, the P-value for OS did not reach the pre-defined threshold for statistical significance [OS NR in either arm, P-value 0.045 (HR 0.71; 95% CI, 0.50 to 0.99)]. As per hierarchal methodology, unless statistical significance was reached for OS, all other secondary endpoints would not be considered to be significant. Figure 3 below show the results of the overall survival analysis (a secondary endpoint).4 \n",
    " NUBEQA®    (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Figure 3 ARAMIS: Overall Survival (OS) KM Curve3 \n",
    " Time to Pain Progression\n",
    "Darolutamide demonstrated an improvement in Time to Pain Progression (TTPP) of 40.3 months [95% CI 33.2 – 41.2] vs.25.4 months [95% CI 19.09 – 29.36] in the placebo arm; HR .65 (95% CI 0.53 – 0.79);  P  <0.001. TTPP was identified by an increase of ≥2 points from baseline in question three of the BPI-SF [related to the worst pain in the previous 24 hours] take as a 7-day average or initiation of short or long-acting opioids for pain, whichever comes first).4    See figure 4 below.\n",
    " NUBEQA®    (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Figure 4 ARAMIS: Time to Pain Progression (TTPP) KM Curve3 \n",
    " Time to Initiation of First Cytotoxic Chemotherapy\n",
    "Darolutamide demonstrated a significant difference in the Time to Initiation of First Cytotoxic Chemotherapy when compared to placebo. At the time of analysis, 35% (339/955) of patients in the darolutamide arm had terminated treatment versus 64% (354/554) of patients in the placebo arm. Of the patients who terminated treatment in the darolutamide arm, 29.5% (100/339) vs 36.7% (130/354) of patients in the placebo arm, received cytotoxic chemotherapy and/or anti-neoplastic therapy. The median time to initiation of first cytotoxic chemotherapy was 38.2 months (95% CI 35.55 – 41.89) in the placebo arm and not yet reached in the darolutamide arm.; HR 0.43 (0.31 – 0.60), P<0.001.4    See table 4 below.\n",
    "Time to First Symptomatic Skeletal Event (SSE)\n",
    "The time to first symptomatic skeletal event was evaluated between the two groups. At the time of analysis, 1.7% (16/955) of patients in the darolutamide arm experienced a SSE versus 3.2% (18/554) of patients in the placebo arm. The median time to first symptomatic skeletal event was not reached in either arm; HR 0.43 (95%CI 0.22 – 0.84),  P=  0.01.3    See table 4 below.\n",
    "NUBEQA®    (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "  \n",
    " Exploratory Endpoints4  Progression-Free Survival (PFS)\n",
    "PFS was defined as the time between randomization and evidence of any radiographic disease progression, including new pathologic lymph nodes identified above or below the aortic bifurcation, or death from any cause, whichever occurs first.3 \n",
    "At the time of analysis, 26.8% (256/955) events had occurred in the darolutamide arm versus 46.8% (259/554) of events in the placebo arm. The median PFS was 36.8 months (95% CI 32.92 – NR) in the darolutamide arm versus 14.8 months (95% CI 11.83 – 14.33) in the placebo arm; HR 0.38 (0.32 – 0.45),  P<  0.001.4    See table 4 and figure 5 below.\n",
    "Figure 5 ARAMIS: Progression-Free Survival KM Curve3 \n",
    "Time to PSA Progression\n",
    "Time to PSA progression was defined according to PCWG2 Consensus Guidelines.\n",
    "At the time of analysis, 23.7% (226/955) events had occurred in the darolutamide arm versus 66.4% (368/554) of events in the placebo arm. The median Time to PSA Progression was 33.2 months (95% CI 25.89 – NR) in the darolutamide arm versus 7.3 months (95% CI 13.94 – 7.39) in the placebo arm;  P<  0.001; HR 0.13 (95% CI 0.11 – 0.16) demonstrating an 87% decrease in the risk of PSA Progression compared to placebo.4    See table 4 and figure 6 below.\n",
    "NUBEQA®    (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "   \n",
    " Figure 6 ARAMIS: Time to PSA Progression3 \n",
    "    Table 4 Pre-specified Secondary and Exploratory Efficacy End Points (Intention-To-treat)*4 \n",
    "  End Point\n",
    " Darolutamide (N = 955)\n",
    " Placebo (N= 554)\n",
    "  Hazard Ratio (95% CI)\n",
    " P Value\n",
    "  Median Duration mo\n",
    "    No. of Events\n",
    "   Median Duration mo\n",
    "   No. of Events\n",
    "    Secondary end points Overall survival\n",
    "Time to pain progression\n",
    "Time to cytotoxic chemotherapy\n",
    "Time to first symptomatic skeletal\n",
    "event\n",
    "    NR 40.3\n",
    "NR NR\n",
    " 78 251\n",
    "73 16\n",
    "NR 25.4\n",
    "38.2 NR\n",
    "    58 178\n",
    "79 18\n",
    "0.71 (0.50 – 0.99) 0.65 (0.53 – 0.79)\n",
    "0.43 (0.31 – 0.60) 0.43 (0.22 – 0.84)\n",
    "   0.045 <0.001\n",
    "<0.001 0.01\n",
    " Exploratory end points Progression-free survival\n",
    "Time to PSA progression\n",
    "  36.8 33.2\n",
    "    255 226\n",
    "   14.8 7.3\n",
    "   258 368\n",
    "  0.38 (0.32 – 0.45) 0.13 (0.11 – 0.16)\n",
    "   <0.001 <0.001\n",
    "NUBEQA®    (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " NUBEQA®    (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    " Safety Results 3\n",
    "After a median exposure of 14.8 months in the darolutamide arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial\n",
    "(N = 1220/1508; [darolutamide arm, n = 794; placebo arm, n = 426]). The incidence of adverse events were generally similar between treatment arms and the majority were Grade 1 or 2 [54.4% (821/5108)].3    The incidence of common events was low with only fatigue reported at an incidence of >10%. Grades 3 or 4 adverse events occurred in 22.8% (344/1508) of the total safety population (24.7% of patients in the darolutamide arm versus 19.5% of patients in the placebo arm). The most frequent Grade 3 or 4 adverse events included hypertension (3.1% of patients in the darolutamide plus ADT arm versus 2.2% of patients in the placebo plus ADT arm.) and urinary retention (1.6% of patients in the darolutamide plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 \n",
    "Table 5 shows the Treatment Emergent Adverse Events (TEAEs) for the total safety population (N = 1508). TEAEs (all grades) occurring in ≥5% of patients reported in Table 6 below, in the darolutamide versus placebo arms, respectively, included fatigue (including asthenia) (12.1% [115/954, vs 8.7% [48/554]). Other TEAEs occurring in ≥5% in the darolutamide arm included back pain (8.8%), arthralgia (8.1%), diarrhea (6.9%), hypertension (7.3%), constipation (TEAEs occurring in 6.3%), pain in extremity (5.8%), anemia (5.6%) and hot flush (5.2%). Approximately 14% of TEAEs led to a dose modification in the darolutamide arm versus 9.4% of TEAEs in the placebo arm.3 \n",
    "After a median follow-up of 17.9 months, treatment discontinuations were similar between both arms.4    Discontinuations due to adverse events occurred in 8.9% of patients in the darolutamide arm vs 8.7% of patients in the placebo arm. Discontinuations due to metastasis occurred in 11.7% vs 23.3% of patients; and discontinuations due to investigator judgment occurred in 5.7% vs 16.4% of patients, in the daroluamide vs placebo arms, respectively. Discontinuations due to protocol deviation and to other reasons unspecified occurred in 1.4% vs 1.3% and 0.6% vs 0.4% in the darolutamide vs placebo arm, respectively. Additionally, 7.1% vs 14.1% of patients in the darolutamide vs placebo arm respectively decided not to continue trial participation. It should be noted that one person in the darolutamide arm was randomized but did not receive treatment.3 \n",
    "A total of 55 deaths occurred during the trial with 3.9% of deaths occurring in the darolutamide arm versus 3.2% occurring in the placebo arm.3    See Table 5 below.\n",
    "The Institute for Clinical and Economic Review (ICER) has identified events such as falls, fractures, cardiovascular events and deaths due to AE’s, etc. to be TEAE’s of interest for anti-androgen therapies.6    For the incidence of TEAE’s of interest reported for darolutamide, see Tables 7 - 8.6 \n",
    "NUBEQA®    (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "    Table 5. ARAMIS: Summary of TEAEs3 \n",
    "      Darolutamide N = 954\n",
    "     Placebo N = 554\n",
    "  Total N = 1508\n",
    "     Exposure, median (months)\n",
    " 14.8\n",
    "      11.04\n",
    "    Any AE, n (%)\n",
    "  794 (83.2)\n",
    "   426 (76.9)\n",
    "   1220 (80.9)\n",
    "    \n",
    "      Worst grade\n",
    "             Grade 1 or 2\n",
    " 521 (54.6)\n",
    "      300 (54.2)\n",
    "   821 (54.4)\n",
    " Grade 3 or 4\n",
    "   236 (24.7)\n",
    "    108 (19.5)\n",
    "    344 (22.8)\n",
    "     Grade 5\n",
    "37 (3.9)\n",
    "    18 (3.2)\n",
    " 55 (3.6)\n",
    "     Serious\n",
    " 237 (24.8)\n",
    "      111 (20.0)\n",
    "   348 (23.1)\n",
    " Leading to dose modification\n",
    "   135 (14.2)\n",
    "    52 (9.4)\n",
    "    187 (12.4)\n",
    "   Leading to permanent discontinuation\n",
    "85 (8.9)\n",
    "  48 (8.7)\n",
    " 133 (8.8)\n",
    "       AE, adverse event, TEAE, treatment adverse event\n",
    "    Table 6. ARAMIS: Total of TEAEs with an Incidence of  ≥ 5%3 \n",
    "     Preferred term, n (%)\n",
    "   Darolutamide N = 954\n",
    "  Placebo N = 554\n",
    "     Fatigue\n",
    "    115 (12.1)\n",
    "   48 (8.7)\n",
    "     Back pain\n",
    "    84 (8.8)\n",
    "   50 (9.0)\n",
    "     Arthralgia\n",
    "    77 (8.1)\n",
    "   51 (9.2)\n",
    "     Diarrhea\n",
    "    66 (6.9)\n",
    "   31 (5.6)\n",
    "     Hypertension\n",
    "    70 (7.3)\n",
    "   33 (6.0)\n",
    "     Constipation\n",
    "    60 (6.3)\n",
    "   34 (6.1)\n",
    "     Pain in extremity\n",
    "    55 (5.8)\n",
    "   18 (3.2)\n",
    "     Anemia\n",
    "    53 (5.6)\n",
    "   25 (4.2)\n",
    "     Hot flush\n",
    "    50 (5.2)\n",
    "   23 (4.2)\n",
    "     Nausea\n",
    "    48 (5.0)\n",
    "   32 (5.8)\n",
    "     Bone Fracture\n",
    "    40 (4.2)\n",
    "   21 (3.8)\n",
    "     Fall\n",
    "    40 (4.2)\n",
    "   26 (4.7)\n",
    "     Rash\n",
    "    24 (2.6)\n",
    "   4 (0.7)\n",
    " Weight decreased\n",
    "    34 (3.6)\n",
    "    12 (2.2)\n",
    "                    Table 7. ARAMIS: TEAEs of Interest3 \n",
    "    Darolutamide N=954\n",
    "Placebo N=554\n",
    "                        AE\n",
    "Any Grade, n (%)\n",
    "Grade 3, %\n",
    "Grade 4 %\n",
    "Grade 5, %\n",
    "Any Grade, n (%)\n",
    "Grade 3, %\n",
    "Grade 4 %\n",
    "Grade 5, %\n",
    "                                Bone Fracture\n",
    "40 (4.2)\n",
    "0.9\n",
    "0\n",
    "0\n",
    "21 (3.8)\n",
    "0.9\n",
    "0\n",
    "0\n",
    "                    Fall\n",
    "40 (4.2)\n",
    "0.8\n",
    "0\n",
    "0\n",
    "26 (4.7)\n",
    "0.7\n",
    "0\n",
    "0\n",
    "                      Fatigue, including asthenia\n",
    "151 (15.8)\n",
    "0.6\n",
    "0\n",
    "0\n",
    "63 (11.4)\n",
    "1.1\n",
    "0\n",
    "0\n",
    "                    Seizure\n",
    "2 (0.2)\n",
    "0\n",
    "1 (0.2)\n",
    "0\n",
    "                      Cognitive disorder\n",
    "4 (0.4)\n",
    "0\n",
    "0\n",
    "0\n",
    "1 (0.2)\n",
    "0\n",
    "0\n",
    "0\n",
    "                                Memory impairment\n",
    "5 (0.5)\n",
    "0\n",
    "0\n",
    "0\n",
    "7 (1.3)\n",
    "0\n",
    "0\n",
    "0\n",
    "                                Disturbance in attention\n",
    "0\n",
    "0\n",
    "0\n",
    "0\n",
    "1 (0.2)\n",
    "0\n",
    "0\n",
    "0\n",
    "                                Amnesia\n",
    "1 (0.1)\n",
    "0\n",
    "0\n",
    "0\n",
    "3 (0.5)\n",
    "0\n",
    "0\n",
    "0\n",
    "                    Rash\n",
    "24 (2.6)\n",
    "0.1\n",
    "0\n",
    "0\n",
    "4 (0.7)\n",
    "0\n",
    "0\n",
    "0\n",
    "                      Weight decreased\n",
    "34 (3.6)\n",
    "0\n",
    "0\n",
    "0\n",
    "12 (2.2)\n",
    "0\n",
    "0\n",
    "0\n",
    "                    Hot flush\n",
    "50 (5.2)\n",
    "0\n",
    "-\n",
    "-\n",
    "23 (4.6)\n",
    "0\n",
    "-\n",
    "-\n",
    "                 Increased bilirubin\n",
    "18 (1.9)\n",
    "0.1\n",
    "0\n",
    "0\n",
    "0\n",
    "0\n",
    "0\n",
    "0\n",
    "                 NUBEQA®    (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    "     Table 8. ARAMIS: TEAEs of Interest3    continued\n",
    "    Darolutamide N=954\n",
    "Placebo N=554\n",
    "                        AE\n",
    "Any Grade, n (%)\n",
    "Grade 3, %\n",
    "Grade 4 %\n",
    "Grade 5, %\n",
    "Any Grade, n (%)\n",
    "Grade 3, %\n",
    "Grade 4 %\n",
    "Grade 5, %\n",
    "                    Hypertension\n",
    "70 (7.3)\n",
    "3.4\n",
    "0\n",
    "0\n",
    "33 (6.0)\n",
    "2.3\n",
    "0\n",
    "0\n",
    "                      Cerebral and intracranial hemorrhage\n",
    "2 (0.2)\n",
    "0\n",
    "0\n",
    "0\n",
    "2 (0.4)\n",
    "0.2\n",
    "0\n",
    "0.2\n",
    "                    Cerebral infarction and stroke\n",
    "4 (0.4)\n",
    "0.3\n",
    "0\n",
    "0\n",
    "4 (0.7)\n",
    "0.4\n",
    "0\n",
    "0.2\n",
    "                      Cerebral ischemic infarction and stroke\n",
    "5 (0.5)\n",
    "0.1\n",
    "0.2\n",
    "0.1\n",
    "2 (0.4)\n",
    "0.2\n",
    "0\n",
    "0.2\n",
    "                                Acute myocardial infarction\n",
    "5 (0.5)\n",
    "0.2\n",
    "0.2\n",
    "0.1\n",
    "1 (0.2)\n",
    "0\n",
    "0\n",
    "0\n",
    "                    Cardiac failure\n",
    "18 (1.9)\n",
    "0.1\n",
    "0.1\n",
    "0.3\n",
    "5 (0.9)\n",
    "0\n",
    "0\n",
    "0.5\n",
    "                 Coronary artery disorders\n",
    "31 (3.2)\n",
    "1.3\n",
    "0.4\n",
    "0.3\n",
    "14 (2.5)\n",
    "0.4\n",
    "0\n",
    "0.2\n",
    "               Ischemic coronary artery disorders\n",
    "24 (2.5\n",
    "0.7\n",
    "0.4\n",
    "0.2\n",
    "11 (2.0)\n",
    "0.4\n",
    "0\n",
    "0.2\n",
    "             QOL Assessment3 \n",
    "Patient Reported Outcome tools (EORTC Q-PR25, Fact-P PCS and The Brief Pain Inventory – Short Form) were used to assess darolutamide’s impact on health-related quality of life versus placebo. Patient-Reported QoL was similar for darolutamide versus placebo, although clinically meaningful thresholds were not reached.5 \n",
    "REV 0719\n",
    "Reference\n",
    "1. NUBEQA® (darolutamide) tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.\n",
    "2. Data on file. Bayer HealthCare Pharmaceuticals, Whippany, NJ.\n",
    "3. Fizazi K et al. ARAMIS: efficacy and safety of darolutamide in nonmetastatc castration-resistant\n",
    "prostate cancer Oral presentation at: [ASCO GU]; February 14 – 16, 2019; San Francisco CA.\n",
    "#GU19.\n",
    "4. Fizazi K, Shore N, Tammela TL, et. Darolutamide in nonmetastatic castration-resistant prostate\n",
    "cancer;  N Eng J M, 2 019, PP 1 – 12,DOI: 10.1056/NEJMMoa1815671\n",
    "5. Fizazi K, Shore N, Tammela TL, et al. efficacy and safety of darolutamide in nonmetastatc\n",
    "castration-resistant prostate cancer. Poster presented at: ASCO GU]; February 14 – 16, 2019; San Francisco CA. Poster 140.\n",
    "NUBEQA®    (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\n",
    "\n",
    "6. Institute for Clinical and Economic Review (ICER), 2018\n",
    "NUBEQA®    (darolutamide): ARAMIS (nmCRPC)\n",
    "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.\"\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">ARAMIS: A Phase III Study of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in Men with High-risk Non-metastatic Castration-resistant Prostate Cancer</br>Summary</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men being treated with androgen deprivation therapy (ADT*) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (nmCRPC) with a high risk of developing metastases.1    Patients (N = 1509) were randomized 2:1 to receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 600 mg tablets orally twice daily plus ADT* versus matching placebo plus ADT*. The primary \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of the study was metastasis-free survival (MFS). MFS was defined as the time from randomization to evidence of metastasis (new or progressive regional pathological lymph nodes were not defined as metastasis) or death from any cause, whichever occurred first. Secondary endpoints included \n",
       "<mark class=\"entity\" style=\"background: #5c5cd6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    overall survival\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">OS</span>\n",
       "</mark>\n",
       " (OS), Time to Pain Progression (TTPP), Time to Initiation of Cytotoxic Chemotherapy and Time to First Symptomatic Skeletal Event (SSE) and Safety and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ". Exploratory endpoints included Progression-free Survival (PFS), and Time to PSA Progression.2 </br>Primary \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% versus placebo [HR .41 (95% CI 0.34 – 0.50);  P  &lt;0.001].4 </br>Secondary Endpoints</br>o At interim analysis, the secondary \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of median \n",
       "<mark class=\"entity\" style=\"background: #5c5cd6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    overall survival\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">OS</span>\n",
       "</mark>\n",
       " (OS) was not reached [NR;  P-  value = 0.045; HR 0.71 (95% CI 0.50 – 0.99)]. The  P -value did not reach the pre-defined threshold of 0.0005 for statistical significance.</br>▪ The significance of all other secondary endpoints was dependent on OS meeting statistical significance as per hierarchal methodology.</br>o Time to Pain Progression (TTPP) was 40.31 months [95% CI 33.2 – 41.2] in the darolutamide arm vs. 25.36 months [95% CI 19.09 – 29.36] in the placebo arm. The HR of 0.65 [(95% CI 0.53 – 0.79);  P  &lt;0.001] demonstrated a 35% risk reduction in the time to pain progression compared to placebo.4 </br>o The median Time to Initiation of First Cytotoxic Chemotherapy was NR in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs 38.2 months (95% CI 35.55 – 41.89) in the placebo arm. The HR of 0.43 [(95% CI 0.31 – 0.60);  P  &lt;0.001] demonstrated a 57% risk reduction in the time to initiation of First Cytotoxic Chemotherapy compared to placebo.4 </br>The median Time to First Symptomatic Skeletal Event was not reached in either arm. At the time of analysis, 1.7% (16/955) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm experienced a SSE versus 3.2% (18/554) of patients in the placebo arm. The HR 0.43 [(95% CI 0.22 – 0.84),  P=  0.011] demonstrated a 57% risk reduction in the Time to First Symptomatic Skeletal Event compared to placebo.4 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>o</br> * Common previous hormonal therapies for prostate cancer (received by ≥10% of all patients) included leuprolide (52%), goserelin (32%), triptorelin (29%), bicalutamide (66%), \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    flutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (13%), and cyproterone (11%).</br>Exploratory Endpoints</br>o The \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    median\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " PFS was 36.8 months (95% CI 32.92 – NR) in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 14.8 months (95% CI 11.83 – 14.33) in the placebo arm;  P &lt;0.001.4 </br>o The median Time to PSA Progression was 33.2 months (95% CI 25.89 – NR) in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 7.3 months (95% CI 13.94 – 7.39) in the placebo arm;</br>P&lt;  0.001; HR 0.13 (95% CI 0.11 – 0.16) demonstrating an 87% decrease in the risk of PSA Progression compared to placebo.4 </br>Safety</br>o After a median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial (N = 1220/1508; [\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm, n = 794; placebo arm, n = 426]). The majority of adverse events reported in both arms were Grade 1 or 2 [54.4% (821/1508)].2    The incidence of common adverse events were reported in ≤10% of patients in both the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and placebo arms, with only \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") reported at an incidence of &gt;10% in both arms.3 </br>o The most common Grade 3 or 4 events were hypertension (3.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.2% of patients in the placebo plus ADT arm.) and urinary retention (1.6% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 </br>o Treatment discontinuations occurred in 35.5% (339/954) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs. 63.9% (354/554) of patients in the placebo arm.2 </br>Clinical Data</br>Study Design 2</br>ARAMIS, a Phase III, multinational, randomized, double blind, placebo-controlled study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men undergoing treatment with androgen deprivation therapy (ADT*   ) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (nmCRPC) with a high risk of developing \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ". High risk was defined as PSADT of ≤ 10 months and PSA ≥ 2ng/ml. Patients included in the study had an ECOG performance status of 0-1 and adequate hematologic, renal, and liver function. Additionally, patients with a history of seizures or at risk for seizures were included.2 </br>Patients (N=1509) were randomized 2:1 to receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 600 mg tablets orally twice daily with food plus ADT versus matching placebo plus ADT. Key baseline characteristics of the majority of the patient population in the ARAMIS study were: a median age of 74; Gleason score of ≥7; absence of regional pathological lymph nodes; ≥2 prior hormonal therapy agents with a PSADT ≤6 months, and no baseline osteoclast targeted therapy. Patients on the ARAMIS study were stratified according to PSADT (PSADT;  &lt;  6 months vs. &gt; 6 months) and use of</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br> osteoclast-targeted therapy (yes vs. no). All assessments were obtained at baseline and every 16 weeks. For a complete detail of patient demographics and characteristics, see table 1 and 2 below.2 </br>    Table 1. ARAMIS: Patient Demographics3 </br>        \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 955</br>   Placebo N = 554</br>  Total N = 1509</br> Age , median, years</br>    74.0</br>     74.0</br>    74.0</br>     Age group, n (%)</br>     &lt;65</br>   113 (11.8)</br>   84 (15.2)</br>  197 (13.1)</br>     65 - 74</br>    373 (39.1)</br>    216 (39.0)</br>   589 (39.0)</br>     75 – 84</br>    384 (40.2)</br>    209 (37.7)</br>   593 (39.3)</br> ≥85</br>    85 (8.9)</br>     45 (8.1)</br>    130 (8.6)</br>     Race, n (%)*</br>  Asian</br>    122 (12.8)</br>     71 (12.8)</br>    193 (12.8)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Black\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " or African-American</br> 28 (2.9)</br> 24 (4.3)</br> 52 (3.4)</br>     Other</br>    9 (0.9)</br>    6 (1.1)</br>   15 (1.0)</br> White</br>    760 (79.6)</br>     434 (78.3)</br>    1194 (79.1)</br>     Weight</br>     N</br>   953</br>   552</br>  1505</br>     Missing, n</br>    2</br>    2</br>   4</br> Median, kg</br>    82.40</br>     82.00</br>    82.00</br>     Geographical region, n (%)</br>     North America</br>   108 (11.3)</br>   76 (13.7)</br>  184 (12.2)</br>     Asia Pacific</br>    119 (12.5)</br>    67 (12.1)</br>   186 (12.3)</br> Rest of the world</br>    728 (76.2)</br>     411 (74.2)</br>    1139 (75.5)</br>                 *Race data was missing for 36 (3.8%) and 19 (3.4%) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and placebo arms, respectively</br>    Table 2. ARAMIS: Patient Characteristics3 </br>        \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 955</br>   Placebo N = 554</br>  Total N = 1509</br>     Base line PSADT ≤6 months, n (%)</br>    667 (69.8)</br>    371 (67.0)</br>   1038 (68.8)</br>     PSADT, months, mean (median)</br>    4.84 (4.39)</br>    4.89 (4.65)</br>   4.86 (4.45)</br> PSA, ng/mL, mean (median)</br>     18.7 (9.0)</br>      19.8 (9.7)</br>     19.1 (9.3)</br>   No baseline osteoclast-target therapy, n (%)</br>  924 (96.8)</br>   522 (94.2)</br>  1446 (95.8)</br>     ECOG PS, n (%)</br>     0</br>   650 (68.1)</br>   391 (70.6)</br>  1041 (69.0)</br> 1</br>    305 (31.9)</br>     163 (29.4)</br>    468 (31.0)</br>     Gleason total score (Factor1 + Factor2), n (%)</br>     Missing</br>   27 (2.8)</br>   17 (3.1)</br>  44 (2.9)</br> &lt;7</br>     217 (22.7)</br>      142 (25.6)</br>     359 (23.8)</br>   ≥7</br>  711 (74.5)</br>   395 (71.3)</br>  1106 (73.3)</br>     Prior hormonal therapy, n (%)103 (18.6)</br>           \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>      1</br>   177 (18.5)</br>   103 (18.6)</br>  280 (18.6)</br>     ≥2</br>    727 (76.1)</br>    420 (75.8)</br>   1147 (76.0)</br> Not applicable*</br>    51 (5.3)</br>     31 (5.6)</br>    82 (5.4)</br>     Baseline presence of regional pathological lymph nodes by central imaging review, n (%)</br>     No</br>   792 (82.9)</br>   396 (71.5)</br>  1188 (78.7)</br> Yes</br>    163 (17.1)</br>     158 (28.5)</br>    321 (21.3)</br>     *Patients who underwent surgical castration were not required to have been/ be treated with hormonal drug therapy</br>Efficacy Results3  Primary Endpoint: Metastasis Free Survival</br>After a median follow-up of 17.9 months, \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% compared to placebo [HR .41 (95% CI 0.34 – 0.50);  P  &lt;0.001]. This improvement in MFS was consistent among patients irrespective of baseline characteristics, therapy and demographic See table 3 and figures 1 &amp; 2 below.3 </br>     Table 3. ARAMIS: Metastasis-Free Survival (MFS)3 </br>        \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       "</br>  Placebo</br>     N</br>    955</br>   554</br> Events, n (%)</br>     221 (23.1)</br>     216 (39.0)</br>     Median, months (95% CI)</br> 40.37 (34.33 – NR)</br> 18.43 (15.51 – 22.34)</br>     Baseline metastases, n (%)</br>    50 (5.2)</br>    39 (7.0)</br>      2-sided  P -value</br>  &lt;0.001</br> HR (95% CI)</br>   0.41 (0.34 – 0.50)</br>        \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Figure 1 Kaplan-Meier Analysis of Metastasis-free Survival3 </br> \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Figure 2    Subgroup Analysis of Metastasis-free Survival3 </br> Secondary Endpoints4  Overall Survival</br>Due to the data being immature at the time of analysis, the P-value for OS did not reach the pre-defined threshold for statistical significance [OS NR in either arm, P-value 0.045 (HR 0.71; 95% CI, 0.50 to 0.99)]. As per hierarchal methodology, unless statistical significance was reached for OS, all other secondary endpoints would not be considered to be significant. Figure 3 below show the results of the \n",
       "<mark class=\"entity\" style=\"background: #5c5cd6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    overall survival\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">OS</span>\n",
       "</mark>\n",
       " analysis (a secondary endpoint).4 </br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Figure 3 ARAMIS: Overall Survival (OS) KM Curve3 </br> Time to Pain Progression</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " demonstrated an improvement in Time to Pain Progression (TTPP) of 40.3 months [95% CI 33.2 – 41.2] vs.25.4 months [95% CI 19.09 – 29.36] in the placebo arm; HR .65 (95% CI 0.53 – 0.79);  P  &lt;0.001. TTPP was identified by an increase of ≥2 points from baseline in question three of the BPI-SF [related to the worst pain in the previous 24 hours] take as a 7-day average or initiation of short or long-acting opioids for pain, whichever comes first).4    See figure 4 below.</br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Figure 4 ARAMIS: Time to Pain Progression (TTPP) KM Curve3 </br> Time to Initiation of First Cytotoxic Chemotherapy</br>Darolutamide demonstrated a significant difference in the Time to Initiation of First Cytotoxic Chemotherapy when compared to placebo. At the time of analysis, 35% (339/955) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm had terminated treatment versus 64% (354/554) of patients in the placebo arm. Of the patients who terminated treatment in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm, 29.5% (100/339) vs 36.7% (130/354) of patients in the placebo arm, received cytotoxic chemotherapy and/or anti-neoplastic therapy. The median time to initiation of first cytotoxic chemotherapy was 38.2 months (95% CI 35.55 – 41.89) in the placebo arm and not yet reached in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm.; HR 0.43 (0.31 – 0.60), P&lt;0.001.4    See table 4 below.</br>Time to First Symptomatic Skeletal Event (SSE)</br>The time to first symptomatic skeletal event was evaluated between the two groups. At the time of analysis, 1.7% (16/955) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm experienced a SSE versus 3.2% (18/554) of patients in the placebo arm. The median time to first symptomatic skeletal event was not reached in either arm; HR 0.43 (95%CI 0.22 – 0.84),  P=  0.01.3    See table 4 below.</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>  </br> Exploratory Endpoints4  Progression-Free Survival (PFS)</br>PFS was defined as the time between randomization and evidence of any radiographic disease progression, including new pathologic lymph nodes identified above or below the aortic bifurcation, or death from any cause, whichever occurs first.3 </br>At the time of analysis, 26.8% (256/955) events had occurred in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 46.8% (259/554) of events in the placebo arm. The median PFS was 36.8 months (95% CI 32.92 – NR) in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 14.8 months (95% CI 11.83 – 14.33) in the placebo arm; HR 0.38 (0.32 – 0.45),  P&lt;  0.001.4    See table 4 and figure 5 below.</br>Figure 5 ARAMIS: Progression-Free Survival KM Curve3 </br>Time to PSA Progression</br>Time to PSA progression was defined according to PCWG2 Consensus Guidelines.</br>At the time of analysis, 23.7% (226/955) events had occurred in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 66.4% (368/554) of events in the placebo arm. The median Time to PSA Progression was 33.2 months (95% CI 25.89 – NR) in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 7.3 months (95% CI 13.94 – 7.39) in the placebo arm;  P&lt;  0.001; HR 0.13 (95% CI 0.11 – 0.16) demonstrating an 87% decrease in the risk of PSA Progression compared to placebo.4    See table 4 and figure 6 below.</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>   </br> Figure 6 ARAMIS: Time to PSA Progression3 </br>    Table 4 Pre-specified Secondary and Exploratory Efficacy End Points (Intention-To-treat)*4 </br>  End Point</br> \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " (N = 955)</br> Placebo (N= 554)</br>  Hazard Ratio (95% CI)</br> P Value</br>  Median Duration mo</br>    No. of Events</br>   Median Duration mo</br>   No. of Events</br>    Secondary end points \n",
       "<mark class=\"entity\" style=\"background: #5c5cd6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Overall survival\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">OS</span>\n",
       "</mark>\n",
       "</br>Time to pain progression</br>Time to cytotoxic chemotherapy</br>Time to first symptomatic skeletal\n",
       "event</br>    NR 40.3</br>NR NR</br> 78 251</br>73 16</br>NR 25.4</br>38.2 NR</br>    58 178</br>79 18</br>0.71 (0.50 – 0.99) 0.65 (0.53 – 0.79)</br>0.43 (0.31 – 0.60) 0.43 (0.22 – 0.84)</br>   0.045 &lt;0.001</br>&lt;0.001 0.01</br> Exploratory end points Progression-free survival</br>Time to PSA progression</br>  36.8 33.2</br>    255 226</br>   14.8 7.3</br>   258 368</br>  0.38 (0.32 – 0.45) 0.13 (0.11 – 0.16)</br>   &lt;0.001 &lt;0.001</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Safety Results 3</br>After a median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial</br>(N = 1220/1508; [\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm, n = 794; placebo arm, n = 426]). The incidence of adverse events were generally similar between treatment arms and the majority were Grade 1 or 2 [54.4% (821/5108)].3    The incidence of common events was low with only \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " reported at an incidence of &gt;10%. Grades 3 or 4 adverse events occurred in 22.8% (344/1508) of the total \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " population (24.7% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 19.5% of patients in the placebo arm). The most frequent Grade 3 or 4 adverse events included hypertension (3.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.2% of patients in the placebo plus ADT arm.) and urinary retention (1.6% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 </br>Table 5 shows the Treatment Emergent Adverse Events (TEAEs) for the total \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " population (N = 1508). TEAEs (all grades) occurring in ≥5% of patients reported in Table 6 below, in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " versus placebo arms, respectively, included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") (12.1% [115/954, vs 8.7% [48/554]). Other TEAEs occurring in ≥5% in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (8.8%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (8.1%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (6.9%), hypertension (7.3%), constipation (TEAEs occurring in 6.3%), pain in extremity (5.8%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (5.6%) and hot flush (5.2%). Approximately 14% of TEAEs led to a dose modification in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 9.4% of TEAEs in the placebo arm.3 </br>After a median follow-up of 17.9 months, treatment discontinuations were similar between both arms.4    Discontinuations due to adverse events occurred in 8.9% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs 8.7% of patients in the placebo arm. Discontinuations due to metastasis occurred in 11.7% vs 23.3% of patients; and discontinuations due to investigator judgment occurred in 5.7% vs 16.4% of patients, in the daroluamide vs placebo arms, respectively. Discontinuations due to protocol deviation and to other reasons unspecified occurred in 1.4% vs 1.3% and 0.6% vs 0.4% in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arm, respectively. Additionally, 7.1% vs 14.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arm respectively decided not to continue trial participation. It should be noted that one person in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm was randomized but did not receive treatment.3 </br>A total of 55 deaths occurred during the trial with 3.9% of deaths occurring in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 3.2% occurring in the placebo arm.3    See Table 5 below.</br>The Institute for Clinical and Economic Review (ICER) has identified events such as falls, fractures, cardiovascular events and deaths due to AE’s, etc. to be TEAE’s of interest for anti-androgen therapies.6    For the incidence of TEAE’s of interest reported for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", see Tables 7 - 8.6 </br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>    Table 5. ARAMIS: Summary of TEAEs3 </br>      \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 954</br>     Placebo N = 554</br>  Total N = 1508</br>     Exposure, median (months)</br> 14.8</br>      11.04</br>    Any AE, n (%)</br>  794 (83.2)</br>   426 (76.9)</br>   1220 (80.9)</br>    </br>      Worst grade</br>             Grade 1 or 2</br> 521 (54.6)</br>      300 (54.2)</br>   821 (54.4)</br> Grade 3 or 4</br>   236 (24.7)</br>    108 (19.5)</br>    344 (22.8)</br>     Grade 5</br>37 (3.9)</br>    18 (3.2)</br> 55 (3.6)</br>     Serious</br> 237 (24.8)</br>      111 (20.0)</br>   348 (23.1)</br> Leading to dose modification</br>   135 (14.2)</br>    52 (9.4)</br>    187 (12.4)</br>   Leading to permanent discontinuation</br>85 (8.9)</br>  48 (8.7)</br> 133 (8.8)</br>       AE, adverse event, TEAE, treatment adverse event</br>    Table 6. ARAMIS: Total of TEAEs with an Incidence of  ≥ 5%3 </br>     Preferred term, n (%)</br>   \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 954</br>  Placebo N = 554</br>     Fatigue</br>    115 (12.1)</br>   48 (8.7)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    84 (8.8)</br>   50 (9.0)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    77 (8.1)</br>   51 (9.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    66 (6.9)</br>   31 (5.6)</br>     Hypertension</br>    70 (7.3)</br>   33 (6.0)</br>     Constipation</br>    60 (6.3)</br>   34 (6.1)</br>     Pain in extremity</br>    55 (5.8)</br>   18 (3.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    53 (5.6)</br>   25 (4.2)</br>     Hot flush</br>    50 (5.2)</br>   23 (4.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    48 (5.0)</br>   32 (5.8)</br>     Bone Fracture</br>    40 (4.2)</br>   21 (3.8)</br>     Fall</br>    40 (4.2)</br>   26 (4.7)</br>     Rash</br>    24 (2.6)</br>   4 (0.7)</br> Weight decreased</br>    34 (3.6)</br>    12 (2.2)</br>                    Table 7. ARAMIS: TEAEs of Interest3 </br>    \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N=954</br>Placebo N=554</br>                        AE</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>                                Bone Fracture</br>40 (4.2)</br>0.9</br>0</br>0</br>21 (3.8)</br>0.9</br>0</br>0</br>                    Fall</br>40 (4.2)</br>0.8</br>0</br>0</br>26 (4.7)</br>0.7</br>0</br>0</br>                      Fatigue, including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>151 (15.8)</br>0.6</br>0</br>0</br>63 (11.4)</br>1.1</br>0</br>0</br>                    Seizure</br>2 (0.2)</br>0</br>1 (0.2)</br>0</br>                      Cognitive disorder</br>4 (0.4)</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Memory impairment</br>5 (0.5)</br>0</br>0</br>0</br>7 (1.3)</br>0</br>0</br>0</br>                                Disturbance in attention</br>0</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Amnesia</br>1 (0.1)</br>0</br>0</br>0</br>3 (0.5)</br>0</br>0</br>0</br>                    Rash</br>24 (2.6)</br>0.1</br>0</br>0</br>4 (0.7)</br>0</br>0</br>0</br>                      Weight decreased</br>34 (3.6)</br>0</br>0</br>0</br>12 (2.2)</br>0</br>0</br>0</br>                    Hot flush</br>50 (5.2)</br>0</br>-</br>-</br>23 (4.6)</br>0</br>-</br>-</br>                 Increased bilirubin</br>18 (1.9)</br>0.1</br>0</br>0</br>0</br>0</br>0</br>0</br>                 NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>     Table 8. ARAMIS: TEAEs of Interest3    continued</br>    \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N=954</br>Placebo N=554</br>                        AE</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>                    Hypertension</br>70 (7.3)</br>3.4</br>0</br>0</br>33 (6.0)</br>2.3</br>0</br>0</br>                      Cerebral and intracranial hemorrhage</br>2 (0.2)</br>0</br>0</br>0</br>2 (0.4)</br>0.2</br>0</br>0.2</br>                    Cerebral infarction and stroke</br>4 (0.4)</br>0.3</br>0</br>0</br>4 (0.7)</br>0.4</br>0</br>0.2</br>                      Cerebral ischemic infarction and stroke</br>5 (0.5)</br>0.1</br>0.2</br>0.1</br>2 (0.4)</br>0.2</br>0</br>0.2</br>                                Acute myocardial infarction</br>5 (0.5)</br>0.2</br>0.2</br>0.1</br>1 (0.2)</br>0</br>0</br>0</br>                    Cardiac failure</br>18 (1.9)</br>0.1</br>0.1</br>0.3</br>5 (0.9)</br>0</br>0</br>0.5</br>                 Coronary artery disorders</br>31 (3.2)</br>1.3</br>0.4</br>0.3</br>14 (2.5)</br>0.4</br>0</br>0.2</br>               Ischemic coronary artery disorders</br>24 (2.5</br>0.7</br>0.4</br>0.2</br>11 (2.0)</br>0.4</br>0</br>0.2</br>             QOL Assessment3 </br>Patient Reported Outcome tools (EORTC Q-PR25, Fact-P PCS and The Brief Pain Inventory – Short Form) were used to assess \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "’s impact on health-related quality of life versus placebo. Patient-Reported QoL was similar for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " versus placebo, although clinically meaningful thresholds were not reached.5 </br>REV 0719</br>Reference</br>1. NUBEQA® (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.</br>2. Data on file. Bayer HealthCare Pharmaceuticals, Whippany, NJ.</br>3. Fizazi K et al. ARAMIS: efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in nonmetastatc castration-resistant</br>prostate cancer Oral presentation at: [ASCO GU]; February 14 – 16, 2019; San Francisco CA.</br>#GU19.</br>4. Fizazi K, Shore N, Tammela TL, et. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " in nonmetastatic castration-resistant prostate</br>cancer;  N Eng J M, 2 019, PP 1 – 12,DOI: 10.1056/NEJMMoa1815671</br>5. Fizazi K, Shore N, Tammela TL, et al. efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in nonmetastatc</br>castration-resistant prostate cancer. Poster presented at: ASCO GU]; February 14 – 16, 2019; San Francisco CA. Poster 140.</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>6. Institute for Clinical and Economic Review (ICER), 2018</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)\n",
       "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "displacy.render(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/subashgandyer/anaconda3/lib/python3.7/runpy.py:193: UserWarning: [W011] It looks like you're calling displacy.serve from within a Jupyter notebook or a similar environment. This likely means you're already running a local web server, so there's no need to make displaCy start another one. Instead, you should be able to replace displacy.serve with displacy.render to show the visualization.\n",
      "  \"__main__\", mod_spec)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "<html lang=\"en\">\n",
       "    <head>\n",
       "        <title>displaCy</title>\n",
       "    </head>\n",
       "\n",
       "    <body style=\"font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr\">\n",
       "<figure style=\"margin-bottom: 6rem\">\n",
       "<div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">ARAMIS: A Phase III Study of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in Men with High-risk Non-metastatic Castration-resistant Prostate Cancer</br>Summary</br>● \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nubeqa\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") is an \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    androgen receptor inhibitor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ffe6ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    indicated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Indication</span>\n",
       "</mark>\n",
       " for the treatment of patients with \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer.1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " </br>● ARAMIS, a Phase III, randomized, double-blind, placebo-controlled multinational study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men being treated with androgen deprivation therapy (ADT*) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (nmCRPC) with a high risk of developing metastases.1    Patients (N = 1509) were randomized 2:1 to receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 600 mg tablets orally twice daily plus ADT* versus matching placebo plus ADT*. The primary \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of the study was metastasis-free survival (MFS). MFS was defined as the time from randomization to evidence of metastasis (new or progressive regional pathological lymph nodes were not defined as metastasis) or death from any cause, whichever occurred first. Secondary endpoints included \n",
       "<mark class=\"entity\" style=\"background: #5c5cd6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    overall survival\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">OS</span>\n",
       "</mark>\n",
       " (OS), Time to Pain Progression (TTPP), Time to Initiation of Cytotoxic Chemotherapy and Time to First Symptomatic Skeletal Event (SSE) and Safety and \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    tolerability\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ". Exploratory endpoints included Progression-free Survival (PFS), and Time to PSA Progression.2 </br>Primary \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>o \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% versus placebo [HR .41 (95% CI 0.34 – 0.50);  P  &lt;0.001].4 </br>Secondary Endpoints</br>o At interim analysis, the secondary \n",
       "<mark class=\"entity\" style=\"background: #ccddff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    endpoint\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Endpoint</span>\n",
       "</mark>\n",
       " of median \n",
       "<mark class=\"entity\" style=\"background: #5c5cd6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    overall survival\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">OS</span>\n",
       "</mark>\n",
       " (OS) was not reached [NR;  P-  value = 0.045; HR 0.71 (95% CI 0.50 – 0.99)]. The  P -value did not reach the pre-defined threshold of 0.0005 for statistical significance.</br>▪ The significance of all other secondary endpoints was dependent on OS meeting statistical significance as per hierarchal methodology.</br>o Time to Pain Progression (TTPP) was 40.31 months [95% CI 33.2 – 41.2] in the darolutamide arm vs. 25.36 months [95% CI 19.09 – 29.36] in the placebo arm. The HR of 0.65 [(95% CI 0.53 – 0.79);  P  &lt;0.001] demonstrated a 35% risk reduction in the time to pain progression compared to placebo.4 </br>o The median Time to Initiation of First Cytotoxic Chemotherapy was NR in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs 38.2 months (95% CI 35.55 – 41.89) in the placebo arm. The HR of 0.43 [(95% CI 0.31 – 0.60);  P  &lt;0.001] demonstrated a 57% risk reduction in the time to initiation of First Cytotoxic Chemotherapy compared to placebo.4 </br>The median Time to First Symptomatic Skeletal Event was not reached in either arm. At the time of analysis, 1.7% (16/955) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm experienced a SSE versus 3.2% (18/554) of patients in the placebo arm. The HR 0.43 [(95% CI 0.22 – 0.84),  P=  0.011] demonstrated a 57% risk reduction in the Time to First Symptomatic Skeletal Event compared to placebo.4 </br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>o</br> * Common previous hormonal therapies for prostate cancer (received by ≥10% of all patients) included leuprolide (52%), goserelin (32%), triptorelin (29%), bicalutamide (66%), \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    flutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " (13%), and cyproterone (11%).</br>Exploratory Endpoints</br>o The \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    median\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       " PFS was 36.8 months (95% CI 32.92 – NR) in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 14.8 months (95% CI 11.83 – 14.33) in the placebo arm;  P &lt;0.001.4 </br>o The median Time to PSA Progression was 33.2 months (95% CI 25.89 – NR) in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 7.3 months (95% CI 13.94 – 7.39) in the placebo arm;</br>P&lt;  0.001; HR 0.13 (95% CI 0.11 – 0.16) demonstrating an 87% decrease in the risk of PSA Progression compared to placebo.4 </br>Safety</br>o After a median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial (N = 1220/1508; [\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm, n = 794; placebo arm, n = 426]). The majority of adverse events reported in both arms were Grade 1 or 2 [54.4% (821/1508)].2    The incidence of common adverse events were reported in ≤10% of patients in both the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and placebo arms, with only \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") reported at an incidence of &gt;10% in both arms.3 </br>o The most common Grade 3 or 4 events were hypertension (3.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.2% of patients in the placebo plus ADT arm.) and urinary retention (1.6% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 </br>o Treatment discontinuations occurred in 35.5% (339/954) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs. 63.9% (354/554) of patients in the placebo arm.2 </br>Clinical Data</br>Study Design 2</br>ARAMIS, a Phase III, multinational, randomized, double blind, placebo-controlled study, evaluated the efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in men undergoing treatment with androgen deprivation therapy (ADT*   ) for \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    non-metastatic castration-resistant prostate cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       " (nmCRPC) with a high risk of developing \n",
       "<mark class=\"entity\" style=\"background: lavender; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    metastases\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Condition</span>\n",
       "</mark>\n",
       ". High risk was defined as PSADT of ≤ 10 months and PSA ≥ 2ng/ml. Patients included in the study had an ECOG performance status of 0-1 and adequate hematologic, renal, and liver function. Additionally, patients with a history of seizures or at risk for seizures were included.2 </br>Patients (N=1509) were randomized 2:1 to receive \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " 600 mg tablets orally twice daily with food plus ADT versus matching placebo plus ADT. Key baseline characteristics of the majority of the patient population in the ARAMIS study were: a median age of 74; Gleason score of ≥7; absence of regional pathological lymph nodes; ≥2 prior hormonal therapy agents with a PSADT ≤6 months, and no baseline osteoclast targeted therapy. Patients on the ARAMIS study were stratified according to PSADT (PSADT;  &lt;  6 months vs. &gt; 6 months) and use of</br>\n",
       "<mark class=\"entity\" style=\"background: #ffff1a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA ®\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Plasma Concentration</span>\n",
       "</mark>\n",
       "  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br> </br> osteoclast-targeted therapy (yes vs. no). All assessments were obtained at baseline and every 16 weeks. For a complete detail of patient demographics and characteristics, see table 1 and 2 below.2 </br>    Table 1. ARAMIS: Patient Demographics3 </br>        \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 955</br>   Placebo N = 554</br>  Total N = 1509</br> Age , median, years</br>    74.0</br>     74.0</br>    74.0</br>     Age group, n (%)</br>     &lt;65</br>   113 (11.8)</br>   84 (15.2)</br>  197 (13.1)</br>     65 - 74</br>    373 (39.1)</br>    216 (39.0)</br>   589 (39.0)</br>     75 – 84</br>    384 (40.2)</br>    209 (37.7)</br>   593 (39.3)</br> ≥85</br>    85 (8.9)</br>     45 (8.1)</br>    130 (8.6)</br>     Race, n (%)*</br>  Asian</br>    122 (12.8)</br>     71 (12.8)</br>    193 (12.8)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Black\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " or African-American</br> 28 (2.9)</br> 24 (4.3)</br> 52 (3.4)</br>     Other</br>    9 (0.9)</br>    6 (1.1)</br>   15 (1.0)</br> White</br>    760 (79.6)</br>     434 (78.3)</br>    1194 (79.1)</br>     Weight</br>     N</br>   953</br>   552</br>  1505</br>     Missing, n</br>    2</br>    2</br>   4</br> Median, kg</br>    82.40</br>     82.00</br>    82.00</br>     Geographical region, n (%)</br>     North America</br>   108 (11.3)</br>   76 (13.7)</br>  184 (12.2)</br>     Asia Pacific</br>    119 (12.5)</br>    67 (12.1)</br>   186 (12.3)</br> Rest of the world</br>    728 (76.2)</br>     411 (74.2)</br>    1139 (75.5)</br>                 *Race data was missing for 36 (3.8%) and 19 (3.4%) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " and placebo arms, respectively</br>    Table 2. ARAMIS: Patient Characteristics3 </br>        \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 955</br>   Placebo N = 554</br>  Total N = 1509</br>     Base line PSADT ≤6 months, n (%)</br>    667 (69.8)</br>    371 (67.0)</br>   1038 (68.8)</br>     PSADT, months, mean (median)</br>    4.84 (4.39)</br>    4.89 (4.65)</br>   4.86 (4.45)</br> PSA, ng/mL, mean (median)</br>     18.7 (9.0)</br>      19.8 (9.7)</br>     19.1 (9.3)</br>   No baseline osteoclast-target therapy, n (%)</br>  924 (96.8)</br>   522 (94.2)</br>  1446 (95.8)</br>     ECOG PS, n (%)</br>     0</br>   650 (68.1)</br>   391 (70.6)</br>  1041 (69.0)</br> 1</br>    305 (31.9)</br>     163 (29.4)</br>    468 (31.0)</br>     Gleason total score (Factor1 + Factor2), n (%)</br>     Missing</br>   27 (2.8)</br>   17 (3.1)</br>  44 (2.9)</br> &lt;7</br>     217 (22.7)</br>      142 (25.6)</br>     359 (23.8)</br>   ≥7</br>  711 (74.5)</br>   395 (71.3)</br>  1106 (73.3)</br>     Prior hormonal therapy, n (%)103 (18.6)</br>           \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>      1</br>   177 (18.5)</br>   103 (18.6)</br>  280 (18.6)</br>     ≥2</br>    727 (76.1)</br>    420 (75.8)</br>   1147 (76.0)</br> Not applicable*</br>    51 (5.3)</br>     31 (5.6)</br>    82 (5.4)</br>     Baseline presence of regional pathological lymph nodes by central imaging review, n (%)</br>     No</br>   792 (82.9)</br>   396 (71.5)</br>  1188 (78.7)</br> Yes</br>    163 (17.1)</br>     158 (28.5)</br>    321 (21.3)</br>     *Patients who underwent surgical castration were not required to have been/ be treated with hormonal drug therapy</br>Efficacy Results3  Primary Endpoint: Metastasis Free Survival</br>After a median follow-up of 17.9 months, \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " demonstrated a statistically significant improvement in MFS of 40.4 months [95% CI 34.33 – NR] vs 18.4 months [95% CI 15.51 – 22.34] in the placebo arm and reduced the risk of metastasis or death by 59% compared to placebo [HR .41 (95% CI 0.34 – 0.50);  P  &lt;0.001]. This improvement in MFS was consistent among patients irrespective of baseline characteristics, therapy and demographic See table 3 and figures 1 &amp; 2 below.3 </br>     Table 3. ARAMIS: Metastasis-Free Survival (MFS)3 </br>        \n",
       "<mark class=\"entity\" style=\"background: #3399ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Food Interaction</span>\n",
       "</mark>\n",
       "</br>  Placebo</br>     N</br>    955</br>   554</br> Events, n (%)</br>     221 (23.1)</br>     216 (39.0)</br>     Median, months (95% CI)</br> 40.37 (34.33 – NR)</br> 18.43 (15.51 – 22.34)</br>     Baseline metastases, n (%)</br>    50 (5.2)</br>    39 (7.0)</br>      2-sided  P -value</br>  &lt;0.001</br> HR (95% CI)</br>   0.41 (0.34 – 0.50)</br>        \n",
       "<mark class=\"entity\" style=\"background: #ff4da6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Administration</span>\n",
       "</mark>\n",
       " ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Figure 1 Kaplan-Meier Analysis of Metastasis-free Survival3 </br> \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    NUBEQA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " ®  (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Figure 2    Subgroup Analysis of Metastasis-free Survival3 </br> Secondary Endpoints4  Overall Survival</br>Due to the data being immature at the time of analysis, the P-value for OS did not reach the pre-defined threshold for statistical significance [OS NR in either arm, P-value 0.045 (HR 0.71; 95% CI, 0.50 to 0.99)]. As per hierarchal methodology, unless statistical significance was reached for OS, all other secondary endpoints would not be considered to be significant. Figure 3 below show the results of the \n",
       "<mark class=\"entity\" style=\"background: #5c5cd6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    overall survival\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">OS</span>\n",
       "</mark>\n",
       " analysis (a secondary endpoint).4 </br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Figure 3 ARAMIS: Overall Survival (OS) KM Curve3 </br> Time to Pain Progression</br>\n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " demonstrated an improvement in Time to Pain Progression (TTPP) of 40.3 months [95% CI 33.2 – 41.2] vs.25.4 months [95% CI 19.09 – 29.36] in the placebo arm; HR .65 (95% CI 0.53 – 0.79);  P  &lt;0.001. TTPP was identified by an increase of ≥2 points from baseline in question three of the BPI-SF [related to the worst pain in the previous 24 hours] take as a 7-day average or initiation of short or long-acting opioids for pain, whichever comes first).4    See figure 4 below.</br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Figure 4 ARAMIS: Time to Pain Progression (TTPP) KM Curve3 </br> Time to Initiation of First Cytotoxic Chemotherapy</br>Darolutamide demonstrated a significant difference in the Time to Initiation of First Cytotoxic Chemotherapy when compared to placebo. At the time of analysis, 35% (339/955) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm had terminated treatment versus 64% (354/554) of patients in the placebo arm. Of the patients who terminated treatment in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm, 29.5% (100/339) vs 36.7% (130/354) of patients in the placebo arm, received cytotoxic chemotherapy and/or anti-neoplastic therapy. The median time to initiation of first cytotoxic chemotherapy was 38.2 months (95% CI 35.55 – 41.89) in the placebo arm and not yet reached in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm.; HR 0.43 (0.31 – 0.60), P&lt;0.001.4    See table 4 below.</br>Time to First Symptomatic Skeletal Event (SSE)</br>The time to first symptomatic skeletal event was evaluated between the two groups. At the time of analysis, 1.7% (16/955) of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm experienced a SSE versus 3.2% (18/554) of patients in the placebo arm. The median time to first symptomatic skeletal event was not reached in either arm; HR 0.43 (95%CI 0.22 – 0.84),  P=  0.01.3    See table 4 below.</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>  </br> Exploratory Endpoints4  Progression-Free Survival (PFS)</br>PFS was defined as the time between randomization and evidence of any radiographic disease progression, including new pathologic lymph nodes identified above or below the aortic bifurcation, or death from any cause, whichever occurs first.3 </br>At the time of analysis, 26.8% (256/955) events had occurred in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 46.8% (259/554) of events in the placebo arm. The median PFS was 36.8 months (95% CI 32.92 – NR) in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 14.8 months (95% CI 11.83 – 14.33) in the placebo arm; HR 0.38 (0.32 – 0.45),  P&lt;  0.001.4    See table 4 and figure 5 below.</br>Figure 5 ARAMIS: Progression-Free Survival KM Curve3 </br>Time to PSA Progression</br>Time to PSA progression was defined according to PCWG2 Consensus Guidelines.</br>At the time of analysis, 23.7% (226/955) events had occurred in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 66.4% (368/554) of events in the placebo arm. The median Time to PSA Progression was 33.2 months (95% CI 25.89 – NR) in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 7.3 months (95% CI 13.94 – 7.39) in the placebo arm;  P&lt;  0.001; HR 0.13 (95% CI 0.11 – 0.16) demonstrating an 87% decrease in the risk of PSA Progression compared to placebo.4    See table 4 and figure 6 below.</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>   </br> Figure 6 ARAMIS: Time to PSA Progression3 </br>    Table 4 Pre-specified Secondary and Exploratory Efficacy End Points (Intention-To-treat)*4 </br>  End Point</br> \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " (N = 955)</br> Placebo (N= 554)</br>  Hazard Ratio (95% CI)</br> P Value</br>  Median Duration mo</br>    No. of Events</br>   Median Duration mo</br>   No. of Events</br>    Secondary end points \n",
       "<mark class=\"entity\" style=\"background: #5c5cd6; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Overall survival\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">OS</span>\n",
       "</mark>\n",
       "</br>Time to pain progression</br>Time to cytotoxic chemotherapy</br>Time to first symptomatic skeletal\n",
       "event</br>    NR 40.3</br>NR NR</br> 78 251</br>73 16</br>NR 25.4</br>38.2 NR</br>    58 178</br>79 18</br>0.71 (0.50 – 0.99) 0.65 (0.53 – 0.79)</br>0.43 (0.31 – 0.60) 0.43 (0.22 – 0.84)</br>   0.045 &lt;0.001</br>&lt;0.001 0.01</br> Exploratory end points Progression-free survival</br>Time to PSA progression</br>  36.8 33.2</br>    255 226</br>   14.8 7.3</br>   258 368</br>  0.38 (0.32 – 0.45) 0.13 (0.11 – 0.16)</br>   &lt;0.001 &lt;0.001</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br> Safety Results 3</br>After a median exposure of 14.8 months in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 11.04 months in the placebo arm, approximately 80% of patients experienced an adverse event during the trial</br>(N = 1220/1508; [\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm, n = 794; placebo arm, n = 426]). The incidence of adverse events were generally similar between treatment arms and the majority were Grade 1 or 2 [54.4% (821/5108)].3    The incidence of common events was low with only \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " reported at an incidence of &gt;10%. Grades 3 or 4 adverse events occurred in 22.8% (344/1508) of the total \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " population (24.7% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 19.5% of patients in the placebo arm). The most frequent Grade 3 or 4 adverse events included hypertension (3.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.2% of patients in the placebo plus ADT arm.) and urinary retention (1.6% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " plus ADT arm versus 2.0% of patients in the placebo plus ADT arm.).3 </br>Table 5 shows the Treatment Emergent Adverse Events (TEAEs) for the total \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " population (N = 1508). TEAEs (all grades) occurring in ≥5% of patients reported in Table 6 below, in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " versus placebo arms, respectively, included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    fatigue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       ") (12.1% [115/954, vs 8.7% [48/554]). Other TEAEs occurring in ≥5% in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm included \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (8.8%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (8.1%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (6.9%), hypertension (7.3%), constipation (TEAEs occurring in 6.3%), pain in extremity (5.8%), \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       " (5.6%) and hot flush (5.2%). Approximately 14% of TEAEs led to a dose modification in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 9.4% of TEAEs in the placebo arm.3 </br>After a median follow-up of 17.9 months, treatment discontinuations were similar between both arms.4    Discontinuations due to adverse events occurred in 8.9% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm vs 8.7% of patients in the placebo arm. Discontinuations due to metastasis occurred in 11.7% vs 23.3% of patients; and discontinuations due to investigator judgment occurred in 5.7% vs 16.4% of patients, in the daroluamide vs placebo arms, respectively. Discontinuations due to protocol deviation and to other reasons unspecified occurred in 1.4% vs 1.3% and 0.6% vs 0.4% in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arm, respectively. Additionally, 7.1% vs 14.1% of patients in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " vs placebo arm respectively decided not to continue trial participation. It should be noted that one person in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm was randomized but did not receive treatment.3 </br>A total of 55 deaths occurred during the trial with 3.9% of deaths occurring in the \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " arm versus 3.2% occurring in the placebo arm.3    See Table 5 below.</br>The Institute for Clinical and Economic Review (ICER) has identified events such as falls, fractures, cardiovascular events and deaths due to AE’s, etc. to be TEAE’s of interest for anti-androgen therapies.6    For the incidence of TEAE’s of interest reported for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ", see Tables 7 - 8.6 </br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br>    Table 5. ARAMIS: Summary of TEAEs3 </br>      \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 954</br>     Placebo N = 554</br>  Total N = 1508</br>     Exposure, median (months)</br> 14.8</br>      11.04</br>    Any AE, n (%)</br>  794 (83.2)</br>   426 (76.9)</br>   1220 (80.9)</br>    </br>      Worst grade</br>             Grade 1 or 2</br> 521 (54.6)</br>      300 (54.2)</br>   821 (54.4)</br> Grade 3 or 4</br>   236 (24.7)</br>    108 (19.5)</br>    344 (22.8)</br>     Grade 5</br>37 (3.9)</br>    18 (3.2)</br> 55 (3.6)</br>     Serious</br> 237 (24.8)</br>      111 (20.0)</br>   348 (23.1)</br> Leading to dose modification</br>   135 (14.2)</br>    52 (9.4)</br>    187 (12.4)</br>   Leading to permanent discontinuation</br>85 (8.9)</br>  48 (8.7)</br> 133 (8.8)</br>       AE, adverse event, TEAE, treatment adverse event</br>    Table 6. ARAMIS: Total of TEAEs with an Incidence of  ≥ 5%3 </br>     Preferred term, n (%)</br>   \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N = 954</br>  Placebo N = 554</br>     Fatigue</br>    115 (12.1)</br>   48 (8.7)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Back pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    84 (8.8)</br>   50 (9.0)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Arthralgia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    77 (8.1)</br>   51 (9.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Diarrhea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    66 (6.9)</br>   31 (5.6)</br>     Hypertension</br>    70 (7.3)</br>   33 (6.0)</br>     Constipation</br>    60 (6.3)</br>   34 (6.1)</br>     Pain in extremity</br>    55 (5.8)</br>   18 (3.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    53 (5.6)</br>   25 (4.2)</br>     Hot flush</br>    50 (5.2)</br>   23 (4.2)</br>     \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Nausea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>    48 (5.0)</br>   32 (5.8)</br>     Bone Fracture</br>    40 (4.2)</br>   21 (3.8)</br>     Fall</br>    40 (4.2)</br>   26 (4.7)</br>     Rash</br>    24 (2.6)</br>   4 (0.7)</br> Weight decreased</br>    34 (3.6)</br>    12 (2.2)</br>                    Table 7. ARAMIS: TEAEs of Interest3 </br>    \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N=954</br>Placebo N=554</br>                        AE</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>                                Bone Fracture</br>40 (4.2)</br>0.9</br>0</br>0</br>21 (3.8)</br>0.9</br>0</br>0</br>                    Fall</br>40 (4.2)</br>0.8</br>0</br>0</br>26 (4.7)</br>0.7</br>0</br>0</br>                      Fatigue, including \n",
       "<mark class=\"entity\" style=\"background: tomato; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    asthenia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Adverse Event</span>\n",
       "</mark>\n",
       "</br>151 (15.8)</br>0.6</br>0</br>0</br>63 (11.4)</br>1.1</br>0</br>0</br>                    Seizure</br>2 (0.2)</br>0</br>1 (0.2)</br>0</br>                      Cognitive disorder</br>4 (0.4)</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Memory impairment</br>5 (0.5)</br>0</br>0</br>0</br>7 (1.3)</br>0</br>0</br>0</br>                                Disturbance in attention</br>0</br>0</br>0</br>0</br>1 (0.2)</br>0</br>0</br>0</br>                                Amnesia</br>1 (0.1)</br>0</br>0</br>0</br>3 (0.5)</br>0</br>0</br>0</br>                    Rash</br>24 (2.6)</br>0.1</br>0</br>0</br>4 (0.7)</br>0</br>0</br>0</br>                      Weight decreased</br>34 (3.6)</br>0</br>0</br>0</br>12 (2.2)</br>0</br>0</br>0</br>                    Hot flush</br>50 (5.2)</br>0</br>-</br>-</br>23 (4.6)</br>0</br>-</br>-</br>                 Increased bilirubin</br>18 (1.9)</br>0.1</br>0</br>0</br>0</br>0</br>0</br>0</br>                 NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>     Table 8. ARAMIS: TEAEs of Interest3    continued</br>    \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " N=954</br>Placebo N=554</br>                        AE</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>Any Grade, n (%)</br>Grade 3, %</br>Grade 4 %</br>Grade 5, %</br>                    Hypertension</br>70 (7.3)</br>3.4</br>0</br>0</br>33 (6.0)</br>2.3</br>0</br>0</br>                      Cerebral and intracranial hemorrhage</br>2 (0.2)</br>0</br>0</br>0</br>2 (0.4)</br>0.2</br>0</br>0.2</br>                    Cerebral infarction and stroke</br>4 (0.4)</br>0.3</br>0</br>0</br>4 (0.7)</br>0.4</br>0</br>0.2</br>                      Cerebral ischemic infarction and stroke</br>5 (0.5)</br>0.1</br>0.2</br>0.1</br>2 (0.4)</br>0.2</br>0</br>0.2</br>                                Acute myocardial infarction</br>5 (0.5)</br>0.2</br>0.2</br>0.1</br>1 (0.2)</br>0</br>0</br>0</br>                    Cardiac failure</br>18 (1.9)</br>0.1</br>0.1</br>0.3</br>5 (0.9)</br>0</br>0</br>0.5</br>                 Coronary artery disorders</br>31 (3.2)</br>1.3</br>0.4</br>0.3</br>14 (2.5)</br>0.4</br>0</br>0.2</br>               Ischemic coronary artery disorders</br>24 (2.5</br>0.7</br>0.4</br>0.2</br>11 (2.0)</br>0.4</br>0</br>0.2</br>             QOL Assessment3 </br>Patient Reported Outcome tools (EORTC Q-PR25, Fact-P PCS and The Brief Pain Inventory – Short Form) were used to assess \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "’s impact on health-related quality of life versus placebo. Patient-Reported QoL was similar for \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " versus placebo, although clinically meaningful thresholds were not reached.5 </br>REV 0719</br>Reference</br>1. NUBEQA® (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       ") tablets for oral use [Prescribing Information]. Whippany, NJ. Bayer HealthCare Pharmaceuticals, July 2019.</br>2. Data on file. Bayer HealthCare Pharmaceuticals, Whippany, NJ.</br>3. Fizazi K et al. ARAMIS: efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in nonmetastatc castration-resistant</br>prostate cancer Oral presentation at: [ASCO GU]; February 14 – 16, 2019; San Francisco CA.</br>#GU19.</br>4. Fizazi K, Shore N, Tammela TL, et. \n",
       "<mark class=\"entity\" style=\"background: #b3d9ff; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    Darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug Interaction</span>\n",
       "</mark>\n",
       " in nonmetastatic castration-resistant prostate</br>cancer;  N Eng J M, 2 019, PP 1 – 12,DOI: 10.1056/NEJMMoa1815671</br>5. Fizazi K, Shore N, Tammela TL, et al. efficacy and \n",
       "<mark class=\"entity\" style=\"background: #80ff80; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    safety\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Safety</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       " in nonmetastatc</br>castration-resistant prostate cancer. Poster presented at: ASCO GU]; February 14 – 16, 2019; San Francisco CA. Poster 140.</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)</br>Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</br></br>6. Institute for Clinical and Economic Review (ICER), 2018</br>NUBEQA®    (\n",
       "<mark class=\"entity\" style=\"background: #ff9ff0; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em; box-decoration-break: clone; -webkit-box-decoration-break: clone\">\n",
       "    darolutamide\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">Drug</span>\n",
       "</mark>\n",
       "): ARAMIS (nmCRPC)\n",
       "Disclaimer - T  his information is for individual educational purposes only and is not intended to provide medical advice. Please consult the full prescribing information before using or prescribing Bayer Healthcare products. Bayer HealthCare 100 Bayer Boulevard Bldg. 200. Whippany, NJ 07981.</div>\n",
       "</figure>\n",
       "</body>\n",
       "</html>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Using the 'ent' visualizer\n",
      "Serving on http://0.0.0.0:5000 ...\n",
      "\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "127.0.0.1 - - [05/Mar/2020 11:00:23] \"GET / HTTP/1.1\" 200 74218\n",
      "127.0.0.1 - - [05/Mar/2020 11:00:23] \"GET /favicon.ico HTTP/1.1\" 200 74218\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Shutting down server on port 5000.\n"
     ]
    }
   ],
   "source": [
    "displacy.serve(doc, style=\"ent\", options=options)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "testing",
   "language": "python",
   "name": "testing"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
